Anderson, Kenneth
completed student projects: A Model for Biologically-Based Therapeutics: Multiple Myeloma FOR CREDIT ONLY - PASTEUR
eCommons Login: KCA1
first name: Kenneth
last name: Anderson
coauthor of: Richardson, Paul
coauthor of: Hideshima, Teru
coauthor of: Munshi, Nikhil
coauthor of: Raje, Noopur
coauthor of: Ghobrial, Irene
full name: Kenneth Carl Anderson, M.D.
has faculty rank: Full Professor
has network: selected publications
has network: research areas
has network: coauthor of
has network: similar to
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 8381
person in primary position: Kraft Family Professor of Medicine
physical neighbor: Ho, Vincent
physical neighbor: Matulonis, Ursula
physical neighbor: Mayer, Robert
physical neighbor: Ritz, Jerome
physical neighbor: Shipp, Margaret
similar to: Richardson, Paul
similar to: Munshi, Nikhil
similar to: Raje, Noopur
similar to: Ghobrial, Irene
similar to: Laubach, Jacob
type: Agent
type: Person
selected publications: Authorship 1795628
selected publications: Authorship 1781929
selected publications: Authorship 1835774
selected publications: Authorship 1851776
selected publications: Authorship 1793329
selected publications: Authorship 1833676
selected publications: Authorship 1850478
selected publications: Authorship 1792112
selected publications: Authorship 1780370
selected publications: Authorship 1849046
selected publications: Authorship 1744081
selected publications: Authorship 1844159
selected publications: Authorship 1826251
selected publications: Authorship 1752867
selected publications: Authorship 1846531
selected publications: Authorship 1825273
selected publications: Authorship 1749657
selected publications: Authorship 1822901
selected publications: Authorship 1822846
selected publications: Authorship 1748685
selected publications: Authorship 1749167
selected publications: Authorship 1740994
selected publications: Authorship 1711030
selected publications: Authorship 1722378
selected publications: Authorship 1708642
selected publications: Authorship 1734882
selected publications: Authorship 1706933
selected publications: Authorship 1708656
selected publications: Authorship 1724857
selected publications: Authorship 1717456
selected publications: Authorship 1696841
selected publications: Authorship 1668320
selected publications: Authorship 1688544
selected publications: Authorship 1685274
selected publications: Authorship 1689260
selected publications: Authorship 1684393
selected publications: Authorship 1659460
selected publications: Authorship 1677944
selected publications: Authorship 1664549
selected publications: Authorship 1663953
selected publications: Authorship 1626448
selected publications: Authorship 1628031
selected publications: Authorship 1659804
selected publications: Authorship 1661664
selected publications: Authorship 1731327
selected publications: Authorship 1652869
selected publications: Authorship 1653035
selected publications: Authorship 1634442

completed student projects
tag name: catalyst:advisorInMentoringCompletedStudentProject
type: ObjectProperty

eCommons Login
tag name: catalyst:eCommonsLogin
type: DatatypeProperty

Mentoring - Completed Student Project
type: Class

coauthor of
tag name: prns:coAuthorOf
type: ObjectProperty

end date
tag name: prns:endDate
type: DatatypeProperty

Faculty Rank
type: Class

full name
tag name: prns:fullName
type: DatatypeProperty

author list
tag name: prns:hasAuthorList
type: DatatypeProperty

has faculty rank
tag name: prns:hasFacultyRank
type: ObjectProperty

has network
tag name: prns:hasNetwork
type: ObjectProperty

published in
tag name: prns:hasPublicationVenue
type: DatatypeProperty

information resource reference
tag name: prns:informationResourceReference
type: DatatypeProperty

is primary position
tag name: prns:isPrimaryPosition
type: DatatypeProperty

latitude
tag name: prns:latitude
type: DatatypeProperty

longitude
tag name: prns:longitude
type: DatatypeProperty

photo
tag name: prns:mainImage
type: ObjectProperty

maximum weight
tag name: prns:maxWeight
type: DatatypeProperty

journal title abbreviation
tag name: prns:medlineTA
type: DatatypeProperty

MeSH DescriptorUI
tag name: prns:meshDescriptorUI
type: DatatypeProperty

MeSH semantic group name
tag name: prns:meshSemanticGroupName
type: DatatypeProperty

minimum weight
tag name: prns:minWeight
type: DatatypeProperty

number of authors
tag name: prns:numberOfAuthors
type: DatatypeProperty

number of connections
tag name: prns:numberOfConnections
type: DatatypeProperty

number of publications
tag name: prns:numberOfPublications
type: DatatypeProperty

Person ID
tag name: prns:personId
type: DatatypeProperty

person in primary position
tag name: prns:personInPrimaryPosition
type: ObjectProperty

physical neighbor
tag name: prns:physicalNeighborOf
type: ObjectProperty

position in department
tag name: prns:positionInDepartment
type: ObjectProperty

position in division
tag name: prns:positionInDivision
type: ObjectProperty

predicate node
tag name: prns:predicateNode
type: ObjectProperty

principal investigator name
tag name: prns:principalInvestigatorName
type: DatatypeProperty

publication date
tag name: prns:publicationDate
type: DatatypeProperty

similar to
tag name: prns:similarTo
type: ObjectProperty

sort order
tag name: prns:sortOrder
type: DatatypeProperty

start date
tag name: prns:startDate
type: DatatypeProperty

uniqueness weight
tag name: prns:uniquenessWeight
type: DatatypeProperty

year
tag name: prns:year
type: DatatypeProperty

Academic Article
type: Class

Article
type: Class

Document
type: Class

PubMed Identifier
tag name: bibo:pmid
type: DatatypeProperty

Address
type: Class

address line 1
tag name: vivo:address1
type: DatatypeProperty

address line 2
tag name: vivo:address2
type: DatatypeProperty

address line 3
tag name: vivo:address3
type: DatatypeProperty

city
tag name: vivo:addressCity
type: DatatypeProperty
type: FunctionalProperty

postal code
tag name: vivo:addressPostalCode
type: DatatypeProperty
type: FunctionalProperty

state or province
tag name: vivo:addressState
type: DatatypeProperty
type: FunctionalProperty

selected publications
tag name: vivo:authorInAuthorship
type: ObjectProperty

author rank in publication
tag name: vivo:authorRank
type: DatatypeProperty
type: FunctionalProperty

Authorship
type: Class

Department
type: Class

Division
type: Class

Grant
type: Class

research areas
tag name: vivo:hasResearchArea
type: ObjectProperty

research activities
tag name: vivo:hasResearcherRole
type: ObjectProperty

HR job title
tag name: vivo:hrJobTitle
type: DatatypeProperty

Information Resource
type: Class

linked author
tag name: vivo:linkedAuthor
type: ObjectProperty

linked information resource
tag name: vivo:linkedInformationResource
type: ObjectProperty

mailing address
tag name: vivo:mailingAddress
type: ObjectProperty

middle name or initial
tag name: vivo:middleName
type: DatatypeProperty
type: FunctionalProperty

overview
tag name: vivo:overview
type: DatatypeProperty
type: FunctionalProperty

positions
tag name: vivo:personInPosition
type: ObjectProperty

phone
tag name: vivo:phoneNumber
type: DatatypeProperty

Position
type: Class

position in organization
tag name: vivo:positionInOrganization
type: ObjectProperty

preferred title
tag name: vivo:preferredTitle
type: DatatypeProperty
type: FunctionalProperty

Researcher Role
type: Class

researcher role of
tag name: vivo:researcherRoleOf
type: ObjectProperty

contributes to
tag name: vivo:roleContributesTo
type: ObjectProperty

sponsor award id
tag name: vivo:sponsorAwardId
type: DatatypeProperty
type: FunctionalProperty

predicate
tag name: rdf:predicate
type: ObjectProperty

type
tag name: rdf:type
type: ObjectProperty

label
tag name: rdfs:label
type: DatatypeProperty

Concept
type: Class

Agent
type: Class

first name
tag name: foaf:firstName
type: DatatypeProperty
type: FunctionalProperty

last name
tag name: foaf:lastName
type: DatatypeProperty
type: FunctionalProperty

Organization
type: Class

Person
type: Class

Authorship 1047143
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.

Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
PubMed Identifier: 29487385
author list: Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, Munshi NC, Anderson KC
published in: Leukemia
information resource reference: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947.
journal title abbreviation: Leukemia
publication date: 2018-02-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.
PubMed Identifier: 11751905
author list: Podar K, Tai YT, Lin BK, Narsimhan RP, Sattler M, Kijima T, Salgia R, Gupta D, Chauhan D, Anderson KC
published in: The Journal of biological chemistry
information resource reference: Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation. J Biol Chem. 2002 Mar 08; 277(10):7875-81.
journal title abbreviation: J Biol Chem
publication date: 2001-12-20T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
PubMed Identifier: 11877293
author list: Mitsiades N, Mitsiades CS, Poulaki V, Anderson KC, Treon SP
published in: Blood
information resource reference: Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells. Blood. 2002 Mar 15; 99(6):2162-71.
journal title abbreviation: Blood
publication date: 2002-03-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
PubMed Identifier: 12384400
author list: Richardson PG, Schlossman RL, Weller E, Hideshima T, Mitsiades C, Davies F, LeBlanc R, Catley LP, Doss D, Kelly K, McKenney M, Mechlowicz J, Freeman A, Deocampo R, Rich R, Ryoo JJ, Chauhan D, Balinski K, Zeldis J, Anderson KC
published in: Blood
information resource reference: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002 Nov 01; 100(9):3063-7.
journal title abbreviation: Blood
publication date: 2002-11-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.
PubMed Identifier: 12424198
author list: Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC
published in: Blood
information resource reference: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
journal title abbreviation: Blood
publication date: 2002-11-07T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1050562
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
PubMed Identifier: 29517956
author list: Anderson K, Ismaila N, Kyle RA
published in: Journal of oncology practice
information resource reference: Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2018 04; 14(4):266-269.
journal title abbreviation: J Oncol Pract
publication date: 2018-03-08T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1053386
type: Authorship
author rank in publication: 33
linked author: Anderson, Kenneth
linked information resource: Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.

Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma.
PubMed Identifier: 29559475
author list: Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V, Snyder C, Vachon CM, McKay JD, Wang SP, Jayabalan DS, Jacobs LM, Becirovic D, Waller RG, Artomov M, Viale A, Patel J, Phillip J, Chen-Kiang S, Curtin K, Salama M, Atanackovic D, Niesvizky R, Landgren O, Slager SL, Godley LA, Churpek J, Garber JE, Anderson KC, Daly MJ, Roeder RG, Dumontet C, Lynch HT, Mullighan CG, Camp NJ, Offit K, Klein RJ, Yu H, Cerchietti L, Lipkin SM
published in: Cancer research
information resource reference: Germline Lysine-Specific Demethylase 1 (LSD1/KDM1A) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res. 2018 05 15; 78(10):2747-2759.
journal title abbreviation: Cancer Res
publication date: 2018-03-20T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.
PubMed Identifier: 19471019
author list: Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D, Williams SF, Bensinger W, Badros AZ, Vescio R, Kenvin L, Yu Z, Olesnyckyj M, Zeldis J, Knight R, Anderson KC
published in: Blood
information resource reference: Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009 Jul 23; 114(4):772-8.
journal title abbreviation: Blood
publication date: 2009-05-26T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).
PubMed Identifier: 17213309
author list: de la Fuente MA, Sasahara Y, Calamito M, Antón IM, Elkhal A, Gallego MD, Suresh K, Siminovitch K, Ochs HD, Anderson KC, Rosen FS, Geha RS, Ramesh N
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP). Proc Natl Acad Sci U S A. 2007 Jan 16; 104(3):926-31.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2007-01-09T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.
PubMed Identifier: 17475906
author list: Hatjiharissi E, Xu L, Santos DD, Hunter ZR, Ciccarelli BT, Verselis S, Modica M, Cao Y, Manning RJ, Leleu X, Dimmock EA, Kortsaris A, Mitsiades C, Anderson KC, Fox EA, Treon SP
published in: Blood
information resource reference: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism. Blood. 2007 Oct 01; 110(7):2561-4.
journal title abbreviation: Blood
publication date: 2007-05-02T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.
PubMed Identifier: 17761832
author list: Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, Spencer JA, Pitsillides CM, Hatjiharissi E, Roccaro A, O'Sullivan G, McMillin DW, Moreno D, Kiziltepe T, Carrasco R, Treon SP, Hideshima T, Anderson KC, Lin CP, Ghobrial IM
published in: Blood
information resource reference: The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2007 Dec 15; 110(13):4417-26.
journal title abbreviation: Blood
publication date: 2007-08-30T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting proteasomes as therapy in multiple myeloma.
PubMed Identifier: 18437898
author list: Chauhan D, Hideshima T, Anderson KC
published in: Advances in experimental medicine and biology
information resource reference: Targeting proteasomes as therapy in multiple myeloma. Adv Exp Med Biol. 2008; 615:251-60.
journal title abbreviation: Adv Exp Med Biol
publication date: 2008-01-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 110472
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.

The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation.
PubMed Identifier: 12459170
author list: Yamaguchi T, Yamauchi M, Sugimoto T, Chauhan D, Anderson KC, Brown EM, Chihara K
published in: Biochemical and biophysical research communications
information resource reference: The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation. Biochem Biophys Res Commun. 2002 Dec 13; 299(4):532-8.
journal title abbreviation: Biochem Biophys Res Commun
publication date: 2002-12-13T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.
PubMed Identifier: 12480690
author list: Chauhan D, Li G, Auclair D, Hideshima T, Richardson P, Podar K, Mitsiades N, Mitsiades C, Li C, Kim RS, Munshi N, Chen LB, Wong W, Anderson KC
published in: Blood
information resource reference: Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14.
journal title abbreviation: Blood
publication date: 2002-12-12T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.
PubMed Identifier: 18713253
author list: Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL
published in: British journal of haematology
information resource reference: Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(2):222-9.
journal title abbreviation: Br J Haematol
publication date: 2008-08-18T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
PubMed Identifier: 18753647
author list: San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson PG
published in: The New England journal of medicine
information resource reference: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 Aug 28; 359(9):906-17.
journal title abbreviation: N Engl J Med
publication date: 2008-08-28T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Epigenetic modulation in hematologic malignancies: challenges and progress.
PubMed Identifier: 19930971
author list: Mitsiades CS, Anderson KC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Epigenetic modulation in hematologic malignancies: challenges and progress. J Natl Compr Canc Netw. 2009 Nov; 7 Suppl 8:S1-12; quiz S14-6.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2009-11-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
PubMed Identifier: 20371718
author list: Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N
published in: Molecular cancer therapeutics
information resource reference: Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. Mol Cancer Ther. 2010 Apr; 9(4):963-75.
journal title abbreviation: Mol Cancer Ther
publication date: 2010-04-06T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.
PubMed Identifier: 20956629
author list: Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol. 2010 Nov 20; 28(33):4976-84.
journal title abbreviation: J Clin Oncol
publication date: 2010-10-18T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Advances in biology of multiple myeloma: clinical applications.
PubMed Identifier: 15090448
author list: Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC
published in: Blood
information resource reference: Advances in biology of multiple myeloma: clinical applications. Blood. 2004 Aug 01; 104(3):607-18.
journal title abbreviation: Blood
publication date: 2004-04-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.
PubMed Identifier: 15217829
author list: Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Ishitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC
published in: Blood
information resource reference: VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis. Blood. 2004 Nov 01; 104(9):2886-92.
journal title abbreviation: Blood
publication date: 2004-06-24T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
PubMed Identifier: 15355895
author list: Dring AM, Davies FE, Fenton JA, Roddam PL, Scott K, Gonzalez D, Rollinson S, Rawstron AC, Rees-Unwin KS, Li C, Munshi NC, Anderson KC, Morgan GJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 Sep 01; 10(17):5692-701.
journal title abbreviation: Clin Cancer Res
publication date: 2004-09-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.
PubMed Identifier: 15735676
author list: Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, Kumar S, Podar K, Mitsiades C, Hideshima H, Bonham L, Munshi NC, Richardson PG, Singer JW, Anderson KC
published in: Oncogene
information resource reference: Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9.
journal title abbreviation: Oncogene
publication date: 2005-04-28T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.
PubMed Identifier: 15802527
author list: Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC
published in: Blood
information resource reference: SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12.
journal title abbreviation: Blood
publication date: 2005-03-31T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel biological therapies for the treatment of multiple myeloma.
PubMed Identifier: 16026741
author list: Richardson PG, Mitsiades CS, Hideshima T, Anderson KC
published in: Best practice & research. Clinical haematology
information resource reference: Novel biological therapies for the treatment of multiple myeloma. Best Pract Res Clin Haematol. 2005; 18(4):619-34.
journal title abbreviation: Best Pract Res Clin Haematol
publication date: 2005-01-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
PubMed Identifier: 16103102
author list: Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC
published in: Cancer research
information resource reference: FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance. Cancer Res. 2005 Aug 15; 65(16):7478-84.
journal title abbreviation: Cancer Res
publication date: 2005-08-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Dysfunctional T regulatory cells in multiple myeloma.
PubMed Identifier: 16150935
author list: Prabhala RH, Neri P, Bae JE, Tassone P, Shammas MA, Allam CK, Daley JF, Chauhan D, Blanchard E, Thatte HS, Anderson KC, Munshi NC
published in: Blood
information resource reference: Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4.
journal title abbreviation: Blood
publication date: 2005-09-08T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Emerging trends in the clinical use of bortezomib in multiple myeloma.
PubMed Identifier: 16231845
author list: Richardson PG, Schlossman R, Mitsiades C, Hideshima T, Munshi N, Anderson K
published in: Clinical lymphoma & myeloma
information resource reference: Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8.
journal title abbreviation: Clin Lymphoma Myeloma
publication date: 2005-09-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib: a novel therapy approved for multiple myeloma.
PubMed Identifier: 16258456
author list: Richardson PG, Anderson KC
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol. 2003 Oct; 1(10):596-600.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2003-10-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.
PubMed Identifier: 18986387
author list: Lee SJ, Richardson PG, Sonneveld P, Schuster MW, Irwin D, San Miguel JF, Crawford B, Massaro J, Dhawan R, Gupta S, Anderson KC
published in: British journal of haematology
information resource reference: Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study. Br J Haematol. 2008 Nov; 143(4):511-9.
journal title abbreviation: Br J Haematol
publication date: 2008-11-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.
PubMed Identifier: 19164601
author list: Bianchi G, Oliva L, Cascio P, Pengo N, Fontana F, Cerruti F, Orsi A, Pasqualetto E, Mezghrani A, Calbi V, Palladini G, Giuliani N, Anderson KC, Sitia R, Cenci S
published in: Blood
information resource reference: The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition. Blood. 2009 Mar 26; 113(13):3040-9.
journal title abbreviation: Blood
publication date: 2009-01-22T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
PubMed Identifier: 19509164
author list: Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
journal title abbreviation: Clin Cancer Res
publication date: 2009-06-09T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
PubMed Identifier: 17032924
author list: Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC
published in: Blood
information resource reference: Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7.
journal title abbreviation: Blood
publication date: 2006-10-10T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.
PubMed Identifier: 20805366
author list: Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC
published in: Blood
information resource reference: A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood. 2010 Dec 02; 116(23):4906-15.
journal title abbreviation: Blood
publication date: 2010-08-30T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

New proteasome inhibitors in myeloma.
PubMed Identifier: 23065395
author list: Lawasut P, Chauhan D, Laubach J, Hayes C, Fabre C, Maglio M, Mitsiades C, Hideshima T, Anderson KC, Richardson PG
published in: Current hematologic malignancy reports
information resource reference: New proteasome inhibitors in myeloma. Curr Hematol Malig Rep. 2012 Dec; 7(4):258-66.
journal title abbreviation: Curr Hematol Malig Rep
publication date: 2012-12-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.
PubMed Identifier: 23221771
author list: Cea M, Cagnetta A, Patrone F, Nencioni A, Gobbi M, Anderson KC
published in: Autophagy
information resource reference: Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells. Autophagy. 2013 Mar; 9(3):410-2.
journal title abbreviation: Autophagy
publication date: 2013-03-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

The emerging role of novel therapies for the treatment of relapsed myeloma.
PubMed Identifier: 17335684
author list: Richardson PG, Hideshima T, Mitsiades C, Anderson KC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: The emerging role of novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw. 2007 Feb; 5(2):149-62.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2007-02-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.
PubMed Identifier: 17760810
author list: Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC
published in: British journal of haematology
information resource reference: Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91.
journal title abbreviation: Br J Haematol
publication date: 2007-09-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.
PubMed Identifier: 16754936
author list: Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, Singhal S, Siegel DS, Irwin D, Schuster M, Srkalovic G, Alexanian R, Rajkumar SV, Limentani S, Alsina M, Orlowski RZ, Najarian K, Esseltine D, Anderson KC, Amato AA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006 Jul 01; 24(19):3113-20.
journal title abbreviation: J Clin Oncol
publication date: 2006-06-05T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1064891
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.

Authorship 1064321
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.

Authorship 1066033
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.

Authorship 1064043
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

Authorship 1064293
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.

Authorship 1066427
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Meaningful changes in end-of-life care among patients with myeloma.

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.
PubMed Identifier: 29740809
author list: O'Donnell EK, Laubach JP, Yee AJ, Chen T, Huff CA, Basile FG, Wade PM, Paba-Prada CE, Ghobrial IM, Schlossman RL, Burke JN, Harrington CC, Lively KJ, Lyons HF, Munshi NC, Anderson KC, Trippa L, Richardson PG, Raje NS
published in: British journal of haematology
information resource reference: A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
journal title abbreviation: Br J Haematol
publication date: 2018-05-08T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing.
PubMed Identifier: 29749395
author list: Guo G, Raje NS, Seifer C, Kloeber J, Isenhart R, Ha G, Yee AJ, O'Donnell EK, Tai YT, Richardson PG, Bianchi G, Laubach JP, Warren D, Gemme E, Voisine J, Frede J, Kokkalis A, Yun H, Dimitrova V, Vijaykumar T, Meyerson M, Munshi NC, Anderson KC, Knoechel B, Lohr JG
published in: Leukemia
information resource reference: Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
journal title abbreviation: Leukemia
publication date: 2018-03-27T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
PubMed Identifier: 28735890
author list: van Beers EH, van Vliet MH, Kuiper R, de Best L, Anderson KC, Chari A, Jagannath S, Jakubowiak A, Kumar SK, Levy JB, Auclair D, Lonial S, Reece D, Richardson P, Siegel DS, Stewart AK, Trudel S, Vij R, Zimmerman TM, Fonseca R
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2017 09; 17(9):555-562.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2017-07-04T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma.
PubMed Identifier: 29749396
author list: Samur MK, Minvielle S, Gulla A, Fulciniti M, Cleynen A, Aktas Samur A, Szalat R, Shammas M, Magrangeas F, Tai YT, Auclair D, Keats J, Richardson P, Attal M, Moreau P, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC
published in: Leukemia
information resource reference: Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
journal title abbreviation: Leukemia
publication date: 2018-03-29T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
PubMed Identifier: 29748955
author list: Varga C, Laubach JP, Anderson KC, Richardson PG
published in: British journal of haematology
information resource reference: Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma. Br J Haematol. 2018 05; 181(4):433-446.
journal title abbreviation: Br J Haematol
publication date: 2018-05-10T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Meaningful changes in end-of-life care among patients with myeloma.
PubMed Identifier: 29748440
author list: Odejide OO, Li L, Cronin AM, Murillo A, Richardson PG, Anderson KC, Abel GA
published in: Haematologica
information resource reference: Meaningful changes in end-of-life care among patients with myeloma. Haematologica. 2018 08; 103(8):1380-1389.
journal title abbreviation: Haematologica
publication date: 2018-05-10T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.
PubMed Identifier: 17241924
author list: Koreth J, Cutler CS, Djulbegovic B, Behl R, Schlossman RL, Munshi NC, Richardson PG, Anderson KC, Soiffer RJ, Alyea EP
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2007-02-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Hematology: Thalidomide maintenance in multiple myeloma.
PubMed Identifier: 19787000
author list: Laubach JP, Richardson PG, Anderson KC
published in: Nature reviews. Clinical oncology
information resource reference: Hematology: Thalidomide maintenance in multiple myeloma. Nat Rev Clin Oncol. 2009 Oct; 6(10):565-6.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2009-10-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
PubMed Identifier: 19934301
author list: Fulciniti M, Hideshima T, Vermot-Desroches C, Pozzi S, Nanjappa P, Shen Z, Patel N, Smith ES, Wang W, Prabhala R, Tai YT, Tassone P, Anderson KC, Munshi NC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 01; 15(23):7144-52.
journal title abbreviation: Clin Cancer Res
publication date: 2009-11-24T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.
PubMed Identifier: 19965618
author list: Driscoll JJ, Pelluru D, Lefkimmiatis K, Fulciniti M, Prabhala RH, Greipp PR, Barlogie B, Tai YT, Anderson KC, Shaughnessy JD, Annunziata CM, Munshi NC
published in: Blood
information resource reference: The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34.
journal title abbreviation: Blood
publication date: 2009-11-30T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.
PubMed Identifier: 20385792
author list: Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC
published in: Blood
information resource reference: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
journal title abbreviation: Blood
publication date: 2010-04-12T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1067357
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.

Authorship 1068819
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.

Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups.
PubMed Identifier: 29789651
author list: Bolli N, Biancon G, Moarii M, Gimondi S, Li Y, de Philippis C, Maura F, Sathiaseelan V, Tai YT, Mudie L, O'Meara S, Raine K, Teague JW, Butler AP, Carniti C, Gerstung M, Bagratuni T, Kastritis E, Dimopoulos M, Corradini P, Anderson KC, Moreau P, Minvielle S, Campbell PJ, Papaemmanuil E, Avet-Loiseau H, Munshi NC
published in: Leukemia
information resource reference: Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018 12; 32(12):2604-2616.
journal title abbreviation: Leukemia
publication date: 2018-05-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era.
PubMed Identifier: 28725493
author list: Zhang L, Tai YT, Ho MZG, Qiu L, Anderson KC
published in: Experimental hematology & oncology
information resource reference: Interferon-alpha-based immunotherapies in the treatment of B cell-derived hematologic neoplasms in today's treat-to-target era. Exp Hematol Oncol. 2017; 6:20.
journal title abbreviation: Exp Hematol Oncol
publication date: 2017-07-14T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.
PubMed Identifier: 20652865
author list: Ghobrial IM, Xie W, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Poon T, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J
published in: American journal of hematology
information resource reference: Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia. Am J Hematol. 2010 Sep; 85(9):670-4.
journal title abbreviation: Am J Hematol
publication date: 2010-09-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.
PubMed Identifier: 20694078
author list: Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K
published in: Core evidence
information resource reference: Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
journal title abbreviation: Core Evid
publication date: 2010-06-15T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
PubMed Identifier: 21750699
author list: McMillin DW, Delmore J, Negri J, Ooi M, Klippel S, Miduturu CV, Gray NS, Richardson PG, Anderson KC, Kung AL, Mitsiades CS
published in: PloS one
information resource reference: Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation. PLoS One. 2011; 6(7):e20226.
journal title abbreviation: PLoS One
publication date: 2011-07-07T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.
PubMed Identifier: 12482878
author list: Podar K, Tai YT, Cole CE, Hideshima T, Sattler M, Hamblin A, Mitsiades N, Schlossman RL, Davies FE, Morgan GJ, Munshi NC, Chauhan D, Anderson KC
published in: The Journal of biological chemistry
information resource reference: Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801.
journal title abbreviation: J Biol Chem
publication date: 2002-12-12T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.
PubMed Identifier: 12720127
author list: Mitsiades CS, Mitsiades N, Treon SP, Anderson KC
published in: Seminars in oncology
information resource reference: Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias. Semin Oncol. 2003 Apr; 30(2):156-60.
journal title abbreviation: Semin Oncol
publication date: 2003-04-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1069454
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.

Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study.
PubMed Identifier: 29808907
author list: Jagannath S, Laubach J, Wong E, Stockerl-Goldstein K, Rosenbaum C, Dhodapkar M, Jou YM, Lynch M, Robbins M, Shelat S, Anderson KC, Richardson PG
published in: British journal of haematology
information resource reference: Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol. 2018 08; 182(4):495-503.
journal title abbreviation: Br J Haematol
publication date: 2018-05-29T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.
PubMed Identifier: 14559802
author list: Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 10 01; 63(19):6187-94.
journal title abbreviation: Cancer Res
publication date: 2003-10-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.
PubMed Identifier: 21482978
author list: Mitsiades CS, Davies FE, Laubach JP, Joshua D, San Miguel J, Anderson KC, Richardson PG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma. J Clin Oncol. 2011 May 10; 29(14):1916-23.
journal title abbreviation: J Clin Oncol
publication date: 2011-04-11T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.
PubMed Identifier: 21851215
author list: Siegel D, Jagannath S, Vesole DH, Borello I, Mazumder A, Mitsiades C, Goddard J, Dunbar J, Normant E, Adams J, Grayzel D, Anderson KC, Richardson P
published in: Leukemia & lymphoma
information resource reference: A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma. Leuk Lymphoma. 2011 Dec; 52(12):2308-15.
journal title abbreviation: Leuk Lymphoma
publication date: 2011-08-18T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of relapsed and relapsed/refractory multiple myeloma.
PubMed Identifier: 21975917
author list: Laubach JP, Mitsiades CS, Mahindra A, Luskin MR, Rosenblatt J, Ghobrial IM, Schlossman RL, Avigan D, Raje N, Munshi NC, Anderson KC, Richardson PG
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2011-10-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.
PubMed Identifier: 22072815
author list: Hideshima T, Richardson PG, Anderson KC
published in: Molecular cancer therapeutics
information resource reference: Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 2011 Nov; 10(11):2034-42.
journal title abbreviation: Mol Cancer Ther
publication date: 2011-11-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target?
PubMed Identifier: 22745468
author list: Mahindra A, Anderson KC
published in: Journal of the National Cancer Institute
information resource reference: Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target? J Natl Cancer Inst. 2012 Jul 03; 104(13):964-5.
journal title abbreviation: J Natl Cancer Inst
publication date: 2012-06-28T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Dual inhibition of canonical and noncanonical NF-?B pathways demonstrates significant antitumor activities in multiple myeloma.
PubMed Identifier: 22806876
author list: Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Dual inhibition of canonical and noncanonical NF-?B pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012 Sep 01; 18(17):4669-81.
journal title abbreviation: Clin Cancer Res
publication date: 2012-07-17T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

How I treat plasma cell leukemia.
PubMed Identifier: 22837533
author list: van de Donk NW, Lokhorst HM, Anderson KC, Richardson PG
published in: Blood
information resource reference: How I treat plasma cell leukemia. Blood. 2012 Sep 20; 120(12):2376-89.
journal title abbreviation: Blood
publication date: 2012-07-26T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.
PubMed Identifier: 14647474
author list: Hideshima T, Hayashi T, Chauhan D, Akiyama M, Richardson P, Anderson K
published in: Oncogene
information resource reference: Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines. Oncogene. 2003 Nov 27; 22(54):8797-801.
journal title abbreviation: Oncogene
publication date: 2003-11-27T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Mcl-1 regulation and its role in multiple myeloma.
PubMed Identifier: 15467463
author list: Le Gouill S, Podar K, Harousseau JL, Anderson KC
published in: Cell cycle (Georgetown, Tex.)
information resource reference: Mcl-1 regulation and its role in multiple myeloma. Cell Cycle. 2004 Oct; 3(10):1259-62.
journal title abbreviation: Cell Cycle
publication date: 2004-10-03T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibitor therapy in multiple myeloma.
PubMed Identifier: 15827343
author list: Chauhan D, Hideshima T, Mitsiades C, Richardson P, Anderson KC
published in: Molecular cancer therapeutics
information resource reference: Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther. 2005 Apr; 4(4):686-92.
journal title abbreviation: Mol Cancer Ther
publication date: 2005-04-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
PubMed Identifier: 16091734
author list: Chen J, Lee BH, Williams IR, Kutok JL, Mitsiades CS, Duclos N, Cohen S, Adelsperger J, Okabe R, Coburn A, Moore S, Huntly BJ, Fabbro D, Anderson KC, Griffin JD, Gilliland DG
published in: Oncogene
information resource reference: FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies. Oncogene. 2005 Dec 15; 24(56):8259-67.
journal title abbreviation: Oncogene
publication date: 2005-12-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.
PubMed Identifier: 16099887
author list: Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, Jaye DL, Francis D, Giusti S, Torre C, Barlogie B, Berenson JR, Singhal S, Schenkein DP, Esseltine DL, Anderson J, Xiao H, Heffner LT, Anderson KC
published in: Blood
information resource reference: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood. 2005 Dec 01; 106(12):3777-84.
journal title abbreviation: Blood
publication date: 2005-08-11T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
PubMed Identifier: 16397231
author list: Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC
published in: Cancer research
information resource reference: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res. 2006 Jan 01; 66(1):184-91.
journal title abbreviation: Cancer Res
publication date: 2006-01-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).
PubMed Identifier: 17023575
author list: Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, Lin BK, Munshi N, Hideshima T, Chauhan D, Anderson KC
published in: Blood
information resource reference: Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15; 109(4):1669-77.
journal title abbreviation: Blood
publication date: 2006-10-05T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.
PubMed Identifier: 17284528
author list: Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, Leontovich A, Podar K, Kutok J, Daley J, Lazo-Kallanian S, Hatjiharissi E, Raab MS, Xu L, Treon SP, Hideshima T, Anderson KC, Ghobrial IM
published in: Blood
information resource reference: Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood. 2007 Jun 01; 109(11):4964-72.
journal title abbreviation: Blood
publication date: 2007-02-06T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.
PubMed Identifier: 11395643
author list: Treon SP, Mitsiades C, Mitsiades N, Young G, Doss D, Schlossman R, Anderson KC
published in: Journal of immunotherapy : official journal of the Society for Biological Therapy
information resource reference: Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies. J Immunother (1991). 2001 May; 24(3):263-271.
journal title abbreviation: J Immunother (1991)
publication date: 2001-05-01T00:00:00
year: 2001
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.
PubMed Identifier: 11857078
author list: Chauhan D, Auclair D, Robinson EK, Hideshima T, Li G, Podar K, Gupta D, Richardson P, Schlossman RL, Krett N, Chen LB, Munshi NC, Anderson KC
published in: Oncogene
information resource reference: Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58.
journal title abbreviation: Oncogene
publication date: 2002-02-21T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.
PubMed Identifier: 12433678
author list: Tai YT, Podar K, Mitsiades N, Lin B, Mitsiades C, Gupta D, Akiyama M, Catley L, Hideshima T, Munshi NC, Treon SP, Anderson KC
published in: Blood
information resource reference: CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9.
journal title abbreviation: Blood
publication date: 2002-11-14T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1073079
type: Authorship
author rank in publication: 35
linked author: Anderson, Kenneth
linked information resource: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.
PubMed Identifier: 29884741
author list: Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ
published in: Blood
information resource reference: Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597.
journal title abbreviation: Blood
publication date: 2018-06-08T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 113460
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials.

Authorship 1077867
type: Authorship
author rank in publication: 35
linked author: Anderson, Kenneth
linked information resource: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.
PubMed Identifier: 29967379
author list: Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G
published in: Leukemia
information resource reference: A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170.
journal title abbreviation: Leukemia
publication date: 2018-07-02T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation.
PubMed Identifier: 22267603
author list: Biernacki MA, Tai YT, Zhang GL, Alonso A, Zhang W, Prabhala R, Zhang L, Munshi N, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Brusic V, Anderson KC, Wu CJ
published in: Blood
information resource reference: Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
journal title abbreviation: Blood
publication date: 2012-01-20T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.
PubMed Identifier: 22689860
author list: Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao JJ, Cagnetta A, Cea M, Sellitto MA, Zhong MY, Wang Q, Acharya C, Carrasco DR, Buggy JJ, Elias L, Treon SP, Matsui W, Richardson P, Munshi NC, Anderson KC
published in: Blood
information resource reference: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87.
journal title abbreviation: Blood
publication date: 2012-06-11T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.
PubMed Identifier: 22821765
author list: Blotta S, Jakubikova J, Calimeri T, Roccaro AM, Amodio N, Azab AK, Foresta U, Mitsiades CS, Rossi M, Todoerti K, Molica S, Morabito F, Neri A, Tagliaferri P, Tassone P, Anderson KC, Munshi NC
published in: Blood
information resource reference: Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13; 120(25):5002-13.
journal title abbreviation: Blood
publication date: 2012-07-20T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Pathological crystallization of human immunoglobulins.
PubMed Identifier: 22847421
author list: Wang Y, Lomakin A, Hideshima T, Laubach JP, Ogun O, Richardson PG, Munshi NC, Anderson KC, Benedek GB
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2012-07-30T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.
PubMed Identifier: 23016853
author list: Cea M, Cagnetta A, Gobbi M, Patrone F, Richardson PG, Hideshima T, Anderson KC
published in: Current pharmaceutical design
information resource reference: New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. Curr Pharm Des. 2013; 19(4):734-44.
journal title abbreviation: Curr Pharm Des
publication date: 2013-01-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting proteasome inhibition in hematologic malignancies.
PubMed Identifier: 14763162
author list: Hideshima T, Richardson PG, Anderson KC
published in: Reviews in clinical and experimental hematology
information resource reference: Targeting proteasome inhibition in hematologic malignancies. Rev Clin Exp Hematol. 2003 Jun; 7(2):191-204.
journal title abbreviation: Rev Clin Exp Hematol
publication date: 2003-06-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.
PubMed Identifier: 14581890
author list: Richardson PG, Hideshima T, Anderson KC
published in: Cancer control : journal of the Moffitt Cancer Center
information resource reference: Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control. 2003 Sep-Oct; 10(5):361-9.
journal title abbreviation: Cancer Control
publication date: 2003-09-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.
PubMed Identifier: 15086415
author list: Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC
published in: British journal of haematology
information resource reference: Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br J Haematol. 2004 May; 125(3):343-52.
journal title abbreviation: Br J Haematol
publication date: 2004-05-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.
PubMed Identifier: 16020506
author list: Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Hideshima T, Xiao H, Esseltine D, Schenkein D, Anderson KC
published in: Blood
information resource reference: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood. 2005 Nov 01; 106(9):2977-81.
journal title abbreviation: Blood
publication date: 2005-07-14T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.
PubMed Identifier: 16206291
author list: Berenson JR, Jagannath S, Barlogie B, Siegel DT, Alexanian R, Richardson PG, Irwin D, Alsina M, Rajkumar SV, Srkalovic G, Singhal S, Limentani S, Niesvizky R, Esseltine DL, Trehu E, Schenkein DP, Anderson K
published in: Cancer
information resource reference: Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer. 2005 Nov 15; 104(10):2141-8.
journal title abbreviation: Cancer
publication date: 2005-11-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Antimyeloma activity of heat shock protein-90 inhibition.
PubMed Identifier: 16234364
author list: Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, Morgan G, Akiyama M, Shringarpure R, Munshi NC, Richardson PG, Hideshima T, Chauhan D, Gu X, Bailey C, Joseph M, Libermann TA, Rosen NS, Anderson KC
published in: Blood
information resource reference: Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100.
journal title abbreviation: Blood
publication date: 2005-10-18T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
PubMed Identifier: 16344096
author list: Anderson KC, Prince HM
published in: Seminars in hematology
information resource reference: Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma. Semin Hematol. 2005 Oct; 42(4 Suppl 4):S1-2.
journal title abbreviation: Semin Hematol
publication date: 2005-10-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.
PubMed Identifier: 16616336
author list: Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Brennan C, Depinho RA
published in: Cancer cell
information resource reference: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell. 2006 Apr; 9(4):313-25.
journal title abbreviation: Cancer Cell
publication date: 2006-04-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.
PubMed Identifier: 16778216
author list: Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, Irvine AE
published in: Cancer research
information resource reference: Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res. 2006 Jun 15; 66(12):6379-86.
journal title abbreviation: Cancer Res
publication date: 2006-06-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Emerging drugs in multiple myeloma.
PubMed Identifier: 17355220
author list: Ghobrial IM, Leleu X, Hatjiharissi E, Hideshima T, Mitsiades C, Schlossman R, Anderson KC, Richardson P
published in: Expert opinion on emerging drugs
information resource reference: Emerging drugs in multiple myeloma. Expert Opin Emerg Drugs. 2007 Mar; 12(1):155-63.
journal title abbreviation: Expert Opin Emerg Drugs
publication date: 2007-03-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
PubMed Identifier: 17379101
author list: Anderson KC
published in: Experimental hematology
information resource reference: Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol. 2007 Apr; 35(4 Suppl 1):155-62.
journal title abbreviation: Exp Hematol
publication date: 2007-04-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteomic analysis of waldenstrom macroglobulinemia.
PubMed Identifier: 17440091
author list: Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, George D, Lu G, Ghobrial J, Alsayed Y, Zeismer S, Cabanela M, Nehme A, Jia X, Moreau AS, Treon SP, Fonseca R, Gertz MA, Anderson KC, Witzig TE, Ghobrial IM
published in: Cancer research
information resource reference: Proteomic analysis of waldenstrom macroglobulinemia. Cancer Res. 2007 Apr 15; 67(8):3777-84.
journal title abbreviation: Cancer Res
publication date: 2007-04-15T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.
PubMed Identifier: 17451408
author list: Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, San Miguel JF, Cavenagh JD, Anderson KC
published in: British journal of haematology
information resource reference: Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol. 2007 Jun; 137(5):429-35.
journal title abbreviation: Br J Haematol
publication date: 2007-04-19T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.
PubMed Identifier: 18824601
author list: Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H, Chauhan D, Anderson KC, Frank DA
published in: Blood
information resource reference: Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood. 2008 Dec 15; 112(13):5095-102.
journal title abbreviation: Blood
publication date: 2008-09-29T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
PubMed Identifier: 19018094
author list: Raab MS, Breitkreutz I, Tonon G, Zhang J, Hayden PJ, Nguyen T, Fruehauf JH, Lin BK, Chauhan D, Hideshima T, Munshi NC, Anderson KC, Podar K
published in: Blood
information resource reference: Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21.
journal title abbreviation: Blood
publication date: 2008-11-18T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 110755
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.

CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.
PubMed Identifier: 19196658
author list: Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, Li XF, Burger P, Rumizen MJ, Nahar S, Podar K, Hideshima T, Munshi NC, Tonon G, Carrasco RD, Afar DE, Anderson KC
published in: Blood
information resource reference: CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30; 113(18):4309-18.
journal title abbreviation: Blood
publication date: 2009-02-04T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.
PubMed Identifier: 19401561
author list: Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM
published in: Blood
information resource reference: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009 Jun 25; 113(26):6669-80.
journal title abbreviation: Blood
publication date: 2009-04-28T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.
PubMed Identifier: 20142586
author list: Ghobrial IM, Hong F, Padmanabhan S, Badros A, Rourke M, Leduc R, Chuma S, Kunsman J, Warren D, Harris B, Sam A, Anderson KC, Richardson PG, Treon SP, Weller E, Matous J
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1422-8.
journal title abbreviation: J Clin Oncol
publication date: 2010-02-08T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
PubMed Identifier: 20228816
author list: McMillin DW, Delmore J, Weisberg E, Negri JM, Geer DC, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS
published in: Nature medicine
information resource reference: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
journal title abbreviation: Nat Med
publication date: 2010-03-14T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.
PubMed Identifier: 20618338
author list: Richardson PG, Badros AZ, Jagannath S, Tarantolo S, Wolf JL, Albitar M, Berman D, Messina M, Anderson KC
published in: British journal of haematology
information resource reference: Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma. Br J Haematol. 2010 Aug; 150(4):428-37.
journal title abbreviation: Br J Haematol
publication date: 2010-07-07T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1081004
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.

Authorship 1082536
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Promise of Immune Therapies in Multiple Myeloma.

Promise of Immune Therapies in Multiple Myeloma.
PubMed Identifier: 29996072
author list: Anderson KC
published in: Journal of oncology practice
information resource reference: Promise of Immune Therapies in Multiple Myeloma. J Oncol Pract. 2018 07; 14(7):411-413.
journal title abbreviation: J Oncol Pract
publication date: 2018-07-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
PubMed Identifier: 30026574
author list: Liu J, Song T, Zhou W, Xing L, Wang S, Ho M, Peng Z, Tai YT, Hideshima T, Anderson KC, Cang Y
published in: Leukemia
information resource reference: A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity. Leukemia. 2019 01; 33(1):171-180.
journal title abbreviation: Leukemia
publication date: 2018-07-19T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.
PubMed Identifier: 16988581
author list: Richardson PG, Mitsiades C, Ghobrial I, Anderson K
published in: Current opinion in oncology
information resource reference: Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma. Curr Opin Oncol. 2006 Nov; 18(6):598-608.
journal title abbreviation: Curr Opin Oncol
publication date: 2006-11-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
PubMed Identifier: 17164332
author list: Podar K, Tonon G, Sattler M, Tai YT, Legouill S, Yasui H, Ishitsuka K, Kumar S, Kumar R, Pandite LN, Hideshima T, Chauhan D, Anderson KC
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci U S A. 2006 Dec 19; 103(51):19478-83.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2006-12-12T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.
PubMed Identifier: 17308109
author list: Podar K, Raab MS, Tonon G, Sattler M, Barilà D, Zhang J, Tai YT, Yasui H, Raje N, DePinho RA, Hideshima T, Chauhan D, Anderson KC
published in: Cancer research
information resource reference: Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res. 2007 Feb 15; 67(4):1680-8.
journal title abbreviation: Cancer Res
publication date: 2007-02-15T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.
PubMed Identifier: 18006697
author list: Chauhan D, Singh A, Brahmandam M, Podar K, Hideshima T, Richardson P, Munshi N, Palladino MA, Anderson KC
published in: Blood
information resource reference: Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64.
journal title abbreviation: Blood
publication date: 2007-11-15T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.
PubMed Identifier: 18245550
author list: Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
journal title abbreviation: Clin Cancer Res
publication date: 2008-02-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.
PubMed Identifier: 18347188
author list: Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia. Clin Cancer Res. 2008 Mar 15; 14(6):1849-58.
journal title abbreviation: Clin Cancer Res
publication date: 2008-03-15T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Moving toward individualized cancer therapies.
PubMed Identifier: 18676734
author list: Tonon G, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Moving toward individualized cancer therapies. Clin Cancer Res. 2008 Aug 01; 14(15):4682-4.
journal title abbreviation: Clin Cancer Res
publication date: 2008-08-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Thalidomide and rituximab in Waldenstrom macroglobulinemia.
PubMed Identifier: 18713945
author list: Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Briccetti FM, Pasmantier M, Zimbler H, Cooper RB, Moore M, Hill J, Rauch A, Garbo L, Chu L, Chua C, Nantel SH, Lovett DR, Boedeker H, Sonneborn H, Howard J, Musto P, Ciccarelli BT, Hatjiharissi E, Anderson KC
published in: Blood
information resource reference: Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7.
journal title abbreviation: Blood
publication date: 2008-08-19T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.
PubMed Identifier: 22983447
author list: Tian Z, Zhao JJ, Tai YT, Amin SB, Hu Y, Berger AJ, Richardson P, Chauhan D, Anderson KC
published in: Blood
information resource reference: Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells. Blood. 2012 Nov 08; 120(19):3958-67.
journal title abbreviation: Blood
publication date: 2012-09-14T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.
PubMed Identifier: 23287861
author list: Ghobrial IM, Campigotto F, Murphy TJ, Boswell EN, Banwait R, Azab F, Chuma S, Kunsman J, Donovan A, Masood F, Warren D, Rodig S, Anderson KC, Richardson PG, Weller E, Matous J
published in: Blood
information resource reference: Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21; 121(8):1296-303.
journal title abbreviation: Blood
publication date: 2013-01-03T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
PubMed Identifier: 19139079
author list: Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM
published in: Blood
information resource reference: CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
journal title abbreviation: Blood
publication date: 2009-01-12T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.
PubMed Identifier: 19452315
author list: Laubach JP, Mitsiades CS, Roccaro AM, Ghobrial IM, Anderson KC, Richardson PG
published in: Leukemia & lymphoma
information resource reference: Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia. Leuk Lymphoma. 2009 May; 50(5):694-702.
journal title abbreviation: Leuk Lymphoma
publication date: 2009-05-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 117168
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Bortezomib: a novel therapy approved for multiple myeloma.

NCCN clinical practice guidelines in oncology: multiple myeloma.
PubMed Identifier: 19878637
author list: Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN clinical practice guidelines in oncology: multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):908-42.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2009-10-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomic patterns of progression in smoldering multiple myeloma.
PubMed Identifier: 30135448
author list: Bolli N, Maura F, Minvielle S, Gloznik D, Szalat R, Fullam A, Martincorena I, Dawson KJ, Samur MK, Zamora J, Tarpey P, Davies H, Fulciniti M, Shammas MA, Tai YT, Magrangeas F, Moreau P, Corradini P, Anderson K, Alexandrov L, Wedge DC, Avet-Loiseau H, Campbell P, Munshi N
published in: Nature communications
information resource reference: Genomic patterns of progression in smoldering multiple myeloma. Nat Commun. 2018 08 22; 9(1):3363.
journal title abbreviation: Nat Commun
publication date: 2018-08-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
PubMed Identifier: 30135465
author list: Tai YT, Lin L, Xing L, Cho SF, Yu T, Acharya C, Wen K, Hsieh PA, Dulos J, van Elsas A, Munshi N, Richardson P, Anderson KC
published in: Leukemia
information resource reference: APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438.
journal title abbreviation: Leukemia
publication date: 2018-08-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
PubMed Identifier: 30131388
author list: Kinneer K, Meekin J, Tiberghien AC, Tai YT, Phipps S, Kiefer CM, Rebelatto MC, Dimasi N, Moriarty A, Papadopoulos KP, Sridhar S, Gregson SJ, Wick MJ, Masterson L, Anderson KC, Herbst R, Howard PW, Tice DA
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads. Clin Cancer Res. 2018 12 15; 24(24):6570-6582.
journal title abbreviation: Clin Cancer Res
publication date: 2018-08-21T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.
PubMed Identifier: 19170677
author list: Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Boral AL, Esseltine DL, Wen PY, Amato AA, Anderson KC, San Miguel J
published in: British journal of haematology
information resource reference: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009 Mar; 144(6):895-903.
journal title abbreviation: Br J Haematol
publication date: 2009-01-16T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?
PubMed Identifier: 19231786
author list: Mawardi H, Treister N, Richardson P, Anderson K, Munshi N, Faiella RA, Woo SB
published in: Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
information resource reference: Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar; 67(3):593-601.
journal title abbreviation: J Oral Maxillofac Surg
publication date: 2009-03-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Emerging therapies for multiple myeloma.
PubMed Identifier: 19249983
author list: Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC
published in: Expert opinion on emerging drugs
information resource reference: Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar; 14(1):99-127.
journal title abbreviation: Expert Opin Emerg Drugs
publication date: 2009-03-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.
PubMed Identifier: 19330029
author list: van Haaften G, Dalgliesh GL, Davies H, Chen L, Bignell G, Greenman C, Edkins S, Hardy C, O'Meara S, Teague J, Butler A, Hinton J, Latimer C, Andrews J, Barthorpe S, Beare D, Buck G, Campbell PJ, Cole J, Forbes S, Jia M, Jones D, Kok CY, Leroy C, Lin ML, McBride DJ, Maddison M, Maquire S, McLay K, Menzies A, Mironenko T, Mulderrig L, Mudie L, Pleasance E, Shepherd R, Smith R, Stebbings L, Stephens P, Tang G, Tarpey PS, Turner R, Turrell K, Varian J, West S, Widaa S, Wray P, Collins VP, Ichimura K, Law S, Wong J, Yuen ST, Leung SY, Tonon G, DePinho RA, Tai YT, Anderson KC, Kahnoski RJ, Massie A, Khoo SK, Teh BT, Stratton MR, Futreal PA
published in: Nature genetics
information resource reference: Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet. 2009 May; 41(5):521-3.
journal title abbreviation: Nat Genet
publication date: 2009-03-29T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1089351
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.

Authorship 1089722
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.

In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.
PubMed Identifier: 19751238
author list: Negri JM, McMillin DW, Delmore J, Mitsiades N, Hayden P, Klippel S, Hideshima T, Chauhan D, Munshi NC, Buser CA, Pollard J, Richardson PG, Anderson KC, Mitsiades CS
published in: British journal of haematology
information resource reference: In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.
journal title abbreviation: Br J Haematol
publication date: 2009-09-14T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.
PubMed Identifier: 19934289
author list: Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.
journal title abbreviation: Clin Cancer Res
publication date: 2009-11-24T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.
PubMed Identifier: 20505158
author list: Ikeda H, Hideshima T, Fulciniti M, Perrone G, Miura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cristea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC
published in: Blood
information resource reference: PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8.
journal title abbreviation: Blood
publication date: 2010-05-26T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.
PubMed Identifier: 20651070
author list: Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC
published in: Blood
information resource reference: Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
journal title abbreviation: Blood
publication date: 2010-07-22T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.
PubMed Identifier: 21365752
author list: Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P
published in: Proteomics
information resource reference: A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics. 2011 Apr; 11(8):1391-402.
journal title abbreviation: Proteomics
publication date: 2011-02-25T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Antibody-based therapies in multiple myeloma.
PubMed Identifier: 22046572
author list: Tai YT, Anderson KC
published in: Bone marrow research
information resource reference: Antibody-based therapies in multiple myeloma. Bone Marrow Res. 2011; 2011:924058.
journal title abbreviation: Bone Marrow Res
publication date: 2011-03-02T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Latest advances and current challenges in the treatment of multiple myeloma.
PubMed Identifier: 22349016
author list: Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K
published in: Nature reviews. Clinical oncology
information resource reference: Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2012-02-21T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.
PubMed Identifier: 22474168
author list: Rickles RJ, Tam WF, Giordano TP, Pierce LT, Farwell M, McMillin DW, Necheva A, Crowe D, Chen M, Avery W, Kansra V, Nawrocki ST, Carew JS, Giles FJ, Mitsiades CS, Borisy AA, Anderson KC, Lee MS
published in: Molecular cancer therapeutics
information resource reference: Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening. Mol Cancer Ther. 2012 Jul; 11(7):1432-42.
journal title abbreviation: Mol Cancer Ther
publication date: 2012-04-03T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1090430
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.

Authorship 1090531
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.

Authorship 1089967
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.

The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease.
PubMed Identifier: 30148829
author list: Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC, Richardson PG
published in: Clinical advances in hematology & oncology : H&O
information resource reference: The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2018-08-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1.
PubMed Identifier: 30147691
author list: Tai YT, Cho SF, Anderson KC
published in: Frontiers in immunology
information resource reference: Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1. Front Immunol. 2018; 9:1822.
journal title abbreviation: Front Immunol
publication date: 2018-08-10T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
PubMed Identifier: 30147690
author list: Cho SF, Anderson KC, Tai YT
published in: Frontiers in immunology
information resource reference: Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol. 2018; 9:1821.
journal title abbreviation: Front Immunol
publication date: 2018-08-10T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.
PubMed Identifier: 23150997
author list: Owen RG, Kyle RA, Stone MJ, Rawstron AC, Leblond V, Merlini G, Garcia-Sanz R, Ocio EM, Morra E, Morel P, Anderson KC, Patterson CJ, Munshi NC, Tedeschi A, Joshua DE, Kastritis E, Terpos E, Ghobrial IM, Leleu X, Gertz MA, Ansell SM, Morice WG, Kimby E, Treon SP
published in: British journal of haematology
information resource reference: Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
journal title abbreviation: Br J Haematol
publication date: 2012-11-15T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1091636
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: The biological significance of histone modifiers in multiple myeloma: clinical applications.

The biological significance of histone modifiers in multiple myeloma: clinical applications.
PubMed Identifier: 30190472
author list: Ohguchi H, Hideshima T, Anderson KC
published in: Blood cancer journal
information resource reference: The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2018 08 22; 8(9):83.
journal title abbreviation: Blood Cancer J
publication date: 2018-08-22T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.
PubMed Identifier: 20331453
author list: Singh AV, Palladino MA, Lloyd GK, Potts BC, Chauhan D, Anderson KC
published in: British journal of haematology
information resource reference: Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model. Br J Haematol. 2010 May; 149(4):550-9.
journal title abbreviation: Br J Haematol
publication date: 2010-03-12T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.
PubMed Identifier: 21223249
author list: McMillin DW, Delmore J, Negri J, Buon L, Jacobs HM, Laubach J, Jakubikova J, Ooi M, Hayden P, Schlossman R, Munshi NC, Lengauer C, Richardson PG, Anderson KC, Mitsiades CS
published in: British journal of haematology
information resource reference: Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
journal title abbreviation: Br J Haematol
publication date: 2011-01-11T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
PubMed Identifier: 21889194
author list: Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, Chesi M, Schinzel AC, McKeown MR, Heffernan TP, Vakoc CR, Bergsagel PL, Ghobrial IM, Richardson PG, Young RA, Hahn WC, Anderson KC, Kung AL, Bradner JE, Mitsiades CS
published in: Cell
information resource reference: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011 Sep 16; 146(6):904-17.
journal title abbreviation: Cell
publication date: 2011-09-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.
PubMed Identifier: 22246035
author list: Tai YT, Horton HM, Kong SY, Pong E, Chen H, Cemerski S, Bernett MJ, Nguyen DH, Karki S, Chu SY, Lazar GA, Munshi NC, Desjarlais JR, Anderson KC, Muchhal US
published in: Blood
information resource reference: Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 01; 119(9):2074-82.
journal title abbreviation: Blood
publication date: 2012-01-13T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.
PubMed Identifier: 22533610
author list: Bae J, Song W, Smith R, Daley J, Tai YT, Anderson KC, Munshi NC
published in: British journal of haematology
information resource reference: A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol. 2012 Jun; 157(6):687-701.
journal title abbreviation: Br J Haematol
publication date: 2012-04-26T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide after stem-cell transplantation for multiple myeloma.
PubMed Identifier: 22571201
author list: McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, Van Besien K, Gentile T, Isola L, Maziarz RT, Gabriel DA, Bashey A, Landau H, Martin T, Qazilbash MH, Levitan D, McClune B, Schlossman R, Hars V, Postiglione J, Jiang C, Bennett E, Barry S, Bressler L, Kelly M, Seiler M, Rosenbaum C, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Anderson KC, Linker C
published in: The New England journal of medicine
information resource reference: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 May 10; 366(19):1770-81.
journal title abbreviation: N Engl J Med
publication date: 2012-05-10T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting the UPS as therapy in multiple myeloma.
PubMed Identifier: 19007431
author list: Chauhan D, Bianchi G, Anderson KC
published in: BMC biochemistry
information resource reference: Targeting the UPS as therapy in multiple myeloma. BMC Biochem. 2008 Oct 21; 9 Suppl 1:S1.
journal title abbreviation: BMC Biochem
publication date: 2008-10-21T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
PubMed Identifier: 19139110
author list: Burger R, Le Gouill S, Tai YT, Shringarpure R, Tassone P, Neri P, Podar K, Catley L, Hideshima T, Chauhan D, Caulder E, Neilan CL, Vaddi K, Li J, Gramatzki M, Fridman JS, Anderson KC
published in: Molecular cancer therapeutics
information resource reference: Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo. Mol Cancer Ther. 2009 Jan; 8(1):26-35.
journal title abbreviation: Mol Cancer Ther
publication date: 2009-01-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
PubMed Identifier: 19417213
author list: Fulciniti M, Tassone P, Hideshima T, Vallet S, Nanjappa P, Ettenberg SA, Shen Z, Patel N, Tai YT, Chauhan D, Mitsiades C, Prabhala R, Raje N, Anderson KC, Stover DR, Munshi NC
published in: Blood
information resource reference: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9.
journal title abbreviation: Blood
publication date: 2009-05-05T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
PubMed Identifier: 19436050
author list: Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC
published in: Blood
information resource reference: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52.
journal title abbreviation: Blood
publication date: 2009-05-12T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.
PubMed Identifier: 20404562
author list: Podar K, Anderson KC
published in: Cell cycle (Georgetown, Tex.)
information resource reference: A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways. Cell Cycle. 2010 May; 9(9):1722-8.
journal title abbreviation: Cell Cycle
publication date: 2010-05-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.
PubMed Identifier: 20518367
author list: Richardson PG, Laubach J, Mitsiades C, Schlossman RL, Doss D, Colson K, McKenney ML, Noonan K, Warren DL, Ghobrial IM, Munshi NC, Anderson K
published in: Oncology (Williston Park, N.Y.)
information resource reference: Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
journal title abbreviation: Oncology (Williston Park)
publication date: 2010-03-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.
PubMed Identifier: 20962322
author list: Gatt ME, Zhao JJ, Ebert MS, Zhang Y, Chu Z, Mani M, Gazit R, Carrasco DE, Dutta-Simmons J, Adamia S, Minvielle S, Tai YT, Munshi NC, Avet-Loiseau H, Anderson KC, Carrasco DR
published in: Blood
information resource reference: MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010 Oct 20.
journal title abbreviation: Blood
publication date: 2010-10-20T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1093908
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.

Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia.
PubMed Identifier: 30206161
author list: Li N, Lopez MA, Linares M, Kumar S, Oliva S, Martinez-Lopez J, Xu L, Xu Y, Perini T, Senapedis W, Baloglu E, Shammas MA, Hunter Z, Anderson KC, Treon SP, Munshi NC, Fulciniti M
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377.
journal title abbreviation: Clin Cancer Res
publication date: 2018-09-11T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
PubMed Identifier: 21322778
author list: Laubach JP, Schlossman RL, Mitsiades CS, Anderson KC, Richardson PG
published in: Expert review of hematology
information resource reference: Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma. Expert Rev Hematol. 2011 Feb; 4(1):51-60.
journal title abbreviation: Expert Rev Hematol
publication date: 2011-02-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.
PubMed Identifier: 21447828
author list: Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen HE, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, San Miguel J, Lonial S
published in: Blood
information resource reference: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011 Jun 09; 117(23):6063-73.
journal title abbreviation: Blood
publication date: 2011-03-29T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Tanespimycin as antitumor therapy.
PubMed Identifier: 21454186
author list: Dimopoulos MA, Mitsiades CS, Anderson KC, Richardson PG
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Tanespimycin as antitumor therapy. Clin Lymphoma Myeloma Leuk. 2011 Feb; 11(1):17-22.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2011-02-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.
PubMed Identifier: 22512706
author list: Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC
published in: Expert opinion on drug metabolism & toxicology
information resource reference: Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin Drug Metab Toxicol. 2012 May; 8(5):623-33.
journal title abbreviation: Expert Opin Drug Metab Toxicol
publication date: 2012-05-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.
PubMed Identifier: 23054875
author list: Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1211-9.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2012-10-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.
PubMed Identifier: 23074271
author list: Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA
published in: Blood
information resource reference: Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012 Dec 13; 120(25):4929-37.
journal title abbreviation: Blood
publication date: 2012-10-16T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/1107082
PubMed Identifier: 23321251
author list: Xu L, Hunter ZR, Yang G, Zhou Y, Cao Y, Liu X, Morra E, Trojani A, Greco A, Arcaini L, Varettoni M, Varettoni M, Brown JR, Tai YT, Anderson KC, Munshi NC, Patterson CJ, Manning RJ, Tripsas CK, Lindeman NI, Treon SP
published in: Blood
information resource reference: MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8.
journal title abbreviation: Blood
publication date: 2013-01-15T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource
label: MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.

Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.
PubMed Identifier: 23035210
author list: Di Martino MT, Leone E, Amodio N, Foresta U, Lionetti M, Pitari MR, Cantafio ME, Gullà A, Conforti F, Morelli E, Tomaino V, Rossi M, Negrini M, Ferrarini M, Caraglia M, Shammas MA, Munshi NC, Anderson KC, Neri A, Tagliaferri P, Tassone P
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012 Nov 15; 18(22):6260-70.
journal title abbreviation: Clin Cancer Res
publication date: 2012-10-03T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1096325
type: Authorship
author rank in publication: 33
linked author: Anderson, Kenneth
linked information resource: Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.

Authorship 1096657
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.

Accelerating anticancer drug development - opportunities and trade-offs.
PubMed Identifier: 30275514
author list: Nass SJ, Rothenberg ML, Pentz R, Hricak H, Abernethy A, Anderson K, Gee AW, Harvey RD, Piantadosi S, Bertagnolli MM, Schrag D, Schilsky RL
published in: Nature reviews. Clinical oncology
information resource reference: Accelerating anticancer drug development - opportunities and trade-offs. Nat Rev Clin Oncol. 2018 12; 15(12):777-786.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2018-12-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma.
PubMed Identifier: 30279233
author list: Laubach JP, Liu CJ, Raje NS, Yee AJ, Armand P, Schlossman RL, Rosenblatt J, Hedlund J, Martin M, Reynolds C, Shain KH, Zackon I, Stampleman L, Henrick P, Rivotto B, Hornburg KTV, Dumke HJ, Chuma S, Savell A, Handisides DR, Kroll S, Anderson KC, Richardson PG, Ghobrial IM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2019 01 15; 25(2):478-486.
journal title abbreviation: Clin Cancer Res
publication date: 2018-10-02T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
PubMed Identifier: 30249784
author list: Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, Dejoie T, Maheo S, Stoppa AM, Pegourie B, Karlin L, Garderet L, Arnulf B, Doyen C, Meuleman N, Royer B, Eveillard JR, Benboubker L, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Kolb B, Fohrer C, Mohty M, Macro M, Richardson PG, Carlton V, Moorhead M, Willis T, Faham M, Anderson KC, Harousseau JL, Leleu X, Facon T, Moreau P, Attal M, Avet-Loiseau H, Munshi N
published in: Blood
information resource reference: Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 12 06; 132(23):2456-2464.
journal title abbreviation: Blood
publication date: 2018-09-24T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

The role of immunomodulatory drugs in multiple myeloma.
PubMed Identifier: 15015893
author list: Anderson KC
published in: Seminars in hematology
information resource reference: The role of immunomodulatory drugs in multiple myeloma. Semin Hematol. 2003 Oct; 40(4 Suppl 4):23-32.
journal title abbreviation: Semin Hematol
publication date: 2003-10-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 134052
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Cytokines modulate telomerase activity in a human multiple myeloma cell line.

Focus on multiple myeloma.
PubMed Identifier: 15542427
author list: Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC
published in: Cancer cell
information resource reference: Focus on multiple myeloma. Cancer Cell. 2004 Nov; 6(5):439-44.
journal title abbreviation: Cancer Cell
publication date: 2004-11-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 13509
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: how far have we come?

Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
PubMed Identifier: 16140960
author list: Altun M, Galardy PJ, Shringarpure R, Hideshima T, LeBlanc R, Anderson KC, Ploegh HL, Kessler BM
published in: Cancer research
information resource reference: Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. Cancer Res. 2005 Sep 01; 65(17):7896-901.
journal title abbreviation: Cancer Res
publication date: 2005-09-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Caveolin-1 as a potential new therapeutic target in multiple myeloma.
PubMed Identifier: 16473666
author list: Podar K, Anderson KC
published in: Cancer letters
information resource reference: Caveolin-1 as a potential new therapeutic target in multiple myeloma. Cancer Lett. 2006 Feb 20; 233(1):10-5.
journal title abbreviation: Cancer Lett
publication date: 2006-02-20T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.
PubMed Identifier: 16765041
author list: Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC
published in: European journal of cancer (Oxford, England : 1990)
information resource reference: The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73.
journal title abbreviation: Eur J Cancer
publication date: 2006-06-09T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Inhibition of the TGF-beta signaling pathway in tumor cells.
PubMed Identifier: 17607937
author list: Podar K, Raje N, Anderson KC
published in: Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
information resource reference: Inhibition of the TGF-beta signaling pathway in tumor cells. Recent Results Cancer Res. 2007; 172:77-97.
journal title abbreviation: Recent Results Cancer Res
publication date: 2007-01-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.
PubMed Identifier: 18542118
author list: Munshi NC, Mitsiades C, Richardson PG, Anderson KC
published in: Nature clinical practice. Oncology
information resource reference: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5.
journal title abbreviation: Nat Clin Pract Oncol
publication date: 2008-06-10T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1105078
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.
PubMed Identifier: 30315237
author list: Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA
published in: Leukemia
information resource reference: Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells. Leukemia. 2019 03; 33(3):766-771.
journal title abbreviation: Leukemia
publication date: 2018-10-12T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
PubMed Identifier: 20018760
author list: Yoda A, Yoda Y, Chiaretti S, Bar-Natan M, Mani K, Rodig SJ, West N, Xiao Y, Brown JR, Mitsiades C, Sattler M, Kutok JL, DeAngelo DJ, Wadleigh M, Piciocchi A, Dal Cin P, Bradner JE, Griffin JD, Anderson KC, Stone RM, Ritz J, Foà R, Aster JC, Frank DA, Weinstock DM
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2010 Jan 05; 107(1):252-7.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2009-12-15T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Conflicts of interest, authorship, and disclosures in industry-related scientific publications.
PubMed Identifier: 20118399
author list: Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA
published in: Mayo Clinic proceedings
information resource reference: Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
journal title abbreviation: Mayo Clin Proc
publication date: 2010-02-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.
PubMed Identifier: 20141673
author list: Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Canc Netw. 2010 Feb; 8 Suppl 1:S4-S12.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2010-02-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.
PubMed Identifier: 21888257
author list: Richardson PG, Laubach J, Mitsiades CS, Schlossman RL, Ghobrial IM, Munshi NC, Anderson KC
published in: Oncology (Williston Park, N.Y.)
information resource reference: MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
journal title abbreviation: Oncology (Williston Park)
publication date: 2011-06-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 129692
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells.

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
PubMed Identifier: 23243282
author list: Richardson PG, Siegel D, Baz R, Kelley SL, Munshi NC, Laubach J, Sullivan D, Alsina M, Schlossman R, Ghobrial IM, Doss D, Loughney N, McBride L, Bilotti E, Anand P, Nardelli L, Wear S, Larkins G, Chen M, Zaki MH, Jacques C, Anderson KC
published in: Blood
information resource reference: Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
journal title abbreviation: Blood
publication date: 2012-12-14T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1111303
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.

Authorship 1111196
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting.
PubMed Identifier: 30413684
author list: Richardson PG, San Miguel JF, Moreau P, Hajek R, Dimopoulos MA, Laubach JP, Palumbo A, Luptakova K, Romanus D, Skacel T, Kumar SK, Anderson KC
published in: Blood cancer journal
information resource reference: Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting. Blood Cancer J. 2018 11 09; 8(11):109.
journal title abbreviation: Blood Cancer J
publication date: 2018-11-09T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
PubMed Identifier: 30401751
author list: Hunter ZR, Xu L, Tsakmaklis N, Demos MG, Kofides A, Jimenez C, Chan GG, Chen J, Liu X, Munshi M, Gustine J, Meid K, Patterson CJ, Yang G, Dubeau T, Samur MK, Castillo JJ, Anderson KC, Munshi NC, Treon SP
published in: Blood advances
information resource reference: Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946.
journal title abbreviation: Blood Adv
publication date: 2018-11-13T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1113687
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: The power of proteasome inhibition in multiple myeloma.

The power of proteasome inhibition in multiple myeloma.
PubMed Identifier: 30427223
author list: Guerrero-Garcia TA, Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Mitsiades C, Anderson KC, Richardson PG
published in: Expert review of proteomics
information resource reference: The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018 12; 15(12):1033-1052.
journal title abbreviation: Expert Rev Proteomics
publication date: 2018-11-14T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications.
PubMed Identifier: 11882358
author list: Tai YT, Podar K, Kraeft SK, Wang F, Young G, Lin B, Gupta D, Chen LB, Anderson KC
published in: Experimental hematology
information resource reference: Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications. Exp Hematol. 2002 Mar; 30(3):212-20.
journal title abbreviation: Exp Hematol
publication date: 2002-03-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.
PubMed Identifier: 11956087
author list: Lentzsch S, Rogers MS, LeBlanc R, Birsner AE, Shah JH, Treston AM, Anderson KC, D'Amato RJ
published in: Cancer research
information resource reference: S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002 Apr 15; 62(8):2300-5.
journal title abbreviation: Cancer Res
publication date: 2002-04-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.
PubMed Identifier: 12720146
author list: Treon SP, Kelliher A, Keele B, Frankel S, Emmanouilides C, Kimby E, Schlossman R, Mitsiades N, Mitsiades C, Preffer F, Anderson KC
published in: Seminars in oncology
information resource reference: Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations. Semin Oncol. 2003 Apr; 30(2):248-52.
journal title abbreviation: Semin Oncol
publication date: 2003-04-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.
PubMed Identifier: 15367426
author list: Lin B, Catley L, LeBlanc R, Mitsiades C, Burger R, Tai YT, Podar K, Wartmann M, Chauhan D, Griffin JD, Anderson KC
published in: Blood
information resource reference: Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo. Blood. 2005 Jan 01; 105(1):350-7.
journal title abbreviation: Blood
publication date: 2004-09-14T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Perspectives for combination therapy to overcome drug-resistant multiple myeloma.
PubMed Identifier: 16019253
author list: Catley L, Tai YT, Chauhan D, Anderson KC
published in: Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
information resource reference: Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat. 2005 Aug; 8(4):205-18.
journal title abbreviation: Drug Resist Updat
publication date: 2005-07-12T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.
PubMed Identifier: 16357183
author list: Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, Song W, Podar K, Hideshima T, Chauhan D, Schlossman R, Richardson P, Treon SP, Grewal IS, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
journal title abbreviation: Cancer Res
publication date: 2005-12-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.
PubMed Identifier: 16365174
author list: Richardson P, Anderson K
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2006 Jan 20; 24(3):334-6.
journal title abbreviation: J Clin Oncol
publication date: 2005-12-19T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.
PubMed Identifier: 16728695
author list: Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC, Anderson KC
published in: Blood
information resource reference: Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006 Nov 15; 108(10):3441-9.
journal title abbreviation: Blood
publication date: 2006-05-25T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.
PubMed Identifier: 17185464
author list: Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD, Bergsagel PL, Schenkein D, Esseltine DL, Boral A, Anderson KC
published in: Blood
information resource reference: Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007 Apr 15; 109(8):3177-88.
journal title abbreviation: Blood
publication date: 2006-12-21T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
PubMed Identifier: 17646864
author list: Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC
published in: Nature reviews. Cancer
information resource reference: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007 Aug; 7(8):585-98.
journal title abbreviation: Nat Rev Cancer
publication date: 2007-08-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.
PubMed Identifier: 17761288
author list: Ditzel Santos D, Ho AW, Tournilhac O, Hatjiharissi E, Leleu X, Xu L, Tassone P, Neri P, Hunter ZR, Chemaly MA, Branagan AR, Manning RJ, Patterson CJ, Moreau AS, Ciccarelli B, Adamia S, Kriangkum J, Kutok JL, Tai YT, Zhang J, Pilarski LM, Anderson KC, Munshi N, Treon SP
published in: Experimental hematology
information resource reference: Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
journal title abbreviation: Exp Hematol
publication date: 2007-09-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.
PubMed Identifier: 18202175
author list: Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2008-01-17T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
PubMed Identifier: 19725827
author list: Vogl DT, Stadtmauer EA, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Facon T, Harousseau JL, Boral A, Neuwirth R, Anderson KC
published in: British journal of haematology
information resource reference: Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma. Br J Haematol. 2009 Nov; 147(4):531-4.
journal title abbreviation: Br J Haematol
publication date: 2009-09-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib in the management of multiple myeloma.
PubMed Identifier: 21188129
author list: Laubach JP, Mitsiades CS, Hideshima T, Schlossman R, Chauhan D, Munshi N, Ghobrial I, Carreau N, Anderson KC, Richardson PG
published in: Cancer management and research
information resource reference: Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
journal title abbreviation: Cancer Manag Res
publication date: 2009-09-08T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Hematology: Setting the standard for newly diagnosed multiple myeloma.
PubMed Identifier: 21423257
author list: Laubach J, Richardson PG, Anderson K
published in: Nature reviews. Clinical oncology
information resource reference: Hematology: Setting the standard for newly diagnosed multiple myeloma. Nat Rev Clin Oncol. 2011 May; 8(5):255-6.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2011-03-22T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1119960
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist.

Authorship 1120303
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.
PubMed Identifier: 30504296
author list: Wildes TM, Anderson KC
published in: Hematology. American Society of Hematology. Education Program
information resource reference: Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):88-96.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2018-11-30T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist.
PubMed Identifier: 30504295
author list: Facon T, Anderson K
published in: Hematology. American Society of Hematology. Education Program
information resource reference: Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist. Hematology Am Soc Hematol Educ Program. 2018 11 30; 2018(1):83-87.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2018-11-30T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma, version 1.2013.
PubMed Identifier: 23307977
author list: Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Multiple myeloma, version 1.2013. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):11-7.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2013-01-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1122366
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma.
PubMed Identifier: 30590042
author list: Fulciniti M, Lin CY, Samur MK, Lopez MA, Singh I, Lawlor MA, Szalat RE, Ott CJ, Avet-Loiseau H, Anderson KC, Young RA, Bradner JE, Munshi NC
published in: Cell reports
information resource reference: Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6.
journal title abbreviation: Cell Rep
publication date: 2018-12-26T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors.
PubMed Identifier: 11867204
author list: Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, Mizoguchi H, Eto Y, Anderson KC, Yamada H
published in: Cancer letters
information resource reference: Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett. 2002 Apr 25; 178(2):187-97.
journal title abbreviation: Cancer Lett
publication date: 2002-04-25T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Cytokines modulate telomerase activity in a human multiple myeloma cell line.
PubMed Identifier: 12097303
author list: Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 07 01; 62(13):3876-82.
journal title abbreviation: Cancer Res
publication date: 2002-07-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular sequelae of proteasome inhibition in human multiple myeloma cells.
PubMed Identifier: 12391322
author list: Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Treon SP, Munshi NC, Richardson PG, Hideshima T, Anderson KC
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2002-10-21T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.
PubMed Identifier: 14512311
author list: LeBlanc R, Hideshima T, Catley LP, Shringarpure R, Burger R, Mitsiades N, Mitsiades C, Cheema P, Chauhan D, Richardson PG, Anderson KC, Munshi NC
published in: Blood
information resource reference: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90.
journal title abbreviation: Blood
publication date: 2003-09-25T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.
PubMed Identifier: 15217830
author list: Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC
published in: Blood
information resource reference: Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66.
journal title abbreviation: Blood
publication date: 2004-06-24T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
PubMed Identifier: 15569984
author list: Hayashi T, Hideshima T, Nguyen AN, Munoz O, Podar K, Hamasaki M, Ishitsuka K, Yasui H, Richardson P, Chakravarty S, Murphy A, Chauhan D, Higgins LS, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment. Clin Cancer Res. 2004 Nov 15; 10(22):7540-6.
journal title abbreviation: Clin Cancer Res
publication date: 2004-11-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.
PubMed Identifier: 15827128
author list: Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC
published in: Blood
information resource reference: Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 01; 106(3):1042-7.
journal title abbreviation: Blood
publication date: 2005-04-12T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.
PubMed Identifier: 15958804
author list: Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC
published in: The New England journal of medicine
information resource reference: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005 Jun 16; 352(24):2487-98.
journal title abbreviation: N Engl J Med
publication date: 2005-06-16T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.
PubMed Identifier: 17384201
author list: Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC
published in: Blood
information resource reference: JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells. Blood. 2007 Jul 15; 110(2):709-18.
journal title abbreviation: Blood
publication date: 2007-03-23T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.
PubMed Identifier: 17418411
author list: Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, Zheng M, Mani M, Henderson J, Pinkus GS, Munshi N, Horner J, Ivanova EV, Protopopov A, Anderson KC, Tonon G, DePinho RA
published in: Cancer cell
information resource reference: The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007 Apr; 11(4):349-60.
journal title abbreviation: Cancer Cell
publication date: 2007-04-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.
PubMed Identifier: 17854307
author list: Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, Munshi NC, Richardson PG, Anderson KC
published in: British journal of haematology
information resource reference: Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63.
journal title abbreviation: Br J Haematol
publication date: 2007-10-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1125197
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis.

Authorship 1124275
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: PRMT5 inhibitors on the (myeloma) road.

PRMT5 inhibitors on the (myeloma) road.
PubMed Identifier: 30613345
author list: Gulla A, Hideshima T, Anderson KC
published in: Oncotarget
information resource reference: PRMT5 inhibitors on the (myeloma) road. Oncotarget. 2018 Nov 30; 9(94):36646-36647.
journal title abbreviation: Oncotarget
publication date: 2018-11-30T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis.
PubMed Identifier: 30634515
author list: Guang MHZ, Kavanagh EL, Dunne LP, Dowling P, Zhang L, Lindsay S, Bazou D, Goh CY, Hanley C, Bianchi G, Anderson KC, O'Gorman P, McCann A
published in: Cancers
information resource reference: Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis. Cancers (Basel). 2019 01 09; 11(1).
journal title abbreviation: Cancers (Basel)
publication date: 2019-01-09T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib in the front-line treatment of multiple myeloma.
PubMed Identifier: 18588451
author list: Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC
published in: Expert review of anticancer therapy
information resource reference: Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2008-07-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
PubMed Identifier: 19270264
author list: Hideshima T, Chauhan D, Kiziltepe T, Ikeda H, Okawa Y, Podar K, Raje N, Protopopov A, Munshi NC, Richardson PG, Carrasco RD, Anderson KC
published in: Blood
information resource reference: Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36.
journal title abbreviation: Blood
publication date: 2009-03-06T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.
PubMed Identifier: 21902685
author list: Bae J, Tai YT, Anderson KC, Munshi NC
published in: British journal of haematology
information resource reference: Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61.
journal title abbreviation: Br J Haematol
publication date: 2011-09-09T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.
PubMed Identifier: 21995575
author list: Görgün G, Anderson KC
published in: Immunotherapy
information resource reference: Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy. 2011 Oct; 3(10):1253-64.
journal title abbreviation: Immunotherapy
publication date: 2011-10-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
PubMed Identifier: 22640031
author list: Jakubowiak AJ, Richardson PG, Zimmerman T, Alsina M, Kaufman JL, Kandarpa M, Kraftson S, Ross CW, Harvey C, Hideshima T, Sportelli P, Poradosu E, Gardner L, Giusti K, Anderson KC
published in: British journal of haematology
information resource reference: Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study. Br J Haematol. 2012 Aug; 158(4):472-80.
journal title abbreviation: Br J Haematol
publication date: 2012-05-29T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
PubMed Identifier: 22975377
author list: Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MP, Weinstock J, Kingsbury WD, Hideshima T, Shah PK, Minvielle S, Altun M, Kessler BM, Orlowski R, Richardson P, Munshi N, Anderson KC
published in: Cancer cell
information resource reference: A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58.
journal title abbreviation: Cancer Cell
publication date: 2012-09-11T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Bruton's tyrosine kinase: oncotarget in myeloma.
PubMed Identifier: 22989914
author list: Tai YT, Anderson KC
published in: Oncotarget
information resource reference: Bruton's tyrosine kinase: oncotarget in myeloma. Oncotarget. 2012 Sep; 3(9):913-4.
journal title abbreviation: Oncotarget
publication date: 2012-09-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.
PubMed Identifier: 23321256
author list: Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC
published in: Blood
information resource reference: Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
journal title abbreviation: Blood
publication date: 2013-01-15T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1129614
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Contribution of Inhibition of Protein Catabolism in Myeloma.

Contribution of Inhibition of Protein Catabolism in Myeloma.
PubMed Identifier: 30694855
author list: Bianchi G, Anderson KC
published in: Cancer journal (Sudbury, Mass.)
information resource reference: Contribution of Inhibition of Protein Catabolism in Myeloma. Cancer J. 2019 Jan/Feb; 25(1):11-18.
journal title abbreviation: Cancer J
publication date: 2019-01-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.
PubMed Identifier: 30773670
author list: Bustoros M, Kastritis E, Sklavenitis-Pistofidis R, Liu CJ, Hornburg K, Kanellias N, Kim G, Liu D, Gavriatopoulou M, Marinac CR, Roussou M, Migkou M, Noonan K, Reyes K, Rivotto B, Neuse CJ, Ziogas DC, Laubach J, Terpos E, Anderson KC, Richardson PG, Ghobrial IM, Dimopoulos MA
published in: American journal of hematology
information resource reference: Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group. Am J Hematol. 2019 05; 94(5):E146-E149.
journal title abbreviation: Am J Hematol
publication date: 2019-03-06T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1131949
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.

BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.
PubMed Identifier: 30740414
author list: Cho SF, Anderson KC, Tai YT
published in: Annals of translational medicine
information resource reference: BCMA CAR T-cell therapy arrives for multiple myeloma: a reality. Ann Transl Med. 2018 Dec; 6(Suppl 2):S93.
journal title abbreviation: Ann Transl Med
publication date: 2018-12-01T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1136932
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Bone marrow biopsy in low-risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.

Authorship 1138744
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/120064262

Authorship 1136012
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
PubMed Identifier: 30862646
author list: Mikhael J, Richardson P, Usmani SZ, Raje N, Bensinger W, Karanes C, Campana F, Kanagavel D, Dubin F, Liu Q, Semiond D, Anderson K
published in: Blood
information resource reference: A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma. Blood. 2019 07 11; 134(2):123-133.
journal title abbreviation: Blood
publication date: 2019-03-12T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/120064262
PubMed Identifier: 30872779
author list: Bae J, Samur M, Richardson P, Munshi NC, Anderson KC
published in: Leukemia
information resource reference: Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226.
journal title abbreviation: Leukemia
publication date: 2019-03-12T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy.

Antineoplastic Agents
MeSH DescriptorUI: D000970
MeSH semantic group name: Chemicals & Drugs
number of authors: 2917
number of publications: 13871
uniqueness weight: 0.198234
type: Concept

Pyrazines
MeSH DescriptorUI: D011719
MeSH semantic group name: Chemicals & Drugs
number of authors: 340
number of publications: 1253
uniqueness weight: 0.642303
type: Concept

Thalidomide
MeSH DescriptorUI: D013792
MeSH semantic group name: Chemicals & Drugs
number of authors: 259
number of publications: 930
uniqueness weight: 0.663317
type: Concept

Authorship 1144917
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Deciphering the chronology of copy number alterations in Multiple Myeloma.

Authorship 1145068
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.

Authorship 1142010
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.

Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma.
PubMed Identifier: 30930134
author list: Jagannath S, Heffner LT, Ailawadhi S, Munshi NC, Zimmerman TM, Rosenblatt J, Lonial S, Chanan-Khan A, Ruehle M, Rharbaoui F, Haeder T, Wartenberg-Demand A, Anderson KC
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):372-380.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2019-02-21T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma.
PubMed Identifier: 30962579
author list: Song Y, Park PMC, Wu L, Ray A, Picaud S, Li D, Wimalasena VK, Du T, Filippakopoulos P, Anderson KC, Qi J, Chauhan D
published in: Leukemia
information resource reference: Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. 2019 11; 33(11):2685-2694.
journal title abbreviation: Leukemia
publication date: 2019-04-08T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Deciphering the chronology of copy number alterations in Multiple Myeloma.
PubMed Identifier: 30914633
author list: Aktas Samur A, Minvielle S, Shammas M, Fulciniti M, Magrangeas F, Richardson PG, Moreau P, Attal M, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK
published in: Blood cancer journal
information resource reference: Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39.
journal title abbreviation: Blood Cancer J
publication date: 2019-03-26T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Boronic Acids
MeSH DescriptorUI: D001897
MeSH semantic group name: Chemicals & Drugs
number of authors: 167
number of publications: 907
uniqueness weight: 0.733626
type: Concept

Multiple Myeloma
MeSH DescriptorUI: D009101
MeSH semantic group name: Disorders
number of authors: 743
number of publications: 5401
uniqueness weight: 0.276419
type: Concept

Authorship 124515
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Emerging trends in the clinical use of bortezomib in multiple myeloma.

Authorship 1150833
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Correction: Dual Inhibition of Canonical and Noncanonical NF-?B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.

Correction: Dual Inhibition of Canonical and Noncanonical NF-?B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma.
PubMed Identifier: 31043386
author list: Fabre C, Mimura N, Bobb K, Kong SY, Gorgun G, Cirstea D, Hu Y, Minami J, Ohguchi H, Zhang J, Meshulam J, Carrasco RD, Tai YT, Richardson PG, Hideshima T, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Correction: Dual Inhibition of Canonical and Noncanonical NF-?B Pathways Demonstrates Significant Antitumor Activities in Multiple Myeloma. Clin Cancer Res. 2019 May 01; 25(9):2938.
journal title abbreviation: Clin Cancer Res
publication date: 2019-05-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Medicine
type: Department
type: Organization

Hematology/Oncology
type: Division
type: Organization

VA Med Centers
type: Division
type: Organization

Adult Oncology
type: Division
type: Organization

Oncology
type: Division
type: Organization

Dana-Farber Cancer Institute
type: Organization

Massachusetts General Hospital
type: Organization

Ghobrial, Irene
eCommons Login: IG18
first name: Irene
last name: Ghobrial
full name: Irene Ghobrial, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 75208
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Authorship 1154624
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
PubMed Identifier: 31097405
author list: Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M
published in: The Lancet. Oncology
information resource reference: Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019 06; 20(6):781-794.
journal title abbreviation: Lancet Oncol
publication date: 2019-05-13T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Raje, Noopur
eCommons Login: NR5
first name: Noopur
last name: Raje
full name: Noopur Raje, M.D.
has faculty rank: Full Professor
latitude: 42.36241700000000
longitude: -71.06893700000000
Person ID: 14596
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Laubach, Jacob
eCommons Login: JL240
first name: Jacob
last name: Laubach
full name: Jacob Laubach, M.D.
has faculty rank: Associate Professor
latitude: 42.33510370000000
longitude: -71.10616490000000
Person ID: 46718
person in primary position: Associate Professor of Medicine
type: Agent
type: Person
preferred title: Associate Professor of Medicine

Richardson, Paul
eCommons Login: PGR1
first name: Paul
last name: Richardson
full name: Paul Gerard Guy Richardson, M.B.,B.S.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 65832
person in primary position: R.J. Corman Professor of Medicine
type: Agent
type: Person
preferred title: R.J. Corman Professor of Medicine

Authorship 1157851
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.

Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling.
PubMed Identifier: 31142847
author list: Ho M, Chen T, Liu J, Dowling P, Hideshima T, Zhang L, Morelli E, Camci-Unal G, Wu X, Tai YT, Wen K, Samur M, Schlossman RL, Mazitschek R, Kavanagh EL, Lindsay S, Harada T, McCann A, Anderson KC, O'Gorman P, Bianchi G
published in: Leukemia
information resource reference: Targeting histone deacetylase 3 (HDAC3) in the bone marrow microenvironment inhibits multiple myeloma proliferation by modulating exosomes and IL-6 trans-signaling. Leukemia. 2020 01; 34(1):196-209.
journal title abbreviation: Leukemia
publication date: 2019-05-29T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

selected publications
maximum weight: 1
minimum weight: 1
number of connections: 965
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/113
predicate: selected publications
type: Network

research areas
maximum weight: 48.7384
minimum weight: 0.00283724
number of connections: 1452
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/217
predicate: research areas
type: Network

coauthor of
maximum weight: 44.0526
minimum weight: 0.0116919
number of connections: 243
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/363
predicate: coauthor of
type: Network

similar to
maximum weight: 3514.7
minimum weight: 97.8943
number of connections: 60
predicate node: https://connects.catalyst.harvard.edu/Profiles/profile/494
predicate: similar to
type: Network

Matulonis, Ursula
eCommons Login: UAM1
first name: Ursula
last name: Matulonis
full name: Ursula Anne Matulonis, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 87439
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Hideshima, Teru
eCommons Login: TH9
first name: Teru
last name: Hideshima
full name: Teru Hideshima, M.D., Ph.D.
has faculty rank: Other Faculty
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 85624
person in primary position: Principal Associate in Medicine
type: Agent
type: Person
preferred title: Principal Associate in Medicine

Authorship 1159524
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
PubMed Identifier: 31162104
author list: Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S
published in: The Lancet. Oncology
information resource reference: International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019 06; 20(6):e302-e312.
journal title abbreviation: Lancet Oncol
publication date: 2019-06-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Munshi, Nikhil
eCommons Login: NCM4
first name: Nikhil
last name: Munshi
full name: Nikhil C Munshi, M.B.,B.S., M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 72797
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Authorship 1163471
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.

The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma.
PubMed Identifier: 31182781
author list: Adamia S, Abiatari I, Amin SB, Fulciniti M, Minvielle S, Li C, Moreau P, Avet-Loiseau H, Munshi NC, Anderson KC
published in: Leukemia
information resource reference: The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2020 01; 34(1):167-179.
journal title abbreviation: Leukemia
publication date: 2019-06-10T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Shipp, Margaret
eCommons Login: MAS7
first name: Margaret
last name: Shipp
full name: Margaret Ann Shipp, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 26133
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Ritz, Jerome
eCommons Login: JR11
first name: Jerome
last name: Ritz
full name: Jerome Ritz, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
photo: https://connects.catalyst.harvard.edu/Profiles/profile/Modules/CustomViewPersonGeneralInfo/PhotoHandler.ashx
Person ID: 52061
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Ho, Vincent
eCommons Login: VTH1
first name: Vincent
last name: Ho
full name: Vincent T. Ho, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 31222
person in primary position: Professor of Medicine
type: Agent
type: Person
preferred title: Professor of Medicine

Mayer, Robert
eCommons Login: RJM3
first name: Robert
last name: Mayer
full name: Robert James Mayer, M.D.
has faculty rank: Full Professor
latitude: 42.33789600000000
longitude: -71.10724930000000
Person ID: 70527
person in primary position: Stephen B. Kay Family Professor of Medicine
type: Agent
type: Person
preferred title: Stephen B. Kay Family Professor of Medicine

Authorship 1168214
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.

B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
PubMed Identifier: 31277554
author list: Tai YT, Anderson KC
published in: Expert opinion on biological therapy
information resource reference: B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019 11; 19(11):1143-1156.
journal title abbreviation: Expert Opin Biol Ther
publication date: 2019-07-11T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1177356
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia.

Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia.
PubMed Identifier: 31371310
author list: Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, Xu L, Ciccarelli B, Patterson CJ, Ngo HT, Russo D, Vacca A, Dammacco F, Anderson KC, Ghobrial IM, Treon SP
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Correction: Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 Aug 01; 25(15):4860.
journal title abbreviation: Clin Cancer Res
publication date: 2019-08-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1180015
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.

Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics.
PubMed Identifier: 31394933
author list: Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA
published in: Future oncology (London, England)
information resource reference: Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019 Oct; 15(28):3267-3281.
journal title abbreviation: Future Oncol
publication date: 2019-08-09T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 154719
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.

Authorship 1181786
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Genomic landscape and chronological reconstruction of driver events in multiple myeloma.

Authorship 1183066
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.

Authorship 1182376
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

Authorship 1181667
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.

Authorship 1185951
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.

Authorship 1185673
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Insights into the management of older patients with multiple myeloma.

Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma.
PubMed Identifier: 31462737
author list: Ray A, Song Y, Du T, Tai YT, Chauhan D, Anderson KC
published in: Leukemia
information resource reference: Targeting tryptophan catabolic kynurenine pathway enhances antitumor immunity and cytotoxicity in multiple myeloma. Leukemia. 2020 02; 34(2):567-577.
journal title abbreviation: Leukemia
publication date: 2019-08-28T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity.
PubMed Identifier: 31406111
author list: Ray A, Song Y, Chauhan D, Anderson KC
published in: Blood cancer journal
information resource reference: Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity. Blood Cancer J. 2019 08 12; 9(8):64.
journal title abbreviation: Blood Cancer J
publication date: 2019-08-12T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
PubMed Identifier: 31456261
author list: Ghobrial IM, Liu CJ, Zavidij O, Azab AK, Baz R, Laubach JP, Mishima Y, Armand P, Munshi NC, Basile F, Constantine M, Vredenburgh J, Boruchov A, Crilley P, Henrick PM, Hornburg KTV, Leblebjian H, Chuma S, Reyes K, Noonan K, Warren D, Schlossman R, Paba-Prada C, Anderson KC, Weller E, Trippa L, Shain K, Richardson PG
published in: American journal of hematology
information resource reference: Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
journal title abbreviation: Am J Hematol
publication date: 2019-10-04T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Insights into the management of older patients with multiple myeloma.
PubMed Identifier: 31449504
author list: Anderson KC
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Insights into the management of older patients with multiple myeloma. Clin Adv Hematol Oncol. 2019 Jul; 17(7):390-392.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2019-07-01T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomic landscape and chronological reconstruction of driver events in multiple myeloma.
PubMed Identifier: 31444325
author list: Maura F, Bolli N, Angelopoulos N, Dawson KJ, Leongamornlert D, Martincorena I, Mitchell TJ, Fullam A, Gonzalez S, Szalat R, Abascal F, Rodriguez-Martin B, Samur MK, Glodzik D, Roncador M, Fulciniti M, Tai YT, Minvielle S, Magrangeas F, Moreau P, Corradini P, Anderson KC, Tubio JMC, Wedge DC, Gerstung M, Avet-Loiseau H, Munshi N, Campbell PJ
published in: Nature communications
information resource reference: Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835.
journal title abbreviation: Nat Commun
publication date: 2019-08-23T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.
PubMed Identifier: 31427721
author list: Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC
published in: Leukemia
information resource reference: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223.
journal title abbreviation: Leukemia
publication date: 2019-08-19T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 142513
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Lenalidomide in multiple myeloma.

Authorship 150150
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.

Authorship 1193485
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.
PubMed Identifier: 31548533
author list: Cho SF, Lin L, Xing L, Yu T, Wen K, Anderson KC, Tai YT
published in: Antibodies (Basel, Switzerland)
information resource reference: Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma. Antibodies (Basel). 2017 Nov 14; 6(4).
journal title abbreviation: Antibodies (Basel)
publication date: 2017-11-14T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 150339
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies.

Authorship 1197049
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: The impact of response kinetics for multiple myeloma in the era of novel agents.

The impact of response kinetics for multiple myeloma in the era of novel agents.
PubMed Identifier: 31594763
author list: Yan Y, Mao X, Liu J, Fan H, Du C, Li Z, Yi S, Xu Y, Lv R, Liu W, Deng S, Sui W, Wang Q, Zou D, Wang J, Cheng T, Zhan F, Tai YT, Yuan C, Du X, Qiu L, Anderson KC, An G
published in: Blood advances
information resource reference: The impact of response kinetics for multiple myeloma in the era of novel agents. Blood Adv. 2019 10 08; 3(19):2895-2904.
journal title abbreviation: Blood Adv
publication date: 2019-10-08T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 149910
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.

Authorship 1200791
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma.
PubMed Identifier: 31672767
author list: Ghobrial IM, Liu CJ, Redd RA, Perez RP, Baz R, Zavidij O, Sklavenitis-Pistofidis R, Richardson PG, Anderson KC, Laubach J, Henrick P, Savell A, Reyes K, Hornburg K, Chuma S, Sabbatini P, Robbins MD, Becker PS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. Clin Cancer Res. 2020 01 15; 26(2):344-353.
journal title abbreviation: Clin Cancer Res
publication date: 2019-10-31T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1203244
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.

Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma.
PubMed Identifier: 31698455
author list: Schmidts A, Ormhøj M, Choi BD, Taylor AO, Bouffard AA, Scarfò I, Larson RC, Frigault MJ, Gallagher K, Castano AP, Riley LS, Cabral ML, Boroughs AC, Velasco Cárdenas RM, Schamel W, Zhou J, Mackay S, Tai YT, Anderson KC, Maus MV
published in: Blood advances
information resource reference: Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 11 12; 3(21):3248-3260.
journal title abbreviation: Blood Adv
publication date: 2019-11-12T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 136167
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells.

Authorship 125176
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.

Authorship 1205394
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/136114137

https://connects.catalyst.harvard.edu/Profiles/profile/136114137
PubMed Identifier: 31735560
author list: Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC
published in: Lancet (London, England)
information resource reference: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019 12 07; 394(10214):2096-2107.
journal title abbreviation: Lancet
publication date: 2019-11-14T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Hematology/Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Massachusetts General Hospital

Principal Associate in Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Principal Associate in Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Adult Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

R.J. Corman Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: R.J. Corman Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Adult Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 128749
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes.

Authorship 137320
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma. Preface.

Authorship 1400
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Apoptotic signaling in multiple myeloma: therapeutic implications.

Authorship 147016
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Authorship 1219268
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.

Authorship 1219110
type: Authorship
author rank in publication: 55
linked author: Anderson, Kenneth
linked information resource: A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications.
PubMed Identifier: 31949267
author list: Bae J, Parayath N, Ma W, Amiji M, Munshi N, Anderson KC
published in: Leukemia
information resource reference: Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 Jul; 34(7):1971.
journal title abbreviation: Leukemia
publication date: 2020-07-01T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.
PubMed Identifier: 31935283
author list: Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W
published in: Blood advances
information resource reference: A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry. Blood Adv. 2020 01 14; 4(1):181-190.
journal title abbreviation: Blood Adv
publication date: 2020-01-14T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1222810
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
PubMed Identifier: 32024967
author list: Ray A, Song Y, Du T, Chauhan D, Anderson KC
published in: Oncogene
information resource reference: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma. Oncogene. 2020 03; 39(13):2786-2796.
journal title abbreviation: Oncogene
publication date: 2020-02-05T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 121552
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components.

Authorship 1225809
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.

A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma.
PubMed Identifier: 32060401
author list: Xing L, Lin L, Yu T, Li Y, Cho SF, Liu J, Wen K, Hsieh PA, Kinneer K, Munshi N, Anderson KC, Tai YT
published in: Leukemia
information resource reference: A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 08; 34(8):2150-2162.
journal title abbreviation: Leukemia
publication date: 2020-02-14T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1228731
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: The safety of current and emerging therapies for multiple myeloma.

The safety of current and emerging therapies for multiple myeloma.
PubMed Identifier: 32098519
author list: Nadeem O, Anderson KC
published in: Expert opinion on drug safety
information resource reference: The safety of current and emerging therapies for multiple myeloma. Expert Opin Drug Saf. 2020 Mar; 19(3):269-279.
journal title abbreviation: Expert Opin Drug Saf
publication date: 2020-03-03T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1233013
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.

Authorship 1234645
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.

Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
PubMed Identifier: 32193289
author list: Hu Y, Liu H, Fang C, Li C, Xhyliu F, Dysert H, Bodo J, Habermehl G, Russell BE, Li W, Chappell M, Jiang X, Ondrejka SL, Hsi ED, Maciejewski JP, Yi Q, Anderson KC, Munshi NC, Ao G, Valent JN, Lin J, Zhao J
published in: Cancer research
information resource reference: Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 05 15; 80(10):2031-2044.
journal title abbreviation: Cancer Res
publication date: 2020-03-19T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma.
PubMed Identifier: 32187357
author list: Xu Y, Fulciniti M, Samur MK, Ho M, Deng S, Liu L, Wen K, Yu T, Chyra Z, Dereibal S, Zhang L, Yao Y, Chakraborty C, Morelli E, Li N, Lopez MA, Perini T, Mu S, An G, Alonso R, Bianchi G, Tai YT, Anderson KC, Qiu L, Munshi NC
published in: Blood
information resource reference: YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479.
journal title abbreviation: Blood
publication date: 2020-07-23T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1236177
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.

Authorship 1235724
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.

Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
PubMed Identifier: 32213344
author list: Richardson PG, Bringhen S, Voorhees P, Plesner T, Mellqvist UH, Reeves B, Paba-Prada C, Zubair H, Byrne C, Chauhan D, Anderson K, Nordström E, Harmenberg J, Palumbo A, Sonneveld P
published in: The Lancet. Haematology
information resource reference: Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study. Lancet Haematol. 2020 May; 7(5):e395-e407.
journal title abbreviation: Lancet Haematol
publication date: 2020-03-23T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
PubMed Identifier: 32210275
author list: Schauer NJ, Liu X, Magin RS, Doherty LM, Chan WC, Ficarro SB, Hu W, Roberts RM, Iacob RE, Stolte B, Giacomelli AO, Perera S, McKay K, Boswell SA, Weisberg EL, Ray A, Chauhan D, Dhe-Paganon S, Anderson KC, Griffin JD, Li J, Hahn WC, Sorger PK, Engen JR, Stegmaier K, Marto JA, Buhrlage SJ
published in: Scientific reports
information resource reference: Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Sci Rep. 2020 03 24; 10(1):5324.
journal title abbreviation: Sci Rep
publication date: 2020-03-24T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 172427
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.

Authorship 1237085
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.

Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways.
PubMed Identifier: 32238854
author list: Hideshima T, Ogiya D, Liu J, Harada T, Kurata K, Bae J, Massefski W, Anderson KC
published in: Leukemia
information resource reference: Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways. Leukemia. 2021 01; 35(1):177-188.
journal title abbreviation: Leukemia
publication date: 2020-04-01T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
PubMed Identifier: 32312841
author list: Yu T, Du C, Ma X, Sui W, Yu Z, Liu L, Zhao L, Li Z, Xu J, Wei X, Zhou W, Deng S, Zou D, An G, Tai YT, Tricot G, Anderson KC, Qiu L, Zhan F, Hao M
published in: Molecular cancer research : MCR
information resource reference: Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a. Mol Cancer Res. 2020 07; 18(7):1063-1073.
journal title abbreviation: Mol Cancer Res
publication date: 2020-04-20T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Timing the initiation of multiple myeloma.
PubMed Identifier: 32317634
author list: Rustad EH, Yellapantula V, Leongamornlert D, Bolli N, Ledergor G, Nadeu F, Angelopoulos N, Dawson KJ, Mitchell TJ, Osborne RJ, Ziccheddu B, Carniti C, Montefusco V, Corradini P, Anderson KC, Moreau P, Papaemmanuil E, Alexandrov LB, Puente XS, Campo E, Siebert R, Avet-Loiseau H, Landgren O, Munshi N, Campbell PJ, Maura F
published in: Nature communications
information resource reference: Timing the initiation of multiple myeloma. Nat Commun. 2020 04 21; 11(1):1917.
journal title abbreviation: Nat Commun
publication date: 2020-04-21T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
PubMed Identifier: 32325171
author list: Holstein SA, Suman VJ, Owzar K, Santo K, Benson DM, Shea TC, Martin T, Silverman M, Isola L, Vij R, Cheson BD, Linker C, Anderson KC, Richardson PG, McCarthy PL
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma. Biol Blood Marrow Transplant. 2020 08; 26(8):1414-1424.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2020-04-20T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1241832
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Timing the initiation of multiple myeloma.

Authorship 1241746
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.

Authorship 1241268
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.

Authorship 1246821
type: Authorship
author rank in publication: 25
linked author: Anderson, Kenneth
linked information resource: IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.

Authorship 1248005
type: Authorship
author rank in publication: 27
linked author: Anderson, Kenneth
linked information resource: Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.

Authorship 1249695
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.

IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients.
PubMed Identifier: 32421883
author list: Mao XH, Zhuang JL, Zhao DD, Li XQ, Du X, Hao M, Xu Y, Yan YT, Liu JH, Fan HS, Sui WW, Deng SH, Li CW, Zhao JW, Yi SH, Du CX, Zou DH, Li ZJ, Zhao YZ, Zhan FH, Tai YT, Fang BJ, Song YP, Wang JX, Anderson KC, Qiu LG, An G
published in: European journal of haematology
information resource reference: IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients. Eur J Haematol. 2020 Sep; 105(3):326-334.
journal title abbreviation: Eur J Haematol
publication date: 2020-06-09T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression.
PubMed Identifier: 32442065
author list: Bustoros M, Sklavenitis-Pistofidis R, Park J, Redd R, Zhitomirsky B, Dunford AJ, Salem K, Tai YT, Anand S, Mouhieddine TH, Chavda SJ, Boehner C, Elagina L, Neuse CJ, Cha J, Rahmat M, Taylor-Weiner A, Van Allen E, Kumar S, Kastritis E, Leshchiner I, Morgan EA, Laubach J, Casneuf T, Richardson P, Munshi NC, Anderson KC, Trippa L, Aguet F, Stewart C, Dimopoulos MA, Yong K, Bergsagel PL, Manier S, Getz G, Ghobrial IM
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
journal title abbreviation: J Clin Oncol
publication date: 2020-05-22T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13.
PubMed Identifier: 32424294
author list: Du T, Song Y, Ray A, Chauhan D, Anderson KC
published in: Leukemia
information resource reference: Proteomic analysis identifies mechanism(s) of overcoming bortezomib resistance via targeting ubiquitin receptor Rpn13. Leukemia. 2021 02; 35(2):550-561.
journal title abbreviation: Leukemia
publication date: 2020-05-18T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1255307
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.

Authorship 1255158
type: Authorship
author rank in publication: 28
linked author: Anderson, Kenneth
linked information resource: Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma.
PubMed Identifier: 32516895
author list: Cho SF, Lin L, Xing L, Li Y, Yu T, Anderson KC, Tai YT
published in: Cancers
information resource reference: BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma. Cancers (Basel). 2020 Jun 05; 12(6).
journal title abbreviation: Cancers (Basel)
publication date: 2020-06-05T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant.
PubMed Identifier: 32533060
author list: Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, Manier S, Nassar AH, Capelletti M, Huynh D, Bustoros M, Sklavenitis-Pistofidis R, Tahri S, Hornburg K, Dumke H, Itani MM, Boehner CJ, Liu CJ, AlDubayan SH, Reardon B, Van Allen EM, Keats JJ, Stewart C, Mehr S, Auclair D, Schlossman RL, Munshi NC, Anderson KC, Steensma DP, Laubach JP, Richardson PG, Ritz J, Ebert BL, Soiffer RJ, Trippa L, Getz G, Neuberg DS, Ghobrial IM
published in: Nature communications
information resource reference: Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
journal title abbreviation: Nat Commun
publication date: 2020-06-12T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 151019
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: New treatments for multiple myeloma.

Authorship 155089
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibition in multiple myeloma: therapeutic implication.

Authorship 197874
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions.

Authorship 1265600
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.

Authorship 1264970
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.

Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
PubMed Identifier: 32624447
author list: Yu T, Xu Y, An G, Tai YT, Ho M, Li Z, Deng S, Zou D, Yu Z, Hao M, Anderson KC, Qiu L
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China. Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):e652-e659.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2020-05-27T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
PubMed Identifier: 32632095
author list: Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T, Hsieh PA, Chen H, Kurtoglu M, Zhang Y, Andrew Stewart C, Munshi N, Anderson KC, Tai YT
published in: Leukemia
information resource reference: Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2021 03; 35(3):752-763.
journal title abbreviation: Leukemia
publication date: 2020-07-06T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 140888
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Lenalidomide and thalidomide: mechanisms of action--similarities and differences.

Authorship 160448
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.

Authorship 1268662
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.

Authorship 1268068
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.

Authorship 1269903
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: the (r)evolution of current therapy and a glance into future.

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group.
PubMed Identifier: 32687451
author list: Samur MK, Aktas Samur A, Fulciniti M, Szalat R, Han T, Shammas M, Richardson P, Magrangeas F, Minvielle S, Corre J, Moreau P, Thakurta A, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
journal title abbreviation: J Clin Oncol
publication date: 2020-07-20T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab.
PubMed Identifier: 31779273
author list: Martin TG, Corzo K, Chiron M, Velde HV, Abbadessa G, Campana F, Solanki M, Meng R, Lee H, Wiederschain D, Zhu C, Rak A, Anderson KC
published in: Cells
information resource reference: Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab. Cells. 2019 11 26; 8(12).
journal title abbreviation: Cells
publication date: 2019-11-26T00:00:00
year: 2019
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma: the (r)evolution of current therapy and a glance into future.
PubMed Identifier: 32703792
author list: Gulla A, Anderson KC
published in: Haematologica
information resource reference: Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 Jul 23.
journal title abbreviation: Haematologica
publication date: 2020-07-23T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 160922
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Proteomic analysis of waldenstrom macroglobulinemia.

Authorship 163788
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.

Authorship 182166
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.

Authorship 188629
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Thalidomide and immunomodulatory drugs as cancer therapy.

Authorship 1279853
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications.
PubMed Identifier: 32844992
author list: Ogiya D, Liu J, Ohguchi H, Kurata K, Samur MK, Tai YT, Adamia S, Ando K, Hideshima T, Anderson KC
published in: Blood
information resource reference: The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications. Blood. 2020 11 12; 136(20):2334-2345.
journal title abbreviation: Blood
publication date: 2020-11-12T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1282189
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/166352543

Authorship 1281527
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.

https://connects.catalyst.harvard.edu/Profiles/profile/166352543
PubMed Identifier: 32866432
author list: Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV
published in: The Lancet. Oncology
information resource reference: Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol. 2020 10; 21(10):1317-1330.
journal title abbreviation: Lancet Oncol
publication date: 2020-08-28T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.

Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study.
PubMed Identifier: 32887873
author list: Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, Grosicki S, Špicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Matsumoto M, Wu KL, Anderson KC, Jou YM, Ganetsky A, Singhal AK, Richardson PG
published in: Blood cancer journal
information resource reference: Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020 09 04; 10(9):91.
journal title abbreviation: Blood Cancer J
publication date: 2020-09-04T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1288154
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.

Authorship 1288111
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.
PubMed Identifier: 32898244
author list: Cho SF, Lin L, Xing L, Li Y, Wen K, Yu T, Hsieh PA, Munshi N, Wahl J, Matthes K, Friedrich M, Arvedson T, Anderson KC, Tai YT
published in: Blood advances
information resource reference: The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 09 08; 4(17):4195-4207.
journal title abbreviation: Blood Adv
publication date: 2020-09-08T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells.
PubMed Identifier: 32922390
author list: Zhu C, Song Z, Wang A, Srinivasan S, Yang G, Greco R, Theilhaber J, Shehu E, Wu L, Yang ZY, Passe-Coutrin W, Fournier A, Tai YT, Anderson KC, Wiederschain D, Bahjat K, Adrián FJ, Chiron M
published in: Frontiers in immunology
information resource reference: Isatuximab Acts Through Fc-Dependent, Independent, and Direct Pathways to Kill Multiple Myeloma Cells. Front Immunol. 2020; 11:1771.
journal title abbreviation: Front Immunol
publication date: 2020-08-14T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 200872
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Vascular endothelial growth factor-induced migration of multiple myeloma cells is associated with beta 1 integrin- and phosphatidylinositol 3-kinase-dependent PKC alpha activation.

Authorship 1296401
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.

Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma.
PubMed Identifier: 33094839
author list: Dhakal B, D'Souza A, Callander N, Chhabra S, Fraser R, Davila O, Anderson K, Assal A, Badawy SM, Berdeja J, Cerny J, Comenzo R, Chakraborty R, Peter Gale R, Kamble R, Kharfan-Dabaja MA, Krem M, Ganguly S, Janakiram M, Kansagra A, Munker R, Murthy H, Patel S, Kumar S, Shah N, Qazilbash M, Hari P
published in: British journal of haematology
information resource reference: Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. Br J Haematol. 2020 11; 191(3):442-452.
journal title abbreviation: Br J Haematol
publication date: 2020-10-23T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1299245
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Immunotherapeutic and Targeted Approaches in Multiple Myeloma.

Immunotherapeutic and Targeted Approaches in Multiple Myeloma.
PubMed Identifier: 33117743
author list: Nadeem O, Tai YT, Anderson KC
published in: ImmunoTargets and therapy
information resource reference: Immunotherapeutic and Targeted Approaches in Multiple Myeloma. Immunotargets Ther. 2020; 9:201-215.
journal title abbreviation: Immunotargets Ther
publication date: 2020-10-14T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1306262
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset.

Authorship 1303283
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.

Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset.
PubMed Identifier: 33156904
author list: Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong KL, Hungria VTM, Engelhardt M, Gay F, Garcia-Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum CA, Kumar SK, Stadtmauer E, Einsele H, Beksac M, Weisel KC, Anderson KC, Mateos MV, Moreau P, San Miguel J, Munshi NC, Avet-Loiseau H
published in: Blood
information resource reference: Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06.
journal title abbreviation: Blood
publication date: 2020-11-06T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo.
PubMed Identifier: 33149123
author list: Yu T, Chaganty B, Lin L, Xing L, Ramakrishnan B, Wen K, Hsieh PA, Wollacott A, Viswanathan K, Adari H, Cho SF, Li Y, Chen H, Yang W, Xu Y, An G, Qiu L, Munshi N, Babcock G, Shriver Z, Myette JR, Anderson KC, Tai YT
published in: Blood cancer journal
information resource reference: VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020 11 02; 10(11):110.
journal title abbreviation: Blood Cancer J
publication date: 2020-11-02T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 212663
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: The emerging role of novel therapies for the treatment of relapsed myeloma.

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
PubMed Identifier: 33284948
author list: Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N
published in: Blood advances
information resource reference: A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 12 08; 4(23):5988-5999.
journal title abbreviation: Blood Adv
publication date: 2020-12-08T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury.
PubMed Identifier: 33288657
author list: Hu Y, Yang C, Amorim T, Maqbool M, Lin J, Li C, Fang C, Xue L, Kwart A, Fang H, Yin M, Janocha AJ, Tsuchimoto D, Nakabeppu Y, Jiang X, Mejia-Garcia A, Anwer F, Khouri J, Qi X, Zheng QY, Yu JS, Yan S, LaFramboise T, Anderson KC, Herlitz LC, Munshi NC, Lin J, Zhao J
published in: Cancer research
information resource reference: Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 02 01; 81(3):713-723.
journal title abbreviation: Cancer Res
publication date: 2020-12-07T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.
PubMed Identifier: 33296242
author list: Richardson PG, Oriol A, Larocca A, Bladé J, Cavo M, Rodriguez-Otero P, Leleu X, Nadeem O, Hiemenz JW, Hassoun H, Touzeau C, Alegre A, Paner A, Maisel C, Mazumder A, Raptis A, Moreb JS, Anderson KC, Laubach JP, Thuresson S, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Mateos MV
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma. J Clin Oncol. 2021 03 01; 39(7):757-767.
journal title abbreviation: J Clin Oncol
publication date: 2020-12-09T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.
PubMed Identifier: 33278301
author list: Wood WA, Neuberg DS, Thompson JC, Tallman MS, Sekeres MA, Sehn LH, Anderson KC, Goldberg AD, Pennell NA, Niemeyer CM, Tucker E, Hewitt K, Plovnick RM, Hicks LK
published in: Blood advances
information resource reference: Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub. Blood Adv. 2020 12 08; 4(23):5966-5975.
journal title abbreviation: Blood Adv
publication date: 2020-12-08T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1312400
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.

Authorship 1311920
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury.

Authorship 1313509
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma.

Authorship 1315412
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.

Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.
PubMed Identifier: 33367546
author list: Chari A, Samur MK, Martinez-Lopez J, Cook G, Biran N, Yong K, Hungria V, Engelhardt M, Gay F, García Feria A, Oliva S, Oostvogels R, Gozzetti A, Rosenbaum C, Kumar S, Stadtmauer EA, Einsele H, Beksac M, Weisel K, Anderson KC, Mateos MV, Moreau P, San-Miguel J, Munshi NC, Avet-Loiseau H
published in: Blood
information resource reference: Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040.
journal title abbreviation: Blood
publication date: 2020-12-24T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1317578
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Revealing the impact of structural variants in multiple myeloma.

Revealing the impact of structural variants in multiple myeloma.
PubMed Identifier: 33392515
author list: Rustad EH, Yellapantula VD, Glodzik D, Maclachlan KH, Diamond B, Boyle EM, Ashby C, Blaney P, Gundem G, Hultcrantz M, Leongamornlert D, Angelopoulos N, Agnelli L, Auclair D, Zhang Y, Dogan A, Bolli N, Papaemmanuil E, Anderson KC, Moreau P, Avet-Loiseau H, Munshi NC, Keats JJ, Campbell PJ, Morgan GJ, Landgren O, Maura F
published in: Blood cancer discovery
information resource reference: Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020 11; 1(3):258-273.
journal title abbreviation: Blood Cancer Discov
publication date: 2020-09-15T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 148915
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

Authorship 1320882
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Signaling Pathway Mediating Myeloma Cell Growth and Survival.

Authorship 1322299
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: the (r)evolution of current therapy and a glance into future.

Authorship 1321982
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.

Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13.
PubMed Identifier: 33441535
author list: Song Y, Du T, Ray A, Chauhan K, Samur M, Munshi N, Chauhan D, Anderson KC
published in: Blood cancer journal
information resource reference: Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer J. 2021 01 13; 11(1):13.
journal title abbreviation: Blood Cancer J
publication date: 2021-01-13T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Signaling Pathway Mediating Myeloma Cell Growth and Survival.
PubMed Identifier: 33435632
author list: Hideshima T, Anderson KC
published in: Cancers
information resource reference: Signaling Pathway Mediating Myeloma Cell Growth and Survival. Cancers (Basel). 2021 Jan 08; 13(2).
journal title abbreviation: Cancers (Basel)
publication date: 2021-01-08T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma: the (r)evolution of current therapy and a glance into future.
PubMed Identifier: 33054076
author list: Gulla A, Anderson KC
published in: Haematologica
information resource reference: Multiple myeloma: the (r)evolution of current therapy and a glance into future. Haematologica. 2020 10 01; 105(10):2358-2367.
journal title abbreviation: Haematologica
publication date: 2020-10-01T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1324052
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.

Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity.
PubMed Identifier: 33487632
author list: Ray A, Du T, Song Y, Buhrlage SJ, Chauhan D, Anderson KC
published in: Leukemia
information resource reference: Targeting ubiquitin-specific protease-7 in plasmacytoid dendritic cells triggers anti-myeloma immunity. Leukemia. 2021 08; 35(8):2435-2438.
journal title abbreviation: Leukemia
publication date: 2021-01-24T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1328866
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma.
PubMed Identifier: 33558511
author list: Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC
published in: Nature communications
information resource reference: Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.
journal title abbreviation: Nat Commun
publication date: 2021-02-08T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1331126
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities.

Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities.
PubMed Identifier: 33585226
author list: Yamamoto L, Amodio N, Gulla A, Anderson KC
published in: Frontiers in oncology
information resource reference: Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. Front Oncol. 2020; 10:606368.
journal title abbreviation: Front Oncol
publication date: 2021-01-27T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 224968
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

Authorship 1335858
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group.
PubMed Identifier: 33662288
author list: Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C, Einsele H, Sonneveld P, Engelhardt M, Fonseca R, Vangsted A, Weisel K, Baz R, Hungria V, Berdeja JG, Leal da Costa F, Maiolino A, Waage A, Vesole DH, Ocio EM, Quach H, Driessen C, Bladé J, Leleu X, Riva E, Bergsagel PL, Hou J, Chng WJ, Mellqvist UH, Dytfeld D, Harousseau JL, Goldschmidt H, Laubach J, Munshi NC, Gay F, Beksac M, Costa LJ, Kaiser M, Hari P, Boccadoro M, Usmani SZ, Zweegman S, Holstein S, Sezer O, Harrison S, Nahi H, Cook G, Mateos MV, Rajkumar SV, Dimopoulos MA, Richardson PG
published in: The Lancet. Oncology
information resource reference: Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
journal title abbreviation: Lancet Oncol
publication date: 2021-03-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1339436
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.

Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations.
PubMed Identifier: 33724461
author list: Rosiñol L, Beksac M, Zamagni E, Van de Donk NWCJ, Anderson KC, Badros A, Caers J, Cavo M, Dimopoulos MA, Dispenzieri A, Einsele H, Engelhardt M, Fernández de Larrea C, Gahrton G, Gay F, Hájek R, Hungria V, Jurczyszyn A, Kröger N, Kyle RA, Leal da Costa F, Leleu X, Lentzsch S, Mateos MV, Merlini G, Mohty M, Moreau P, Rasche L, Reece D, Sezer O, Sonneveld P, Usmani SZ, Vanderkerken K, Vesole DH, Waage A, Zweegman S, Richardson PG, Bladé J
published in: British journal of haematology
information resource reference: Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021 08; 194(3):496-507.
journal title abbreviation: Br J Haematol
publication date: 2021-03-16T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1342319
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.

Authorship 1341743
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Facts and Hopes in Multiple Myeloma Immunotherapy.

miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.
PubMed Identifier: 33751108
author list: Sewastianik T, Straubhaar JR, Zhao JJ, Samur MK, Adler K, Tanton HE, Shanmugam V, Nadeem O, Dennis PS, Pillai V, Wang J, Jiang M, Lin J, Huang Y, Brooks D, Bouxsein M, Dorfman DM, Pinkus GS, Robbiani DF, Ghobrial IM, Budnik B, Jarolim P, Munshi NC, Anderson KC, Carrasco RD
published in: Blood
information resource reference: miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 04 08; 137(14):1905-1919.
journal title abbreviation: Blood
publication date: 2021-04-08T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Facts and Hopes in Multiple Myeloma Immunotherapy.
PubMed Identifier: 33771856
author list: Sperling AS, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Facts and Hopes in Multiple Myeloma Immunotherapy. Clin Cancer Res. 2021 08 15; 27(16):4468-4477.
journal title abbreviation: Clin Cancer Res
publication date: 2021-03-26T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1360358
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment.

ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment.
PubMed Identifier: 34088671
author list: Liu J, Hideshima T, Xing L, Wang S, Zhou W, Samur MK, Sewastianik T, Ogiya D, An G, Gao S, Yang L, Ji T, Bianchi G, Wen K, Tai YT, Munshi N, Richardson P, Carrasco R, Cang Y, Anderson KC
published in: Science advances
information resource reference: ERK signaling mediates resistance to immunomodulatory drugs in the bone marrow microenvironment. Sci Adv. 2021 06; 7(23).
journal title abbreviation: Sci Adv
publication date: 2021-06-04T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1364463
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.

The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.
PubMed Identifier: 34132782
author list: Yang G, Wang J, Tan L, Munshi M, Liu X, Kofides A, Chen JG, Tsakmaklis N, Demos MG, Guerrera ML, Xu L, Hunter ZR, Che J, Patterson CJ, Meid K, Castillo JJ, Munshi NC, Anderson KC, Cameron M, Buhrlage SJ, Gray NS, Treon SP
published in: Blood
information resource reference: The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance. Blood. 2021 11 18; 138(20):1966-1979.
journal title abbreviation: Blood
publication date: 2021-11-18T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1373614
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Changing the Paradigm.

Authorship 1370768
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.

Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare.
PubMed Identifier: 34179821
author list: Gormley N, Fashoyin-Aje L, Locke T, Unger JM, Little RF, Nooka A, Mezzi K, Popa-McKiver M, Kobos R, Biru Y, Williams TH, Anderson KC
published in: Blood cancer discovery
information resource reference: Recommendations on eliminating racial disparities in multiple myeloma therapies: a step toward achieving equity in healthcare. Blood Cancer Discov. 2021 03; 2(2):119-124.
journal title abbreviation: Blood Cancer Discov
publication date: 2021-03-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Changing the Paradigm.
PubMed Identifier: 32212133
author list: Anderson KC
published in: Oncology (Williston Park, N.Y.)
information resource reference: Changing the Paradigm. Oncology (Williston Park). 2020 Mar 19; 34(3).
journal title abbreviation: Oncology (Williston Park)
publication date: 2020-03-19T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1374754
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.

Authorship 1375885
type: Authorship
author rank in publication: 28
linked author: Anderson, Kenneth
linked information resource: Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.

ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment.
PubMed Identifier: 34268498
author list: Bianchi G, Czarnecki PG, Ho M, Roccaro AM, Sacco A, Kawano Y, Gullà A, Samur AA, Chen T, Wen K, Tai YT, Moscvin M, Wu X, Camci-Unal G, Da Vià MC, Bolli N, Sewastianik T, Carrasco RD, Ghobrial IM, Anderson KC
published in: Blood cancer discovery
information resource reference: ROBO1 Promotes Homing, Dissemination, and Survival of Multiple Myeloma within the Bone Marrow Microenvironment. Blood Cancer Discov. 2021 07; 2(4):338-353.
journal title abbreviation: Blood Cancer Discov
publication date: 2021-07-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
PubMed Identifier: 34258103
author list: Ohguchi H, Park PMC, Wang T, Gryder BE, Ogiya D, Kurata K, Zhang X, Li D, Pei C, Masuda T, Johansson C, Wimalasena VK, Kim Y, Hino S, Usuki S, Kawano Y, Samur MK, Tai YT, Munshi NC, Matsuoka M, Ohtsuki S, Nakao M, Minami T, Lauberth S, Khan J, Oppermann U, Durbin AD, Anderson KC, Hideshima T, Qi J
published in: Blood cancer discovery
information resource reference: Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma. Blood Cancer Discov. 2021 07; 2(4):370-387.
journal title abbreviation: Blood Cancer Discov
publication date: 2021-04-10T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1376940
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.

Authorship 1377860
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.

Authorship 1378255
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.

Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
PubMed Identifier: 33049118
author list: Belch A, Bahlis N, White D, Cheung M, Chen C, Shustik C, Song K, Tosikyan A, Dispenzieri A, Anderson K, Brown D, Robinson S, Srinivasan S, Facon T
published in: Cancer medicine
information resource reference: Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients. Cancer Med. 2020 12; 9(23):8923-8930.
journal title abbreviation: Cancer Med
publication date: 2020-10-13T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma.
PubMed Identifier: 34290359
author list: Bae J, Accardi F, Hideshima T, Tai YT, Prabhala R, Shambley A, Wen K, Rowell S, Richardson PG, Munshi NC, Anderson KC
published in: Leukemia
information resource reference: Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia. 2022 01; 36(1):138-154.
journal title abbreviation: Leukemia
publication date: 2021-07-21T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression.
PubMed Identifier: 34301753
author list: Xing L, Wang S, Liu J, Yu T, Chen H, Wen K, Li Y, Lin L, Hsieh PA, Cho SF, An G, Qiu L, Kinneer K, Munshi N, Anderson KC, Tai YT
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression. Clin Cancer Res. 2021 10 01; 27(19):5376-5388.
journal title abbreviation: Clin Cancer Res
publication date: 2021-10-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1379601
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration.
PubMed Identifier: 34321279
author list: Anderson KC, Auclair D, Adam SJ, Agarwal A, Anderson M, Avet-Loiseau H, Bustoros M, Chapman J, Connors DE, Dash A, Di Bacco A, Du L, Facon T, Flores-Montero J, Gay F, Ghobrial IM, Gormley NJ, Gupta I, Higley H, Hillengass J, Kanapuru B, Kazandjian D, Kelloff GJ, Kirsch IR, Kremer B, Landgren O, Lightbody E, Lomas OC, Lonial S, Mateos MV, Montes de Oca R, Mukundan L, Munshi NC, O'Donnell EK, Orfao A, Paiva B, Patel R, Pugh TJ, Ramasamy K, Ray J, Roshal M, Ross JA, Sigman CC, Thoren KL, Trudel S, Ulaner G, Valente N, Weiss BM, Zamagni E, Kumar SK
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration. Clin Cancer Res. 2021 10 01; 27(19):5195-5212.
journal title abbreviation: Clin Cancer Res
publication date: 2021-10-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 199092
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Targeting signalling pathways for the treatment of multiple myeloma.

Authorship 1386096
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Proteomics-inspired precision medicine for treating and understanding multiple myeloma.

Proteomics-inspired precision medicine for treating and understanding multiple myeloma.
PubMed Identifier: 34414281
author list: Ho M, Bianchi G, Anderson KC
published in: Expert review of precision medicine and drug development
information resource reference: Proteomics-inspired precision medicine for treating and understanding multiple myeloma. Expert Rev Precis Med Drug Dev. 2020; 5(2):67-85.
journal title abbreviation: Expert Rev Precis Med Drug Dev
publication date: 2020-02-24T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1388561
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.

Authorship 1388562
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor.
PubMed Identifier: 34434061
author list: Joseph NS, Tai YT, Anderson KC, Lonial S
published in: Clinical pharmacology : advances and applications
information resource reference: Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. Clin Pharmacol. 2021; 13:169-180.
journal title abbreviation: Clin Pharmacol
publication date: 2021-08-18T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
PubMed Identifier: 34434504
author list: Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC
published in: Oncotarget
information resource reference: Correction: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2021 Aug 17; 12(17):1736.
journal title abbreviation: Oncotarget
publication date: 2021-08-17T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1390541
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Corrigendum to <'Novel therapeutic strategies for multiple myeloma'> <[Experimental Hematology 2015; 43: 732-741]>.

Corrigendum to <'Novel therapeutic strategies for multiple myeloma'> <[Experimental Hematology 2015; 43: 732-741]>.
PubMed Identifier: 34469754
author list: Mimura N, Hideshima T, Anderson KC
published in: Experimental hematology
information resource reference: Corrigendum to <'Novel therapeutic strategies for multiple myeloma'> <[Experimental Hematology 2015; 43: 732-741]>. Exp Hematol. 2021 Nov; 103:75.
journal title abbreviation: Exp Hematol
publication date: 2021-08-29T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1392388
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma.

Authorship 1392481
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.

Authorship 1394750
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.

Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma.
PubMed Identifier: 34518309
author list: Waldschmidt JM, Kloeber JA, Anand P, Frede J, Kokkalis A, Dimitrova V, Potdar S, Nair MS, Vijaykumar T, Im NG, Guillaumet-Adkins A, Chopra N, Stuart H, Budano L, Sotudeh N, Guo G, Grassberger C, Yee AJ, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple Myeloma. Clin Cancer Res. 2021 12 01; 27(23):6432-6444.
journal title abbreviation: Clin Cancer Res
publication date: 2021-09-13T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
PubMed Identifier: 34529955
author list: Kelly KR, Ailawadhi S, Siegel DS, Heffner LT, Somlo G, Jagannath S, Zimmerman TM, Munshi NC, Madan S, Chanan-Khan A, Lonial S, Chandwani S, Minasyan A, Ruehle M, Barmaki-Rad F, Abdolzade-Bavil A, Rharbaoui F, Herrmann-Keiner E, Haeder T, Wartenberg-Demand A, Anderson KC
published in: The Lancet. Haematology
information resource reference: Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. Lancet Haematol. 2021 Nov; 8(11):e794-e807.
journal title abbreviation: Lancet Haematol
publication date: 2021-09-13T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma.
PubMed Identifier: 34489552
author list: Ray A, Song Y, Du T, Chauhan D, Anderson KC
published in: Oncogene
information resource reference: Correction: Preclinical validation of Alpha-Enolase (ENO1) as a novel immunometabolic target in multiple myeloma. Oncogene. 2021 Oct; 40(41):6057.
journal title abbreviation: Oncogene
publication date: 2021-10-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1396185
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: A 3D-Bioprinted Multiple Myeloma Model.

A 3D-Bioprinted Multiple Myeloma Model.
PubMed Identifier: 34558232
author list: Wu D, Wang Z, Li J, Song Y, Perez MEM, Wang Z, Cao X, Cao C, Maharjan S, Anderson KC, Chauhan D, Zhang YS
published in: Advanced healthcare materials
information resource reference: A 3D-Bioprinted Multiple Myeloma Model. Adv Healthc Mater. 2022 04; 11(7):e2100884.
journal title abbreviation: Adv Healthc Mater
publication date: 2021-09-23T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1400653
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications.

Authorship 1399928
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.

Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation.
PubMed Identifier: 34568832
author list: Gulla A, Morelli E, Samur MK, Botta C, Hideshima T, Bianchi G, Fulciniti M, Malvestiti S, Prabhala RH, Talluri S, Wen K, Tai YT, Richardson PG, Chauhan D, Sewastianik T, Carrasco RD, Munshi NC, Anderson KC
published in: Blood cancer discovery
information resource reference: Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. Blood Cancer Discov. 2021 09; 2(5):468-483.
journal title abbreviation: Blood Cancer Discov
publication date: 2021-04-23T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications.
PubMed Identifier: 34615855
author list: Ohguchi H, Hideshima T, Anderson KC
published in: Blood cancer journal
information resource reference: Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications. Blood Cancer J. 2021 Oct 06; 11(10):165.
journal title abbreviation: Blood Cancer J
publication date: 2021-10-06T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1403678
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.

Authorship 1403292
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.

Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.
PubMed Identifier: 34649278
author list: Chen T, Ho M, Briere J, Moscvin M, Czarnecki PG, Anderson KC, Blackwell TK, Bianchi G
published in: Blood advances
information resource reference: Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival. Blood Adv. 2022 01 25; 6(2):429-440.
journal title abbreviation: Blood Adv
publication date: 2022-01-25T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH.
PubMed Identifier: 34653241
author list: Yan Y, Qin X, Liu J, Fan H, Yan W, Liu L, Du C, Yu Z, Xu Y, Hao M, Deng S, Sui W, Lyu R, Liu W, Wang Q, Zou D, Hu L, Wang J, Tai YT, Anderson KC, Zhang L, Cheng T, Zetterberg A, Munshi NC, Qiu L, An G
published in: Blood advances
information resource reference: Clonal phylogeny and evolution of critical cytogenetic aberrations in multiple myeloma at single-cell level by QM-FISH. Blood Adv. 2022 01 25; 6(2):441-451.
journal title abbreviation: Blood Adv
publication date: 2022-01-25T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1404330
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Don't Compromise Myeloma Care Due to COVID-19 Pandemic!

Authorship 1404232
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology.

Authorship 1404245
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma.

ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology.
PubMed Identifier: 34673922
author list: Wood WA, Marks P, Plovnick RM, Hewitt K, Neuberg DS, Walters S, Dolan BK, Tucker EA, Abrams CS, Thompson AA, Anderson KC, Kluetz P, Farrell A, Rivera D, Gertzog M, Pappas G
published in: Blood advances
information resource reference: ASH Research Collaborative: a real-world data infrastructure to support real-world evidence development and learning healthcare systems in hematology. Blood Adv. 2021 12 14; 5(23):5429-5438.
journal title abbreviation: Blood Adv
publication date: 2021-12-14T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma.
PubMed Identifier: 34675390
author list: Frede J, Anand P, Sotudeh N, Pinto RA, Nair MS, Stuart H, Yee AJ, Vijaykumar T, Waldschmidt JM, Potdar S, Kloeber JA, Kokkalis A, Dimitrova V, Mann M, Laubach JP, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG
published in: Nature cell biology
information resource reference: Dynamic transcriptional reprogramming leads to immunotherapeutic vulnerabilities in myeloma. Nat Cell Biol. 2021 11; 23(11):1199-1211.
journal title abbreviation: Nat Cell Biol
publication date: 2021-10-21T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Don't Compromise Myeloma Care Due to COVID-19 Pandemic!
PubMed Identifier: 34661145
author list: Munshi NC, Anderson KC
published in: Blood cancer discovery
information resource reference: Don't Compromise Myeloma Care Due to COVID-19 Pandemic! Blood Cancer Discov. 2020 11; 1(3):218-220.
journal title abbreviation: Blood Cancer Discov
publication date: 2020-10-13T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1414389
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.

IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM.
PubMed Identifier: 34792571
author list: Bazarbachi AH, Avet-Loiseau H, Szalat R, Samur AA, Hunter Z, Shammas M, Corre J, Fulciniti M, Anderson KC, Parmigiani G, Treon SP, Mohty M, Munshi NC, Samur MK
published in: Blood
information resource reference: IgM-MM is predominantly a pre-germinal center disorder and has a distinct genomic and transcriptomic signature from WM. Blood. 2021 11 18; 138(20):1980-1985.
journal title abbreviation: Blood
publication date: 2021-11-18T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1417498
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.

Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma.
PubMed Identifier: 34885245
author list: Cho SF, Xing L, Anderson KC, Tai YT
published in: Cancers
information resource reference: Promising Antigens for the New Frontier of Targeted Immunotherapy in Multiple Myeloma. Cancers (Basel). 2021 Dec 06; 13(23).
journal title abbreviation: Cancers (Basel)
publication date: 2021-12-06T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Blood Cancer Discovery Turns One.
PubMed Identifier: 34661157
author list: Dalla-Favera R, Anderson KC
published in: Blood cancer discovery
information resource reference: Blood Cancer Discovery Turns One. Blood Cancer Discov. 2021 07; 2(4):289-290.
journal title abbreviation: Blood Cancer Discov
publication date: 2021-07-01T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Blood Cancer Discovery Turns One.
PubMed Identifier: 35015678
author list: Dalla-Favera R, Anderson KC
published in: Blood cancer discovery
information resource reference: Blood Cancer Discovery Turns One. Blood Cancer Discov. 2021 Jul; 2(4):289-290.
journal title abbreviation: Blood Cancer Discov
publication date: 2021-07-02T00:00:00
year: 2021
type: Academic Article
type: Article
type: Document
type: Information Resource

Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.
PubMed Identifier: 35027656
author list: Waldschmidt JM, Yee AJ, Vijaykumar T, Pinto RA, Frede J, Anand P, Bianchi G, Guo G, Potdar S, Seifer C, Nair MS, Kokkalis A, Kloeber JA, Shapiro S, Budano L, Mann M, Friedman R, Lipe B, Campagnaro E, O'Donnell EK, Zhang CZ, Laubach JP, Munshi NC, Richardson PG, Anderson KC, Raje NS, Knoechel B, Lohr JG
published in: Leukemia
information resource reference: Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma. Leukemia. 2022 04; 36(4):1078-1087.
journal title abbreviation: Leukemia
publication date: 2022-01-13T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
PubMed Identifier: 35013207
author list: Ajore R, Niroula A, Pertesi M, Cafaro C, Thodberg M, Went M, Bao EL, Duran-Lozano L, Lopez de Lapuente Portilla A, Olafsdottir T, Ugidos-Damboriena N, Magnusson O, Samur M, Lareau CA, Halldorsson GH, Thorleifsson G, Norddahl GL, Gunnarsdottir K, Försti A, Goldschmidt H, Hemminki K, van Rhee F, Kimber S, Sperling AS, Kaiser M, Anderson K, Jonsdottir I, Munshi N, Rafnar T, Waage A, Weinhold N, Thorsteinsdottir U, Sankaran VG, Stefansson K, Houlston R, Nilsson B
published in: Nature communications
information resource reference: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nat Commun. 2022 01 10; 13(1):151.
journal title abbreviation: Nat Commun
publication date: 2022-01-10T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1424855
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Blood Cancer Discovery Turns One.

Authorship 1425981
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Blood Cancer Discovery Turns One.

Authorship 1426168
type: Authorship
author rank in publication: 26
linked author: Anderson, Kenneth
linked information resource: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.

Authorship 1426470
type: Authorship
author rank in publication: 25
linked author: Anderson, Kenneth
linked information resource: Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma.

Authorship 1428509
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
PubMed Identifier: 35082402
author list: Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso MS, Abiatari I, Letai A, Dorfman DM, Hideshima T, Anderson KC
published in: Leukemia
information resource reference: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia. 2022 04; 36(4):1088-1101.
journal title abbreviation: Leukemia
publication date: 2022-01-27T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 217961
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers.

Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.
PubMed Identifier: 35134130
author list: Anderson GSF, Ballester-Beltran J, Giotopoulos G, Guerrero JA, Surget S, Williamson JC, So T, Bloxham D, Aubareda A, Asby R, Walker I, Jenkinson L, Soilleux EJ, Roy JP, Teodósio A, Ficken C, Officer-Jones L, Nasser S, Skerget S, Keats JJ, Greaves P, Tai YT, Anderson KC, MacFarlane M, Thaventhiran JE, Huntly BJP, Lehner PJ, Chapman MA
published in: Blood
information resource reference: Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood. 2022 04 21; 139(16):2471-2482.
journal title abbreviation: Blood
publication date: 2022-04-21T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response.
PubMed Identifier: 35121621
author list: Cho SF, Anderson KC, Tai YT
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response. Clin Cancer Res. 2022 04 14; 28(8):1479-1481.
journal title abbreviation: Clin Cancer Res
publication date: 2022-04-14T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1431898
type: Authorship
author rank in publication: 32
linked author: Anderson, Kenneth
linked information resource: Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.

Authorship 1432198
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma.

Authorship 1430208
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Microenvironment Is a Key Determinant of Immune Checkpoint Inhibitor Response.

Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
PubMed Identifier: 35114152
author list: Raje NS, Anaissie E, Kumar SK, Lonial S, Martin T, Gertz MA, Krishnan A, Hari P, Ludwig H, O'Donnell E, Yee A, Kaufman JL, Cohen AD, Garderet L, Wechalekar AF, Terpos E, Khatry N, Niesvizky R, Yi Q, Joshua DE, Saikia T, Leung N, Engelhardt M, Mothy M, Branagan A, Chari A, Reiman AJ, Lipe B, Richter J, Rajkumar SV, Miguel JS, Anderson KC, Stadtmauer EA, Prabhala RH, McCarthy PL, Munshi NC
published in: The Lancet. Haematology
information resource reference: Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol. 2022 Feb; 9(2):e143-e161.
journal title abbreviation: Lancet Haematol
publication date: 2022-02-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1435314
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.

Authorship 1440262
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.

Authorship 1438146
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/194566892

Authorship 1436229
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.

Authorship 1441132
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.

Authorship 1441230
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.

Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma.
PubMed Identifier: 35365613
author list: Ray A, Song Y, Du T, Buon L, Tai YT, Chauhan D, Anderson KC
published in: Blood cancer journal
information resource reference: Identification and validation of ecto-5' nucleotidase as an immunotherapeutic target in multiple myeloma. Blood Cancer J. 2022 04 01; 12(4):50.
journal title abbreviation: Blood Cancer J
publication date: 2022-04-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment.
PubMed Identifier: 35211412
author list: Cerchione C, Usmani SZ, Stewart AK, Kaiser M, Rasche L, Kortüm M, Mateos MV, Spencer A, Sonneveld P, Anderson KC
published in: Frontiers in oncology
information resource reference: Gene Expression Profiling in Multiple Myeloma: Redefining the Paradigm of Risk-Adapted Treatment. Front Oncol. 2022; 12:820768.
journal title abbreviation: Front Oncol
publication date: 2022-02-08T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma.
PubMed Identifier: 35167125
author list: O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Hu BY, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Richardson PG, Raje NS, El-Jawahri A
published in: Cancer
information resource reference: Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma. Cancer. 2022 05 15; 128(10):1996-2004.
journal title abbreviation: Cancer
publication date: 2022-02-15T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/194566892
PubMed Identifier: 35151415
author list: Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC
published in: The Lancet. Oncology
information resource reference: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 2022 03; 23(3):416-427.
journal title abbreviation: Lancet Oncol
publication date: 2022-02-10T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.

A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.
PubMed Identifier: 35255496
author list: Munshi M, Liu X, Kofides A, Tsakmaklis N, Guerrera ML, Hunter ZR, Palomba ML, Argyropoulos KV, Patterson CJ, Canning AG, Meid K, Gustine J, Branagan AR, Flynn CA, Sarosiek S, Castillo JJ, Wang J, Buhrlage SJ, Gray NS, Munshi NC, Anderson KC, Treon SP, Yang G
published in: Blood advances
information resource reference: A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. Blood Adv. 2022 06 14; 6(11):3332-3338.
journal title abbreviation: Blood Adv
publication date: 2022-06-14T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.
PubMed Identifier: 35344764
author list: Yu Z, Wei X, Liu L, Sun H, Fang T, Wang L, Li Y, Sui W, Wang K, He Y, Zhao Y, Huang W, An G, Meng F, Huang C, Yu T, Anderson KC, Cheng T, Qiu L, Hao M
published in: EBioMedicine
information resource reference: Indirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma. EBioMedicine. 2022 Apr; 78:103950.
journal title abbreviation: EBioMedicine
publication date: 2022-03-26T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 27365
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Authorship 1445393
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.

Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
PubMed Identifier: 35513704
author list: Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso MS, Abiatari I, Letai A, Dorfman DM, Hideshima T, Anderson KC
published in: Leukemia
information resource reference: Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma. Leukemia. 2022 Jun; 36(6):1700.
journal title abbreviation: Leukemia
publication date: 2022-06-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 298610
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: An update of novel therapeutic approaches for multiple myeloma.

Authorship 336921
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.

Authorship 35889
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.

Authorship 36906
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Advances in biology of multiple myeloma: clinical applications.

Authorship 1465654
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

Authorship 1465787
type: Authorship
author rank in publication: 55
linked author: Anderson, Kenneth
linked information resource: Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

Authorship 1460612
type: Authorship
author rank in publication: 29
linked author: Anderson, Kenneth
linked information resource: Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.

Authorship 1459887
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.

Authorship 1460670
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.

Authorship 1465757
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma.

Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma.
PubMed Identifier: 35848842
author list: O'Donnell EK, Shapiro YN, Yee AJ, Nadeem O, Laubach JP, Branagan AR, Anderson KC, Mo CC, Munshi NC, Ghobrial IM, Sperling AS, Agyemang EA, Burke JN, Harrington CC, Hu BY, Richardson PG, Raje NS, El-Jawahri A
published in: Blood advances
information resource reference: Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma. Blood Adv. 2022 09 13; 6(17):4967-4974.
journal title abbreviation: Blood Adv
publication date: 2022-09-13T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15.
PubMed Identifier: 35882498
author list: Fernandez RA, Mayoral JE, Pierre-Louis L, Yao Y, Xu Y, Mu S, Martinez-Lopez J, Primo D, Miyazaki T, Prabhala R, Anderson KC, Overwijk WW, Munshi NC, Fulciniti M
published in: Blood advances
information resource reference: Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15. Blood Adv. 2023 01 10; 7(1):9-19.
journal title abbreviation: Blood Adv
publication date: 2023-01-10T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.
PubMed Identifier: 35653592
author list: Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, Brousset P, Cerroni L, de Leval L, Dirnhofer S, Dogan A, Feldman AL, Fend F, Friedberg JW, Gaulard P, Ghia P, Horwitz SM, King RL, Salles G, San-Miguel J, Seymour JF, Treon SP, Vose JM, Zucca E, Advani R, Ansell S, Au WY, Barrionuevo C, Bergsagel L, Chan WC, Cohen JI, d'Amore F, Davies A, Falini B, Ghobrial IM, Goodlad JR, Gribben JG, Hsi ED, Kahl BS, Kim WS, Kumar S, LaCasce AS, Laurent C, Lenz G, Leonard JP, Link MP, Lopez-Guillermo A, Mateos MV, Macintyre E, Melnick AM, Morschhauser F, Nakamura S, Narbaitz M, Pavlovsky A, Pileri SA, Piris M, Pro B, Rajkumar V, Rosen ST, Sander B, Sehn L, Shipp MA, Smith SM, Staudt LM, Thieblemont C, Tousseyn T, Wilson WH, Yoshino T, Zinzani PL, Dreyling M, Scott DW, Winter JN, Zelenetz AD
published in: Blood
information resource reference: The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 09 15; 140(11):1229-1253.
journal title abbreviation: Blood
publication date: 2022-09-15T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.
PubMed Identifier: 35660812
author list: Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, Medvedova E, McCarthy PL, Libby EN, Voorhees PM, Orlowski RZ, Anderson LD, Zonder JA, Milner CP, Gasparetto C, Agha ME, Khan AM, Hurd DD, Gowin K, Kamble RT, Jagannath S, Nathwani N, Alsina M, Cornell RF, Hashmi H, Campagnaro EL, Andreescu AC, Gentile T, Liedtke M, Godby KN, Cohen AD, Openshaw TH, Pasquini MC, Giralt SA, Kaufman JL, Yee AJ, Scott E, Torka P, Foley A, Fulciniti M, Hebert K, Samur MK, Masone K, Maglio ME, Zeytoonjian AA, Nadeem O, Schlossman RL, Laubach JP, Paba-Prada C, Ghobrial IM, Perrot A, Moreau P, Avet-Loiseau H, Attal M, Anderson KC, Munshi NC
published in: The New England journal of medicine
information resource reference: Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022 07 14; 387(2):132-147.
journal title abbreviation: N Engl J Med
publication date: 2022-06-05T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma.
PubMed Identifier: 35653112
author list: Davies FE, Pawlyn C, Usmani SZ, San-Miguel JF, Einsele H, Boyle EM, Corre J, Auclair D, Cho HJ, Lonial S, Sonneveld P, Stewart AK, Bergsagel PL, Kaiser MF, Weisel K, Keats JJ, Mikhael JR, Morgan KE, Ghobrial IM, Orlowski RZ, Landgren CO, Gay F, Caers J, Chng WJ, Chari A, Walker BA, Kumar SK, Costa LJ, Anderson KC, Morgan GJ
published in: Blood cancer discovery
information resource reference: Perspectives on the Risk-Stratified Treatment of Multiple Myeloma. Blood Cancer Discov. 2022 07 06; 3(4):273-284.
journal title abbreviation: Blood Cancer Discov
publication date: 2022-07-06T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.
PubMed Identifier: 35847734
author list: Richardson PG, Nagler A, Ben-Yehuda D, Badros A, Hari PN, Hajek R, Spicka I, Kaya H, LeBlanc R, Yoon SS, Kim K, Martinez-Lopez J, Mittelman M, Shpilberg O, Blake P, Hideshima T, Colson K, Laubach JP, Ghobrial IM, Leiba M, Gatt ME, Sportelli P, Chen M, Anderson KC
published in: EJHaem
information resource reference: Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib. EJHaem. 2020 Jul; 1(1):94-102.
journal title abbreviation: EJHaem
publication date: 2020-04-06T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 15951
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibition in the treatment of cancer.

Authorship 403161
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.

Authorship 413785
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.

Authorship 1502722
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1484024
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma.

Authorship 1502492
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1490090
type: Authorship
author rank in publication: 30
linked author: Anderson, Kenneth
linked information resource: A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.

Authorship 1494377
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1502923
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Bispecific antibodies in multiple myeloma treatment: A journey in progress.

Authorship 1493667
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Genomic patterns of progression in smoldering multiple myeloma.

Authorship 1502489
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1494177
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.

Authorship 1502725
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1502483
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1493907
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: ?-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.

Authorship 1502495
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1494591
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Authorship 1502486
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36325690
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Molecular cancer therapeutics
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Mol Cancer Ther. 2022 11 03; 21(11):1625-1631.
journal title abbreviation: Mol Cancer Ther
publication date: 2022-11-03T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma.
PubMed Identifier: 36010596
author list: Johnstone M, Vinaixa D, Turi M, Morelli E, Anderson KC, Gulla A
published in: Cells
information resource reference: Promises and Challenges of Immunogenic Chemotherapy in Multiple Myeloma. Cells. 2022 08 14; 11(16).
journal title abbreviation: Cells
publication date: 2022-08-14T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36321298
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Cancer immunology research
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Immunol Res. 2022 11 02; 10(11):1282-1288.
journal title abbreviation: Cancer Immunol Res
publication date: 2022-11-02T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Bispecific antibodies in multiple myeloma treatment: A journey in progress.
PubMed Identifier: 36330495
author list: Cho SF, Yeh TJ, Anderson KC, Tai YT
published in: Frontiers in oncology
information resource reference: Bispecific antibodies in multiple myeloma treatment: A journey in progress. Front Oncol. 2022; 12:1032775.
journal title abbreviation: Front Oncol
publication date: 2022-10-18T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

?-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation.
PubMed Identifier: 35973981
author list: Chen H, Yu T, Lin L, Xing L, Cho SF, Wen K, Aardalen K, Oka A, Lam J, Daley M, Lu H, Munshi N, Anderson KC, Tai YT
published in: Blood cancer journal
information resource reference: ?-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022 08 16; 12(8):118.
journal title abbreviation: Blood Cancer J
publication date: 2022-08-16T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36321264
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Cancer research
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Res. 2022 11 02; 82(21):3861-3867.
journal title abbreviation: Cancer Res
publication date: 2022-11-02T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth.
PubMed Identifier: 36126301
author list: Morelli E, Fulciniti M, Samur MK, Ribeiro CF, Wert-Lamas L, Henninger JE, Gullà A, Aktas-Samur A, Todoerti K, Talluri S, Park WD, Federico C, Scionti F, Amodio N, Bianchi G, Johnstone M, Liu N, Gramegna D, Maisano D, Russo NA, Lin C, Tai YT, Neri A, Chauhan D, Hideshima T, Shammas MA, Tassone P, Gryaznov S, Young RA, Anderson KC, Novina CD, Loda M, Munshi NC
published in: Blood
information resource reference: A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth. Blood. 2023 01 26; 141(4):391-405.
journal title abbreviation: Blood
publication date: 2023-01-26T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36321301
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Epidemiol Biomarkers Prev. 2022 11 02; 31(11):1995-2001.
journal title abbreviation: Cancer Epidemiol Biomarkers Prev
publication date: 2022-11-02T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
PubMed Identifier: 36273105
author list: Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diepstra A, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF, Gabbas A, Ghesquières H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N
published in: Leukemia
information resource reference: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. 2022 12; 36(12):2835-2844.
journal title abbreviation: Leukemia
publication date: 2022-10-22T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36325685
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Molecular cancer research : MCR
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Mol Cancer Res. 2022 11 03; 20(11):1591-1597.
journal title abbreviation: Mol Cancer Res
publication date: 2022-11-03T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36321306
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Cancer discovery
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Discov. 2022 11 02; 12(11):2475-2481.
journal title abbreviation: Cancer Discov
publication date: 2022-11-02T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36321294
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Blood cancer discovery
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Blood Cancer Discov. 2022 11 02; 3(6):469-475.
journal title abbreviation: Blood Cancer Discov
publication date: 2022-11-02T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36317374
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Clin Cancer Res. 2022 11 01; 28(21):4593-4599.
journal title abbreviation: Clin Cancer Res
publication date: 2022-11-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.
PubMed Identifier: 36317369
author list: Anderson KC, Cantley LC, Dalla-Favera R, Dang CV, Diaz LA, DuBois RN, Flaherty KT, Greenberg PD, Loda M, Mardis ER, Platz EA, Pollak MN, Schreiber RD, Siu LL, Teicher BA
published in: Cancer prevention research (Philadelphia, Pa.)
information resource reference: The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Prev Res (Phila). 2022 11 01; 15(11):705-712.
journal title abbreviation: Cancer Prev Res (Phila)
publication date: 2022-11-01T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 194334
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: WIP is a chaperone for Wiskott-Aldrich syndrome protein (WASP).

Authorship 1511105
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.

Authorship 1513380
type: Authorship
author rank in publication: 26
linked author: Anderson, Kenneth
linked information resource: Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.

Authorship 1513807
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.

Authorship 1514739
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.

Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk.
PubMed Identifier: 36513657
author list: Ajore R, Niroula A, Pertesi M, Cafaro C, Thodberg M, Went M, Bao EL, Duran-Lozano L, Lopez de Lapuente Portilla A, Olafsdottir T, Ugidos-Damboriena N, Magnusson O, Samur M, Lareau CA, Halldorsson GH, Thorleifsson G, Norddahl GL, Gunnarsdottir K, Försti A, Goldschmidt H, Hemminki K, van Rhee F, Kimber S, Sperling AS, Kaiser M, Anderson K, Jonsdottir I, Munshi N, Rafnar T, Waage A, Weinhold N, Thorsteinsdottir U, Sankaran VG, Stefansson K, Houlston R, Nilsson B
published in: Nature communications
information resource reference: Author Correction: Functional dissection of inherited non-coding variation influencing multiple myeloma risk. Nat Commun. 2022 Dec 13; 13(1):7725.
journal title abbreviation: Nat Commun
publication date: 2022-12-13T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.
PubMed Identifier: 36533670
author list: Cholujova D, Beke G, Hunter ZR, Hideshima T, Flores L, Zeleznikova T, Harrachova D, Klucar L, Leiba M, Drgona L, Treon SP, Kastritis E, Dorfman DM, Anderson KC, Jakubikova J
published in: International journal of cancer
information resource reference: Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia. Int J Cancer. 2023 05 01; 152(9):1947-1963.
journal title abbreviation: Int J Cancer
publication date: 2022-12-30T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
PubMed Identifier: 36603186
author list: Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC
published in: Blood
information resource reference: High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma. Blood. 2023 04 06; 141(14):1724-1736.
journal title abbreviation: Blood
publication date: 2023-04-06T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors.
PubMed Identifier: 36535935
author list: Aktas Samur A, Fulciniti M, Avet-Loiseau H, Lopez MA, Derebail S, Corre J, Minvielle S, Magrangeas F, Moreau P, Anderson KC, Parmigiani G, Samur MK, Munshi NC
published in: Blood cancer journal
information resource reference: In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors. Blood Cancer J. 2022 12 20; 12(12):171.
journal title abbreviation: Blood Cancer J
publication date: 2022-12-20T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1516731
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.

Authorship 1516776
type: Authorship
author rank in publication: 28
linked author: Anderson, Kenneth
linked information resource: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma.
PubMed Identifier: 36630605
author list: Du T, Song Y, Ray A, Wan X, Yao Y, Samur MK, Shen C, Penailillo J, Sewastianik T, Tai YT, Fulciniti M, Munshi NC, Wu H, Carrasco RD, Chauhan D, Anderson KC
published in: Blood
information resource reference: Ubiquitin receptor PSMD4/Rpn10 is a novel therapeutic target in multiple myeloma. Blood. 2023 05 25; 141(21):2599-2614.
journal title abbreviation: Blood
publication date: 2023-05-25T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
PubMed Identifier: 36631435
author list: Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U
published in: Blood cancer journal
information resource reference: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. Blood Cancer J. 2023 01 12; 13(1):12.
journal title abbreviation: Blood Cancer J
publication date: 2023-01-12T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1521083
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics.

Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics.
PubMed Identifier: 36737429
author list: Ogiya D, Chyra Z, Verselis SJ, O'Keefe M, Cobb J, Abiatari I, Talluri S, Sithara AA, Hideshima T, Chu MP, Hájek R, Dorfman DM, Pilarski LM, Anderson KC, Adamia S
published in: Blood cancer journal
information resource reference: Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics. Blood Cancer J. 2023 02 03; 13(1):23.
journal title abbreviation: Blood Cancer J
publication date: 2023-02-03T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 246731
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.

Associate Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Oncology
sort order: 1
type: Position
HR job title: Associate Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1524856
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.

Authorship 1523781
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.

Authorship 1523168
type: Authorship
author rank in publication: 28
linked author: Anderson, Kenneth
linked information resource: Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.

Authorship 1523423
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
PubMed Identifier: 36746923
author list: Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U
published in: Blood cancer journal
information resource reference: Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma. Blood Cancer J. 2023 Feb 07; 13(1):24.
journal title abbreviation: Blood Cancer J
publication date: 2023-02-07T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1.
PubMed Identifier: 36826833
author list: Lu W, Liu Y, Gao Y, Geng Q, Gurbani D, Li L, Ficarro SB, Meyer CJ, Sinha D, You I, Tse J, He Z, Ji W, Che J, Kim AY, Yu T, Wen K, Anderson KC, Marto JA, Westover KD, Zhang T, Gray NS
published in: Journal of medicinal chemistry
information resource reference: Development of a Covalent Inhibitor of c-Jun N-Terminal Protein Kinase (JNK) 2/3 with Selectivity over JNK1. J Med Chem. 2023 03 09; 66(5):3356-3371.
journal title abbreviation: J Med Chem
publication date: 2023-02-24T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
PubMed Identifier: 36752202
author list: Jakubikova J, Cholujova D, Beke G, Hideshima T, Klucar L, Leiba M, Jamroziak K, Richardson PG, Kastritis E, Dorfman DM, Anderson KC
published in: JCI insight
information resource reference: Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma. JCI Insight. 2023 02 08; 8(3).
journal title abbreviation: JCI Insight
publication date: 2023-02-08T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
PubMed Identifier: 36780189
author list: Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. Clin Cancer Res. 2023 05 01; 29(9):1807-1821.
journal title abbreviation: Clin Cancer Res
publication date: 2023-05-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1531835
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.
PubMed Identifier: 36877894
author list: Yao Y, Ng JF, Park WD, Samur M, Morelli E, Encinas Mayoral J, Chyra Z, Xu Y, Derebail S, Epstein C, Nabet B, Chesi M, Gray NS, Young RA, Kwiatkowski N, Mitsiades C, Anderson KC, Lin CY, Munshi NC, Fulciniti M
published in: Blood
information resource reference: CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma. Blood. 2023 06 08; 141(23):2841-2852.
journal title abbreviation: Blood
publication date: 2023-06-08T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 194915
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Caveolin-1 as a potential new therapeutic target in multiple myeloma.

Authorship 195020
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.

Authorship 498316
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Authorship 261508
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Translocation of Ku86/Ku70 to the multiple myeloma cell membrane: functional implications.

Authorship 1562288
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Determinants of response and resistance to T cell-engaging therapies in multiple myeloma.

Authorship 1559256
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.

Authorship 1553011
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs.

Authorship 1564251
type: Authorship
author rank in publication: 27
linked author: Anderson, Kenneth
linked information resource: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease.

Authorship 1559535
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: A pandemic preparedness network for individuals living with compromised immune systems.

Authorship 1562144
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.

Authorship 1557151
type: Authorship
author rank in publication: 27
linked author: Anderson, Kenneth
linked information resource: Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease.

Authorship 1556631
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria.
PubMed Identifier: 37173155
author list: Treon SP, Tedeschi A, San-Miguel J, Garcia-Sanz R, Anderson KC, Kimby E, Minnema MC, Benevolo G, Qiu L, Yi S, Terpos E, Tam CS, Castillo JJ, Morel P, Dimopoulos M, Owen RG
published in: Seminars in hematology
information resource reference: Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Semin Hematol. 2023 03; 60(2):97-106.
journal title abbreviation: Semin Hematol
publication date: 2023-04-20T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Determinants of response and resistance to T cell-engaging therapies in multiple myeloma.
PubMed Identifier: 37173587
author list: Midha S, Anderson KC
published in: Nature reviews. Clinical oncology
information resource reference: Determinants of response and resistance to T cell-engaging therapies in multiple myeloma. Nat Rev Clin Oncol. 2023 08; 20(8):505-506.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2023-08-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease.
PubMed Identifier: 37198323
author list: Rizq O, Mimura N, Oshima M, Momose S, Takayama N, Itokawa N, Koide S, Shibamiya A, Miyamoto-Nagai Y, Rizk M, Nakajima-Takagi Y, Aoyama K, Wang C, Saraya A, Ito R, Seimiya M, Watanabe M, Yamasaki S, Shibata T, Yamaguchi K, Furukawa Y, Chiba T, Sakaida E, Nakaseko C, Tamaru JI, Tai YT, Anderson KC, Honda H, Iwama A
published in: Leukemia
information resource reference: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. Leukemia. 2023 09; 37(9):1895-1907.
journal title abbreviation: Leukemia
publication date: 2023-05-17T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease.
PubMed Identifier: 37464071
author list: Rizq O, Mimura N, Oshima M, Momose S, Takayama N, Itokawa N, Koide S, Shibamiya A, Miyamoto-Nagai Y, Rizk M, Nakajima-Takagi Y, Aoyama K, Wang C, Saraya A, Ito R, Seimiya M, Watanabe M, Yamasaki S, Shibata T, Yamaguchi K, Furukawa Y, Chiba T, Sakaida E, Nakaseko C, Tamaru JI, Tai YT, Anderson KC, Honda H, Iwama A
published in: Leukemia
information resource reference: Correction: UTX inactivation in germinal center B cells promotes the development of multiple myeloma with extramedullary disease. Leukemia. 2023 Sep; 37(9):1952.
journal title abbreviation: Leukemia
publication date: 2023-09-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

A pandemic preparedness network for individuals living with compromised immune systems.
PubMed Identifier: 37023227
author list: Wood WA, Anderson KC, Kumar SK, Semmel EA, Hewitt K, Plovnick RM, Pappas G
published in: Blood advances
information resource reference: A pandemic preparedness network for individuals living with compromised immune systems. Blood Adv. 2023 08 08; 7(15):3925-3927.
journal title abbreviation: Blood Adv
publication date: 2023-08-08T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma.
PubMed Identifier: 37021929
author list: Bumma N, Dhakal B, Fraser R, Estrada-Merly N, Anderson K, Freytes CO, Hildebrandt GC, Holmberg L, Krem MM, Lee C, Lekakis L, Lazarus HM, Mian H, Murthy HS, Nathan S, Nishihori T, Parrondo R, Patel SS, Solh M, Strouse C, Vesole DH, Kumar S, Qazilbash MH, Shah N, D'Souza A, Sidana S
published in: Cancer
information resource reference: Impact of bortezomib-based versus lenalidomide maintenance therapy on outcomes of patients with high-risk multiple myeloma. Cancer. 2023 07 15; 129(14):2179-2191.
journal title abbreviation: Cancer
publication date: 2023-04-06T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs.
PubMed Identifier: 37421589
author list: Liu X, Moscvin M, Oh S, Chen T, Choi W, Evans B, Rowell SM, Nadeem O, Mo CC, Sperling AS, Anderson KC, Yaqoob Z, Bianchi G, Sung Y
published in: Clinical and experimental medicine
information resource reference: Characterizing dry mass and volume changes in human multiple myeloma cells upon treatment with proteotoxic and genotoxic drugs. Clin Exp Med. 2023 Nov; 23(7):3821-3832.
journal title abbreviation: Clin Exp Med
publication date: 2023-07-08T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.
PubMed Identifier: 37463058
author list: Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Somaiya Dutt P, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 12 01; 29(23):4784-4796.
journal title abbreviation: Clin Cancer Res
publication date: 2023-12-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 213113
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: A strategic framework for novel drug development in multiple myeloma.

Authorship 321438
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.

Authorship 1592077
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.

Authorship 1591549
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.

Authorship 1585320
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Monoallelic deletion of BCMA is a frequent feature in multiple myeloma.

Authorship 1585110
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.

Authorship 1583755
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.

Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes.
PubMed Identifier: 37666943
author list: Berndt SI, Vijai J, Benavente Y, Camp NJ, Nieters A, Wang Z, Smedby KE, Kleinstern G, Hjalgrim H, Besson C, Skibola CF, Morton LM, Brooks-Wilson AR, Teras LR, Breeze C, Arias J, Adami HO, Albanes D, Anderson KC, Ansell SM, Bassig B, Becker N, Bhatti P, Birmann BM, Boffetta P, Bracci PM, Brennan P, Brown EE, Burdett L, Cannon-Albright LA, Chang ET, Chiu BCH, Chung CC, Clavel J, Cocco P, Colditz G, Conde L, Conti DV, Cox DG, Curtin K, Casabonne D, De Vivo I, Diepstra A, Diver WR, Dogan A, Edlund CK, Foretova L, Fraumeni JF, Gabbas A, Ghesquières H, Giles GG, Glaser S, Glenn M, Glimelius B, Gu J, Habermann TM, Haiman CA, Haioun C, Hofmann JN, Holford TR, Holly EA, Hutchinson A, Izhar A, Jackson RD, Jarrett RF, Kaaks R, Kane E, Kolonel LN, Kong Y, Kraft P, Kricker A, Lake A, Lan Q, Lawrence C, Li D, Liebow M, Link BK, Magnani C, Maynadie M, McKay J, Melbye M, Miligi L, Milne RL, Molina TJ, Monnereau A, Montalvan R, North KE, Novak AJ, Onel K, Purdue MP, Rand KA, Riboli E, Riby J, Roman E, Salles G, Sborov DW, Severson RK, Shanafelt TD, Smith MT, Smith A, Song KW, Song L, Southey MC, Spinelli JJ, Staines A, Stephens D, Sutherland HJ, Tkachuk K, Thompson CA, Tilly H, Tinker LF, Travis RC, Turner J, Vachon CM, Vajdic CM, Van Den Berg A, Van Den Berg DJ, Vermeulen RCH, Vineis P, Wang SS, Weiderpass E, Weiner GJ, Weinstein S, Doo NW, Ye Y, Yeager M, Yu K, Zeleniuch-Jacquotte A, Zhang Y, Zheng T, Ziv E, Sampson J, Chatterjee N, Offit K, Cozen W, Wu X, Cerhan JR, Chanock SJ, Slager SL, Rothman N
published in: Leukemia
information resource reference: Correction: Distinct germline genetic susceptibility profiles identified for common non-Hodgkin lymphoma subtypes. Leukemia. 2023 Oct; 37(10):2142.
journal title abbreviation: Leukemia
publication date: 2023-10-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
PubMed Identifier: 37528088
author list: Raje N, Anderson K, Einsele H, Efebera Y, Gay F, Hammond SP, Lesokhin AM, Lonial S, Ludwig H, Moreau P, Patel K, Ramasamy K, Mateos MV
published in: Blood cancer journal
information resource reference: Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 2023 08 01; 13(1):116.
journal title abbreviation: Blood Cancer J
publication date: 2023-08-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma.
PubMed Identifier: 37611163
author list: Samur MK, Aktas Samur A, Corre J, Lannes R, Shah P, Anderson K, Avet-Loiseau H, Munshi N
published in: Blood advances
information resource reference: Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023 11 14; 7(21):6599-6603.
journal title abbreviation: Blood Adv
publication date: 2023-11-14T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
PubMed Identifier: 37608773
author list: Richardson PG, Durie BG, Rosiñol L, Mateos MV, Dispenzieri A, Moreau P, Kumar S, Raje N, Munshi N, Laubach JP, O'Gorman P, O'Donnell E, Voorhees P, Facon T, Bladé J, Lonial S, Perrot A, Anderson KC
published in: Haematologica
information resource reference: Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma. Haematologica. 2023 11 01; 108(11):2894-2912.
journal title abbreviation: Haematologica
publication date: 2023-11-01T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment.
PubMed Identifier: 37680953
author list: Liu J, Yan W, Fan H, Xu J, Li L, Du C, Mao X, Yan Y, Xu Y, Sui W, Deng S, Yi S, Anderson KC, Qiu L, Zou D, An G
published in: Cancer research communications
information resource reference: Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. Cancer Res Commun. 2023 09; 3(9):1770-1780.
journal title abbreviation: Cancer Res Commun
publication date: 2023-09-06T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 402209
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Molecular sequelae of histone deacetylase inhibition in human malignant B cells.

Stephen B. Kay Family Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Adult Oncology
sort order: 1
type: Position
HR job title: Stephen B. Kay Family Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 41714
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.

Authorship 443752
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: The extracellular calcium Ca2+o-sensing receptor is expressed in myeloma cells and modulates cell proliferation.

Authorship 1601327
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8aß+ T cells targeting multiple myeloma.

Authorship 1600634
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.

Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8aß+ T cells targeting multiple myeloma.
PubMed Identifier: 37890146
author list: Bae J, Kitayama S, Herbert Z, Daheron L, Kurata K, Keskin DB, Livak K, Li S, Tarannum M, Romee R, Samur M, Munshi NC, Kaneko S, Ritz J, Anderson KC
published in: Blood
information resource reference: Differentiation of BCMA-specific induced pluripotent stem cells into rejuvenated CD8aß+ T cells targeting multiple myeloma. Blood. 2024 03 07; 143(10):895-911.
journal title abbreviation: Blood
publication date: 2024-03-07T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma.
PubMed Identifier: 37846845
author list: Yan W, Xu J, Fan H, Li L, Cui J, Du C, Deng S, Sui W, Xu Y, Hao M, Anderson KC, Zou D, Qiu L, An G
published in: Cancer
information resource reference: Early relapse within 18 months is a powerful dynamic predictor for prognosis and could revise static risk distribution in multiple myeloma. Cancer. 2024 02 01; 130(3):421-432.
journal title abbreviation: Cancer
publication date: 2023-10-17T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 495235
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.

BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.
PubMed Identifier: 38072962
author list: Dutta D, Liu J, Wen K, Kurata K, Fulciniti M, Gulla A, Hideshima T, Anderson KC
published in: Blood cancer journal
information resource reference: BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma. Blood Cancer J. 2023 12 11; 13(1):184.
journal title abbreviation: Blood Cancer J
publication date: 2023-12-11T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1613568
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myeloma.

Authorship 1613761
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.

Authorship 1614333
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/227997846

Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells.
PubMed Identifier: 38139060
author list: Edri A, Ben-Haim N, Hailu A, Brycman N, Berhani-Zipori O, Rifman J, Cohen S, Yackoubov D, Rosenberg M, Simantov R, Teru H, Kurata K, Anderson KC, Hendel A, Pato A, Geffen Y
published in: International journal of molecular sciences
information resource reference: Nicotinamide-Expanded Allogeneic Natural Killer Cells with CD38 Deletion, Expressing an Enhanced CD38 Chimeric Antigen Receptor, Target Multiple Myeloma Cells. Int J Mol Sci. 2023 Dec 07; 24(24).
journal title abbreviation: Int J Mol Sci
publication date: 2023-12-07T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/227997846
PubMed Identifier: 38111533
author list: Prabhala R, Pierceall WE, Samur M, Potluri LB, Hong K, Peluso T, Talluri S, Wang A, Katiki A, Vangala SD, Buonopane M, Bade V, Seah H, Krogman A, Derebail S, Fulciniti M, Lazo SB, Richardson P, Anderson K, Corre J, Avet-Loiseau H, Thakurta A, Munshi N
published in: Frontiers in oncology
information resource reference: Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival. Front Oncol. 2023; 13:1271807.
journal title abbreviation: Front Oncol
publication date: 2023-12-04T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival.

Authorship 550235
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma.

Authorship 1622815
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.

Authorship 1623970
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
PubMed Identifier: 38273148
author list: Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD
published in: Nature medicine
information resource reference: Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2024 Apr; 30(4):1210.
journal title abbreviation: Nat Med
publication date: 2024-04-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma.
PubMed Identifier: 38249329
author list: Cui J, Yu T, Lv R, Liu J, Fan H, Yan W, Xu J, Du C, Deng S, Sui W, Ho M, Xu Y, Anderson KC, Dong X, Qiu L, An G
published in: Therapeutic advances in medical oncology
information resource reference: Longitudinal genetically detectable minimal residual disease by fluorescence in situ hybridization confers a poor prognosis in myeloma. Ther Adv Med Oncol. 2024; 16:17588359231221340.
journal title abbreviation: Ther Adv Med Oncol
publication date: 2024-01-19T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1626448
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.

Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
PubMed Identifier: 38299578
author list: Richardson PG, Perrot A, Miguel JS, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Macé S, Zhang R, Dubin F, Morisse MC, Anderson KC
published in: Haematologica
information resource reference: Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024 07 01; 109(7):2239-2249.
journal title abbreviation: Haematologica
publication date: 2024-07-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1628031
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Role of minimal residual disease assessment in multiple myeloma.

Role of minimal residual disease assessment in multiple myeloma.
PubMed Identifier: 38328864
author list: Szalat R, Anderson K, Munshi N
published in: Haematologica
information resource reference: Role of minimal residual disease assessment in multiple myeloma. Haematologica. 2024 07 01; 109(7):2049-2059.
journal title abbreviation: Haematologica
publication date: 2024-07-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.
PubMed Identifier: 38355622
author list: Liu J, Xing L, Li J, Wen K, Liu N, Liu Y, Wu G, Wang S, Ogiya D, Song TY, Kurata K, Penailillo J, Morelli E, Wang T, Hong X, Gulla A, Tai YT, Munshi N, Richardson P, Carrasco R, Hideshima T, Anderson KC
published in: Nature communications
information resource reference: Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma. Nat Commun. 2024 Feb 14; 15(1):1367.
journal title abbreviation: Nat Commun
publication date: 2024-02-14T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1632402
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator.

Authorship 1632590
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: ESAs not the culprit: more studies required.

Authorship 1630502
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub.

Authorship 1631421
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Authorship 1629275
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.

Authorship 1630479
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: A workshop on the marrow microenvironment and hematological malignancy.

Authorship 1629816
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage.

Authorship 1631175
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: "Gigantiform" peripheral ossifying fibroma: report of a case.

Authorship 1632473
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Bortezomib therapy for myeloma.

Authorship 1630600
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.

Authorship 1633640
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers.

Authorship 1632380
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma.

Authorship 1630468
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: "Sowing dragon's teeth?" Myeloma and AML.

Authorship 1632543
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/232759548

Authorship 1629271
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.

Authorship 1632339
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Accelerating anticancer drug development - opportunities and trade-offs.

Authorship 1630673
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Shrinking the divide: improving myeloma CART access.

Authorship 1631398
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Epigenetic regulation of CD38/CD48 by KDM6A mediates NK cell response in multiple myeloma.

Authorship 1631844
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy.

Authorship 1632422
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake.

Authorship 1632531
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authorship 1632463
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: a clinical overview.

Authorship 1631655
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.

Authorship 1632474
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Stem cell transplantation for myeloma.

Authorship 1632529
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: CA125 expression in spontaneous ovarian adenocarcinomas from laying hens.

DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy.
PubMed Identifier: 38366728
author list: Cifric S, Turi M, Folino P, Clericuzio C, Barello F, Maciel T, Anderson KC, Gulla A
published in: Antioxidants & redox signaling
information resource reference: DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy. Antioxid Redox Signal. 2024 Oct; 41(10-12):661-674.
journal title abbreviation: Antioxid Redox Signal
publication date: 2024-03-22T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Stem cell transplantation for myeloma.
PubMed Identifier: 14695853
author list: Anderson KC
published in: Current hematology reports
information resource reference: Stem cell transplantation for myeloma. Curr Hematol Rep. 2004 Jan; 3(1):65-6.
journal title abbreviation: Curr Hematol Rep
publication date: 2004-01-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma: a clinical overview.
PubMed Identifier: 25188477
author list: Anderson KC
published in: Oncology (Williston Park, N.Y.)
information resource reference: Multiple myeloma: a clinical overview. Oncology (Williston Park). 2011 Nov 15; 25 Suppl 2:3-9.
journal title abbreviation: Oncology (Williston Park)
publication date: 2011-11-15T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

CA125 expression in spontaneous ovarian adenocarcinomas from laying hens.
PubMed Identifier: 16942793
author list: Jackson E, Anderson K, Ashwell C, Petitte J, Mozdziak PE
published in: Gynecologic oncology
information resource reference: CA125 expression in spontaneous ovarian adenocarcinomas from laying hens. Gynecol Oncol. 2007 Jan; 104(1):192-8.
journal title abbreviation: Gynecol Oncol
publication date: 2006-08-30T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Shrinking the divide: improving myeloma CART access.
PubMed Identifier: 38194242
author list: Nooka AK, Hartley-Brown MA, Anderson KC, Lonial S
published in: Blood advances
information resource reference: Shrinking the divide: improving myeloma CART access. Blood Adv. 2024 01 09; 8(1):248-250.
journal title abbreviation: Blood Adv
publication date: 2024-01-09T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

"Sowing dragon's teeth?" Myeloma and AML.
PubMed Identifier: 21998330
author list: McCarthy PL, Owzar K, Anderson K
published in: Blood
information resource reference: "Sowing dragon's teeth?" Myeloma and AML. Blood. 2011 Oct 13; 118(15):4008-9.
journal title abbreviation: Blood
publication date: 2011-10-13T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A workshop on the marrow microenvironment and hematological malignancy.
PubMed Identifier: 14612557
author list: Choi YS, Anderson K, Mufson RA
published in: Cancer research
information resource reference: A workshop on the marrow microenvironment and hematological malignancy. Cancer Res. 2003 Nov 01; 63(21):7539-41.
journal title abbreviation: Cancer Res
publication date: 2003-11-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.
PubMed Identifier: 38355975
author list: McMillin DW, Delmore J, Weisberg E, Negri JM, Geer CD, Klippel S, Mitsiades N, Schlossman RL, Munshi NC, Kung AL, Griffin JD, Richardson PG, Anderson KC, Mitsiades CS
published in: Nature medicine
information resource reference: Author Correction: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2024 Apr; 30(4):1214.
journal title abbreviation: Nat Med
publication date: 2024-04-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake.
PubMed Identifier: 35383108
author list: Hove VN, Anderson K, Hayden ER, Pasquariello KZ, Gibson AA, Shen S, Qu J, Jin Y, Miecznikowski JC, Hu S, Sprowl JA
published in: Molecular pharmacology
information resource reference: Influence of Tyrosine Kinase Inhibition on Organic Anion Transporting Polypeptide 1B3-Mediated Uptake. Mol Pharmacol. 2022 06; 101(6):381-389.
journal title abbreviation: Mol Pharmacol
publication date: 2022-04-05T00:00:00
year: 2022
type: Academic Article
type: Article
type: Document
type: Information Resource

ESAs not the culprit: more studies required.
PubMed Identifier: 18785638
author list: Ludwig H, Anderson K, Dammacco F, Hedenus M, Osterborg A, Durie B
published in: American journal of hematology
information resource reference: ESAs not the culprit: more studies required. Am J Hematol. 2008 Nov; 83(11):880; author reply 880-1.
journal title abbreviation: Am J Hematol
publication date: 2008-11-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo.
PubMed Identifier: 22942257
author list: Raab MS, Breitkreutz I, Anderhub S, Rønnest MH, Leber B, Larsen TO, Weiz L, Konotop G, Hayden PJ, Podar K, Fruehauf J, Nissen F, Mier W, Haberkorn U, Ho AD, Goldschmidt H, Anderson KC, Clausen MH, Krämer A
published in: Cancer research
information resource reference: GF-15, a novel inhibitor of centrosomal clustering, suppresses tumor cell growth in vitro and in vivo. Cancer Res. 2012 Oct 15; 72(20):5374-85.
journal title abbreviation: Cancer Res
publication date: 2012-08-31T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib therapy for myeloma.
PubMed Identifier: 14695852
author list: Anderson KC
published in: Current hematology reports
information resource reference: Bortezomib therapy for myeloma. Curr Hematol Rep. 2004 Jan; 3(1):65.
journal title abbreviation: Curr Hematol Rep
publication date: 2004-01-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma.
PubMed Identifier: 38247315
author list: Mao X, Yan W, Mery D, Liu J, Fan H, Xu J, Xu Y, Sui W, Deng S, Zou D, Du C, Yi S, van Rhee F, Barlogie B, Shaughnessy JD, Anderson KC, Zhan F, Qiu L, An G
published in: American journal of hematology
information resource reference: Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma. Am J Hematol. 2024 04; 99(4):523-533.
journal title abbreviation: Am J Hematol
publication date: 2024-01-21T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma.
PubMed Identifier: 21410373
author list: Palumbo A, Anderson K
published in: The New England journal of medicine
information resource reference: Multiple myeloma. N Engl J Med. 2011 Mar 17; 364(11):1046-60.
journal title abbreviation: N Engl J Med
publication date: 2011-03-17T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage.
PubMed Identifier: 38416013
author list: Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, Anderson KC
published in: Journal of immunology (Baltimore, Md. : 1950)
information resource reference: Retraction: Ku86 Variant Expression and Function in Multiple Myeloma Cells Is Associated with Increased Sensitivity to DNA Damage. J Immunol. 2024 Apr 15; 212(8):1392.
journal title abbreviation: J Immunol
publication date: 2024-04-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/232759548
PubMed Identifier: 36982699
author list: Turi M, Anilkumar Sithara A, Hofmanová L, Žihala D, Radhakrishnan D, Vdovin A, Knápková S, Ševcíková T, Chyra Z, Jelínek T, Šimícek M, Gullà A, Anderson KC, Hájek R, Hrdinka M
published in: International journal of molecular sciences
information resource reference: Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-?B Signaling. Int J Mol Sci. 2023 Mar 15; 24(6).
journal title abbreviation: Int J Mol Sci
publication date: 2023-03-15T00:00:00
year: 2023
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-?B Signaling.

"Gigantiform" peripheral ossifying fibroma: report of a case.
PubMed Identifier: 22310455
author list: Sacks HG, Amrani S, Anderson K
published in: Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
information resource reference: "Gigantiform" peripheral ossifying fibroma: report of a case. J Oral Maxillofac Surg. 2012 Nov; 70(11):2610-3.
journal title abbreviation: J Oral Maxillofac Surg
publication date: 2012-02-04T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment.
PubMed Identifier: 38362725
author list: Huston A, Leleu X, Jia X, Moreau AS, Ngo HT, Runnels J, Anderson J, Alsayed Y, Roccaro A, Vallet S, Hatjiharissi E, Tai YT, Sportelli P, Munshi N, Richardson P, Hideshima T, Roodman DG, Anderson KC, Ghobrial IM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Editor's Note: Targeting Akt and Heat Shock Protein 90 Produces Synergistic Multiple Myeloma Cell Cytotoxicity in the Bone Marrow Microenvironment. Clin Cancer Res. 2024 Feb 16; 30(4):922.
journal title abbreviation: Clin Cancer Res
publication date: 2024-02-16T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
PubMed Identifier: 32054831
author list: Dimopoulos MA, Jakubowiak AJ, McCarthy PL, Orlowski RZ, Attal M, Bladé J, Goldschmidt H, Weisel KC, Ramasamy K, Zweegman S, Spencer A, Huang JSY, Lu J, Sunami K, Iida S, Chng WJ, Holstein SA, Rocci A, Skacel T, Labotka R, Palumbo A, Anderson KC
published in: Blood cancer journal
information resource reference: Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma. Blood Cancer J. 2020 02 13; 10(2):17.
journal title abbreviation: Blood Cancer J
publication date: 2020-02-13T00:00:00
year: 2020
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1634442
type: Authorship
author rank in publication: 30
linked author: Anderson, Kenneth
linked information resource: Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.

Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma.
PubMed Identifier: 38441243
author list: Ghobrial IM, Gormley N, Kumar SK, Mateos MV, Bergsagel PL, Chesi M, Dhodapkar MV, Dispenzieri A, Fonseca R, Getz G, Kastritis E, Kristinsson SY, Martinez-Climent JA, Manier S, Marinac CR, Maura F, Morgan GJ, Davies FE, Nadeem O, Nuvolone M, Paiva B, O'Donnell E, Prosper F, Shah UA, Sklavenitis-Pistofidis R, Sperling AS, Vassiliou GS, Munshi NC, Castle PE, Anderson KC, San Miguel JF
published in: Blood cancer discovery
information resource reference: Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma. Blood Cancer Discov. 2024 May 01; 5(3):146-152.
journal title abbreviation: Blood Cancer Discov
publication date: 2024-05-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Adult Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 1637885
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Retraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line.

Authorship 1637905
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Retraction: Nuclear Factor-?B p65 Mediates Tumor Necrosis Factor a-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein.

Authorship 1637911
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications.

Authorship 1637895
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of ß1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling.

Authorship 1637891
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Retraction: Effects of Oligonucleotide N3'?P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells.

Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications.
PubMed Identifier: 38486489
author list: Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Retraction: Mechanisms by which SGN-40, a Humanized Anti-CD40 Antibody, Induces Cytotoxicity in Human Multiple Myeloma Cells: Clinical Implications. Cancer Res. 2024 Mar 15; 84(6):936.
journal title abbreviation: Cancer Res
publication date: 2024-03-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Retraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line.
PubMed Identifier: 38486482
author list: Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Retraction: Cytokines Modulate Telomerase Activity in a Human Multiple Myeloma Cell Line. Cancer Res. 2024 Mar 15; 84(6):940.
journal title abbreviation: Cancer Res
publication date: 2024-03-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.
PubMed Identifier: 38551812
author list: Gulla A, Morelli E, Johnstone M, Turi M, Samur MK, Botta C, Cifric S, Folino P, Vinaixa D, Barello F, Clericuzio C, Favasuli VK, Maisano D, Talluri S, Prabhala R, Bianchi G, Fulciniti M, Wen K, Kurata K, Liu J, Penailillo J, Bragoni A, Sapino A, Richardson PG, Chauhan D, Carrasco RD, Hideshima T, Munshi NC, Anderson KC
published in: Blood
information resource reference: Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma. Blood. 2024 06 20; 143(25):2612-2626.
journal title abbreviation: Blood
publication date: 2024-06-20T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Retraction: Effects of Oligonucleotide N3'?P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells.
PubMed Identifier: 38486483
author list: Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Retraction: Effects of Oligonucleotide N3'?P5' Thio-phosphoramidate (GRN163) Targeting Telomerase RNA in Human Multiple Myeloma Cells. Cancer Res. 2024 Mar 15; 84(6):937.
journal title abbreviation: Cancer Res
publication date: 2024-03-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of ß1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling.
PubMed Identifier: 38486484
author list: Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC
published in: Cancer research
information resource reference: Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of ß1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling. Cancer Res. 2024 Mar 15; 84(6):938.
journal title abbreviation: Cancer Res
publication date: 2024-03-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Retraction: Nuclear Factor-?B p65 Mediates Tumor Necrosis Factor a-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein.
PubMed Identifier: 38486487
author list: Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Retraction: Nuclear Factor-?B p65 Mediates Tumor Necrosis Factor a-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein. Cancer Res. 2024 Mar 15; 84(6):939.
journal title abbreviation: Cancer Res
publication date: 2024-03-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1641109
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.

A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death.
PubMed Identifier: 38594241
author list: Ray A, Du T, Wan X, Song Y, Pillai SC, Musa MA, Fang T, Moore J, Blank B, Du X, Chen X, Warne R, Sutimantanapi D, Lui F, Zavorotinskaya T, Colas C, Friedman L, Junttila MR, Chauhan D, Anderson KC
published in: Blood cancer journal
information resource reference: A novel small molecule inhibitor of CD73 triggers immune-mediated multiple myeloma cell death. Blood Cancer J. 2024 04 09; 14(1):58.
journal title abbreviation: Blood Cancer J
publication date: 2024-04-09T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 15528
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.

Authorship 164918
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel therapies for multiple myeloma.

Authorship 242015
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.

Authorship 1652869
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Authorship 1651179
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.

Authorship 1653035
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma.

Authorship 1652557
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/240862814

Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
PubMed Identifier: 38745477
author list: Gullà A, Martino MTD, Cantafio MEG, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Editor's Note: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2024 May 15; 30(10):2288.
journal title abbreviation: Clin Cancer Res
publication date: 2024-05-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors.
PubMed Identifier: 38622290
author list: Bae J, Hideshima T, Tai YT, Song Y, Richardson P, Raje N, Munshi NC, Anderson KC
published in: Leukemia
information resource reference: Correction to: Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2024 May; 38(5):1189-1190.
journal title abbreviation: Leukemia
publication date: 2024-05-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma.
PubMed Identifier: 38747543
author list: Kumar S, Rajkumar SV, Jevremovic D, Kyle RA, Shifrin Y, Nguyen M, Husain Z, Alikhah A, Jafari A, Mai S, Anderson K, Louis S
published in: American journal of hematology
information resource reference: Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma. Am J Hematol. 2024 08; 99(8):1532-1539.
journal title abbreviation: Am J Hematol
publication date: 2024-05-15T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/240862814
PubMed Identifier: 38699307
author list: Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson K, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM
published in: medRxiv : the preprint server for health sciences
information resource reference: Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone. medRxiv. 2024 Apr 19.
journal title abbreviation: medRxiv
publication date: 2024-04-19T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Long-Term Follow-Up Defines the Population That Benefits from Early Interception in a High-Risk Smoldering Multiple Myeloma Clinical Trial Using the Combination of Ixazomib, Lenalidomide, and Dexamethasone.

Authorship 326281
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Moving toward individualized cancer therapies.

Authorship 1661664
type: Authorship
author rank in publication: 29
linked author: Anderson, Kenneth
linked information resource: Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.

Authorship 1659804
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Editorial Expression of Concern: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.

Authorship 1659460
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.

Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies.
PubMed Identifier: 38861273
author list: Deng S, Derebail S, Weiler VJ, Fong Ng J, Maroto-Martin E, Chatterjee M, Giorgetti G, Chakraborty C, Kalhotra P, Du T, Yao Y, Prabhala R, Shammas M, Gulla A, Aktas Samur A, Samur MK, Qiu L, Anderson KC, Fulciniti M, Munshi NC
published in: Blood advances
information resource reference: Venetoclax resistance leads to broad resistance to standard-of-care anti-MM agents, but not to immunotherapies. Blood Adv. 2024 08 13; 8(15):4025-4034.
journal title abbreviation: Blood Adv
publication date: 2024-08-13T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.
PubMed Identifier: 38865661
author list: Ozdemirli M, Loughney TM, Deniz E, Chahine JJ, Albitar M, Pittaluga S, Sadigh S, Armand P, Uren A, Anderson KC
published in: The New England journal of medicine
information resource reference: Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy. N Engl J Med. 2024 06 13; 390(22):2074-2082.
journal title abbreviation: N Engl J Med
publication date: 2024-06-13T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Editorial Expression of Concern: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma.
PubMed Identifier: 38867079
author list: Hideshima T, Nakamura N, Chauhan D, Anderson KC
published in: Oncogene
information resource reference: Editorial Expression of Concern: Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2024 07; 43(31):2447.
journal title abbreviation: Oncogene
publication date: 2024-07-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1664549
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Authorship 1663953
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.

Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins.
PubMed Identifier: 38961233
author list: Neri P, Leblay N, Lee H, Gulla A, Bahlis NJ, Anderson KC
published in: Nature reviews. Clinical oncology
information resource reference: Just scratching the surface: novel treatment approaches for multiple myeloma targeting cell membrane proteins. Nat Rev Clin Oncol. 2024 Aug; 21(8):590-609.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2024-07-03T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
PubMed Identifier: 38969881
author list: Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD
published in: Nature medicine
information resource reference: Author Correction: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2024 Aug; 30(8):2372.
journal title abbreviation: Nat Med
publication date: 2024-08-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 35667
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.

Authorship 1668320
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Improving Collection and Analysis of Overall Survival Data.

Improving Collection and Analysis of Overall Survival Data.
PubMed Identifier: 39037364
author list: Rodriguez LR, Gormley NJ, Lu R, Amatya AK, Demetri GD, Flaherty KT, Mesa RA, Pazdur R, Sekeres MA, Shan M, Snapinn S, Theoret MR, Umoja R, Vallejo J, Warren NJH, Xu Q, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Improving Collection and Analysis of Overall Survival Data. Clin Cancer Res. 2024 Sep 13; 30(18):3974-3982.
journal title abbreviation: Clin Cancer Res
publication date: 2024-09-13T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Adult Oncology
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Professor of Medicine
is primary position: true
position in department: Medicine
position in division: VA Med Centers
sort order: 1
type: Position
HR job title: Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Kraft Family Professor of Medicine
is primary position: true
position in department: Medicine
position in division: Adult Oncology
sort order: 1
type: Position
HR job title: Kraft Family Professor of Medicine
position in organization: Dana-Farber Cancer Institute

Authorship 476895
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma.

Authorship 1677944
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies.

Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies.
PubMed Identifier: 39111377
author list: Cholujova D, Bujnakova ZL, Dutkova E, Valuskova Z, Csicsatkova N, Suroviakova K, Marinkovicova ME, Zbellova L, Koklesova L, Sedlak J, Hideshima T, Anderson KC, Jakubikova J
published in: Nanomedicine : nanotechnology, biology, and medicine
information resource reference: Exploring the anti-myeloma potential of composite nanoparticles As4S4/Fe3O4: Insights from in vitro, ex vivo and in vivo studies. Nanomedicine. 2024 11; 62:102777.
journal title abbreviation: Nanomedicine
publication date: 2024-08-05T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 48132
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.

Authorship 313056
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.

Authorship 1684393
type: Authorship
author rank in publication: 55
linked author: Anderson, Kenneth
linked information resource: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Authorship 1685274
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

Authorship 1688544
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.

Authorship 1689260
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
PubMed Identifier: 39160255
author list: Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, Orloff G, Jakubowiak A, Niesvizky R, Liles D, Berdeja J, Levy M, Wolf J, Usmani SZ, Christofferson AW, Nasser S, Aldrich JL, Legendre C, Benard B, Miller C, Turner B, Kurdoglu A, Washington M, Yellapantula V, Adkins JR, Cuyugan L, Boateng M, Helland A, Kyman S, McDonald J, Reiman R, Stephenson K, Tassone E, Blanski A, Livermore B, Kirchhoff M, Rohrer DC, D'Agostino M, Gambella M, Collison K, Stumph J, Kidd P, Donnelly A, Zaugg B, Toone M, McBride K, DeRome M, Rogers J, Craig D, Liang WS, Gutierrez NC, Jewell SD, Carpten J, Anderson KC, Cho HJ, Auclair D, Lonial S, Keats JJ
published in: Nature genetics
information resource reference: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2024 Sep; 56(9):1878-1889.
journal title abbreviation: Nat Genet
publication date: 2024-08-19T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
PubMed Identifier: 39209967
author list: Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC
published in: Oncogene
information resource reference: Editorial Expression of Concern: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2024 09; 43(40):3018.
journal title abbreviation: Oncogene
publication date: 2024-09-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.
PubMed Identifier: 39237766
author list: Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, Rosen S, Krett N, Husson H, Avraham S, Kharbanda S, Anderson KC
published in: Oncogene
information resource reference: Editorial Expression of Concern: RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 2024 09; 43(40):3019.
journal title abbreviation: Oncogene
publication date: 2024-09-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma.
PubMed Identifier: 39224021
author list: Kurata K, Samur MK, Liow P, Wen K, Yamamoto L, Liu J, Morelli E, Gulla A, Tai YT, Qi J, Hideshima T, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Correction: BRD9 Degradation Disrupts Ribosome Biogenesis in Multiple Myeloma. Clin Cancer Res. 2024 Sep 03; 30(17):3956.
journal title abbreviation: Clin Cancer Res
publication date: 2024-09-03T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.
PubMed Identifier: 23454749
author list: Roccaro AM, Sacco A, Maiso P, Azab AK, Tai YT, Reagan M, Azab F, Flores LM, Campigotto F, Weller E, Anderson KC, Scadden DT, Ghobrial IM
published in: The Journal of clinical investigation
information resource reference: BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest. 2013 Apr; 123(4):1542-55.
journal title abbreviation: J Clin Invest
publication date: 2013-04-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 635444
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.

Authorship 636365
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Role of liposomal anthracyclines in the treatment of multiple myeloma.

Authorship 638622
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibition as a novel therapeutic target in human cancer.

Authorship 638602
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.

Authorship 641001
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.

Authorship 634958
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.

Authorship 635659
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Authorship 638152
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Drug insight: thalidomide as a treatment for multiple myeloma.

Authorship 639048
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma.

Authorship 639598
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Hematology: Setting the standard for newly diagnosed multiple myeloma.

Authorship 642097
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.

Authorship 647643
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Clinical challenges associated with bortezomib therapy in multiple myeloma and Waldenströms Macroglobulinemia.

Authorship 653815
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Investigational agent MLN9708/2238 targets tumor-suppressor miR33b in MM cells.

Authorship 655890
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

Authorship 657134
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authorship 659850
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.

Authorship 661359
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.

Authorship 664336
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Overview of the AACR Clinical and Translational Cancer Research Think Tank meeting.

Authorship 666361
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia.

Authorship 666581
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Prognostic significance of copy-number alterations in multiple myeloma.

Authorship 643304
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Tailoring treatment for multiple myeloma patients with relapsed and refractory disease.

Authorship 644437
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.

Authorship 645448
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.

Authorship 647626
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.

Authorship 648634
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation.

Authorship 649438
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.

Authorship 640054
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Authorship 641019
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Authorship 641028
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma.

Authorship 642351
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.

Authorship 643654
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.

Authorship 645470
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Antibody-based therapies in multiple myeloma.

Authorship 647517
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.

Authorship 657629
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.

Authorship 639630
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

Authorship 640037
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.

Authorship 660261
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Management of relapsed and relapsed/refractory multiple myeloma.

Authorship 660610
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.

Authorship 641039
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Authorship 636306
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma.

Authorship 638542
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma.

Authorship 642254
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Monoclonal gammopathy of undetermined significance: a consensus statement.

Authorship 643526
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Authorship 641415
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.

Authorship 643520
type: Authorship
author rank in publication: 25
linked author: Anderson, Kenneth
linked information resource: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

Authorship 642644
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity.

Authorship 657187
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.

Authorship 659547
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.

Authorship 650181
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Gauging progress in a decades-old fight.

Authorship 352770
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Preclinical studies of novel targeted therapies.

Authorship 663889
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration.

Authorship 666462
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Authorship 652854
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: biology of the disease.

Authorship 648182
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression.

Authorship 656815
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Comparison of twin and autologous transplants for multiple myeloma.

Authorship 653510
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.

Authorship 654485
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.

Authorship 654903
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.

Authorship 655608
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.

Authorship 657419
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.

Authorship 659496
type: Authorship
author rank in publication: 62
linked author: Anderson, Kenneth
linked information resource: Conflicts of interest, authorship, and disclosures in industry-related scientific publications.

Authorship 661053
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.

Authorship 663153
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma, version 1.2013.

Authorship 638468
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.

Authorship 642992
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Lenalidomide enhances anti-myeloma cellular immunity.

Authorship 643752
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: A phase 1 study of IPI-504 (retaspimycin hydrochloride) in patients with relapsed or relapsed and refractory multiple myeloma.

Authorship 646021
type: Authorship
author rank in publication: 25
linked author: Anderson, Kenneth
linked information resource: Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma.

Authorship 638977
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Clinically relevant end points and new drug approvals for myeloma.

Authorship 639426
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.

Authorship 662345
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.

Authorship 662473
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Adenosine A2A and beta-2 adrenergic receptor agonists: novel selective and synergistic multiple myeloma targets discovered through systematic combination screening.

Authorship 663072
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.

Authorship 640358
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma.

Authorship 640558
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Bortezomib in the management of multiple myeloma.

Authorship 641260
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.

Authorship 639472
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Novel therapies in the treatment of multiple myeloma.

Authorship 640362
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.

Authorship 665987
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.

Authorship 666129
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.

Authorship 666582
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.

Authorship 641149
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: What can CCR do for you?

Authorship 641454
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.

Authorship 641946
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.

Authorship 642380
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.

Authorship 637303
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.

Authorship 645284
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma.

Authorship 643919
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Authorship 640786
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.

Authorship 641302
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The International Myeloma Society comes of age.

Authorship 644279
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.

Authorship 651849
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.

Authorship 658671
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma.

Authorship 643910
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Authorship 644052
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.

Authorship 644991
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.

Authorship 646430
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Targeting the UPS as therapy in multiple myeloma.

Authorship 652659
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia.

Authorship 664166
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Setting the standard for translational cancer research.

Authorship 661323
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.

Authorship 650735
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome.

Authorship 661854
type: Authorship
author rank in publication: 39
linked author: Anderson, Kenneth
linked information resource: Lenalidomide after stem-cell transplantation for multiple myeloma.

Authorship 651427
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.

Authorship 651639
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Emerging therapies for the treatment of relapsed or refractory multiple myeloma.

Authorship 653875
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.

Authorship 666290
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Histone deacetylase inhibitors in the treatment for multiple myeloma.

Authorship 667603
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.

Authorship 641470
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: From the guest editor: the evolving treatment paradigm in multiple myeloma.

Authorship 641774
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Lenalidomide for the treatment of relapsed and refractory multiple myeloma.

Authorship 653660
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

Authorship 643706
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.

Authorship 658867
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.

Authorship 651796
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Individualizing treatment of patients with myeloma in the era of novel agents.

Authorship 647671
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma.

Authorship 666257
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia.

Authorship 666455
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/913533

Authorship 667020
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition.

Authorship 654889
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Epigenetic modulation in hematologic malignancies: challenges and progress.

Authorship 655690
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Disentangling the myeloma web.

Authorship 642672
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.

Authorship 645185
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Future directions of next-generation novel therapies, combination approaches, and the development of personalized medicine in myeloma.

Authorship 656651
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma.

Authorship 657141
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.

Authorship 662512
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma.

Authorship 657670
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia.

Authorship 653738
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

Authorship 653842
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma. Clinical practice guidelines in oncology.

Authorship 654552
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.

Authorship 655440
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.

Authorship 659890
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.

Authorship 659965
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: The treatment of multiple myeloma patients not eligible for asct.

Authorship 660380
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Minimal residual disease in multiple myeloma.

Authorship 660488
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.

Authorship 661294
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.

Authorship 661833
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibitors in multiple myeloma.

Authorship 664136
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/978739

Authorship 664462
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?

Authorship 666235
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Latest advances and current challenges in the treatment of multiple myeloma.

Authorship 661646
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.

Authorship 652995
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Re: When you look matters: the effect of assessment schedule on progression-free survival.

Authorship 663812
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: New insights into the treatment of multiple myeloma with histone deacetylase inhibitors.

Authorship 667096
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3.

Authorship 665328
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Authorship 657375
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.

Authorship 647665
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.

Authorship 643708
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465.

Authorship 643788
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma.

Authorship 645468
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas.

Authorship 636254
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.

Authorship 649969
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Role of interleukin 16 in multiple myeloma pathogenesis: a potential novel therapeutic target?

Authorship 651462
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.

Authorship 651739
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma.

Authorship 652839
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.

Authorship 655663
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer.

Authorship 640686
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibitor drugs on the rise.

Authorship 658872
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.

Authorship 647014
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.

Authorship 651335
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.

Authorship 654183
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.

Authorship 640091
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.

Authorship 640216
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Tanespimycin as antitumor therapy.

Authorship 641931
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Oncogenomics to target myeloma in the bone marrow microenvironment.

Authorship 642357
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.

Authorship 644071
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.

Authorship 646859
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.

Authorship 646902
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.

Authorship 653919
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.

Authorship 667755
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: New strategies in the treatment of multiple myeloma.

Authorship 667407
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.

Authorship 657072
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients.

Authorship 661795
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.

Authorship 663838
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013.

Authorship 663973
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Pathogenesis of myeloma.

Authorship 666168
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.

Authorship 659458
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Pathological crystallization of human immunoglobulins.

Authorship 651082
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Initial genome sequencing and analysis of multiple myeloma.

Authorship 637783
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells.

Authorship 638335
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.

Authorship 641441
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: What's Your Line?

Authorship 651999
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.

Authorship 654733
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma.

Authorship 661519
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Novel therapies in MM: from the aspect of preclinical studies.

Authorship 642400
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: BET bromodomain inhibition as a therapeutic strategy to target c-Myc.

Authorship 657212
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: NCCN clinical practice guidelines in oncology: multiple myeloma.

Authorship 659114
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: New proteasome inhibitors in myeloma.

Authorship 645610
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.

Authorship 659173
type: Authorship
author rank in publication: 25
linked author: Anderson, Kenneth
linked information resource: Thalidomide and rituximab in Waldenstrom macroglobulinemia.

Authorship 660705
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Velcade and vitamin C: too much of a good thing?

Authorship 661553
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Significant biological role of sp1 transactivation in multiple myeloma.

Authorship 663328
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132.

Authorship 665949
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Intracellular NAD(+) depletion induces autophagic death in multiple myeloma cells.

Authorship 648567
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.

Authorship 648664
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.

Authorship 648909
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.

Authorship 651991
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: CCR1 as a target for multiple myeloma.

Authorship 653685
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.

Authorship 654163
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Management of myeloma-associated renal dysfunction in the era of novel therapies.

Authorship 655561
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model.

Authorship 657777
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authorship 659545
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.

Authorship 660710
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: The current landscape of multiple myeloma treatment.

Authorship 661001
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma.

Authorship 666146
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

Authorship 650104
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.

Authorship 650920
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.

Authorship 654062
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications.

Authorship 660185
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Hematology: Thalidomide maintenance in multiple myeloma.

Authorship 660767
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Dual inhibition of canonical and noncanonical NF-?B pathways demonstrates significant antitumor activities in multiple myeloma.

Authorship 664383
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.

Authorship 664487
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.

Authorship 667589
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.

Authorship 665718
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.

Authorship 656613
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.

Authorship 656633
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.

Authorship 636094
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Introducing the clinical connection.

Authorship 661430
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.

Authorship 661947
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: How I treat plasma cell leukemia.

Authorship 665090
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: New insights into therapeutic targets in myeloma.

Authorship 640969
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Maximizing the clinical benefit of novel therapies in multiple myeloma.

Authorship 641807
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Kidney disease associated with plasma cell dyscrasias.

Authorship 642253
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.

Authorship 655483
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Emerging therapies for multiple myeloma.

Authorship 657333
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.

Authorship 643790
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.

Authorship 644600
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.

Authorship 649037
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.

Authorship 649134
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.

Authorship 665377
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: The evolution and impact of therapy in multiple myeloma.

Authorship 656561
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias.

Authorship 657228
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group.

Authorship 662522
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/1107082

Authorship 643254
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.

Authorship 647074
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.

Authorship 658666
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

Authorship 658983
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.

Authorship 659003
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.

Authorship 648930
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.

Authorship 654369
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.

Authorship 655403
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop.

Authorship 658469
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence.

Authorship 660302
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.

Authorship 667529
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Bortezomib is associated with better health-related quality of life than high-dose dexamethasone in patients with relapsed multiple myeloma: results from the APEX study.

Overview of the AACR Clinical and Translational Cancer Research Think Tank meeting.
PubMed Identifier: 22298892
author list: Anderson KC, DuBois RN
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Overview of the AACR Clinical and Translational Cancer Research Think Tank meeting. Clin Cancer Res. 2012 Feb 01; 18(3):607-11.
journal title abbreviation: Clin Cancer Res
publication date: 2012-02-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

From the guest editor: the evolving treatment paradigm in multiple myeloma.
PubMed Identifier: 20010163
author list: Anderson KC
published in: Cancer journal (Sudbury, Mass.)
information resource reference: From the guest editor: the evolving treatment paradigm in multiple myeloma. Cancer J. 2009 Nov-Dec; 15(6):456.
journal title abbreviation: Cancer J
publication date: 2009-11-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibitor drugs on the rise.
PubMed Identifier: 16861477
author list: Joazeiro CA, Anderson KC, Hunter T
published in: Cancer research
information resource reference: Proteasome inhibitor drugs on the rise. Cancer Res. 2006 Aug 15; 66(16):7840-2.
journal title abbreviation: Cancer Res
publication date: 2006-08-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity.
PubMed Identifier: 23647456
author list: Gatt ME, Takada K, Mani M, Lerner M, Pick M, Hideshima T, Carrasco DE, Protopopov A, Ivanova E, Sangfelt O, Grandér D, Barlogie B, Shaughnessy JD, Anderson KC, Carrasco DR
published in: British journal of haematology
information resource reference: TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity. Br J Haematol. 2013 Jul; 162(2):210-20.
journal title abbreviation: Br J Haematol
publication date: 2013-05-07T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Drug insight: thalidomide as a treatment for multiple myeloma.
PubMed Identifier: 16264962
author list: Kumar S, Anderson KC
published in: Nature clinical practice. Oncology
information resource reference: Drug insight: thalidomide as a treatment for multiple myeloma. Nat Clin Pract Oncol. 2005 May; 2(5):262-70.
journal title abbreviation: Nat Clin Pract Oncol
publication date: 2005-05-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.
PubMed Identifier: 23446999
author list: Leone E, Morelli E, Di Martino MT, Amodio N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, Anderson KC, Tagliaferri P, Tassone P
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013 Apr 15; 19(8):2096-106.
journal title abbreviation: Clin Cancer Res
publication date: 2013-02-27T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibitors in multiple myeloma.
PubMed Identifier: 19393832
author list: Anderson KC
published in: Seminars in oncology
information resource reference: Proteasome inhibitors in multiple myeloma. Semin Oncol. 2009 Apr; 36(2 Suppl 1):S20-6.
journal title abbreviation: Semin Oncol
publication date: 2009-04-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
PubMed Identifier: 23836557
author list: Yang G, Zhou Y, Liu X, Xu L, Cao Y, Manning RJ, Patterson CJ, Buhrlage SJ, Gray N, Tai YT, Anderson KC, Hunter ZR, Treon SP
published in: Blood
information resource reference: A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia. Blood. 2013 Aug 15; 122(7):1222-32.
journal title abbreviation: Blood
publication date: 2013-07-08T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity.
PubMed Identifier: 18624684
author list: Breitkreutz I, Anderson KC
published in: Expert opinion on drug metabolism & toxicology
information resource reference: Thalidomide in multiple myeloma--clinical trials and aspects of drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2008 Jul; 4(7):973-85.
journal title abbreviation: Expert Opin Drug Metab Toxicol
publication date: 2008-07-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Velcade and vitamin C: too much of a good thing?
PubMed Identifier: 16397016
author list: Catley L, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Velcade and vitamin C: too much of a good thing? Clin Cancer Res. 2006 Jan 01; 12(1):3-4.
journal title abbreviation: Clin Cancer Res
publication date: 2006-01-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
PubMed Identifier: 22288662
author list: Wolf JL, Siegel D, Goldschmidt H, Hazell K, Bourquelot PM, Bengoudifa BR, Matous J, Vij R, de Magalhaes-Silverman M, Abonour R, Anderson KC, Lonial S
published in: Leukemia & lymphoma
information resource reference: Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma. Leuk Lymphoma. 2012 Sep; 53(9):1820-3.
journal title abbreviation: Leuk Lymphoma
publication date: 2012-03-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
PubMed Identifier: 16432076
author list: Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006 Feb 20; 24(6):929-36.
journal title abbreviation: J Clin Oncol
publication date: 2006-01-23T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Minimal residual disease in multiple myeloma.
PubMed Identifier: 23733782
author list: Munshi NC, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Minimal residual disease in multiple myeloma. J Clin Oncol. 2013 Jul 10; 31(20):2523-6.
journal title abbreviation: J Clin Oncol
publication date: 2013-06-03T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells.
PubMed Identifier: 23584492
author list: Chauhan D, Ray A, Viktorsson K, Spira J, Paba-Prada C, Munshi N, Richardson P, Lewensohn R, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31.
journal title abbreviation: Clin Cancer Res
publication date: 2013-04-12T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

The current landscape of multiple myeloma treatment.
PubMed Identifier: 18954677
author list: Cavo M, Attal M, Gertz MA, Giralt S, Ludwig H, Morgan GJ, Anderson KC
published in: Leukemia research
information resource reference: The current landscape of multiple myeloma treatment. Leuk Res. 2008 Dec; 32 Suppl 1:S1-24.
journal title abbreviation: Leuk Res
publication date: 2008-12-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Synopsis of a roundtable on validating novel therapeutics for multiple myeloma.
PubMed Identifier: 17121878
author list: Dalton W, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Synopsis of a roundtable on validating novel therapeutics for multiple myeloma. Clin Cancer Res. 2006 Nov 15; 12(22):6603-10.
journal title abbreviation: Clin Cancer Res
publication date: 2006-11-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Monoclonal gammopathy of undetermined significance: a consensus statement.
PubMed Identifier: 20507313
author list: Berenson JR, Anderson KC, Audell RA, Boccia RV, Coleman M, Dimopoulos MA, Drake MT, Fonseca R, Harousseau JL, Joshua D, Lonial S, Niesvizky R, Palumbo A, Roodman GD, San-Miguel JF, Singhal S, Weber DM, Zangari M, Wirtschafter E, Yellin O, Kyle RA
published in: British journal of haematology
information resource reference: Monoclonal gammopathy of undetermined significance: a consensus statement. Br J Haematol. 2010 Jul; 150(1):28-38.
journal title abbreviation: Br J Haematol
publication date: 2010-05-09T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma.
PubMed Identifier: 12202673
author list: Berenson JR, Hillner BE, Kyle RA, Anderson K, Lipton A, Yee GC, Biermann JS
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002 Sep 01; 20(17):3719-36.
journal title abbreviation: J Clin Oncol
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Introducing the clinical connection.
PubMed Identifier: 17606703
author list: Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Introducing the clinical connection. Clin Cancer Res. 2007 Jul 01; 13(13):3761.
journal title abbreviation: Clin Cancer Res
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Oncogenomics to target myeloma in the bone marrow microenvironment.
PubMed Identifier: 21411438
author list: Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res. 2011 Mar 15; 17(6):1225-33.
journal title abbreviation: Clin Cancer Res
publication date: 2011-03-15T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

New insights into therapeutic targets in myeloma.
PubMed Identifier: 22160032
author list: Anderson KC
published in: Hematology. American Society of Hematology. Education Program
information resource reference: New insights into therapeutic targets in myeloma. Hematology Am Soc Hematol Educ Program. 2011; 2011:184-90.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2011-01-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.
PubMed Identifier: 22215754
author list: Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma. J Clin Oncol. 2012 Feb 01; 30(4):445-52.
journal title abbreviation: J Clin Oncol
publication date: 2012-01-03T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

What's Your Line?
PubMed Identifier: 19549765
author list: Potash J, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: What's Your Line? Clin Cancer Res. 2009 Jul 01; 15(13):4251.
journal title abbreviation: Clin Cancer Res
publication date: 2009-06-23T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Role of liposomal anthracyclines in the treatment of multiple myeloma.
PubMed Identifier: 15717741
author list: Hussein MA, Anderson KC
published in: Seminars in oncology
information resource reference: Role of liposomal anthracyclines in the treatment of multiple myeloma. Semin Oncol. 2004 Dec; 31(6 Suppl 13):147-60.
journal title abbreviation: Semin Oncol
publication date: 2004-12-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.
PubMed Identifier: 15934516
author list: Anderson KC, Palumbo A
published in: Oncology (Williston Park, N.Y.)
information resource reference: Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation. Oncology (Williston Park). 2005 Apr; 19(4):447-50.
journal title abbreviation: Oncology (Williston Park)
publication date: 2005-04-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Gauging progress in a decades-old fight.
PubMed Identifier: 22977189
author list: Potash J, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Gauging progress in a decades-old fight. Clin Cancer Res. 2012 Nov 01; 18(21):5833.
journal title abbreviation: Clin Cancer Res
publication date: 2012-09-11T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias.
PubMed Identifier: 23589314
author list: O'Connor R, Ooi MG, Meiller J, Jakubikova J, Klippel S, Delmore J, Richardson P, Anderson K, Clynes M, Mitsiades CS, O'Gorman P
published in: Cancer chemotherapy and pharmacology
information resource reference: The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias. Cancer Chemother Pharmacol. 2013 May; 71(5):1357-68.
journal title abbreviation: Cancer Chemother Pharmacol
publication date: 2013-04-16T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma. Clinical practice guidelines in oncology.
PubMed Identifier: 17335683
author list: Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Comenzo RL, De Castro CM, Djulbegovic B, Farag S, Huff CA, Meredith R, Schriber J, Shrieve D, Singhal S, Smith MR, Stockerl-Goldstein K, Vose JM, Weber D, Yahalom J, Yunus F
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2007 Feb; 5(2):118-47.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2007-02-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Setting the standard for translational cancer research.
PubMed Identifier: 19118025
author list: Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Setting the standard for translational cancer research. Clin Cancer Res. 2009 Jan 01; 15(1):1.
journal title abbreviation: Clin Cancer Res
publication date: 2009-01-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

What can CCR do for you?
PubMed Identifier: 20682715
author list: Potash J, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: What can CCR do for you? Clin Cancer Res. 2010 Aug 15; 16(16):4069-70.
journal title abbreviation: Clin Cancer Res
publication date: 2010-08-03T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Emerging therapies for the treatment of relapsed or refractory multiple myeloma.
PubMed Identifier: 20942854
author list: Dimopoulos MA, San-Miguel JF, Anderson KC
published in: European journal of haematology
information resource reference: Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol. 2011 Jan; 86(1):1-15.
journal title abbreviation: Eur J Haematol
publication date: 2010-11-25T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Disentangling the myeloma web.
PubMed Identifier: 21989063
author list: Tonon G, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Disentangling the myeloma web. Clin Cancer Res. 2011 Dec 01; 17(23):7210-2.
journal title abbreviation: Clin Cancer Res
publication date: 2011-10-11T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

The International Myeloma Society comes of age.
PubMed Identifier: 22321670
author list: Anderson KC, Jagannath S
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: The International Myeloma Society comes of age. Clin Lymphoma Myeloma Leuk. 2012 Feb; 12(1):1.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2012-02-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.
PubMed Identifier: 23685836
author list: Rosenblatt J, Avivi I, Vasir B, Uhl L, Munshi NC, Katz T, Dey BR, Somaiya P, Mills H, Campigotto F, Weller E, Joyce R, Levine JD, Tzachanis D, Richardson P, Laubach J, Raje N, Boussiotis V, Yuan YE, Bisharat L, Held V, Rowe J, Anderson K, Kufe D, Avigan D
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
journal title abbreviation: Clin Cancer Res
publication date: 2013-05-17T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity.
PubMed Identifier: 23823317
author list: Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC
published in: Blood
information resource reference: Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55.
journal title abbreviation: Blood
publication date: 2013-07-03T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Individualizing treatment of patients with myeloma in the era of novel agents.
PubMed Identifier: 18427148
author list: San-Miguel J, Harousseau JL, Joshua D, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Individualizing treatment of patients with myeloma in the era of novel agents. J Clin Oncol. 2008 Jun 01; 26(16):2761-6.
journal title abbreviation: J Clin Oncol
publication date: 2008-04-21T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma.
PubMed Identifier: 23582718
author list: Richardson PG, Mitsiades CS, Laubach JP, Hajek R, Spicka I, Dimopoulos MA, Moreau P, Siegel DS, Jagannath S, Anderson KC
published in: Leukemia research
information resource reference: Preclinical data and early clinical experience supporting the use of histone deacetylase inhibitors in multiple myeloma. Leuk Res. 2013 Jul; 37(7):829-37.
journal title abbreviation: Leuk Res
publication date: 2013-04-09T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

New strategies in the treatment of multiple myeloma.
PubMed Identifier: 23515406
author list: Munshi NC, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013 Jul 01; 19(13):3337-44.
journal title abbreviation: Clin Cancer Res
publication date: 2013-03-20T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration.
PubMed Identifier: 23545332
author list: Giralt S, McCarthy PL, Anderson KC, Carter SL, Richardson PG, Rajkumar SV, Laport GG, Stadtmauer EA, Pasquini MC, Horowitz MM
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: Anatomy of a successful practice-changing study: a Blood and Marrow Transplantation Clinical Trials Network-National Cancer Institute Cooperative Group collaboration. Biol Blood Marrow Transplant. 2013 Jun; 19(6):858-9.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2013-03-29T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia.
PubMed Identifier: 23664025
author list: Treon SP, Patterson CJ, Munshi NC, Anderson KC
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):181-3.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2013-04-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1696841
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/260509431

https://connects.catalyst.harvard.edu/Profiles/profile/260509431
PubMed Identifier: 39350638
author list: Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, Devine S, Dutt PS, Efebera Y, Geller N, Ghiasuddin H, Hematti P, Holmberg L, Howard A, Johnson B, Karagkouni D, Lazarus HM, Malek E, McCarthy P, McKenna D, Mendizabal A, Nooka A, Munshi N, O'Donnell L, Patel K, Rapoport AP, Reese J, Rosenblatt J, Soiffer R, Stroopinsky D, Uhl L, Vlachos IS, Waller EK, Young JW, Pasquini MC, Avigan D
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2024 Oct 01; 30(19):4542.
journal title abbreviation: Clin Cancer Res
publication date: 2024-10-01T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401.

Authorship 378827
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.

Authorship 1708656
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Development of hyperdiploidy starts at an early age and takes a decade to complete.

Authorship 1706933
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Editorial Expression of Concern: Activation of NF-?B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Authorship 1708642
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Serum free light chains in a racially diverse population including African Americans and populations from South Africa.

Editorial Expression of Concern: Activation of NF-?B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
PubMed Identifier: 39528816
author list: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
published in: Oncogene
information resource reference: Editorial Expression of Concern: Activation of NF-?B and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2025 Feb; 44(4):269.
journal title abbreviation: Oncogene
publication date: 2025-02-01T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Serum free light chains in a racially diverse population including African Americans and populations from South Africa.
PubMed Identifier: 39571144
author list: Bertamini L, Alberge JB, Lee DJ, El-Khoury H, Kim S, Fleming G, Murphy C, Colchie J, Davis MI, Perry J, Lightbody ED, Allam S, Goqwana LN, Philip V, Smyth N, Sakrikar D, Perkins M, Harding S, Troske D, Getz G, Karlson EW, Munshi N, Anderson KC, Trippa L, Marinac CR, Chen WC, Joffe M, Ghobrial IM
published in: Blood
information resource reference: Serum free light chains in a racially diverse population including African Americans and populations from South Africa. Blood. 2025 Feb 20; 145(8):840-849.
journal title abbreviation: Blood
publication date: 2025-02-20T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Development of hyperdiploidy starts at an early age and takes a decade to complete.
PubMed Identifier: 39571146
author list: Samur MK, Aktas Samur A, Shah P, Park JS, Fulciniti M, Shammas M, Corre J, Anderson KC, Parmigiani G, Avet-Loiseau H, Munshi NC
published in: Blood
information resource reference: Development of hyperdiploidy starts at an early age and takes a decade to complete. Blood. 2025 01 30; 145(5):520-525.
journal title abbreviation: Blood
publication date: 2025-01-30T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 74799
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.

Authorship 1711030
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
PubMed Identifier: 39626297
author list: Yee AJ, Laubach JP, Campagnaro EL, Lipe BC, Nadeem O, Friedman RS, Cole CE, O'Donnell EK, Bianchi G, Branagan AR, Schlossman RL, Shapiro SJ, Harrington CC, Burke JN, Gammon MT, Lively KJ, Reimonn CA, Andrade DX, Redd R, Lohr JG, Anderson KC, Richardson PG, Raje NS
published in: Blood advances
information resource reference: Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1163-1170.
journal title abbreviation: Blood Adv
publication date: 2025-03-11T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 505915
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: therapeutic applications and considerations.

Authorship 53174
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/782568

Authorship 536093
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: The treatment of relapsed and refractory multiple myeloma.

Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.
PubMed Identifier: 39753553
author list: Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, Alberge JB, Bertamini L, Dutta AK, El-Khoury H, Bustoros M, Laubach JP, Bianchi G, O'Donnell E, Wu T, Tsuji J, Anderson KC, Getz G, Trippa L, Richardson PG, Sklavenitis-Pistofidis R, Ghobrial IM
published in: Nature communications
information resource reference: Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial. Nat Commun. 2025 01 03; 16(1):358.
journal title abbreviation: Nat Commun
publication date: 2025-01-03T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.
PubMed Identifier: 39813623
author list: Waldschmidt JM, Sotudeh N, Arora S, Vijaykumar T, Anand P, Stuart H, Frede J, Campbell T, Kaiser SM, Zheng X, Munshi NC, Anderson KC, Einsele H, Yee AJ, Knoechel B, Lohr JG, Raje NS
published in: Blood advances
information resource reference: Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma. Blood Adv. 2025 Mar 11; 9(5):1132-1136.
journal title abbreviation: Blood Adv
publication date: 2025-03-11T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1717456
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

Authorship 1722378
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma.

Authorship 21531
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.

Authorship 1724857
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.

A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma.
PubMed Identifier: 39851267
author list: Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang SY, Minarik J, Cavo M, Prince HM, Anderson KC
published in: Future oncology (London, England)
information resource reference: A plain language summary of the ICARIA study, comparing isatuximab-pomalidomide- dexamethasone with pomalidomide- dexamethasone in people with multiple myeloma. Future Oncol. 2025 Mar; 21(6):653-663.
journal title abbreviation: Future Oncol
publication date: 2025-01-24T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 676486
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.

Authorship 202644
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Telomerase inhibitors as anticancer therapy.

Authorship 679325
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Phase transitions in human IgG solutions.

Authorship 678849
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Announcing the AACR Cancer Progress Report 2013.

Authorship 678851
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets.

Authorship 679935
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.

Authorship 680306
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Clinical translation in multiple myeloma: from bench to bedside.

Authorship 680736
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma.

Authorship 679799
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities.

Authorship 680743
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Announcing the AACR Cancer Progress Report 2013.
PubMed Identifier: 24130218
author list: Potash J, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Announcing the AACR Cancer Progress Report 2013. Clin Cancer Res. 2013 Oct 15; 19(20):5545.
journal title abbreviation: Clin Cancer Res
publication date: 2013-10-15T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets.
PubMed Identifier: 24135398
author list: Lawasut P, Groen RW, Dhimolea E, Richardson PG, Anderson KC, Mitsiades CS
published in: Seminars in oncology
information resource reference: Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets. Semin Oncol. 2013 Oct; 40(5):537-48.
journal title abbreviation: Semin Oncol
publication date: 2013-10-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma.
PubMed Identifier: 24019544
author list: San-Miguel JF, Richardson PG, Günther A, Sezer O, Siegel D, Bladé J, LeBlanc R, Sutherland H, Sopala M, Mishra KK, Mu S, Bourquelot PM, Victoria Mateos M, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. J Clin Oncol. 2013 Oct 10; 31(29):3696-703.
journal title abbreviation: J Clin Oncol
publication date: 2013-09-09T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical translation in multiple myeloma: from bench to bedside.
PubMed Identifier: 24135399
author list: Laubach J, Hideshima T, Richardson P, Anderson K
published in: Seminars in oncology
information resource reference: Clinical translation in multiple myeloma: from bench to bedside. Semin Oncol. 2013 Oct; 40(5):549-53.
journal title abbreviation: Semin Oncol
publication date: 2013-10-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase transitions in human IgG solutions.
PubMed Identifier: 24089716
author list: Wang Y, Lomakin A, Latypov RF, Laubach JP, Hideshima T, Richardson PG, Munshi NC, Anderson KC, Benedek GB
published in: The Journal of chemical physics
information resource reference: Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
journal title abbreviation: J Chem Phys
publication date: 2013-09-28T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma.
PubMed Identifier: 24032635
author list: Kang YJ, Zeng W, Song W, Reinhold B, Choi J, Brusic V, Yamashita T, Munshi A, Li C, Minvielle S, Anderson KC, Munshi N, Reinherz EL, Sasada T
published in: British journal of haematology
information resource reference: Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma. Br J Haematol. 2013 Nov; 163(3):343-51.
journal title abbreviation: Br J Haematol
publication date: 2013-08-30T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.
PubMed Identifier: 24055414
author list: Dimopoulos M, Siegel DS, Lonial S, Qi J, Hajek R, Facon T, Rosinol L, Williams C, Blacklock H, Goldschmidt H, Hungria V, Spencer A, Palumbo A, Graef T, Eid JE, Houp J, Sun L, Vuocolo S, Anderson KC
published in: The Lancet. Oncology
information resource reference: Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study. Lancet Oncol. 2013 Oct; 14(11):1129-1140.
journal title abbreviation: Lancet Oncol
publication date: 2013-09-19T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities.
PubMed Identifier: 24133830
author list: Richardson PG, Laubach J, Paba-Prada C, Anderson KC
published in: Oncology (Williston Park, N.Y.)
information resource reference: IgD and IgE variants of myeloma: valuable insights and therapeutic opportunities. Oncology (Williston Park). 2013 Aug; 27(8):803-4, 806.
journal title abbreviation: Oncology (Williston Park)
publication date: 2013-08-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 690317
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: AACR Cancer Progress Report 2013.

AACR Cancer Progress Report 2013.
PubMed Identifier: 24045178
author list: Sawyers CL, Abate-Shen C, Anderson KC, Barker A, Baselga J, Berger NA, Foti M, Jemal A, Lawrence TS, Li CI, Mardis ER, Neumann PJ, Pardoll DM, Prendergast GC, Reed JC, Weiner GJ
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: AACR Cancer Progress Report 2013. Clin Cancer Res. 2013 Oct 15; 19(20 Suppl):S4-98.
journal title abbreviation: Clin Cancer Res
publication date: 2013-09-16T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 307991
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.

Authorship 308706
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/821586

Authorship 30924
type: Authorship
author rank in publication: 47
linked author: Anderson, Kenneth
linked information resource: High-throughput oncogene mutation profiling in human cancer.

Authorship 1734882
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.

Authorship 1731327
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Indolent CD4+ CAR T-Cell Lymphoma after Cilta-cel CAR T-Cell Therapy.

Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials.
PubMed Identifier: 39938021
author list: Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, Orfao A, Moreau P, Sonneveld P, Kumar SK, Dixon JG, Patel R, Bartlett BJ, Schecter J, McCarthy P, Hose D, Seckinger A, Mattia D, Goldschmidt H, Oliva S, Owen RG, Anderson KC, San-Miguel J, Durie BGM, Munshi N
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Minimal Residual Disease-Based End Point for Accelerated Assessment of Clinical Trials in Multiple Myeloma: A Pooled Analysis of Individual Patient Data From Multiple Randomized Trials. J Clin Oncol. 2025 Apr 10; 43(11):1289-1301.
journal title abbreviation: J Clin Oncol
publication date: 2025-02-12T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 351758
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The role of immunomodulatory drugs in multiple myeloma.

Authorship 197325
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Molecular sequelae of proteasome inhibition in human multiple myeloma cells.

Authorship 224078
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.

Authorship 230530
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.

Authorship 1740994
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: New therapies in multiple myeloma: benefits and limitations.

Authorship 1744081
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.

Authorship 1749167
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Authorship 1749657
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma.

Authorship 1748685
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.

New therapies in multiple myeloma: benefits and limitations.
PubMed Identifier: 40231696
author list: Jurczyszyn A, Bator M, Vesole DH, Salman T, Richardson PG, Anderson K
published in: Polish archives of internal medicine
information resource reference: New therapies in multiple myeloma: benefits and limitations. Pol Arch Intern Med. 2025 04 24; 135(4).
journal title abbreviation: Pol Arch Intern Med
publication date: 2025-04-14T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
PubMed Identifier: 40370044
author list: Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2025 May 15; 31(10):2063.
journal title abbreviation: Clin Cancer Res
publication date: 2025-05-15T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma.
PubMed Identifier: 40090008
author list: Chakraborty C, Talluri S, Binder M, Morelli E, Mayoral JE, Derebail S, Samur AA, Epstein C, Anderson KC, Shammas M, Samur MK, Fulciniti M, Munshi NC
published in: Blood
information resource reference: Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma. Blood. 2025 Jul 03; 146(1):104-114.
journal title abbreviation: Blood
publication date: 2025-07-03T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.
PubMed Identifier: 40053701
author list: Morelli E, Ribeiro CF, Rodrigues SD, Gao C, Socciarelli F, Maisano D, Favasuli V, Liu N, Todoerti K, Chakraborty C, Yao Y, Fulciniti M, Samur M, Aktas-Samur A, Amodio N, Turi M, Barello F, Penailillo J, Giallongo C, Romano A, Gulla A, Anderson KC, Inghirami G, Munshi NC, Loda M
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. Clin Cancer Res. 2025 May 15; 31(10):1975-1987.
journal title abbreviation: Clin Cancer Res
publication date: 2025-05-15T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma.
PubMed Identifier: 40311068
author list: Ray A, Buon L, Wan X, Du T, Song Y, Pillai SC, Musa MA, Fang T, Wang M, Anderson KC
published in: Blood advances
information resource reference: Targeting Siglec-sialic acid checkpoint to reverse immune dysfunction mediated by plasmacytoid dendritic cells in myeloma. Blood Adv. 2025 Oct 14; 9(19):5085-5090.
journal title abbreviation: Blood Adv
publication date: 2025-10-14T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 387404
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Molecular mechanisms of novel therapeutic approaches for multiple myeloma.

Authorship 1752867
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.
PubMed Identifier: 40403231
author list: Morelli E, Aktas-Samur A, Maisano D, Gao C, Favasuli V, Papaioannou D, De Nola G, Henninger JE, Liu N, Turi M, Folino P, Vreux L, Cumerlato M, Chen L, Aifantis I, Fulciniti M, Anderson KC, Lytton-Jean AKR, Gullà A, Young RA, Samur MK, Munshi NC
published in: Blood
information resource reference: CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs. Blood. 2025 Aug 14; 146(7):847-860.
journal title abbreviation: Blood
publication date: 2025-08-14T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 221083
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis.

Authorship 235611
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Targeting proteasomes as therapy in multiple myeloma.

Authorship 704904
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.

Authorship 704270
type: Authorship
author rank in publication: 33
linked author: Anderson, Kenneth
linked information resource: Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
PubMed Identifier: 24429703
author list: Bolli N, Avet-Loiseau H, Wedge DC, Van Loo P, Alexandrov LB, Martincorena I, Dawson KJ, Iorio F, Nik-Zainal S, Bignell GR, Hinton JW, Li Y, Tubio JM, McLaren S, O' Meara S, Butler AP, Teague JW, Mudie L, Anderson E, Rashid N, Tai YT, Shammas MA, Sperling AS, Fulciniti M, Richardson PG, Parmigiani G, Magrangeas F, Minvielle S, Moreau P, Attal M, Facon T, Futreal PA, Anderson KC, Campbell PJ, Munshi NC
published in: Nature communications
information resource reference: Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.
journal title abbreviation: Nat Commun
publication date: 2014-01-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation.
PubMed Identifier: 24120758
author list: Fan F, Tonon G, Bashari MH, Vallet S, Antonini E, Goldschmidt H, Schulze-Bergkamen H, Opferman JT, Sattler M, Anderson KC, Jäger D, Podar K
published in: Cancer letters
information resource reference: Targeting Mcl-1 for multiple myeloma (MM) therapy: drug-induced generation of Mcl-1 fragment Mcl-1(128-350) triggers MM cell death via c-Jun upregulation. Cancer Lett. 2014 Feb 28; 343(2):286-94.
journal title abbreviation: Cancer Lett
publication date: 2013-10-08T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 243740
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.

Authorship 282664
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.

Authorship 258837
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.

Authorship 259340
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: A phase 2 study of bortezomib in relapsed, refractory myeloma.

Authorship 185702
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.

Authorship 271752
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.

Authorship 62923
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.

Authorship 429005
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.

Authorship 259905
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.

Authorship 260491
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.

A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.
PubMed Identifier: 40700574
author list: Dutta D, Liu J, Wen K, Ray A, Salatino A, Liu X, Gulla A, Hideshima T, Song Y, Anderson KC
published in: Blood
information resource reference: A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma. Blood. 2025 Nov 06; 146(19):2322-2335.
journal title abbreviation: Blood
publication date: 2025-11-06T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 709594
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma clinical practice guidelines in oncoloqy.

Authorship 712362
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.

Authorship 713595
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Bruton's tyrosine kinase: oncotarget in myeloma.

Authorship 713187
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity.

Authorship 720908
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.

Authorship 717541
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Authorship 714077
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/872526

Authorship 711254
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Therapeutic advances in relapsed or refractory multiple myeloma.

Authorship 721120
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: IKKß inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.

Authorship 721031
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/878773

Authorship 716954
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.

Authorship 721261
type: Authorship
author rank in publication: 26
linked author: Anderson, Kenneth
linked information resource: A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Authorship 713446
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway.

Authorship 723454
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Daratumumab granted breakthrough drug status.

Authorship 718736
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma.

Authorship 712020
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.

Authorship 724496
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Reply to M. Roschewski et al.

Authorship 716351
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Future agents and treatment directions in multiple myeloma.

Authorship 720099
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.

Multiple myeloma clinical practice guidelines in oncoloqy.
PubMed Identifier: 19795598
author list: Anderson KC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Multiple myeloma clinical practice guidelines in oncoloqy. J Natl Compr Canc Netw. 2004 Jul; 2(4):350-69.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2004-07-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.
PubMed Identifier: 24335104
author list: Mulligan G, Lichter DI, Di Bacco A, Blakemore SJ, Berger A, Koenig E, Bernard H, Trepicchio W, Li B, Neuwirth R, Chattopadhyay N, Bolen JB, Dorner AJ, van de Velde H, Ricci D, Jagannath S, Berenson JR, Richardson PG, Stadtmauer EA, Orlowski RZ, Lonial S, Anderson KC, Sonneveld P, San Miguel JF, Esseltine DL, Schu M
published in: Blood
information resource reference: Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy. Blood. 2014 Jan 30; 123(5):632-9.
journal title abbreviation: Blood
publication date: 2013-12-11T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Future agents and treatment directions in multiple myeloma.
PubMed Identifier: 24350987
author list: Ocio EM, Mitsiades CS, Orlowski RZ, Anderson KC
published in: Expert review of hematology
information resource reference: Future agents and treatment directions in multiple myeloma. Expert Rev Hematol. 2014 Feb; 7(1):127-41.
journal title abbreviation: Expert Rev Hematol
publication date: 2013-12-18T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Reply to M. Roschewski et al.
PubMed Identifier: 24419117
author list: Munshi NC, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Reply to M. Roschewski et al. J Clin Oncol. 2014 Feb 10; 32(5):478.
journal title abbreviation: J Clin Oncol
publication date: 2014-01-13T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.
PubMed Identifier: 24419113
author list: Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, Dimopoulos MA, Richardson PG, Cavo M, Spencer A, Stewart AK, Shimizu K, Lonial S, Sonneveld P, Durie BG, Moreau P, Orlowski RZ
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 2014 Feb 20; 32(6):587-600.
journal title abbreviation: J Clin Oncol
publication date: 2014-01-13T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapeutic advances in relapsed or refractory multiple myeloma.
PubMed Identifier: 23704241
author list: Anderson KC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Therapeutic advances in relapsed or refractory multiple myeloma. J Natl Compr Canc Netw. 2013 May; 11(5 Suppl):676-9.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2013-05-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

IKKß inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
PubMed Identifier: 24481412
author list: Hideshima H, Yoshida Y, Ikeda H, Hide M, Iwasaki A, Anderson KC, Hideshima T
published in: International journal of oncology
information resource reference: IKKß inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells. Int J Oncol. 2014 Apr; 44(4):1171-6.
journal title abbreviation: Int J Oncol
publication date: 2014-01-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

The heavy chain diseases: clinical and pathologic features.
PubMed Identifier: 24683718
author list: Bianchi G, Anderson KC, Harris NL, Sohani AR
published in: Oncology (Williston Park, N.Y.)
information resource reference: The heavy chain diseases: clinical and pathologic features. Oncology (Williston Park). 2014 Jan; 28(1):45-53.
journal title abbreviation: Oncology (Williston Park)
publication date: 2014-01-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
PubMed Identifier: 24421329
author list: Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, Chen C, Lonial S, Jakubowiak A, Bahlis N, Song K, Belch A, Raje N, Shustik C, Lentzsch S, Lacy M, Mikhael J, Matous J, Vesole D, Chen M, Zaki MH, Jacques C, Yu Z, Anderson KC
published in: Blood
information resource reference: Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014 Mar 20; 123(12):1826-32.
journal title abbreviation: Blood
publication date: 2014-01-13T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Daratumumab granted breakthrough drug status.
PubMed Identifier: 24555809
author list: Laubach JP, Tai YT, Richardson PG, Anderson KC
published in: Expert opinion on investigational drugs
information resource reference: Daratumumab granted breakthrough drug status. Expert Opin Investig Drugs. 2014 Apr; 23(4):445-52.
journal title abbreviation: Expert Opin Investig Drugs
publication date: 2014-02-20T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
PubMed Identifier: 24429336
author list: Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, Ghobrial IM, Schlossman RL, Munshi NC, Mazumder A, Vesole DH, Kaufman JL, Colson K, McKenney M, Lunde LE, Feather J, Maglio ME, Warren D, Francis D, Hideshima T, Knight R, Esseltine DL, Mitsiades CS, Weller E, Anderson KC
published in: Blood
information resource reference: A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
journal title abbreviation: Blood
publication date: 2014-01-15T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.
PubMed Identifier: 24525202
author list: Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto P, Offidani M, Petrucci MT, Evangelista A, Zweegman S, Nooka AK, Spencer A, Dimopoulos MA, Hajek R, Cavo M, Richardson P, Lonial S, Ciccone G, Boccadoro M, Anderson K, Barlogie B, Sonneveld P, McCarthy PL
published in: The Lancet. Oncology
information resource reference: Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014 Mar; 15(3):333-42.
journal title abbreviation: Lancet Oncol
publication date: 2014-02-11T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance.
PubMed Identifier: 24319254
author list: Tian Z, D'Arcy P, Wang X, Ray A, Tai YT, Hu Y, Carrasco RD, Richardson P, Linder S, Chauhan D, Anderson KC
published in: Blood
information resource reference: A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood. 2014 Jan 30; 123(5):706-16.
journal title abbreviation: Blood
publication date: 2013-12-06T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma.
PubMed Identifier: 24611431
author list: Jones DR, Wu Z, Chauhan D, Anderson KC, Peng J
published in: Analytical chemistry
information resource reference: A nano ultra-performance liquid chromatography-high resolution mass spectrometry approach for global metabolomic profiling and case study on drug-resistant multiple myeloma. Anal Chem. 2014 Apr 01; 86(7):3667-75.
journal title abbreviation: Anal Chem
publication date: 2014-03-20T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway.
PubMed Identifier: 24599134
author list: Zhao JJ, Lin J, Zhu D, Wang X, Brooks D, Chen M, Chu ZB, Takada K, Ciccarelli B, Admin S, Tao J, Tai YT, Treon S, Pinkus G, Kuo WP, Hideshima T, Bouxsein M, Munshi N, Anderson K, Carrasco R
published in: Cancer research
information resource reference: miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13.
journal title abbreviation: Cancer Res
publication date: 2014-03-05T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 214308
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: NF-kappa B as a therapeutic target in multiple myeloma.

Authorship 333385
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.

Authorship 337441
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

Authorship 337452
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.

Authorship 271092
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.

MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.
PubMed Identifier: 24622324
author list: Fulciniti M, Amodio N, Bandi RL, Munshi M, Yang G, Xu L, Hunter Z, Tassone P, Anderson KC, Treon SP, Munshi NC
published in: Blood
information resource reference: MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014 Apr 24; 123(17):2673-81.
journal title abbreviation: Blood
publication date: 2014-03-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 345510
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.

Authorship 729916
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: advances reported in 2013 are useful in the clinic.

Authorship 731119
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

Multiple myeloma: advances reported in 2013 are useful in the clinic.
PubMed Identifier: 24853222
author list: Anderson K
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Multiple myeloma: advances reported in 2013 are useful in the clinic. J Natl Compr Canc Netw. 2014 May; 12(5 Suppl):808-11.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2014-05-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.
PubMed Identifier: 24569262
author list: Tai YT, Mayes PA, Acharya C, Zhong MY, Cea M, Cagnetta A, Craigen J, Yates J, Gliddon L, Fieles W, Hoang B, Tunstead J, Christie AL, Kung AL, Richardson P, Munshi NC, Anderson KC
published in: Blood
information resource reference: Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15; 123(20):3128-38.
journal title abbreviation: Blood
publication date: 2014-02-25T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 176103
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.

Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series.
PubMed Identifier: 41723035
author list: Ahmed Z, Hamouche W, Ahmad SO, Yu J, Chowdhury R, Gupta S, Sullivan D, Duffy C, Ahmad S, Anderson KC, Laubach J, Jacobson C, Nadeem O
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series. Clin Lymphoma Myeloma Leuk. 2026 Apr; 26(4):249-256.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2026-02-03T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 732385
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.
PubMed Identifier: 24813251
author list: Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G
published in: Nature medicine
information resource reference: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. Nat Med. 2014 Jun; 20(6):599-606.
journal title abbreviation: Nat Med
publication date: 2014-05-11T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 259909
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Identification of genes modulated in multiple myeloma using genetically identical twin samples.

Authorship 1780370
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma.

Authorship 1781929
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Safety and Tolerability of CAR T-Cell Therapy in Patients With End-Stage Kidney Disease on Hemodialysis: A Case Series.

Authorship 273917
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.

Authorship 1786479
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Cancer clinical trials--do we need a new algorithm in the age of stratified medicine?

Authorship 1792112
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.

Authorship 1793329
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.

Authorship 1794065
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Treating Addictions: Harm Reduction in Clinical Care and Prevention.

Authorship 1795628
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma.

Authorship 1822901
type: Authorship
author rank in publication: 55
linked author: Anderson, Kenneth
linked information resource: Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Authorship 1822846
type: Authorship
author rank in publication: 42
linked author: Anderson, Kenneth
linked information resource: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.

Authorship 1825273
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma.

Authorship 1826251
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: CyTOF profiling of bone marrow immune dynamics across myeloma stages.

Authorship 1833676
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.

Authorship 1834766
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Standing on the Shoulders of the Giants: Dr. Kenneth Anderson.

Authorship 1835774
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.

Authorship 1844159
type: Authorship
author rank in publication: 27
linked author: Anderson, Kenneth
linked information resource: Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.

Authorship 1846531
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Cancer vaccines: Discovery, development, and challenges for clinical translation.

Authorship 1849046
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Prevalence of Sleep Apnea and Echocardiographic Correlates in a Community-Based Cohort of Cardio-Oncology Patients.

Authorship 1850478
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.

Authorship 1851776
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein Degradation.

Treating Addictions: Harm Reduction in Clinical Care and Prevention.
PubMed Identifier: 27112489
author list: Drucker E, Anderson K, Haemmig R, Heimer R, Small D, Walley A, Wood E, van Beek I
published in: Journal of bioethical inquiry
information resource reference: Treating Addictions: Harm Reduction in Clinical Care and Prevention. J Bioeth Inq. 2016 Jun; 13(2):239-49.
journal title abbreviation: J Bioeth Inq
publication date: 2016-04-26T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Cancer clinical trials--do we need a new algorithm in the age of stratified medicine?
PubMed Identifier: 23814160
author list: Doroshow JH, Sleijfer S, Stupp R, Anderson K
published in: The oncologist
information resource reference: Cancer clinical trials--do we need a new algorithm in the age of stratified medicine? Oncologist. 2013 Jun; 18(6):651-2.
journal title abbreviation: Oncologist
publication date: 2013-06-01T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia.
PubMed Identifier: 40472329
author list: Branagan AR, Mo C, Lei M, Gustine JN, Yee AJ, O'Donnell E, Castillo JJ, Nadeem O, Flynn C, Bernstein Z, Nakamoto-Matsubara R, Meid K, Verma R, Hunter ZR, Guerrera ML, Alter G, Burke J, Harrington C, Agyemang E, Gammon M, Lively K, Packer L, Horick N, Laubach J, Mitsiades CS, Munshi N, Anderson KC, Treon SP, Richardson PG, Raje NS, Sarosiek SR
published in: Blood advances
information resource reference: Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579.
journal title abbreviation: Blood Adv
publication date: 2025-09-23T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
PubMed Identifier: 40489728
author list: Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, Kaiser MF, Raab MS, Weinhold N, Gutierrez NC, Paiva B, Neri P, Weisel K, Maura F, Walker BA, Bustoros M, Stewart AK, Usmani SZ, Hillengass J, Chng WJ, Keats JJ, Martinez-Lopez J, Sperling AS, Touzeau C, Zhan F, Raje NS, Cavo M, Bolli N, Ghobrial IM, Dhodapkar MV, Jagannath S, Spencer A, Parekh S, Bahlis NJ, Lonial S, Sonneveld P, Bergsagel L, Orlowski RZ, Morgan G, Mateos MV, Rajkumar SV, San Miguel JF, Anderson KC, Moreau P, Kumar S, Prósper F, Munshi NC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025 Aug 20; 43(24):2739-2751.
journal title abbreviation: J Clin Oncol
publication date: 2025-06-09T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma.
PubMed Identifier: 40691968
author list: Luo K, Zhang Z, Yao S, Wang Y, Amiji M, Anderson KC
published in: Journal of controlled release : official journal of the Controlled Release Society
information resource reference: Advances in RNA therapeutics and its delivery strategies against Multiple Myeloma. J Control Release. 2025 Sep 10; 385:114048.
journal title abbreviation: J Control Release
publication date: 2025-07-19T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

CyTOF profiling of bone marrow immune dynamics across myeloma stages.
PubMed Identifier: 40820826
author list: Cholujova D, Beke G, Klucar L, Drgona L, Valuskova Z, Leiba M, Kastritis E, Dorfman DM, Anderson KC, Jakubikova J
published in: Oncoimmunology
information resource reference: CyTOF profiling of bone marrow immune dynamics across myeloma stages. Oncoimmunology. 2025 Dec; 14(1):2542333.
journal title abbreviation: Oncoimmunology
publication date: 2025-08-18T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.
PubMed Identifier: 40490515
author list: Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, Orloff G, Jakubowiak A, Niesvizky R, Liles D, Berdeja J, Levy M, Wolf J, Usmani SZ, Christofferson AW, Nasser S, Aldrich JL, Legendre C, Benard B, Miller C, Turner B, Kurdoglu A, Washington M, Yellapantula V, Adkins JR, Cuyugan L, Boateng M, Helland A, Kyman S, McDonald J, Reiman R, Stephenson K, Tassone E, Blanski A, Livermore B, Kirchhoff M, Rohrer DC, D'Agostino M, Gambella M, Collison K, Stumph J, Kidd P, Donnelly A, Zaugg B, Toone M, McBride K, DeRome M, Rogers J, Craig D, Liang WS, Gutierrez NC, Jewell SD, Carpten J, Anderson KC, Cho HJ, Auclair D, Lonial S, Keats JJ
published in: Nature genetics
information resource reference: Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet. 2025 Jul; 57(7):1789.
journal title abbreviation: Nat Genet
publication date: 2025-07-01T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma.
PubMed Identifier: 41380103
author list: Aktas Samur A, Corre J, Talluri S, Shah P, Graffeuil A, Rivera J, Fan Y, Dakiki Korucu B, Szalat R, Fulciniti M, Anderson KC, Sperling A, Parmigiani G, Avet-Loiseau H, Munshi NC, Samur MK
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Genomically Smoldering Multiple Myeloma Is Not a Distinct Entity But a Collection of Monoclonal Gammopathy of Undetermined Significance or Multiple Myeloma. J Clin Oncol. 2026 Feb; 44(4):321-334.
journal title abbreviation: J Clin Oncol
publication date: 2025-12-11T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma.
PubMed Identifier: 41410549
author list: Valuskova Z, Cholujova D, Beke G, Hucko M, Marinkovicova ME, Suroviakova K, Klucar L, Drgona L, Leiba M, Kastritis E, Dorfman DM, Anderson KC, Jakubikova J
published in: Cancer biology & therapy
information resource reference: RVd and CyBorD therapies remodel B-cell maturation signaling and alter immune and clonal architecture in multiple myeloma. Cancer Biol Ther. 2025 Dec 31; 26(1):2603100.
journal title abbreviation: Cancer Biol Ther
publication date: 2025-12-18T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Standing on the Shoulders of the Giants: Dr. Kenneth Anderson.
PubMed Identifier: 38817697
author list: Mohty M, Anderson KC
published in: Clinical hematology international
information resource reference: Standing on the Shoulders of the Giants: Dr. Kenneth Anderson. Clin Hematol Int. 2024; 6(1):39-42.
journal title abbreviation: Clin Hematol Int
publication date: 2024-02-05T00:00:00
year: 2024
type: Academic Article
type: Article
type: Document
type: Information Resource

Cancer vaccines: Discovery, development, and challenges for clinical translation.
PubMed Identifier: 40795707
author list: Zhang Z, Yao S, Wang Y, Luo K, Amiji M, Anderson KC
published in: Biomaterials
information resource reference: Cancer vaccines: Discovery, development, and challenges for clinical translation. Biomaterials. 2026 Feb; 325:123615.
journal title abbreviation: Biomaterials
publication date: 2025-08-07T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma.
PubMed Identifier: 40758944
author list: Rivera J, Yan Q, Daneshmandi S, Lannes R, Katsuta E, Choi J, Singh P, Belal A, Alberico R, Lund I, Schaefer M, Hassan H, Parker S, Anderson KC, Munshi NC, Samur M, McCarthy PL, Hillengass J, Mohammadpour H
published in: Blood
information resource reference: Deciphering neutrophil dynamics in the focal lesion tumor microenvironment to overcome immunosuppression in multiple myeloma. Blood. 2025 Nov 13; 146(20):2392-2405.
journal title abbreviation: Blood
publication date: 2025-11-13T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

Prevalence of Sleep Apnea and Echocardiographic Correlates in a Community-Based Cohort of Cardio-Oncology Patients.
PubMed Identifier: 41151394
author list: Das MK, Huber JL, Kemp JD, McFarland RM, Cardarelli R, Cronin SN, Anderson KC
published in: JACC. Advances
information resource reference: Prevalence of Sleep Apnea and Echocardiographic Correlates in a Community-Based Cohort of Cardio-Oncology Patients. JACC Adv. 2025 Nov; 4(11 Pt 1):102256.
journal title abbreviation: JACC Adv
publication date: 2025-10-28T00:00:00
year: 2025
type: Academic Article
type: Article
type: Document
type: Information Resource

ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3.
PubMed Identifier: 41104834
author list: Fulciniti M, Yao Y, Perini T, Fong Ng J, Schavgoulidze A, Deng S, Cui J, Encinas Mayoral J, Ladisa F, Young RM, Epstein CB, White CM, Ott CJ, Gulla A, Matulis SM, Sperling AS, Morelli E, Boise LH, Binder M, Szalat R, Samur MK, Anderson KC, Munshi NC
published in: Blood cancer discovery
information resource reference: ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3. Blood Cancer Discov. 2026 Jan 12; 7(1):129-141.
journal title abbreviation: Blood Cancer Discov
publication date: 2026-01-12T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma.
PubMed Identifier: 41734388
author list: Wood WA, Kumar SK, Semmel E, James S, Schroeder MA, Chung DJ, Rosenberg AS, Zonder JA, Rubinstein SM, D'Souza A, Martin T, Chari A, Vij R, Nooka AK, Anderson KC, Neuberg DS, Richard S, Torres K, Weiss BM, Pederson LD, Derkach A, Geyer S, Usmani SZ
published in: Blood advances
information resource reference: Feasibility of Decentralized Real-World Monitoring of SARS-CoV-2 Booster Vaccines and COVID-19 Outcomes in Myeloma. Blood Adv. 2026 Feb 24.
journal title abbreviation: Blood Adv
publication date: 2026-02-24T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein Degradation.
PubMed Identifier: 41556619
author list: Song C, Liu Q, Wang T, Song Y, Sigua LH, Park PM, Ficarro S, Lee S, Picaud S, Filippakopoulos P, Marto JA, Kostic M, Durbin AD, Anderson K, Qi J
published in: Angewandte Chemie (International ed. in English)
information resource reference: Proteasome Cap Targeting Chimeras for Ubiquitination-Independent Targeted Protein Degradation. Angew Chem Int Ed Engl. 2026 Feb 23; 65(9):e20039.
journal title abbreviation: Angew Chem Int Ed Engl
publication date: 2026-01-20T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma.
PubMed Identifier: 41632828
author list: Du T, Fang T, Pillai SC, Ray A, Wang M, Wan X, Wen K, Liu Y, Xu J, Musa MA, Liu X, Fulciniti M, Munshi NC, Garbicz F, Carrasco RD, Yao Y, Zhang Z, Song Y, Anderson KC
published in: Blood
information resource reference: Proteasome Subunit PSMD1 is a Key Therapeutic Target in Multiple Myeloma. Blood. 2026 Feb 03.
journal title abbreviation: Blood
publication date: 2026-02-03T00:00:00
year: 2026
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 740171
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Monoclonal antibodies in the treatment of multiple myeloma.

Monoclonal antibodies in the treatment of multiple myeloma.
PubMed Identifier: 21777223
author list: Richardson PG, Lonial S, Jakubowiak AJ, Harousseau JL, Anderson KC
published in: British journal of haematology
information resource reference: Monoclonal antibodies in the treatment of multiple myeloma. Br J Haematol. 2011 Sep; 154(6):745-54.
journal title abbreviation: Br J Haematol
publication date: 2011-07-21T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 743709
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Looking forward: an update to the CCR instructions for authors.

Authorship 744556
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Best treatment strategies in high-risk multiple myeloma: navigating a gray area.

Best treatment strategies in high-risk multiple myeloma: navigating a gray area.
PubMed Identifier: 24888801
author list: Bianchi G, Richardson PG, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Best treatment strategies in high-risk multiple myeloma: navigating a gray area. J Clin Oncol. 2014 Jul 10; 32(20):2125-32.
journal title abbreviation: J Clin Oncol
publication date: 2014-06-02T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Looking forward: an update to the CCR instructions for authors.
PubMed Identifier: 25028504
author list: Potash J, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Looking forward: an update to the CCR instructions for authors. Clin Cancer Res. 2014 Jul 15; 20(14):3629.
journal title abbreviation: Clin Cancer Res
publication date: 2014-07-15T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 401152
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.

Authorship 407335
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma.

Authorship 328541
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.

Authorship 337455
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

Authorship 276468
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel therapies for multiple myeloma.

Authorship 290630
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Biologic sequelae of c-Jun NH(2)-terminal kinase (JNK) activation in multiple myeloma cell lines.

Authorship 399723
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Development of effective new treatments for multiple myeloma.

Authorship 472673
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.

Authorship 489250
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.

Authorship 493921
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors.

Authorship 751863
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.

Authorship 747269
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.

Authorship 750354
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.

Authorship 749480
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.

Authorship 751737
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: The challenge of cross-trial comparisons using limited data.

The challenge of cross-trial comparisons using limited data.
PubMed Identifier: 25082787
author list: Laubach JP, Faber EA, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG
published in: Haematologica
information resource reference: The challenge of cross-trial comparisons using limited data. Haematologica. 2014 Aug; 99(8):e145-6.
journal title abbreviation: Haematologica
publication date: 2014-08-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
PubMed Identifier: 21732930
author list: Richardson PG, Laubach J, Mitsiades CS, Schlossman R, Hideshima T, Redman K, Chauhan D, Ghobrial IM, Munshi N, Anderson KC
published in: British journal of haematology
information resource reference: Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
journal title abbreviation: Br J Haematol
publication date: 2011-07-07T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
PubMed Identifier: 24958808
author list: Patel CG, Yee AJ, Scullen TA, Nemani N, Santo L, Richardson PG, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Raje NS
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
journal title abbreviation: Clin Cancer Res
publication date: 2014-06-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
PubMed Identifier: 24761838
author list: Yee AJ, Hari P, Marcheselli R, Mahindra AK, Cirstea DD, Scullen TA, Burke JN, Rodig SJ, Hideshima T, Laubach JP, Ghobrial IM, Schlossman RL, Munshi NC, Anderson KC, Weller EA, Richardson PG, Raje NS
published in: British journal of haematology
information resource reference: Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
journal title abbreviation: Br J Haematol
publication date: 2014-04-25T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition.
PubMed Identifier: 24934808
author list: Mimura N, Hideshima T, Shimomura T, Suzuki R, Ohguchi H, Rizq O, Kikuchi S, Yoshida Y, Cottini F, Jakubikova J, Cirstea D, Gorgun G, Minami J, Tai YT, Richardson PG, Utsugi T, Iwama A, Anderson KC
published in: Cancer research
information resource reference: Selective and potent Akt inhibition triggers anti-myeloma activities and enhances fatal endoplasmic reticulum stress induced by proteasome inhibition. Cancer Res. 2014 Aug 15; 74(16):4458-69.
journal title abbreviation: Cancer Res
publication date: 2014-06-16T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 506932
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.

Authorship 350023
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia.

Authorship 754885
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The future of treatment for patients with relapsed/refractory multiple myeloma.

The future of treatment for patients with relapsed/refractory multiple myeloma.
PubMed Identifier: 25188476
author list: Anderson KC
published in: Oncology (Williston Park, N.Y.)
information resource reference: The future of treatment for patients with relapsed/refractory multiple myeloma. Oncology (Williston Park). 2011 Nov 15; 25 Suppl 2:2.
journal title abbreviation: Oncology (Williston Park)
publication date: 2011-11-15T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 756884
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma.

Multiple myeloma.
PubMed Identifier: 25212892
author list: Anderson KC
published in: Hematology/oncology clinics of North America
information resource reference: Multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):xi-xii.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2014-10-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.
PubMed Identifier: 25172964
author list: Cirstea D, Santo L, Hideshima T, Eda H, Mishima Y, Nemani N, Mahindra A, Yee A, Gorgun G, Hu Y, Ohguchi H, Suzuki R, Cottini F, Guichard SM, Anderson KC, Raje N
published in: Molecular cancer therapeutics
information resource reference: Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma. Mol Cancer Ther. 2014 Nov; 13(11):2489-500.
journal title abbreviation: Mol Cancer Ther
publication date: 2014-08-29T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 350163
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Emerging drugs in multiple myeloma.

Authorship 760731
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: AACR cancer progress report 2014: transforming lives through research.

AACR cancer progress report 2014: transforming lives through research.
PubMed Identifier: 25228533
author list: Potash J, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: AACR cancer progress report 2014: transforming lives through research. Clin Cancer Res. 2014 Oct 01; 20(19):4977.
journal title abbreviation: Clin Cancer Res
publication date: 2014-09-16T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 381631
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis.

Authorship 762550
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.
PubMed Identifier: 25027391
author list: Dimopoulos MA, Kastritis E, Owen RG, Kyle RA, Landgren O, Morra E, Leleu X, García-Sanz R, Munshi N, Anderson KC, Terpos E, Ghobrial IM, Morel P, Maloney D, Rummel M, Leblond V, Advani RH, Gertz MA, Kyriakou C, Thomas SK, Barlogie B, Gregory SA, Kimby E, Merlini G, Treon SP
published in: Blood
information resource reference: Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11.
journal title abbreviation: Blood
publication date: 2014-07-15T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 405982
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: A clinically relevant SCID-hu in vivo model of human multiple myeloma.

Authorship 45413
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.

Authorship 765285
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Novel targeted agents in the treatment of multiple myeloma.

Authorship 766379
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.

Authorship 765580
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.

Authorship 765315
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Pyk2 promotes tumor progression in multiple myeloma.

Authorship 765291
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Immunotherapy strategies in multiple myeloma.

Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.
PubMed Identifier: 25322877
author list: Dowling P, Hayes C, Ting KR, Hameed A, Meiller J, Mitsiades C, Anderson KC, Clynes M, Clarke C, Richardson P, O'Gorman P
published in: BMC genomics
information resource reference: Identification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease. BMC Genomics. 2014 Oct 17; 15:904.
journal title abbreviation: BMC Genomics
publication date: 2014-10-17T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel targeted agents in the treatment of multiple myeloma.
PubMed Identifier: 25212889
author list: Varga C, Laubach J, Hideshima T, Chauhan D, Anderson KC, Richardson PG
published in: Hematology/oncology clinics of North America
information resource reference: Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):903-25.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2014-08-05T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee.
PubMed Identifier: 25066040
author list: Raje N, Faiman B, Harvey RD, Kurtin SE, Lonial S, Kumar SK, Cohen AD, Conde MA, Giralt SA, Recine MS, Tombler ER, Stadtmauer E, Jagannath S, Anderson KC
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: Identifying professional education gaps and barriers in multiple myeloma patient care: findings of the Managing Myeloma Continuing Educational Initiative Advisory Committee. Clin Lymphoma Myeloma Leuk. 2014 Oct; 14(5):356-69.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2014-06-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunotherapy strategies in multiple myeloma.
PubMed Identifier: 25212890
author list: Bae J, Munshi NC, Anderson KC
published in: Hematology/oncology clinics of North America
information resource reference: Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):927-43.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2014-10-01T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Pyk2 promotes tumor progression in multiple myeloma.
PubMed Identifier: 25217697
author list: Zhang Y, Moschetta M, Huynh D, Tai YT, Zhang Y, Zhang W, Mishima Y, Ring JE, Tam WF, Xu Q, Maiso P, Reagan M, Sahin I, Sacco A, Manier S, Aljawai Y, Glavey S, Munshi NC, Anderson KC, Pachter J, Roccaro AM, Ghobrial IM
published in: Blood
information resource reference: Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014 Oct 23; 124(17):2675-86.
journal title abbreviation: Blood
publication date: 2014-09-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 767853
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myeloma.

Authorship 769363
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Differential and limited expression of mutant alleles in multiple myeloma.

Authorship 768930
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.

Differential and limited expression of mutant alleles in multiple myeloma.
PubMed Identifier: 25237203
author list: Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, Shammas MA, Fulciniti M, Samur MK, Richardson PG, Magrangeas F, Minvielle S, Futreal PA, Anderson KC, Avet-Loiseau H, Campbell PJ, Parmigiani G, Munshi NC
published in: Blood
information resource reference: Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7.
journal title abbreviation: Blood
publication date: 2014-09-18T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
PubMed Identifier: 25266555
author list: Bianchi G, Anderson KC
published in: CA: a cancer journal for clinicians
information resource reference: Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back. CA Cancer J Clin. 2014 Nov-Dec; 64(6):422-44.
journal title abbreviation: CA Cancer J Clin
publication date: 2014-09-29T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 486121
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

Authorship 438932
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.

Authorship 439478
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

Targeting the bone marrow microenvironment in multiple myeloma.
PubMed Identifier: 25510276
author list: Kawano Y, Moschetta M, Manier S, Glavey S, Görgün GT, Roccaro AM, Anderson KC, Ghobrial IM
published in: Immunological reviews
information resource reference: Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015 Jan; 263(1):160-72.
journal title abbreviation: Immunol Rev
publication date: 2015-01-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 475422
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.

Authorship 480522
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia.

Authorship 775338
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.

Authorship 775757
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Targeting the bone marrow microenvironment in multiple myeloma.

Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo.
PubMed Identifier: 25312543
author list: Ashley JD, Stefanick JF, Schroeder VA, Suckow MA, Alves NJ, Suzuki R, Kikuchi S, Hideshima T, Anderson KC, Kiziltepe T, Bilgicer B
published in: Journal of controlled release : official journal of the Controlled Release Society
information resource reference: Liposomal carfilzomib nanoparticles effectively target multiple myeloma cells and demonstrate enhanced efficacy in vivo. J Control Release. 2014 Dec 28; 196:113-21.
journal title abbreviation: J Control Release
publication date: 2014-10-12T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 508734
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.

Authorship 512609
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.

Authorship 778666
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Clinical Cancer Research: the 20th anniversary.

Authorship 778259
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.
PubMed Identifier: 25261096
author list: Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG
published in: Haematologica
information resource reference: Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma. Haematologica. 2015 Jan; 100(1):100-6.
journal title abbreviation: Haematologica
publication date: 2014-09-26T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical Cancer Research: the 20th anniversary.
PubMed Identifier: 25564568
author list: Anderson KC, Potash J
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Clinical Cancer Research: the 20th anniversary. Clin Cancer Res. 2015 Jan 01; 21(1):3.
journal title abbreviation: Clin Cancer Res
publication date: 2015-01-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 566489
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.

Authorship 573017
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.

Authorship 569911
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.

Authorship 63077
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.

Authorship 83549
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.

Authorship 258805
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.

Authorship 277835
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays.

Authorship 313941
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Mcl-1 regulation and its role in multiple myeloma.

Authorship 529766
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.

Authorship 568116
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.

Authorship 80191
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.

Authorship 81783
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Novel biologically based therapies for Waldenstrom's macroglobulinemia.

Authorship 389517
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors.

Authorship 4270
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.

Authorship 47544
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/910232

Authorship 347968
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.

Authorship 351456
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.

Authorship 352551
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: New frontiers in the treatment of multiple myeloma.

Authorship 299864
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Intracellular protein degradation and its therapeutic implications.

Authorship 467498
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Thalidomide: emerging role in cancer medicine.

Authorship 54317
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Novel biologically based therapies for multiple myeloma.

Authorship 550645
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism.

Authorship 59539
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibition as a new therapeutic principle in hematological malignancies.

Authorship 576752
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Bortezomib in the front-line treatment of multiple myeloma.

Authorship 9175
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.

Authorship 251440
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Novel therapeutic avenues in myeloma: changing the treatment paradigm.

Authorship 446791
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibition as a therapeutic strategy for hematologic malignancies.

Authorship 498382
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.

Authorship 65298
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Authorship 231448
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma.

Authorship 244994
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?

Authorship 245249
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.

Authorship 273895
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.

Authorship 318599
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

Authorship 20606
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice.

Authorship 364541
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Novel biological therapies for the treatment of multiple myeloma.

Authorship 26348
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.

Authorship 295348
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

Authorship 316499
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

Authorship 317069
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.

Authorship 337958
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.

Authorship 432892
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.

Authorship 284276
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Moving disease biology from the lab to the clinic.

Authorship 292819
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.

Authorship 31988
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.

Authorship 323881
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Can thalidomide improve outcome in patients with multiple myeloma?

Authorship 433886
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma.

Authorship 498762
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Inhibition of the TGF-beta signaling pathway in tumor cells.

Authorship 258053
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Strategies to improve the outcome of stem cell transplantation in multiple myeloma.

Authorship 522734
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Time-domain frequency-selective processing in nuclear magnetic resonance: a spatial-spectral holographic perspective.

Authorship 2642
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl).

Authorship 534174
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: New drugs for multiple myeloma.

Authorship 280281
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenström's macroglobulinemia.

Authorship 288261
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.

Authorship 366765
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: New agents and approaches in the treatment of multiple myeloma.

Authorship 446678
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.

Authorship 456742
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

Authorship 260584
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Targeting proteasome inhibition in hematologic malignancies.

Authorship 290285
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.

Authorship 383853
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.

Authorship 444157
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.

Authorship 167903
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.

Authorship 249321
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: From the bench to the bedside: emerging new treatments in multiple myeloma.

Authorship 467664
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Body mass index, physical activity, and risk of multiple myeloma.

Authorship 31547
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Focus on multiple myeloma.

Authorship 329413
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.

Authorship 330101
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Beyond single-agent bortezomib: combination regimens in relapsed multiple myeloma.

Authorship 346379
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Thalidomide and lenalidomide: Mechanism-based potential drug combinations.

Authorship 352299
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).

Authorship 378785
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.

Authorship 458888
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.

Authorship 459135
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Proteomic analyses in Waldenstrom's macroglobulinemia and other plasma cell dyscrasias.

Authorship 474974
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment.

Authorship 496151
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.

Authorship 568506
type: Authorship
author rank in publication: 26
linked author: Anderson, Kenneth
linked information resource: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.
PubMed Identifier: 25557740
author list: Mateos MV, Richardson PG, Dimopoulos MA, Palumbo A, Anderson KC, Shi H, Elliott J, Dow E, van de Velde H, Niculescu L, San Miguel JF
published in: American journal of hematology
information resource reference: Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study. Am J Hematol. 2015 Apr; 90(4):314-9.
journal title abbreviation: Am J Hematol
publication date: 2015-02-27T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.
PubMed Identifier: 25833301
author list: Weinstock M, Aljawai Y, Morgan EA, Laubach J, Gannon M, Roccaro AM, Varga C, Mitsiades CS, Paba-Prada C, Schlossman R, Munshi N, Anderson KC, Richardson PP, Weller E, Ghobrial IM
published in: British journal of haematology
information resource reference: Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
journal title abbreviation: Br J Haematol
publication date: 2015-04-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
PubMed Identifier: 25652456
author list: An G, Li Z, Tai YT, Acharya C, Li Q, Qin X, Yi S, Xu Y, Feng X, Li C, Zhao J, Shi L, Zang M, Deng S, Sui W, Hao M, Zou D, Zhao Y, Qi J, Cheng T, Ru K, Wang J, Anderson KC, Qiu L
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma. Clin Cancer Res. 2015 May 01; 21(9):2148-56.
journal title abbreviation: Clin Cancer Res
publication date: 2015-02-04T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.
PubMed Identifier: 26005854
author list: Zhu D, Wang Z, Zhao JJ, Calimeri T, Meng J, Hideshima T, Fulciniti M, Kang Y, Ficarro SB, Tai YT, Hunter Z, McMilin D, Tong H, Mitsiades CS, Wu CJ, Treon SP, Dorfman DM, Pinkus G, Munshi NC, Tassone P, Marto JA, Anderson KC, Carrasco RD
published in: Nature medicine
information resource reference: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
journal title abbreviation: Nat Med
publication date: 2015-05-25T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
PubMed Identifier: 25984343
author list: Cowley GS, Weir BA, Vazquez F, Tamayo P, Scott JA, Rusin S, East-Seletsky A, Ali LD, Gerath WF, Pantel SE, Lizotte PH, Jiang G, Hsiao J, Tsherniak A, Dwinell E, Aoyama S, Okamoto M, Harrington W, Gelfand E, Green TM, Tomko MJ, Gopal S, Wong TC, Wong TC, Li H, Howell S, Stransky N, Liefeld T, Jang D, Bistline J, Hill Meyers B, Armstrong SA, Anderson KC, Stegmaier K, Reich M, Pellman D, Boehm JS, Mesirov JP, Golub TR, Root DE, Hahn WC
published in: Scientific data
information resource reference: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data. 2014; 1:140035.
journal title abbreviation: Sci Data
publication date: 2014-09-30T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
PubMed Identifier: 25439696
author list: Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF
published in: The Lancet. Oncology
information resource reference: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 Nov; 15(12):e538-48.
journal title abbreviation: Lancet Oncol
publication date: 2014-10-26T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?
PubMed Identifier: 25696864
author list: Richardson PG, Laubach JP, Munshi NC, Anderson KC
published in: Hematology. American Society of Hematology. Education Program
information resource reference: Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2014-11-18T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
PubMed Identifier: 25628469
author list: Palumbo A, Bringhen S, Mateos MV, Larocca A, Facon T, Kumar SK, Offidani M, McCarthy P, Evangelista A, Lonial S, Zweegman S, Musto P, Terpos E, Belch A, Hajek R, Ludwig H, Stewart AK, Moreau P, Anderson K, Einsele H, Durie BG, Dimopoulos MA, Landgren O, San Miguel JF, Richardson P, Sonneveld P, Rajkumar SV
published in: Blood
information resource reference: Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015 Mar 26; 125(13):2068-74.
journal title abbreviation: Blood
publication date: 2015-01-27T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.
PubMed Identifier: 25605835
author list: Dimopoulos MA, Hillengass J, Usmani S, Zamagni E, Lentzsch S, Davies FE, Raje N, Sezer O, Zweegman S, Shah J, Badros A, Shimizu K, Moreau P, Chim CS, Lahuerta JJ, Hou J, Jurczyszyn A, Goldschmidt H, Sonneveld P, Palumbo A, Ludwig H, Cavo M, Barlogie B, Anderson K, Roodman GD, Rajkumar SV, Durie BG, Terpos E
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement. J Clin Oncol. 2015 Feb 20; 33(6):657-64.
journal title abbreviation: J Clin Oncol
publication date: 2015-01-20T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
PubMed Identifier: 25832873
author list: Richardson PG, Moreau P, Laubach JP, Gupta N, Hui AM, Anderson KC, San Miguel JF, Kumar S
published in: Future oncology (London, England)
information resource reference: The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma. Future Oncol. 2015; 11(8):1153-68.
journal title abbreviation: Future Oncol
publication date: 2015-01-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
PubMed Identifier: 26032514
author list: Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG
published in: British journal of haematology
information resource reference: Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
journal title abbreviation: Br J Haematol
publication date: 2015-06-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Current treatment landscape for relapsed and/or refractory multiple myeloma.
PubMed Identifier: 25421279
author list: Dimopoulos MA, Richardson PG, Moreau P, Anderson KC
published in: Nature reviews. Clinical oncology
information resource reference: Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015 Jan; 12(1):42-54.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2014-11-25T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 269760
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authorship 302118
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/825068

Authorship 475465
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.

Authorship 483874
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Mouse models of human myeloma.

Authorship 505021
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authorship 546316
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells.

Authorship 378164
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

Authorship 508346
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies.

Authorship 545338
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.

Authorship 57675
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Bortezomib: proteasome inhibition as an effective anticancer therapy.

Authorship 176161
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling.

Authorship 469164
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.

Promising therapies in multiple myeloma.
PubMed Identifier: 26031917
author list: Bianchi G, Richardson PG, Anderson KC
published in: Blood
information resource reference: Promising therapies in multiple myeloma. Blood. 2015 Jul 16; 126(3):300-10.
journal title abbreviation: Blood
publication date: 2015-06-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 314223
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo.

Authorship 819162
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.

Authorship 818193
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Promising therapies in multiple myeloma.

Authorship 819165
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all?

Authorship 819086
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Authorship 819420
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.

Authorship 819393
type: Authorship
author rank in publication: 33
linked author: Anderson, Kenneth
linked information resource: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Authorship 819459
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Authorship 818746
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation.

Authorship 820376
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: CCR 20th anniversary commentary: In the beginning, there was PS-341.

Authorship 820757
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.

Authorship 820877
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells.

Authorship 819971
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: Salvage second hematopoietic cell transplantation in myeloma.

Authorship 820371
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.

Authorship 820545
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Stem cell transplant for first relapse from the multiple myeloma research foundation.

Authorship 820876
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma: new uses for available agents, excitement for the future.

Authorship 820899
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Current treatment landscape for relapsed and/or refractory multiple myeloma.

Authorship 821277
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib-melphalan-prednisone in the phase III VISTA study.

Authorship 820450
type: Authorship
author rank in publication: 32
linked author: Anderson, Kenneth
linked information resource: International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

CCR 20th anniversary commentary: In the beginning, there was PS-341.
PubMed Identifier: 25733705
author list: Teicher BA, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: CCR 20th anniversary commentary: In the beginning, there was PS-341. Clin Cancer Res. 2015 Mar 01; 21(5):939-41.
journal title abbreviation: Clin Cancer Res
publication date: 2015-03-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Stem cell transplant for first relapse from the multiple myeloma research foundation.
PubMed Identifier: 17263130
author list: Anderson KC, Vesole DH
published in: Oncology (Williston Park, N.Y.)
information resource reference: Stem cell transplant for first relapse from the multiple myeloma research foundation. Oncology (Williston Park). 2006 Dec; 20(14):1818, 1820-1, 1825-6.
journal title abbreviation: Oncology (Williston Park)
publication date: 2006-12-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma: new uses for available agents, excitement for the future.
PubMed Identifier: 25995433
author list: Anderson KC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Multiple myeloma: new uses for available agents, excitement for the future. J Natl Compr Canc Netw. 2015 May; 13(5 Suppl):694-6.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2015-05-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
PubMed Identifier: 25184863
author list: Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T
published in: The New England journal of medicine
information resource reference: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 Sep 04; 371(10):906-17.
journal title abbreviation: N Engl J Med
publication date: 2014-09-04T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Salvage second hematopoietic cell transplantation in myeloma.
PubMed Identifier: 23298856
author list: Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobadi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Mikhael J, Kindwall-Keller T, Stiff PJ, Gibson J, Lonial S, Krishnan A, Dispenzieri A, Hari P
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: Salvage second hematopoietic cell transplantation in myeloma. Biol Blood Marrow Transplant. 2013 May; 19(5):760-6.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2013-01-05T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 426230
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays.

Authorship 824547
type: Authorship
author rank in publication: 27
linked author: Anderson, Kenneth
linked information resource: Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
PubMed Identifier: 26035255
author list: Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, Walter-Croneck A, Moreau P, Mateos MV, Magen H, Belch A, Reece D, Beksac M, Spencer A, Oakervee H, Orlowski RZ, Taniwaki M, Röllig C, Einsele H, Wu KL, Singhal A, San-Miguel J, Matsumoto M, Katz J, Bleickardt E, Poulart V, Anderson KC, Richardson P
published in: The New England journal of medicine
information resource reference: Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2015 Aug 13; 373(7):621-31.
journal title abbreviation: N Engl J Med
publication date: 2015-06-02T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 455341
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Novel immunomodulatory therapies in the treatment of multiple myeloma.

Authorship 826199
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel therapeutic strategies for multiple myeloma.

Novel therapeutic strategies for multiple myeloma.
PubMed Identifier: 26118499
author list: Mimura N, Hideshima T, Anderson KC
published in: Experimental hematology
information resource reference: Novel therapeutic strategies for multiple myeloma. Exp Hematol. 2015 Aug; 43(8):732-41.
journal title abbreviation: Exp Hematol
publication date: 2015-06-26T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 489636
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Fatty acid synthase is a novel therapeutic target in multiple myeloma.

Authorship 554113
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authorship 572555
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: New drugs for myeloma.

Authorship 834839
type: Authorship
author rank in publication: 26
linked author: Anderson, Kenneth
linked information resource: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.

Authorship 833870
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.

Authorship 833521
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Novel therapeutic targets in multiple myeloma.

Novel therapeutic targets in multiple myeloma.
PubMed Identifier: 26352582
author list: Cottini F, Anderson K
published in: Clinical advances in hematology & oncology : H&O
information resource reference: Novel therapeutic targets in multiple myeloma. Clin Adv Hematol Oncol. 2015 Apr; 13(4):236-48.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2015-04-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma.
PubMed Identifier: 26080835
author list: Cottini F, Hideshima T, Suzuki R, Tai YT, Bianchini G, Richardson PG, Anderson KC, Tonon G
published in: Cancer discovery
information resource reference: Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov. 2015 Sep; 5(9):972-87.
journal title abbreviation: Cancer Discov
publication date: 2015-06-16T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.
PubMed Identifier: 26240224
author list: Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BG, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015 Sep 10; 33(26):2863-9.
journal title abbreviation: J Clin Oncol
publication date: 2015-08-03T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 72234
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Authorship 77298
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.

Authorship 79718
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.

Authorship 369964
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.

Authorship 838174
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine.

AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine.
PubMed Identifier: 26429978
author list: Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: AACR Cancer Progress Report 2015: Transforming Lives Through Precision Medicine. Clin Cancer Res. 2015 Oct 01; 21(19):4247.
journal title abbreviation: Clin Cancer Res
publication date: 2015-10-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 377636
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Clinical update: novel targets in multiple myeloma.

Authorship 841548
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia.

Authorship 841218
type: Authorship
author rank in publication: 17
linked author: Anderson, Kenneth
linked information resource: Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.

Authorship 841487
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.

Authorship 841062
type: Authorship
author rank in publication: 56
linked author: Anderson, Kenneth
linked information resource: Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.

Authorship 841343
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.

Authorship 841680
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: The heavy chain diseases: clinical and pathologic features.

Authorship 841730
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation.

Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.
PubMed Identifier: 26249174
author list: Zhao JJ, Chu ZB, Hu Y, Lin J, Wang Z, Jiang M, Chen M, Wang X, Kang Y, Zhou Y, Ni Chonghaile T, Johncilla ME, Tai YT, Cheng JQ, Letai A, Munshi NC, Anderson KC, Carrasco RD
published in: Cancer research
information resource reference: Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015 Oct 15; 75(20):4384-4397.
journal title abbreviation: Cancer Res
publication date: 2015-08-06T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
PubMed Identifier: 25979485
author list: Görgün G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE, White RE, Singh A, Ohguchi H, Suzuki R, Kikuchi S, Harada T, Hideshima T, Tai YT, Laubach JP, Raje N, Magrangeas F, Minvielle S, Avet-Loiseau H, Munshi NC, Dorfman DM, Richardson PG, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
journal title abbreviation: Clin Cancer Res
publication date: 2015-05-15T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 433956
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.

Targeting B-cell maturation antigen in multiple myeloma.
PubMed Identifier: 26370838
author list: Tai YT, Anderson KC
published in: Immunotherapy
information resource reference: Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015; 7(11):1187-99.
journal title abbreviation: Immunotherapy
publication date: 2015-09-15T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 465485
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.

Authorship 498702
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.

Authorship 509566
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Targeting NF-kappaB in Waldenstrom macroglobulinemia.

Authorship 848719
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Targeting B-cell maturation antigen in multiple myeloma.

Authorship 848258
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Authorship 849935
type: Authorship
author rank in publication: 24
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/62368550

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.
PubMed Identifier: 26553768
author list: Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2015 Nov; 13(11):1398-435.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2015-11-01T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/62368550
PubMed Identifier: 26428082
author list: Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant. 2015 Dec; 21(12):2039-2051.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2015-09-30T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource
label: American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma.

Authorship 851268
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.

Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.
PubMed Identifier: 26630652
author list: Suzuki R, Kikuchi S, Harada T, Mimura N, Minami J, Ohguchi H, Yoshida Y, Sagawa M, Gorgun G, Cirstea D, Cottini F, Jakubikova J, Tai YT, Chauhan D, Richardson PG, Munshi N, Ando K, Utsugi T, Hideshima T, Anderson KC
published in: PloS one
information resource reference: Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847.
journal title abbreviation: PLoS One
publication date: 2015-12-02T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 42357
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.

Authorship 852917
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
PubMed Identifier: 26686406
author list: Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S
published in: The Lancet. Haematology
information resource reference: Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Lancet Haematol. 2015 Dec; 2(12):e516-27.
journal title abbreviation: Lancet Haematol
publication date: 2015-11-16T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 449943
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Current therapeutic uses of lenalidomide in multiple myeloma.

Authorship 855841
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
PubMed Identifier: 26728187
author list: Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC
published in: Nature communications
information resource reference: The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
journal title abbreviation: Nat Commun
publication date: 2016-01-05T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 514296
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel therapies in myeloma.

Authorship 860209
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.

Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide.
PubMed Identifier: 26456076
author list: Das DS, Ray A, Song Y, Richardson P, Trikha M, Chauhan D, Anderson KC
published in: British journal of haematology
information resource reference: Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide. Br J Haematol. 2015 Dec; 171(5):798-812.
journal title abbreviation: Br J Haematol
publication date: 2015-10-12T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
PubMed Identifier: 26659815
author list: Xu L, Hunter ZR, Tsakmaklis N, Cao Y, Yang G, Chen J, Liu X, Kanan S, Castillo JJ, Tai YT, Zehnder JL, Brown JR, Carrasco RD, Advani R, Sabile JM, Argyropoulos K, Lia Palomba M, Morra E, Trojani A, Greco A, Tedeschi A, Varettoni M, Arcaini L, Munshi NM, Anderson KC, Treon SP
published in: British journal of haematology
information resource reference: Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol. 2016 Mar; 172(5):735-44.
journal title abbreviation: Br J Haematol
publication date: 2015-12-13T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 863290
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Authorship 864090
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.

Authorship 870612
type: Authorship
author rank in publication: 25
linked author: Anderson, Kenneth
linked information resource: Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.

A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.
PubMed Identifier: 26527748
author list: Gullà A, Di Martino MT, Gallo Cantafio ME, Morelli E, Amodio N, Botta C, Pitari MR, Lio SG, Britti D, Stamato MA, Hideshima T, Munshi NC, Anderson KC, Tagliaferri P, Tassone P
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2016 Mar 01; 22(5):1222-33.
journal title abbreviation: Clin Cancer Res
publication date: 2015-11-02T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells.
PubMed Identifier: 26675349
author list: Cea M, Cagnetta A, Adamia S, Acharya C, Tai YT, Fulciniti M, Ohguchi H, Munshi A, Acharya P, Bhasin MK, Zhong L, Carrasco R, Monacelli F, Ballestrero A, Richardson P, Gobbi M, Lemoli RM, Munshi N, Hideshima T, Nencioni A, Chauhan D, Anderson KC
published in: Blood
information resource reference: Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50.
journal title abbreviation: Blood
publication date: 2015-12-16T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 71899
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications.

Authorship 336552
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Recent advances in the treatment of Multiple Myeloma.

Authorship 871924
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.

Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study.
PubMed Identifier: 26644410
author list: Raje N, Vescio R, Montgomery CW, Badros A, Munshi N, Orlowski R, Hadala JT, Warsi G, Argonza-Aviles E, Ericson SG, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016 Mar 15; 22(6):1378-84.
journal title abbreviation: Clin Cancer Res
publication date: 2015-12-07T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 34430
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: The malignant clone and the bone-marrow environment.

Authorship 361789
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.

Authorship 875195
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.

Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.
PubMed Identifier: 26787413
author list: Ting KR, Brady JJ, Hameed A, Le G, Meiller J, Verburgh E, Bayers C, Benjamin D, Anderson KC, Richardson PG, Dowling P, Clynes M, Fitzgibbon MC, O'Gorman P
published in: British journal of haematology
information resource reference: Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma. Br J Haematol. 2016 Apr; 173(1):82-8.
journal title abbreviation: Br J Haematol
publication date: 2016-01-20T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator.
PubMed Identifier: 24374007
author list: Brandish PE, Anderson K, Baltus GA, Bai C, Bungard CJ, Bunting P, Byford A, Chiu CS, Cicmil M, Corcoran H, Euler D, Fisher JE, Gambone C, Hasbun-Manning M, Kuklin N, Landis E, Lifsted TQ, McElwee-Witmer S, McIntosh IS, Meissner RS, Miao J, Mitchell HJ, Musselman A, Schmidt A, Shin J, Szczerba P, Thompson CD, Tribouley C, Vogel RL, Warrier S, Hershey JC
published in: European journal of pharmacology
information resource reference: The preclinical efficacy, selectivity and pharmacologic profile of MK-5932, an insulin-sparing selective glucocorticoid receptor modulator. Eur J Pharmacol. 2014 Feb 05; 724:102-11.
journal title abbreviation: Eur J Pharmacol
publication date: 2013-12-27T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 876507
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
PubMed Identifier: 27059188
author list: Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. J Natl Compr Canc Netw. 2016 04; 14(4):389-400.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2016-04-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 41270
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications.

Authorship 494350
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.

Authorship 500882
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Antimyeloma activity of heat shock protein-90 inhibition.

A Model for Biologically-Based Therapeutics: Multiple Myeloma FOR CREDIT ONLY - PASTEUR
end date: 2002-06-30T00:00:00
start date: 2001-07-02T00:00:00
type: Mentoring - Completed Student Project
overview: Full Time/Year Long

Authorship 882356
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The Rapid Evolution of Novel Therapies in Multiple Myeloma.

The Rapid Evolution of Novel Therapies in Multiple Myeloma.
PubMed Identifier: 27160227
author list: Anderson KC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: The Rapid Evolution of Novel Therapies in Multiple Myeloma. J Natl Compr Canc Netw. 2016 05; 14(5):493-6.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2016-05-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 883277
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: MUC1-C drives MYC in multiple myeloma.

Authorship 883522
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: NCCN Guidelines Update for Multiple Myeloma.

NCCN Guidelines Update for Multiple Myeloma.
PubMed Identifier: 27226512
author list: Anderson KC
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: NCCN Guidelines Update for Multiple Myeloma. J Natl Compr Canc Netw. 2016 05; 14(5 Suppl):675-7.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2016-05-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

MUC1-C drives MYC in multiple myeloma.
PubMed Identifier: 26907633
author list: Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D
published in: Blood
information resource reference: MUC1-C drives MYC in multiple myeloma. Blood. 2016 05 26; 127(21):2587-97.
journal title abbreviation: Blood
publication date: 2016-02-23T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 884844
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.

Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1.
PubMed Identifier: 27009059
author list: Richardson PG, Zimmerman TM, Hofmeister CC, Talpaz M, Chanan-Khan AA, Kaufman JL, Laubach JP, Chauhan D, Jakubowiak AJ, Reich S, Trikha M, Anderson KC
published in: Blood
information resource reference: Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. Blood. 2016 06 02; 127(22):2693-700.
journal title abbreviation: Blood
publication date: 2016-03-23T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 886175
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.

Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma.
PubMed Identifier: 27196750
author list: Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P
published in: Molecular cancer therapeutics
information resource reference: Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. Mol Cancer Ther. 2016 06; 15(6):1364-75.
journal title abbreviation: Mol Cancer Ther
publication date: 2016-05-18T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 887197
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.

Authorship 887094
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.

VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma.
PubMed Identifier: 27025160
author list: Siegel DS, Dimopoulos M, Jagannath S, Goldschmidt H, Durrant S, Kaufman JL, Leleu X, Nagler A, Offner F, Graef T, Eid JE, Houp J, Gause C, Vuocolo S, Anderson KC
published in: Clinical lymphoma, myeloma & leukemia
information resource reference: VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2016 06; 16(6):329-334.e1.
journal title abbreviation: Clin Lymphoma Myeloma Leuk
publication date: 2016-03-04T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers.
PubMed Identifier: 27308358
author list: Cottini F, Anderson KC, Tonon G
published in: Molecular & cellular oncology
information resource reference: Awakening the Hippo co-activator YAP1, a mercurial cancer gene, in hematologic cancers. Mol Cell Oncol. 2014 Jul-Sep; 1(3):e970055.
journal title abbreviation: Mol Cell Oncol
publication date: 2014-12-23T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.
PubMed Identifier: 27002115
author list: Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, Caers J, Hillengass J, San Miguel J, van de Donk NW, Einsele H, Bladé J, Durie BG, Goldschmidt H, Mateos MV, Palumbo A, Orlowski R
published in: Blood
information resource reference: Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016 06 16; 127(24):2955-62.
journal title abbreviation: Blood
publication date: 2016-03-21T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 96293
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.

Authorship 561951
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibitor therapy in multiple myeloma.

Authorship 564603
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel biologically based therapeutic strategies in myeloma.

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.
PubMed Identifier: 27127303
author list: Tai YT, Acharya C, An G, Moschetta M, Zhong MY, Feng X, Cea M, Cagnetta A, Wen K, van Eenennaam H, van Elsas A, Qiu L, Richardson P, Munshi N, Anderson KC
published in: Blood
information resource reference: APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36.
journal title abbreviation: Blood
publication date: 2016-04-28T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.
PubMed Identifier: 27207793
author list: Lin J, Zhang W, Zhao JJ, Kwart AH, Yang C, Ma D, Ren X, Tai YT, Anderson KC, Handin RI, Munshi NC
published in: Blood
information resource reference: A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood. 2016 07 14; 128(2):249-52.
journal title abbreviation: Blood
publication date: 2016-05-18T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.
PubMed Identifier: 27287071
author list: Cea M, Cagnetta A, Acharya C, Acharya P, Tai YT, Yang C, Lovera D, Soncini D, Miglino M, Fraternali-Orcioni G, Mastracci L, Nencioni A, Montecucco F, Monacelli F, Ballestrero A, Hideshima T, Chauhan D, Gobbi M, Lemoli RM, Munshi N, Treon SP, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109.
journal title abbreviation: Clin Cancer Res
publication date: 2016-06-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 889296
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.

Associate Professor
sort order: 1
type: Faculty Rank

Full Professor
sort order: 0
type: Faculty Rank

Other Faculty
sort order: 5
type: Faculty Rank

Authorship 86125
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibitors as therapeutics.

Authorship 91692
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.

Authorship 96159
type: Authorship
author rank in publication: 18
linked author: Anderson, Kenneth
linked information resource: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.

Authorship 892396
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy.

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.
PubMed Identifier: 27418644
author list: An G, Acharya C, Feng X, Wen K, Zhong M, Zhang L, Munshi NC, Qiu L, Tai YT, Anderson KC
published in: Blood
information resource reference: Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016 09 22; 128(12):1590-603.
journal title abbreviation: Blood
publication date: 2016-07-14T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

A new era of immune therapy in multiple myeloma.
PubMed Identifier: 27445408
author list: Tai YT, Anderson KC
published in: Blood
information resource reference: A new era of immune therapy in multiple myeloma. Blood. 2016 07 21; 128(3):318-9.
journal title abbreviation: Blood
publication date: 2016-07-21T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 894001
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.

Authorship 894702
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: A new era of immune therapy in multiple myeloma.

A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
PubMed Identifier: 27098276
author list: Ray A, Ravillah D, Das DS, Song Y, Nordström E, Gullbo J, Richardson PG, Chauhan D, Anderson KC
published in: British journal of haematology
information resource reference: A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol. 2016 08; 174(3):397-409.
journal title abbreviation: Br J Haematol
publication date: 2016-04-20T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 80407
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Identification and validation of novel therapeutic targets for multiple myeloma.

Authorship 545331
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Dysfunctional T regulatory cells in multiple myeloma.

Authorship 563164
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.

Authorship 897371
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Authorship 896772
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.

Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.
PubMed Identifier: 27301862
author list: Hunter ZR, Xu L, Yang G, Tsakmaklis N, Vos JM, Liu X, Chen J, Manning RJ, Chen JG, Brodsky P, Patterson CJ, Gustine J, Dubeau T, Castillo JJ, Anderson KC, Munshi NM, Treon SP
published in: Blood
information resource reference: Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood. 2016 08 11; 128(6):827-38.
journal title abbreviation: Blood
publication date: 2016-06-14T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
PubMed Identifier: 27511158
author list: Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Bladé J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H
published in: The Lancet. Oncology
information resource reference: International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346.
journal title abbreviation: Lancet Oncol
publication date: 2016-08-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 904271
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.

Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution.
PubMed Identifier: 27006493
author list: Tang M, Zhao R, van de Velde H, Tross JG, Mitsiades C, Viselli S, Neuwirth R, Esseltine DL, Anderson K, Ghobrial IM, San Miguel JF, Richardson PG, Tomasson MH, Michor F
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Myeloma Cell Dynamics in Response to Treatment Supports a Model of Hierarchical Differentiation and Clonal Evolution. Clin Cancer Res. 2016 Aug 15; 22(16):4206-4214.
journal title abbreviation: Clin Cancer Res
publication date: 2016-03-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 908472
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.

Authorship 908840
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.

Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
PubMed Identifier: 27099225
author list: Harada T, Hideshima T, Anderson KC
published in: International journal of hematology
information resource reference: Histone deacetylase inhibitors in multiple myeloma: from bench to bedside. Int J Hematol. 2016 Sep; 104(3):300-9.
journal title abbreviation: Int J Hematol
publication date: 2016-04-20T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients.
PubMed Identifier: 27161872
author list: Levin N, Spencer A, Harrison SJ, Chauhan D, Burrows FJ, Anderson KC, Reich SD, Richardson PG, Trikha M
published in: British journal of haematology
information resource reference: Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol. 2016 Sep; 174(5):711-20.
journal title abbreviation: Br J Haematol
publication date: 2016-05-09T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 910305
type: Authorship
author rank in publication: 28
linked author: Anderson, Kenneth
linked information resource: BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.

BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice.
PubMed Identifier: 27455953
author list: Hamouda MA, Jacquel A, Robert G, Puissant A, Richez V, Cassel R, Fenouille N, Roulland S, Gilleron J, Griessinger E, Dubois A, Bailly-Maitre B, Goncalves D, Mallavialle A, Colosetti P, Marchetti S, Amiot M, Gomez-Bougie P, Rochet N, Deckert M, Avet-Loiseau H, Hofman P, Karsenti JM, Jeandel PY, Blin-Wakkach C, Nadel B, Cluzeau T, Anderson KC, Fuzibet JG, Auberger P, Luciano F
published in: The Journal of experimental medicine
information resource reference: BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. J Exp Med. 2016 08 22; 213(9):1705-22.
journal title abbreviation: J Exp Med
publication date: 2016-07-25T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma
end date: 2021-06-30
principal investigator name: ANDERSON, KENNETH C.
start date: 2016-07-15
type: Grant
sponsor award id: R01CA207237

Functional and biologic significance of deacetylase3 inhibition in myeloma
end date: 2020-08-31
principal investigator name: HIDESHIMA, TERU
start date: 2014-09-01
type: Grant
sponsor award id: R01CA178264

Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications
end date: 2021-05-31
principal investigator name: ANDERSON, KENNETH C.
start date: 1990-12-01
type: Grant
sponsor award id: R01CA050947

SPORE in Multiple Myeloma
end date: 2024-05-31
principal investigator name: ANDERSON, KENNETH C.
start date: 2003-09-01
type: Grant
sponsor award id: P50CA100707

Host-tumor cell interaction in myeloma: therapeutic applications
end date: 2016-03-31
principal investigator name: ANDERSON, KENNETH C.
start date: 1998-08-01
type: Grant
sponsor award id: P01CA078378

Integrative Oncogenomics of Multiple Myeloma
end date: 2028-07-31
principal investigator name: MUNSHI, NIKHIL C.
start date: 2011-09-01
type: Grant
sponsor award id: P01CA155258

Co-Principal Investigator
type: Researcher Role
researcher role of: Anderson, Kenneth
contributes to: Integrative Oncogenomics of Multiple Myeloma

Principal Investigator
type: Researcher Role
researcher role of: Anderson, Kenneth
contributes to: Therapeutically Targeting Plasmacytoid Dendritic Cells in Multiple Myeloma

Principal Investigator
type: Researcher Role
researcher role of: Anderson, Kenneth
contributes to: SPORE in Multiple Myeloma

Principal Investigator
type: Researcher Role
researcher role of: Anderson, Kenneth
contributes to: Functional and biologic significance of deacetylase3 inhibition in myeloma

Principal Investigator
type: Researcher Role
researcher role of: Anderson, Kenneth
contributes to: Molecular Sequelae of Myeloma-Bone Marrow Interactions: Therapeutic Applications

Principal Investigator
type: Researcher Role
researcher role of: Anderson, Kenneth
contributes to: Host-tumor cell interaction in myeloma: therapeutic applications

Authorship 8395
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: S-3-Amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice.

Authorship 915894
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.

Authorship 359281
type: Authorship
author rank in publication: 19
linked author: Anderson, Kenneth
linked information resource: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib.

Authorship 362450
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.

Authorship 364083
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.

Authorship 402468
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.

Authorship 404880
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.

Authorship 922901
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: AACR Cancer Progress Report 2016: Improving Lives Through Research.

Authorship 920476
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Vision Statement for Multiple Myeloma: Future Directions.

Authorship 924909
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple Myeloma: New Insights and Therapeutic Approaches.

Authorship 927473
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.

Authorship 928323
type: Authorship
author rank in publication: 7
linked author: Anderson, Kenneth
linked information resource: Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors.

Multiple Myeloma: New Insights and Therapeutic Approaches.
PubMed Identifier: 11701540
author list: Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J
published in: Hematology. American Society of Hematology. Education Program
information resource reference: Multiple Myeloma: New Insights and Therapeutic Approaches. Hematology Am Soc Hematol Educ Program. 2000; 147-165.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2000-01-01T00:00:00
year: 2000
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors.
PubMed Identifier: 27668268
author list: Bae J, Keskin DB, Cowens K, Lee AH, Dranoff G, Munshi NC, Anderson KC
published in: Journal of leukemia (Los Angeles, Calif.)
information resource reference: Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2).
journal title abbreviation: J Leuk (Los Angel)
publication date: 2015-04-21T00:00:00
year: 2015
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications.
PubMed Identifier: 27764795
author list: Jakubikova J, Cholujova D, Hideshima T, Gronesova P, Soltysova A, Harada T, Joo J, Kong SY, Szalat RE, Richardson PG, Munshi NC, Dorfman DM, Anderson KC
published in: Oncotarget
information resource reference: A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341.
journal title abbreviation: Oncotarget
publication date: 2016-11-22T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Vision Statement for Multiple Myeloma: Future Directions.
PubMed Identifier: 27696255
author list: Anderson KC
published in: Cancer treatment and research
information resource reference: Vision Statement for Multiple Myeloma: Future Directions. Cancer Treat Res. 2016; 169:15-22.
journal title abbreviation: Cancer Treat Res
publication date: 2016-01-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

AACR Cancer Progress Report 2016: Improving Lives Through Research.
PubMed Identifier: 27697990
author list: Tessmer MS, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: AACR Cancer Progress Report 2016: Improving Lives Through Research. Clin Cancer Res. 2016 10 01; 22(19):4759.
journal title abbreviation: Clin Cancer Res
publication date: 2016-10-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 512242
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Moving disease biology from the laboratory to the clinic.

Authorship 541035
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.

Authorship 558812
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.

Authorship 932678
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status.

Authorship 932780
type: Authorship
author rank in publication: 20
linked author: Anderson, Kenneth
linked information resource: Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.

Authorship 932508
type: Authorship
author rank in publication: 14
linked author: Anderson, Kenneth
linked information resource: Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.

Authorship 936526
type: Authorship
author rank in publication: 91
linked author: Anderson, Kenneth
linked information resource: A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.

Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma.
PubMed Identifier: 27799547
author list: Hideshima T, Qi J, Paranal RM, Tang W, Greenberg E, West N, Colling ME, Estiu G, Mazitschek R, Perry JA, Ohguchi H, Cottini F, Mimura N, Görgün G, Tai YT, Richardson PG, Carrasco RD, Wiest O, Schreiber SL, Anderson KC, Bradner JE
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. Proc Natl Acad Sci U S A. 2016 11 15; 113(46):13162-13167.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2016-10-31T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma.
PubMed Identifier: 27287072
author list: Raje NS, Faber EA, Richardson PG, Schiller G, Hohl RJ, Cohen AD, Forero A, Carpenter S, Nguyen TS, Conti I, Kaiser CJ, Cronier DM, Wooldridge JE, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase 1 Study of Tabalumab, a Human Anti-B-Cell Activating Factor Antibody, and Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma. Clin Cancer Res. 2016 Dec 01; 22(23):5688-5695.
journal title abbreviation: Clin Cancer Res
publication date: 2016-06-10T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci.
PubMed Identifier: 27587788
author list: Rand KA, Song C, Dean E, Serie DJ, Curtin K, Sheng X, Hu D, Huff CA, Bernal-Mizrachi L, Tomasson MH, Ailawadhi S, Singhal S, Pawlish K, Peters ES, Bock CH, Stram A, Van Den Berg DJ, Edlund CK, Conti DV, Zimmerman T, Hwang AE, Huntsman S, Graff J, Nooka A, Kong Y, Pregja SL, Berndt SI, Blot WJ, Carpten J, Casey G, Chu L, Diver WR, Stevens VL, Lieber MR, Goodman PJ, Hennis AJ, Hsing AW, Mehta J, Kittles RA, Kolb S, Klein EA, Leske C, Murphy AB, Nemesure B, Neslund-Dudas C, Strom SS, Vij R, Rybicki BA, Stanford JL, Signorello LB, Witte JS, Ambrosone CB, Bhatti P, John EM, Bernstein L, Zheng W, Olshan AF, Hu JJ, Ziegler RG, Nyante SJ, Bandera EV, Birmann BM, Ingles SA, Press MF, Atanackovic D, Glenn MJ, Cannon-Albright LA, Jones B, Tricot G, Martin TG, Kumar SK, Wolf JL, Deming Halverson SL, Rothman N, Brooks-Wilson AR, Rajkumar SV, Kolonel LN, Chanock SJ, Slager SL, Severson RK, Janakiraman N, Terebelo HR, Brown EE, De Roos AJ, Mohrbacher AF, Colditz GA, Giles GG, Spinelli JJ, Chiu BC, Munshi NC, Anderson KC, Levy J, Zonder JA, Orlowski RZ, Lonial S, Camp NJ, Vachon CM, Ziv E, Stram DO, Hazelett DJ, Haiman CA, Cozen W
published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
information resource reference: A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618.
journal title abbreviation: Cancer Epidemiol Biomarkers Prev
publication date: 2016-09-01T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 205865
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: A SCID-hu in vivo model of human Waldenström macroglobulinemia.

Authorship 291347
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma.

Authorship 32144
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Perspectives for combination therapy to overcome drug-resistant multiple myeloma.

Authorship 343103
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.

Authorship 366612
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Proteasome inhibition in hematologic malignancies.

Authorship 945019
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Authorship 945299
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.

Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis.
PubMed Identifier: 27632282
author list: Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, Sherrington P, Samur MK, Georgieva A, Anderson KC, Gregory WM
published in: JAMA oncology
information resource reference: Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017 Jan 01; 3(1):28-35.
journal title abbreviation: JAMA Oncol
publication date: 2017-01-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.
PubMed Identifier: 28018601
author list: Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV
published in: Journal for immunotherapy of cancer
information resource reference: The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.
journal title abbreviation: J Immunother Cancer
publication date: 2016-12-20T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 433051
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Novel therapeutic approaches for multiple myeloma.

Authorship 446601
type: Authorship
author rank in publication: 13
linked author: Anderson, Kenneth
linked information resource: Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.

Authorship 479952
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Arsenic trioxide in multiple myeloma: rationale and future directions.

Authorship 948536
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma.
PubMed Identifier: 28082445
author list: Hideshima T, Cottini F, Nozawa Y, Seo HS, Ohguchi H, Samur MK, Cirstea D, Mimura N, Iwasawa Y, Richardson PG, Munshi NC, Chauhan D, Massefski W, Utsugi T, Dhe-Paganon S, Anderson KC
published in: Blood
information resource reference: p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319.
journal title abbreviation: Blood
publication date: 2017-01-12T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 950967
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.

Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
PubMed Identifier: 28096095
author list: Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, Munshi NC
published in: Blood
information resource reference: Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
journal title abbreviation: Blood
publication date: 2017-01-17T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 557426
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Cytokines and signal transduction.

Authorship 952719
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.
PubMed Identifier: 28107546
author list: Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D
published in: British journal of haematology
information resource reference: Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. Br J Haematol. 2017 03; 176(6):929-938.
journal title abbreviation: Br J Haematol
publication date: 2017-01-20T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 954130
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Immune Therapies in Multiple Myeloma.

Authorship 953479
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Progress and Paradigms in Multiple Myeloma.

Progress and Paradigms in Multiple Myeloma.
PubMed Identifier: 28151709
author list: Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Progress and Paradigms in Multiple Myeloma. Clin Cancer Res. 2016 Nov 15; 22(22):5419-5427.
journal title abbreviation: Clin Cancer Res
publication date: 2016-11-15T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Immune Therapies in Multiple Myeloma.
PubMed Identifier: 28151713
author list: Kumar SK, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Immune Therapies in Multiple Myeloma. Clin Cancer Res. 2016 Nov 15; 22(22):5453-5460.
journal title abbreviation: Clin Cancer Res
publication date: 2016-11-15T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12.
PubMed Identifier: 11895787
author list: Gong J, Koido S, Chen D, Tanaka Y, Huang L, Avigan D, Anderson K, Ohno T, Kufe D
published in: Blood
information resource reference: Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood. 2002 Apr 01; 99(7):2512-7.
journal title abbreviation: Blood
publication date: 2002-04-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
PubMed Identifier: 15050914
author list: Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D, Joseph M, Libermann TA, García-Echeverría C, Pearson MA, Hofmann F, Anderson KC, Kung AL
published in: Cancer cell
information resource reference: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell. 2004 Mar; 5(3):221-30.
journal title abbreviation: Cancer Cell
publication date: 2004-03-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
PubMed Identifier: 15094775
author list: Chauhan D, Li G, Hideshima T, Podar K, Shringarpure R, Mitsiades C, Munshi N, Yew PR, Anderson KC
published in: Oncogene
information resource reference: Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene. 2004 Apr 29; 23(20):3597-602.
journal title abbreviation: Oncogene
publication date: 2004-04-29T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells.
PubMed Identifier: 12665525
author list: Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Munshi N, Kharbanda S, Anderson KC
published in: The Journal of biological chemistry
information resource reference: JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6.
journal title abbreviation: J Biol Chem
publication date: 2003-03-28T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma.
PubMed Identifier: 14627979
author list: Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC
published in: Oncogene
information resource reference: Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93.
journal title abbreviation: Oncogene
publication date: 2003-11-20T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Strategies to improve the outcome of stem cell transplantation in multiple myeloma.
PubMed Identifier: 14745425
author list: Catley L, Anderson K
published in: The hematology journal : the official journal of the European Haematology Association
information resource reference: Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J. 2004; 5(1):9-23.
journal title abbreviation: Hematol J
publication date: 2004-01-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.
PubMed Identifier: 15070698
author list: Chauhan D, Li G, Podar K, Hideshima T, Shringarpure R, Catley L, Mitsiades C, Munshi N, Tai YT, Suh N, Gribble GW, Honda T, Schlossman R, Richardson P, Sporn MB, Anderson KC
published in: Blood
information resource reference: The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66.
journal title abbreviation: Blood
publication date: 2003-12-11T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

44 Binney St
type: Address
address line 1: Dana Farber Cancer Institute
address line 2: Blood Compont, D289
address line 3: 44 Binney St
city: Boston
postal code: 02115
state or province: MA

Proteasome inhibition in the treatment of cancer.
PubMed Identifier: 15655370
author list: Richardson PG, Mitsiades C, Hideshima T, Anderson KC
published in: Cell cycle (Georgetown, Tex.)
information resource reference: Proteasome inhibition in the treatment of cancer. Cell Cycle. 2005 Feb; 4(2):290-6.
journal title abbreviation: Cell Cycle
publication date: 2005-02-03T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 963761
type: Authorship
author rank in publication: 15
linked author: Anderson, Kenneth
linked information resource: Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma.

Authorship 964975
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.

Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells.
PubMed Identifier: 25941601
author list: Bae J, Samur M, Munshi A, Hideshima T, Keskin D, Kimmelman A, Lee AH, Dranoff G, Anderson KC, Munshi NC
published in: Oncoimmunology
information resource reference: Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914.
journal title abbreviation: Oncoimmunology
publication date: 2014-12-02T00:00:00
year: 2014
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma.
PubMed Identifier: 27022108
author list: Amodio N, Stamato MA, Gullà AM, Morelli E, Romeo E, Raimondi L, Pitari MR, Ferrandino I, Misso G, Caraglia M, Perrotta I, Neri A, Fulciniti M, Rolfo C, Anderson KC, Munshi NC, Tagliaferri P, Tassone P
published in: Molecular cancer therapeutics
information resource reference: Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016 Mar 28.
journal title abbreviation: Mol Cancer Ther
publication date: 2016-03-28T00:00:00
year: 2016
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 968732
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

Authorship 970195
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
PubMed Identifier: 28270494
author list: Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289.
journal title abbreviation: Clin Cancer Res
publication date: 2017-03-07T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.
PubMed Identifier: 28249894
author list: Feng X, Zhang L, Acharya C, An G, Wen K, Qiu L, Munshi NC, Tai YT, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. 2017 Aug 01; 23(15):4290-4300.
journal title abbreviation: Clin Cancer Res
publication date: 2017-03-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

New treatments for multiple myeloma.
PubMed Identifier: 16506632
author list: Richardson PG, Schlossman R, Hideshima T, Anderson KC
published in: Oncology (Williston Park, N.Y.)
information resource reference: New treatments for multiple myeloma. Oncology (Williston Park). 2005 Dec; 19(14):1781-92; discussion 1792, 1795-7.
journal title abbreviation: Oncology (Williston Park)
publication date: 2005-12-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications.
PubMed Identifier: 12010810
author list: Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi N, Treon SP, Anderson KC
published in: Blood
information resource reference: Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
journal title abbreviation: Blood
publication date: 2002-06-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment.
PubMed Identifier: 17546631
author list: Mitsiades CS, Mitsiades NS, Richardson PG, Munshi NC, Anderson KC
published in: Journal of cellular biochemistry
information resource reference: Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68.
journal title abbreviation: J Cell Biochem
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.
PubMed Identifier: 17715391
author list: Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC
published in: Blood
information resource reference: MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts. Blood. 2007 Nov 15; 110(10):3744-52.
journal title abbreviation: Blood
publication date: 2007-08-22T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies.
PubMed Identifier: 17996586
author list: Mitsiades CS, McMillin DW, Klippel S, Hideshima T, Chauhan D, Richardson PG, Munshi NC, Anderson KC
published in: Hematology/oncology clinics of North America
information resource reference: The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
PubMed Identifier: 18297527
author list: Richardson P, Mitsiades C, Colson K, Reilly E, McBride L, Chiao J, Sun L, Ricker J, Rizvi S, Oerth C, Atkins B, Fearen I, Anderson K, Siegel D
published in: Leukemia & lymphoma
information resource reference: Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma. 2008 Mar; 49(3):502-7.
journal title abbreviation: Leuk Lymphoma
publication date: 2008-03-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma.
PubMed Identifier: 18783399
author list: Jagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Esseltine DL, Anderson KC
published in: British journal of haematology
information resource reference: Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Br J Haematol. 2008 Nov; 143(4):537-40.
journal title abbreviation: Br J Haematol
publication date: 2008-09-06T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells.
PubMed Identifier: 19738061
author list: Mani M, Carrasco DE, Zhang Y, Takada K, Gatt ME, Dutta-Simmons J, Ikeda H, Diaz-Griffero F, Pena-Cruz V, Bertagnolli M, Myeroff LL, Markowitz SD, Anderson KC, Carrasco DR
published in: Cancer research
information resource reference: BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells. Cancer Res. 2009 Oct 01; 69(19):7577-86.
journal title abbreviation: Cancer Res
publication date: 2009-09-08T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Arsenic trioxide in multiple myeloma: rationale and future directions.
PubMed Identifier: 11895198
author list: Anderson KC, Boise LH, Louie R, Waxman S
published in: Cancer journal (Sudbury, Mass.)
information resource reference: Arsenic trioxide in multiple myeloma: rationale and future directions. Cancer J. 2002 Jan-Feb; 8(1):12-25.
journal title abbreviation: Cancer J
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma.
PubMed Identifier: 12446425
author list: Anderson KC, Shaughnessy JD, Barlogie B, Harousseau JL, Roodman GD
published in: Hematology. American Society of Hematology. Education Program
information resource reference: Multiple myeloma. Hematology Am Soc Hematol Educ Program. 2002; 214-40.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma.
PubMed Identifier: 12479272
author list: Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Gupta D, Richardson P, Munshi N, Anderson KC
published in: Molecular cancer therapeutics
information resource reference: The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. Mol Cancer Ther. 2002 May; 1(7):539-44.
journal title abbreviation: Mol Cancer Ther
publication date: 2002-05-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel biologically based therapies for Waldenstrom's macroglobulinemia.
PubMed Identifier: 12720159
author list: Mitsiades CS, Mitsiades N, Richardson PG, Treon SP, Anderson KC
published in: Seminars in oncology
information resource reference: Novel biologically based therapies for Waldenstrom's macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):309-12.
journal title abbreviation: Semin Oncol
publication date: 2003-04-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications.
PubMed Identifier: 14583463
author list: Mitsiades CS, Mitsiades NS, Bronson RT, Chauhan D, Munshi N, Treon SP, Maxwell CA, Pilarski L, Hideshima T, Hoffman RM, Anderson KC
published in: Cancer research
information resource reference: Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96.
journal title abbreviation: Cancer Res
publication date: 2003-10-15T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibition in hematologic malignancies.
PubMed Identifier: 15224657
author list: Richardson PG, Hideshima T, Mitsiades C, Anderson K
published in: Annals of medicine
information resource reference: Proteasome inhibition in hematologic malignancies. Ann Med. 2004; 36(4):304-14.
journal title abbreviation: Ann Med
publication date: 2004-01-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibition as a novel therapeutic target in human cancer.
PubMed Identifier: 15659509
author list: Rajkumar SV, Richardson PG, Hideshima T, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 2005 Jan 20; 23(3):630-9.
journal title abbreviation: J Clin Oncol
publication date: 2005-01-20T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor.
PubMed Identifier: 15692072
author list: Bellucci R, Alyea EP, Chiaretti S, Wu CJ, Zorn E, Weller E, Wu B, Canning C, Schlossman R, Munshi NC, Anderson KC, Ritz J
published in: Blood
information resource reference: Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
journal title abbreviation: Blood
publication date: 2005-02-03T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Cytokines and signal transduction.
PubMed Identifier: 16026734
author list: Hideshima T, Podar K, Chauhan D, Anderson KC
published in: Best practice & research. Clinical haematology
information resource reference: Cytokines and signal transduction. Best Pract Res Clin Haematol. 2005; 18(4):509-24.
journal title abbreviation: Best Pract Res Clin Haematol
publication date: 2005-01-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells.
PubMed Identifier: 12135668
author list: Gupta D, Podar K, Tai YT, Lin B, Hideshima T, Akiyama M, LeBlanc R, Catley L, Mitsiades N, Mitsiades C, Chauhan D, Munshi NC, Anderson KC
published in: Experimental hematology
information resource reference: beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20.
journal title abbreviation: Exp Hematol
publication date: 2002-07-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
PubMed Identifier: 12208756
author list: Lin B, Podar K, Gupta D, Tai YT, Li S, Weller E, Hideshima T, Lentzsch S, Davies F, Li C, Weisberg E, Schlossman RL, Richardson PG, Griffin JD, Wood J, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
journal title abbreviation: Cancer Res
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery.
PubMed Identifier: 12516971
author list: Anderson KC, Dalton WS
published in: Molecular cancer therapeutics
information resource reference: Synopsis of a research roundtable presented on cell signaling in myeloma: regulation of growth and apoptosis--opportunities for new drug discovery. Mol Cancer Ther. 2002 Dec; 1(14):1361-5.
journal title abbreviation: Mol Cancer Ther
publication date: 2002-12-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapeutic approaches for multiple myeloma.
PubMed Identifier: 12846814
author list: Hideshima T, Richardson P, Anderson KC
published in: Immunological reviews
information resource reference: Novel therapeutic approaches for multiple myeloma. Immunol Rev. 2003 Aug; 194:164-76.
journal title abbreviation: Immunol Rev
publication date: 2003-08-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens.
PubMed Identifier: 14563636
author list: Bellucci R, Wu CJ, Chiaretti S, Weller E, Davies FE, Alyea EP, Dranoff G, Anderson KC, Munshi NC, Ritz J
published in: Blood
information resource reference: Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
journal title abbreviation: Blood
publication date: 2003-10-16T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
PubMed Identifier: 14644994
author list: Podar K, Catley LP, Tai YT, Shringarpure R, Carvalho P, Hayashi T, Burger R, Schlossman RL, Richardson PG, Pandite LN, Kumar R, Hideshima T, Chauhan D, Anderson KC
published in: Blood
information resource reference: GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment. Blood. 2004 May 01; 103(9):3474-9.
journal title abbreviation: Blood
publication date: 2003-11-26T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 975223
type: Authorship
author rank in publication: 16
linked author: Anderson, Kenneth
linked information resource: The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.

Authorship 976340
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Authorship 976299
type: Authorship
author rank in publication: 25
linked author: Anderson, Kenneth
linked information resource: Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.

The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma.
PubMed Identifier: 28380360
author list: Mishima Y, Paiva B, Shi J, Park J, Manier S, Takagi S, Massoud M, Perilla-Glen A, Aljawai Y, Huynh D, Roccaro AM, Sacco A, Capelletti M, Detappe A, Alignani D, Anderson KC, Munshi NC, Prosper F, Lohr JG, Ha G, Freeman SS, Van Allen EM, Adalsteinsson VA, Michor F, San Miguel JF, Ghobrial IM
published in: Cell reports
information resource reference: The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224.
journal title abbreviation: Cell Rep
publication date: 2017-04-04T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
PubMed Identifier: 28379796
author list: Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P
published in: The New England journal of medicine
information resource reference: Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 04 06; 376(14):1311-1320.
journal title abbreviation: N Engl J Med
publication date: 2017-04-06T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group.
PubMed Identifier: 28368259
author list: Cavo M, Terpos E, Nanni C, Moreau P, Lentzsch S, Zweegman S, Hillengass J, Engelhardt M, Usmani SZ, Vesole DH, San-Miguel J, Kumar SK, Richardson PG, Mikhael JR, da Costa FL, Dimopoulos MA, Zingaretti C, Abildgaard N, Goldschmidt H, Orlowski RZ, Chng WJ, Einsele H, Lonial S, Barlogie B, Anderson KC, Rajkumar SV, Durie BGM, Zamagni E
published in: The Lancet. Oncology
information resource reference: Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017 04; 18(4):e206-e217.
journal title abbreviation: Lancet Oncol
publication date: 2017-04-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.
PubMed Identifier: 15638853
author list: Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC
published in: British journal of haematology
information resource reference: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005 Jan; 128(2):192-203.
journal title abbreviation: Br J Haematol
publication date: 2005-01-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
PubMed Identifier: 15940263
author list: Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, Roccaro AM, Tai YZ, Chauhan D, Fram R, Tamura K, Jain J, Anderson KC
published in: Oncogene
information resource reference: Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway. Oncogene. 2005 Sep 01; 24(38):5888-96.
journal title abbreviation: Oncogene
publication date: 2005-09-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial.
PubMed Identifier: 16470606
author list: Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, Rajkumar SV, Srkalovic G, Alsina M, Anderson KC
published in: Cancer
information resource reference: Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial. Cancer. 2006 Mar 15; 106(6):1316-9.
journal title abbreviation: Cancer
publication date: 2006-03-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/782568
PubMed Identifier: 17575103
author list: Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC
published in: Molecular cancer therapeutics
information resource reference: 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007 Jun; 6(6):1718-27.
journal title abbreviation: Mol Cancer Ther
publication date: 2007-06-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource
label: 5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.

Moving disease biology from the lab to the clinic.
PubMed Identifier: 12548578
author list: Anderson KC
published in: Cancer
information resource reference: Moving disease biology from the lab to the clinic. Cancer. 2003 Feb 01; 97(3 Suppl):796-801.
journal title abbreviation: Cancer
publication date: 2003-02-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel biologically based therapeutic strategies in myeloma.
PubMed Identifier: 12616700
author list: Gupta D, Hideshima T, Anderson KC
published in: Reviews in clinical and experimental hematology
information resource reference: Novel biologically based therapeutic strategies in myeloma. Rev Clin Exp Hematol. 2002 Sep; 6(3):301-24.
journal title abbreviation: Rev Clin Exp Hematol
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
PubMed Identifier: 12720120
author list: Gertz MA, Anagnostopoulos A, Anderson K, Branagan AR, Coleman M, Frankel SR, Giralt S, Levine T, Munshi N, Pestronk A, Rajkumar V, Treon SP
published in: Seminars in oncology
information resource reference: Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6.
journal title abbreviation: Semin Oncol
publication date: 2003-04-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
PubMed Identifier: 12816865
author list: Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D, Munshi NC, Schlossman R, Richardson P, Griffin J, Anderson KC
published in: Blood
information resource reference: NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
journal title abbreviation: Blood
publication date: 2003-06-19T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase 2 study of bortezomib in relapsed, refractory myeloma.
PubMed Identifier: 12826635
author list: Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC
published in: The New England journal of medicine
information resource reference: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003 Jun 26; 348(26):2609-17.
journal title abbreviation: N Engl J Med
publication date: 2003-06-26T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance.
PubMed Identifier: 12855565
author list: Chauhan D, Li G, Hideshima T, Podar K, Mitsiades C, Mitsiades N, Catley L, Tai YT, Hayashi T, Shringarpure R, Burger R, Munshi N, Ohtake Y, Saxena S, Anderson KC
published in: Blood
information resource reference: Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86.
journal title abbreviation: Blood
publication date: 2003-07-10T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Thalidomide: emerging role in cancer medicine.
PubMed Identifier: 11818493
author list: Richardson P, Hideshima T, Anderson K
published in: Annual review of medicine
information resource reference: Thalidomide: emerging role in cancer medicine. Annu Rev Med. 2002; 53:629-57.
journal title abbreviation: Annu Rev Med
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia?
PubMed Identifier: 12007974
author list: Benjamin RJ, Anderson KC
published in: Critical reviews in oncology/hematology
information resource reference: What is the proper threshold for platelet transfusion in patients with chemotherapy-induced thrombocytopenia? Crit Rev Oncol Hematol. 2002 May; 42(2):163-71.
journal title abbreviation: Crit Rev Oncol Hematol
publication date: 2002-05-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.
PubMed Identifier: 12091368
author list: Brander C, Raje N, O'Connor PG, Davies F, Davis J, Chauhan D, Hideshima T, Martin J, Osmond D, Kedes DH, Walker BD, Scadden DT, Anderson KC
published in: Blood
information resource reference: Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma. Blood. 2002 Jul 15; 100(2):698-700.
journal title abbreviation: Blood
publication date: 2002-07-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 978591
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Authorship 978855
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.

Authorship 978409
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: Risks of cancer among a cohort of 23,935 men and women with osteoporosis.

Risks of cancer among a cohort of 23,935 men and women with osteoporosis.
PubMed Identifier: 18074348
author list: McGlynn KA, Gridley G, Mellemkjaer L, Brinton LA, Anderson KC, Caporaso NE, Landgren O, Olsen JH
published in: International journal of cancer
information resource reference: Risks of cancer among a cohort of 23,935 men and women with osteoporosis. Int J Cancer. 2008 Apr 15; 122(8):1879-84.
journal title abbreviation: Int J Cancer
publication date: 2008-04-15T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.
PubMed Identifier: 28428191
author list: Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res. 2017 Aug 01; 23(15):3980-3993.
journal title abbreviation: Clin Cancer Res
publication date: 2017-04-20T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma.
PubMed Identifier: 23939198
author list: Costa LJ, Zhang MJ, Zhong X, Dispenzieri A, Lonial S, Krishnan A, Freytes C, Vesole D, Gale RP, Anderson K, Wirk B, Savani BN, Waller EK, Schouten H, Lazarus H, Meehan K, Sharma M, Kamble R, Vij R, Kumar S, Nishihori T, Kindwall-Keller T, Saber W, Hari PN
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant. 2013 Nov; 19(11):1615-24.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2013-08-11T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells.
PubMed Identifier: 12200384
author list: Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, Sattler M, Richardson P, Schlossman RL, Podar K, Weller E, Munshi N, Anderson KC
published in: Blood
information resource reference: 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94.
journal title abbreviation: Blood
publication date: 2002-09-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications.
PubMed Identifier: 15471951
author list: Podar K, Anderson KC
published in: Blood
information resource reference: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood. 2005 Feb 15; 105(4):1383-95.
journal title abbreviation: Blood
publication date: 2004-10-07T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Development of effective new treatments for multiple myeloma.
PubMed Identifier: 16145064
author list: Anderson KC, Pazdur R, Farrell AT
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Development of effective new treatments for multiple myeloma. J Clin Oncol. 2005 Oct 01; 23(28):7207-11.
journal title abbreviation: J Clin Oncol
publication date: 2005-09-06T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications.
PubMed Identifier: 11924912
author list: Treon SP, Pilarski LM, Belch AR, Kelliher A, Preffer FI, Shima Y, Mitsiades CS, Mitsiades NS, Szczepek AJ, Ellman L, Harmon D, Grossbard ML, Anderson KC
published in: Journal of immunotherapy (Hagerstown, Md. : 1997)
information resource reference: CD20-directed serotherapy in patients with multiple myeloma: biologic considerations and therapeutic applications. J Immunother. 2002 Jan-Feb; 25(1):72-81.
journal title abbreviation: J Immunother
publication date: 2002-01-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma.
PubMed Identifier: 21630305
author list: Ghobrial IM, Munshi NC, Harris BN, Shi P, Porter NM, Schlossman RL, Laubach JP, Anderson KC, Desaiah D, Myrand SP, Wooldridge JE, Richardson PG, Abonour R
published in: American journal of hematology
information resource reference: A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
journal title abbreviation: Am J Hematol
publication date: 2011-05-31T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas.
PubMed Identifier: 22034840
author list: Chauhan D, Anderson KC
published in: BMC biology
information resource reference: Proteasome inhibition, the pursuit of new cancer therapeutics, and the adaptor molecule p130Cas. BMC Biol. 2011 Oct 28; 9:72.
journal title abbreviation: BMC Biol
publication date: 2011-10-28T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.
PubMed Identifier: 23293352
author list: Bae J, Munshi A, Li C, Samur M, Prabhala R, Mitsiades C, Anderson KC, Munshi NC
published in: Journal of immunology (Baltimore, Md. : 1950)
information resource reference: Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71.
journal title abbreviation: J Immunol
publication date: 2013-01-04T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma.
PubMed Identifier: 17428175
author list: Podar K, Richardson PG, Chauhan D, Anderson KC
published in: Expert review of anticancer therapy
information resource reference: Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2007 Apr; 7(4):551-66.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2007-04-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular mechanisms of novel therapeutic approaches for multiple myeloma.
PubMed Identifier: 12459731
author list: Hideshima T, Anderson KC
published in: Nature reviews. Cancer
information resource reference: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer. 2002 Dec; 2(12):927-37.
journal title abbreviation: Nat Rev Cancer
publication date: 2002-12-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma: how far have we come?
PubMed Identifier: 12528872
author list: Anderson KC
published in: Mayo Clinic proceedings
information resource reference: Multiple myeloma: how far have we come? Mayo Clin Proc. 2003 Jan; 78(1):15-7.
journal title abbreviation: Mayo Clin Proc
publication date: 2003-01-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.
PubMed Identifier: 12714512
author list: Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, Anderson KC
published in: Blood
information resource reference: Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes. Blood. 2003 Aug 15; 102(4):1435-42.
journal title abbreviation: Blood
publication date: 2003-04-24T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Apoptotic signaling in multiple myeloma: therapeutic implications.
PubMed Identifier: 12953804
author list: Chauhan D, Hideshima T, Anderson KC
published in: International journal of hematology
information resource reference: Apoptotic signaling in multiple myeloma: therapeutic implications. Int J Hematol. 2003 Aug; 78(2):114-20.
journal title abbreviation: Int J Hematol
publication date: 2003-08-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
PubMed Identifier: 14522909
author list: Tai YT, Podar K, Catley L, Tseng YH, Akiyama M, Shringarpure R, Burger R, Hideshima T, Chauhan D, Mitsiades N, Richardson P, Munshi NC, Kahn CR, Mitsiades C, Anderson KC
published in: Cancer research
information resource reference: Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 09 15; 63(18):5850-8.
journal title abbreviation: Cancer Res
publication date: 2003-09-15T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
PubMed Identifier: 15231675
author list: Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, Munshi NC
published in: Cancer research
information resource reference: In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004 Jul 01; 64(13):4629-36.
journal title abbreviation: Cancer Res
publication date: 2004-07-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
PubMed Identifier: 15492276
author list: Podar K, Shringarpure R, Tai YT, Simoncini M, Sattler M, Ishitsuka K, Richardson PG, Hideshima T, Chauhan D, Anderson KC
published in: Cancer research
information resource reference: Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res. 2004 Oct 15; 64(20):7500-6.
journal title abbreviation: Cancer Res
publication date: 2004-10-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.
PubMed Identifier: 16803565
author list: Neri P, Yasui H, Hideshima T, Tassone P, Raje N, Catley LP, Laurence CP, Ishitsuka K, Blotta S, Kiziltepe T, Ocio EM, Fulciniti M, Kanekal S, Elliott GT, Munshi NC, Anderson KC
published in: British journal of haematology
information resource reference: In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol. 2006 Jul; 134(1):37-44.
journal title abbreviation: Br J Haematol
publication date: 2006-07-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.
PubMed Identifier: 12393500
author list: Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC
published in: Blood
information resource reference: Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4.
journal title abbreviation: Blood
publication date: 2002-09-26T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.
PubMed Identifier: 17020458
author list: Raje N, Hideshima T, Anderson KC
published in: Expert review of anticancer therapy
information resource reference: Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma. Expert Rev Anticancer Ther. 2006 Sep; 6(9):1239-47.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2006-09-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.
PubMed Identifier: 17020997
author list: Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94.
journal title abbreviation: Clin Cancer Res
publication date: 2006-10-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Recent advances in the treatment of Multiple Myeloma.
PubMed Identifier: 17076653
author list: Yasui H, Hideshima T, Richardson PG, Anderson KC
published in: Current pharmaceutical biotechnology
information resource reference: Recent advances in the treatment of Multiple Myeloma. Curr Pharm Biotechnol. 2006 Oct; 7(5):381-93.
journal title abbreviation: Curr Pharm Biotechnol
publication date: 2006-10-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma.
PubMed Identifier: 17119115
author list: Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Côté D, Veilleux I, Hedin KE, Roodman GD, Witzig TE, Kung AL, Hideshima T, Anderson KC, Lin CP, Ghobrial IM
published in: Blood
information resource reference: Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007 Apr 01; 109(7):2708-17.
journal title abbreviation: Blood
publication date: 2007-04-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.
PubMed Identifier: 18219387
author list: Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT
published in: The Journal of clinical investigation
information resource reference: Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest. 2008 Feb; 118(2):491-504.
journal title abbreviation: J Clin Invest
publication date: 2008-02-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells.
PubMed Identifier: 12752100
author list: Hayashi T, Treon SP, Hideshima T, Tai YT, Akiyama M, Richardson P, Chauhan D, Grewal IS, Anderson KC
published in: British journal of haematology
information resource reference: Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells. Br J Haematol. 2003 May; 121(4):592-6.
journal title abbreviation: Br J Haematol
publication date: 2003-05-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

New agents and approaches in the treatment of multiple myeloma.
PubMed Identifier: 16224394
author list: Anderson KC
published in: Clinical advances in hematology & oncology : H&O
information resource reference: New agents and approaches in the treatment of multiple myeloma. Clin Adv Hematol Oncol. 2003 Mar; 1(3):151-2.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2003-03-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.
PubMed Identifier: 16487170
author list: Kumar S, Raje N, Hideshima T, Ishitsuka K, Podar K, Le Gouille S, Chauhan D, Richardson P, Munshi NC, Anderson K
published in: British journal of haematology
information resource reference: FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704.
journal title abbreviation: Br J Haematol
publication date: 2006-03-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Kidney disease associated with plasma cell dyscrasias.
PubMed Identifier: 20462963
author list: Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG
published in: Blood
information resource reference: Kidney disease associated with plasma cell dyscrasias. Blood. 2010 Sep 02; 116(9):1397-404.
journal title abbreviation: Blood
publication date: 2010-05-12T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of genes modulated in multiple myeloma using genetically identical twin samples.
PubMed Identifier: 12969976
author list: Munshi NC, Hideshima T, Carrasco D, Shammas M, Auclair D, Davies F, Mitsiades N, Mitsiades C, Kim RS, Li C, Rajkumar SV, Fonseca R, Bergsagel L, Chauhan D, Anderson KC
published in: Blood
information resource reference: Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806.
journal title abbreviation: Blood
publication date: 2003-09-11T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.
PubMed Identifier: 21187443
author list: de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW
published in: Journal of immunology (Baltimore, Md. : 1950)
information resource reference: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011 Feb 01; 186(3):1840-8.
journal title abbreviation: J Immunol
publication date: 2010-12-27T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular sequelae of histone deacetylase inhibition in human malignant B cells.
PubMed Identifier: 12531799
author list: Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC
published in: Blood
information resource reference: Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.
journal title abbreviation: Blood
publication date: 2003-01-16T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
PubMed Identifier: 14559800
author list: Chauhan D, Li G, Shringarpure R, Podar K, Ohtake Y, Hideshima T, Anderson KC
published in: Cancer research
information resource reference: Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res. 2003 Oct 01; 63(19):6174-7.
journal title abbreviation: Cancer Res
publication date: 2003-10-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components.
PubMed Identifier: 14641857
author list: Anderson K
published in: Transfusion
information resource reference: Broadening the spectrum of patient groups at risk for transfusion-associated GVHD: implications for universal irradiation of cellular blood components. Transfusion. 2003 Dec; 43(12):1652-4.
journal title abbreviation: Transfusion
publication date: 2003-12-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.
PubMed Identifier: 14749474
author list: Ikeda T, Nakata Y, Kimura F, Sato K, Anderson K, Motoyoshi K, Sporn M, Kufe D
published in: Molecular cancer therapeutics
information resource reference: Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid. Mol Cancer Ther. 2004 Jan; 3(1):39-45.
journal title abbreviation: Mol Cancer Ther
publication date: 2004-01-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells.
PubMed Identifier: 15010462
author list: Podar K, Mostoslavsky G, Sattler M, Tai YT, Hayashi T, Catley LP, Hideshima T, Mulligan RC, Chauhan D, Anderson KC
published in: The Journal of biological chemistry
information resource reference: Critical role for hematopoietic cell kinase (Hck)-mediated phosphorylation of Gab1 and Gab2 docking proteins in interleukin 6-induced proliferation and survival of multiple myeloma cells. J Biol Chem. 2004 May 14; 279(20):21658-65.
journal title abbreviation: J Biol Chem
publication date: 2004-03-09T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/821586
PubMed Identifier: 15244383
author list: Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, Weller E, Mitsiades C, Hideshima T, Davies F, Doss D, Freeman A, Bosch J, Patin J, Knight R, Zeldis J, Dalton W, Anderson K
published in: Mayo Clinic proceedings
information resource reference: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc. 2004 Jul; 79(7):875-82.
journal title abbreviation: Mayo Clin Proc
publication date: 2004-07-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.

Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells.
PubMed Identifier: 15292058
author list: Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, Hylander-Gans LL, Carrasco DR, Hideshima T, Shringarpure R, Shi J, Allam CK, Wijdenes J, Venuta S, Munshi NC, Anderson KC
published in: Blood
information resource reference: Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 01; 104(12):3688-96.
journal title abbreviation: Blood
publication date: 2004-08-03T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.
PubMed Identifier: 15705788
author list: Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H, Shiraishi N, Raje N, Kumar S, Picker DH, Jacob GS, Richardson PG, Munshi NC, Anderson KC
published in: Blood
information resource reference: Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6.
journal title abbreviation: Blood
publication date: 2005-02-10T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibition in multiple myeloma: therapeutic implication.
PubMed Identifier: 15822185
author list: Chauhan D, Hideshima T, Anderson KC
published in: Annual review of pharmacology and toxicology
information resource reference: Proteasome inhibition in multiple myeloma: therapeutic implication. Annu Rev Pharmacol Toxicol. 2005; 45:465-76.
journal title abbreviation: Annu Rev Pharmacol Toxicol
publication date: 2005-01-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.
PubMed Identifier: 21990396
author list: Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
journal title abbreviation: J Clin Oncol
publication date: 2011-10-11T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma.
PubMed Identifier: 22262760
author list: Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, Cirstea D, Rodig S, Eda H, Scullen T, Canavese M, Bradner J, Anderson KC, Jones SS, Raje N
published in: Blood
information resource reference: Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 2012 Mar 15; 119(11):2579-89.
journal title abbreviation: Blood
publication date: 2012-01-19T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

New frontiers in the treatment of multiple myeloma.
PubMed Identifier: 17160337
author list: Hwang JJ, Ghobrial IM, Anderson KC
published in: TheScientificWorldJournal
information resource reference: New frontiers in the treatment of multiple myeloma. ScientificWorldJournal. 2006 Dec 06; 6:1475-503.
journal title abbreviation: ScientificWorldJournal
publication date: 2006-12-06T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/825068
PubMed Identifier: 17173546
author list: Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC
published in: British journal of haematology
information resource reference: BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth. Br J Haematol. 2007 Feb; 136(3):414-23.
journal title abbreviation: Br J Haematol
publication date: 2006-12-14T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource
label: BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

Can thalidomide improve outcome in patients with multiple myeloma?
PubMed Identifier: 17080171
author list: Richardson PG, Mitsiades CS, Munshi NC, Anderson KC
published in: Nature clinical practice. Oncology
information resource reference: Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1.
journal title abbreviation: Nat Clin Pract Oncol
publication date: 2006-11-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

High-throughput oncogene mutation profiling in human cancer.
PubMed Identifier: 17293865
author list: Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA
published in: Nature genetics
information resource reference: High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
journal title abbreviation: Nat Genet
publication date: 2007-02-11T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies.
PubMed Identifier: 17351339
author list: Podar K, Anderson KC
published in: Cell cycle (Georgetown, Tex.)
information resource reference: Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle. 2007 Mar 01; 6(5):538-42.
journal title abbreviation: Cell Cycle
publication date: 2007-03-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapies in myeloma.
PubMed Identifier: 17898564
author list: Hayden PJ, Mitsiades CS, Anderson KC, Richardson PG
published in: Current opinion in hematology
information resource reference: Novel therapies in myeloma. Curr Opin Hematol. 2007 Nov; 14(6):609-15.
journal title abbreviation: Curr Opin Hematol
publication date: 2007-11-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model.
PubMed Identifier: 17588472
author list: Catley L, Hideshima T, Chauhan D, Neri P, Tassone P, Bronson R, Song W, Tai YT, Munshi NC, Anderson KC
published in: Experimental hematology
information resource reference: Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul; 35(7):1038-46.
journal title abbreviation: Exp Hematol
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.
PubMed Identifier: 17606706
author list: Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, Anderson KC, Ghobrial IM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res. 2007 Jul 01; 13(13):3771-5.
journal title abbreviation: Clin Cancer Res
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Fatty acid synthase is a novel therapeutic target in multiple myeloma.
PubMed Identifier: 18410446
author list: Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC
published in: British journal of haematology
information resource reference: Fatty acid synthase is a novel therapeutic target in multiple myeloma. Br J Haematol. 2008 May; 141(5):659-71.
journal title abbreviation: Br J Haematol
publication date: 2008-04-10T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo.
PubMed Identifier: 18593922
author list: Mitsiades CS, Ocio EM, Pandiella A, Maiso P, Gajate C, Garayoa M, Vilanova D, Montero JC, Mitsiades N, McMullan CJ, Munshi NC, Hideshima T, Chauhan D, Aviles P, Otero G, Faircloth G, Mateos MV, Richardson PG, Mollinedo F, San-Miguel JF, Anderson KC
published in: Cancer research
information resource reference: Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.
journal title abbreviation: Cancer Res
publication date: 2008-07-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study.
PubMed Identifier: 18711175
author list: Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol. 2008 Oct 10; 26(29):4784-90.
journal title abbreviation: J Clin Oncol
publication date: 2008-08-18T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
PubMed Identifier: 19074725
author list: Roccaro AM, Sacco A, Chen C, Runnels J, Leleu X, Azab F, Azab AK, Jia X, Ngo HT, Melhem MR, Burwick N, Varticovski L, Novina CD, Rollins BJ, Anderson KC, Ghobrial IM
published in: Blood
information resource reference: microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia. Blood. 2009 Apr 30; 113(18):4391-402.
journal title abbreviation: Blood
publication date: 2008-12-12T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.
PubMed Identifier: 16809610
author list: Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC
published in: Blood
information resource reference: Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10.
journal title abbreviation: Blood
publication date: 2006-06-29T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

An update of novel therapeutic approaches for multiple myeloma.
PubMed Identifier: 15115651
author list: Richardson P, Hideshima T, Anderson KC
published in: Current treatment options in oncology
information resource reference: An update of novel therapeutic approaches for multiple myeloma. Curr Treat Options Oncol. 2004 Jun; 5(3):227-38.
journal title abbreviation: Curr Treat Options Oncol
publication date: 2004-06-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 989804
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.

Authorship 990440
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
PubMed Identifier: 28621266
author list: Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J
published in: Oncotarget
information resource reference: Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Jun 08.
journal title abbreviation: Oncotarget
publication date: 2017-06-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
PubMed Identifier: 28610537
author list: Guang MHZ, McCann A, Bianchi G, Zhang L, Dowling P, Bazou D, O'Gorman P, Anderson KC
published in: Leukemia & lymphoma
information resource reference: Overcoming multiple myeloma drug resistance in the era of cancer 'omics'. Leuk Lymphoma. 2018 03; 59(3):542-561.
journal title abbreviation: Leuk Lymphoma
publication date: 2017-06-13T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinically relevant end points and new drug approvals for myeloma.
PubMed Identifier: 17972944
author list: Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson P
published in: Leukemia
information resource reference: Clinically relevant end points and new drug approvals for myeloma. Leukemia. 2008 Feb; 22(2):231-9.
journal title abbreviation: Leukemia
publication date: 2007-11-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma.
PubMed Identifier: 17515569
author list: Kyle RA, Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S, Orlowski RZ, Roodman DG, Twilde P, Anderson K
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007 Jun 10; 25(17):2464-72.
journal title abbreviation: J Clin Oncol
publication date: 2007-05-21T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma.
PubMed Identifier: 15249587
author list: Richardson P, Anderson K
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Immunomodulatory analogs of thalidomide: an emerging new therapy in myeloma. J Clin Oncol. 2004 Aug 15; 22(16):3212-4.
journal title abbreviation: J Clin Oncol
publication date: 2004-07-12T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 991168
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: MUC1-C is a target in lenalidomide resistant multiple myeloma.

MUC1-C is a target in lenalidomide resistant multiple myeloma.
PubMed Identifier: 28643330
author list: Yin L, Tagde A, Gali R, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D
published in: British journal of haematology
information resource reference: MUC1-C is a target in lenalidomide resistant multiple myeloma. Br J Haematol. 2017 09; 178(6):914-926.
journal title abbreviation: Br J Haematol
publication date: 2017-06-23T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

NF-kappa B as a therapeutic target in multiple myeloma.
PubMed Identifier: 11872748
author list: Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC
published in: The Journal of biological chemistry
information resource reference: NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47.
journal title abbreviation: J Biol Chem
publication date: 2002-02-28T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.
PubMed Identifier: 19652203
author list: Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR
published in: Blood
information resource reference: Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression. Blood. 2009 Sep 24; 114(13):2699-708.
journal title abbreviation: Blood
publication date: 2009-08-03T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapies for multiple myeloma.
PubMed Identifier: 12163002
author list: Ryoo JJ, Cole CE, Anderson KC
published in: Blood reviews
information resource reference: Novel therapies for multiple myeloma. Blood Rev. 2002 Sep; 16(3):167-74.
journal title abbreviation: Blood Rev
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu.
PubMed Identifier: 12393542
author list: Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D, Anderson KC
published in: Blood
information resource reference: Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood. 2003 Jan 15; 101(2):703-5.
journal title abbreviation: Blood
publication date: 2002-09-05T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma.
PubMed Identifier: 18728702
author list: Hideshima T, Raje N, Richardson PG, Anderson KC
published in: Therapeutics and clinical risk management
information resource reference: A review of lenalidomide in combination with dexamethasone for the treatment of multiple myeloma. Ther Clin Risk Manag. 2008 Feb; 4(1):129-36.
journal title abbreviation: Ther Clin Risk Manag
publication date: 2008-02-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
PubMed Identifier: 20053869
author list: Palumbo A, Larocca A, Genuardi M, Kotwica K, Gay F, Rossi D, Benevolo G, Magarotto V, Cavallo F, Bringhen S, Rus C, Masini L, Iacobelli M, Gaidano G, Mitsiades C, Anderson K, Boccadoro M, Richardson P
published in: Haematologica
information resource reference: Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial. Haematologica. 2010 Jul; 95(7):1144-9.
journal title abbreviation: Haematologica
publication date: 2010-01-06T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone.
PubMed Identifier: 22689802
author list: Saboo SS, Fennessy F, Benajiba L, Laubach J, Anderson KC, Richardson PG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Imaging features of extramedullary, relapsed, and refractory multiple myeloma involving the liver across treatment with cyclophosphamide, lenalidomide, bortezomib, and dexamethasone. J Clin Oncol. 2012 Jul 10; 30(20):e175-9.
journal title abbreviation: J Clin Oncol
publication date: 2012-06-11T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide enhances anti-myeloma cellular immunity.
PubMed Identifier: 22733396
author list: Luptakova K, Rosenblatt J, Glotzbecker B, Mills H, Stroopinsky D, Kufe T, Vasir B, Arnason J, Tzachanis D, Zwicker JI, Joyce RM, Levine JD, Anderson KC, Kufe D, Avigan D
published in: Cancer immunology, immunotherapy : CII
information resource reference: Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
journal title abbreviation: Cancer Immunol Immunother
publication date: 2012-06-24T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 993295
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.

Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma.
PubMed Identifier: 28442502
author list: Sagawa M, Ohguchi H, Harada T, Samur MK, Tai YT, Munshi NC, Kizaki M, Hideshima T, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237.
journal title abbreviation: Clin Cancer Res
publication date: 2017-04-25T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
PubMed Identifier: 19118065
author list: Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Chu L, Musto P, Baron AD, Nunnink JC, Kash JJ, Terjanian TO, Hyman PM, Nawfel EL, Sharon DJ, Munshi NC, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60.
journal title abbreviation: Clin Cancer Res
publication date: 2009-01-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
PubMed Identifier: 19528374
author list: Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
journal title abbreviation: J Clin Oncol
publication date: 2009-06-15T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival.
PubMed Identifier: 14632778
author list: Burger R, Bakker F, Guenther A, Baum W, Schmidt-Arras D, Hideshima T, Tai YT, Shringarpure R, Catley L, Senaldi G, Gramatzki M, Anderson KC
published in: British journal of haematology
information resource reference: Functional significance of novel neurotrophin-1/B cell-stimulating factor-3 (cardiotrophin-like cytokine) for human myeloma cell growth and survival. Br J Haematol. 2003 Dec; 123(5):869-78.
journal title abbreviation: Br J Haematol
publication date: 2003-12-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.
PubMed Identifier: 15480425
author list: Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC
published in: Oncogene
information resource reference: p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
journal title abbreviation: Oncogene
publication date: 2004-11-18T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.
PubMed Identifier: 15870175
author list: Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC
published in: Blood
information resource reference: Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis. Blood. 2005 Sep 01; 106(5):1794-800.
journal title abbreviation: Blood
publication date: 2005-05-03T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

A SCID-hu in vivo model of human Waldenström macroglobulinemia.
PubMed Identifier: 15886318
author list: Tassone P, Neri P, Kutok JL, Tournilhac O, Santos DD, Hatjiharissi E, Munshi V, Venuta S, Anderson KC, Treon SP, Munshi NC
published in: Blood
information resource reference: A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood. 2005 Aug 15; 106(4):1341-5.
journal title abbreviation: Blood
publication date: 2005-05-10T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting signalling pathways for the treatment of multiple myeloma.
PubMed Identifier: 15934921
author list: Podar K, Hideshima T, Chauhan D, Anderson KC
published in: Expert opinion on therapeutic targets
information resource reference: Targeting signalling pathways for the treatment of multiple myeloma. Expert Opin Ther Targets. 2005 Apr; 9(2):359-81.
journal title abbreviation: Expert Opin Ther Targets
publication date: 2005-04-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
PubMed Identifier: 16001954
author list: Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC
published in: Expert review of anticancer therapy
information resource reference: Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Rev Anticancer Ther. 2005 Jun; 5(3):465-76.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification and validation of novel therapeutic targets for multiple myeloma.
PubMed Identifier: 16155018
author list: Hideshima T, Chauhan D, Richardson P, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Identification and validation of novel therapeutic targets for multiple myeloma. J Clin Oncol. 2005 Sep 10; 23(26):6345-50.
journal title abbreviation: J Clin Oncol
publication date: 2005-09-10T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 995426
type: Authorship
author rank in publication: 21
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/84963089

https://connects.catalyst.harvard.edu/Profiles/profile/84963089
PubMed Identifier: 28686535
author list: Moreau P, Attal M, Caillot D, Macro M, Karlin L, Garderet L, Facon T, Benboubker L, Escoffre-Barbe M, Stoppa AM, Laribi K, Hulin C, Perrot A, Marit G, Eveillard JR, Caillon F, Bodet-Milin C, Pegourie B, Dorvaux V, Chaleteix C, Anderson K, Richardson P, Munshi NC, Avet-Loiseau H, Gaultier A, Nguyen JM, Dupas B, Frampas E, Kraeber-Bodere F
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 01; 35(25):2911-2918.
journal title abbreviation: J Clin Oncol
publication date: 2017-07-07T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
PubMed Identifier: 28708596
author list: Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC
published in: Oncotarget
information resource reference: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017 Jul 05.
journal title abbreviation: Oncotarget
publication date: 2017-07-05T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical update: novel targets in multiple myeloma.
PubMed Identifier: 15799242
author list: Anderson KC
published in: Seminars in oncology
information resource reference: Clinical update: novel targets in multiple myeloma. Semin Oncol. 2004 Dec; 31(6 Suppl 16):27-32; discussion 33.
journal title abbreviation: Semin Oncol
publication date: 2004-12-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib.
PubMed Identifier: 15846363
author list: Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ
published in: Nature methods
information resource reference: Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods. 2005 May; 2(5):357-62.
journal title abbreviation: Nat Methods
publication date: 2005-04-21T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation.
PubMed Identifier: 15916692
author list: Vasir B, Borges V, Wu Z, Grosman D, Rosenblatt J, Irie M, Anderson K, Kufe D, Avigan D
published in: British journal of haematology
information resource reference: Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700.
journal title abbreviation: Br J Haematol
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone.
PubMed Identifier: 16818280
author list: Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, Srkalovic G, Schenkein DP, Esseltine DL, Anderson KC
published in: Haematologica
information resource reference: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica. 2006 Jul; 91(7):929-34.
journal title abbreviation: Haematologica
publication date: 2006-07-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 998339
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.
PubMed Identifier: 17906076
author list: Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, Lee AI, Podar K, Hideshima T, Rice AG, van Abbema A, Jesaitis L, Caras I, Law D, Weller E, Xie W, Richardson P, Munshi NC, Mathiot C, Avet-Loiseau H, Afar DE, Anderson KC
published in: Blood
information resource reference: Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37.
journal title abbreviation: Blood
publication date: 2007-09-28T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

From the bench to the bedside: emerging new treatments in multiple myeloma.
PubMed Identifier: 18070720
author list: Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG
published in: Best practice & research. Clinical haematology
information resource reference: From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol. 2007 Dec; 20(4):797-816.
journal title abbreviation: Best Pract Res Clin Haematol
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.
PubMed Identifier: 18397345
author list: Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC
published in: British journal of haematology
information resource reference: p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008 May; 141(5):598-606.
journal title abbreviation: Br J Haematol
publication date: 2008-04-07T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma.
PubMed Identifier: 18673366
author list: Niesvizky R, Richardson PG, Rajkumar SV, Coleman M, Rosiñol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine DL, Anderson KC, Bladé J
published in: British journal of haematology
information resource reference: The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. Br J Haematol. 2008 Oct; 143(1):46-53.
journal title abbreviation: Br J Haematol
publication date: 2008-07-31T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients.
PubMed Identifier: 18715819
author list: Sonis ST, Watkins BA, Lyng GD, Lerman MA, Anderson KC
published in: Oral oncology
information resource reference: Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients. Oral Oncol. 2009 Feb; 45(2):164-72.
journal title abbreviation: Oral Oncol
publication date: 2008-08-19T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Comparison of twin and autologous transplants for multiple myeloma.
PubMed Identifier: 18804041
author list: Bashey A, Pérez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant. 2008 Oct; 14(10):1118-1124.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2008-10-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor.
PubMed Identifier: 18986388
author list: Neri P, Tagliaferri P, Di Martino MT, Calimeri T, Amodio N, Bulotta A, Ventura M, Eramo PO, Viscomi C, Arbitrio M, Rossi M, Caraglia M, Munshi NC, Anderson KC, Tassone P
published in: British journal of haematology
information resource reference: In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol. 2008 Nov; 143(4):520-31.
journal title abbreviation: Br J Haematol
publication date: 2008-11-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Prognostic significance of copy-number alterations in multiple myeloma.
PubMed Identifier: 19687334
author list: Avet-Loiseau H, Li C, Magrangeas F, Gouraud W, Charbonnel C, Harousseau JL, Attal M, Marit G, Mathiot C, Facon T, Moreau P, Anderson KC, Campion L, Munshi NC, Minvielle S
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009 Sep 20; 27(27):4585-90.
journal title abbreviation: J Clin Oncol
publication date: 2009-08-17T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapies in the treatment of multiple myeloma.
PubMed Identifier: 19878638
author list: Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2009-10-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia.
PubMed Identifier: 20142598
author list: Ghobrial IM, Gertz M, Laplant B, Camoriano J, Hayman S, Lacy M, Chuma S, Harris B, Leduc R, Rourke M, Ansell SM, Deangelo D, Dispenzieri A, Bergsagel L, Reeder C, Anderson KC, Richardson PG, Treon SP, Witzig TE
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10; 28(8):1408-14.
journal title abbreviation: J Clin Oncol
publication date: 2010-02-08T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapies in MM: from the aspect of preclinical studies.
PubMed Identifier: 21881879
author list: Hideshima T, Anderson KC
published in: International journal of hematology
information resource reference: Novel therapies in MM: from the aspect of preclinical studies. Int J Hematol. 2011 Oct; 94(4):344-354.
journal title abbreviation: Int J Hematol
publication date: 2011-09-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms.
PubMed Identifier: 21991938
author list: Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Mitsiades CS, Rosenblatt J, Mahindra A, Raje N, Munshi N, Anderson KC
published in: European journal of haematology
information resource reference: The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
journal title abbreviation: Eur J Haematol
publication date: 2011-11-22T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?
PubMed Identifier: 17534287
author list: Munshi NC, Mitsiades CS, Richardson PG, Anderson KC
published in: Nature clinical practice. Oncology
information resource reference: Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5.
journal title abbreviation: Nat Clin Pract Oncol
publication date: 2007-05-29T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

New drugs for myeloma.
PubMed Identifier: 17602058
author list: Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K
published in: The oncologist
information resource reference: New drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89.
journal title abbreviation: Oncologist
publication date: 2007-06-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.
PubMed Identifier: 17922632
author list: Podar K, Raab MS, Chauhan D, Anderson KC
published in: Expert opinion on investigational drugs
information resource reference: The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs. 2007 Oct; 16(10):1693-707.
journal title abbreviation: Expert Opin Investig Drugs
publication date: 2007-10-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma.
PubMed Identifier: 17947482
author list: Rajkumar SV, Richardson PG, Lacy MQ, Dispenzieri A, Greipp PR, Witzig TE, Schlossman R, Sidor CF, Anderson KC, Gertz MA
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma. Clin Cancer Res. 2007 Oct 15; 13(20):6162-7.
journal title abbreviation: Clin Cancer Res
publication date: 2007-10-15T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Preclinical studies of novel targeted therapies.
PubMed Identifier: 17996589
author list: Hideshima T, Anderson KC
published in: Hematology/oncology clinics of North America
information resource reference: Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1071-91, viii-ix.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

The treatment of relapsed and refractory multiple myeloma.
PubMed Identifier: 18024646
author list: Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D, Munshi N, Anderson K
published in: Hematology. American Society of Hematology. Education Program
information resource reference: The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
journal title abbreviation: Hematology Am Soc Hematol Educ Program
publication date: 2007-01-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

The malignant clone and the bone-marrow environment.
PubMed Identifier: 18070708
author list: Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC
published in: Best practice & research. Clinical haematology
information resource reference: The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol. 2007 Dec; 20(4):597-612.
journal title abbreviation: Best Pract Res Clin Haematol
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells.
PubMed Identifier: 18575761
author list: Kawano T, Ahmad R, Nogi H, Agata N, Anderson K, Kufe D
published in: International journal of oncology
information resource reference: MUC1 oncoprotein promotes growth and survival of human multiple myeloma cells. Int J Oncol. 2008 Jul; 33(1):153-9.
journal title abbreviation: Int J Oncol
publication date: 2008-07-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.
PubMed Identifier: 21219297
author list: Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC
published in: British journal of haematology
information resource reference: Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol. 2011 Feb; 152(4):367-79.
journal title abbreviation: Br J Haematol
publication date: 2011-01-10T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
PubMed Identifier: 21724551
author list: Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N, Richardson P, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res. 2011 Aug 15; 17(16):5311-21.
journal title abbreviation: Clin Cancer Res
publication date: 2011-06-30T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
PubMed Identifier: 21923653
author list: Podar K, Zimmerhackl A, Fulciniti M, Tonon G, Hainz U, Tai YT, Vallet S, Halama N, Jäger D, Olson DL, Sattler M, Chauhan D, Anderson KC
published in: British journal of haematology
information resource reference: The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications. Br J Haematol. 2011 Nov; 155(4):438-48.
journal title abbreviation: Br J Haematol
publication date: 2011-09-19T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia.
PubMed Identifier: 20110419
author list: Roccaro AM, Sacco A, Aujay M, Ngo HT, Azab AK, Azab F, Quang P, Maiso P, Runnels J, Anderson KC, Demo S, Ghobrial IM
published in: Blood
information resource reference: Selective inhibition of chymotrypsin-like activity of the immunoproteasome and constitutive proteasome in Waldenstrom macroglobulinemia. Blood. 2010 May 20; 115(20):4051-60.
journal title abbreviation: Blood
publication date: 2010-01-28T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.
PubMed Identifier: 22291084
author list: Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar DE, Singhal AK, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma. J Clin Oncol. 2012 Jun 01; 30(16):1960-5.
journal title abbreviation: J Clin Oncol
publication date: 2012-01-30T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/872526
PubMed Identifier: 22300348
author list: Richardson PG, Laubach JP, Schlossman RL, Ghobrial IM, Redman KC, McKenney M, Warren D, Noonan K, Lunde L, Doss D, Colson K, Hideshima T, Mitsiades C, Munshi NC, Anderson KC
published in: European journal of haematology
information resource reference: The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
journal title abbreviation: Eur J Haematol
publication date: 2012-03-07T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders.
PubMed Identifier: 22753586
author list: Bae J, Smith R, Daley J, Mimura N, Tai YT, Anderson KC, Munshi NC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012 Sep 01; 18(17):4850-60.
journal title abbreviation: Clin Cancer Res
publication date: 2012-07-02T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy.
PubMed Identifier: 23372151
author list: Voorhees PM, Laubach J, Anderson KC, Richardson PG
published in: Blood
information resource reference: Peripheral neuropathy in multiple myeloma patients receiving lenalidomide, bortezomib, and dexamethasone (RVD) therapy. Blood. 2013 Jan 31; 121(5):858.
journal title abbreviation: Blood
publication date: 2013-01-31T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1001347
type: Authorship
author rank in publication: 37
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/87484647

https://connects.catalyst.harvard.edu/Profiles/profile/87484647
PubMed Identifier: 28826616
author list: Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL
published in: The Lancet. Haematology
information resource reference: Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
journal title abbreviation: Lancet Haematol
publication date: 2017-08-17T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial.

The evolution and impact of therapy in multiple myeloma.
PubMed Identifier: 20169425
author list: Laubach JP, Richardson PG, Anderson KC
published in: Medical oncology (Northwood, London, England)
information resource reference: The evolution and impact of therapy in multiple myeloma. Med Oncol. 2010 Jun; 27 Suppl 1:S1-6.
journal title abbreviation: Med Oncol
publication date: 2010-02-19T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo.
PubMed Identifier: 20331454
author list: Kim K, Kong SY, Fulciniti M, Li X, Song W, Nahar S, Burger P, Rumizen MJ, Podar K, Chauhan D, Hideshima T, Munshi NC, Richardson P, Clark A, Ogden J, Goutopoulos A, Rastelli L, Anderson KC, Tai YT
published in: British journal of haematology
information resource reference: Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49.
journal title abbreviation: Br J Haematol
publication date: 2010-03-12T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma: biology of the disease.
PubMed Identifier: 21126636
author list: Mahindra A, Hideshima T, Anderson KC
published in: Blood reviews
information resource reference: Multiple myeloma: biology of the disease. Blood Rev. 2010 Nov; 24 Suppl 1:S5-11.
journal title abbreviation: Blood Rev
publication date: 2010-11-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/878773
PubMed Identifier: 21375521
author list: Richardson P, Schlag R, Khuageva N, Dimopoulos M, Shpilberg O, Kropff M, Vekemans MC, Petrucci MT, Rossiev V, Hou J, Robak T, Mateos MV, Anderson K, Esseltine DL, Cakana A, Liu K, Deraedt W, van de Velde H, San Miguel JF
published in: British journal of haematology
information resource reference: Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial. Br J Haematol. 2011 Apr; 153(2):212-21.
journal title abbreviation: Br J Haematol
publication date: 2011-03-06T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Characterization of haematological parameters with bortezomib-melphalan-prednisone versus melphalan-prednisone in newly diagnosed myeloma, with evaluation of long-term outcomes and risk of thromboembolic events with use of erythropoiesis-stimulating agents: analysis of the VISTA trial.

Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
PubMed Identifier: 21430070
author list: Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig S, Vallet S, Pozzi S, Patel K, Unitt C, Squires M, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje N
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15; 17(10):3259-71.
journal title abbreviation: Clin Cancer Res
publication date: 2011-03-23T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1008610
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.

Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.
PubMed Identifier: 28677826
author list: Dimopoulos MA, Lonial S, White D, Moreau P, Palumbo A, San-Miguel J, Shpilberg O, Anderson K, Grosicki S, Spicka I, Walter-Croneck A, Magen H, Mateos MV, Belch A, Reece D, Beksac M, Bleickardt E, Poulart V, Sheng J, Sy O, Katz J, Singhal A, Richardson P
published in: British journal of haematology
information resource reference: Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017 Sep; 178(6):896-905.
journal title abbreviation: Br J Haematol
publication date: 2017-07-05T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
PubMed Identifier: 15930364
author list: Tassone P, Neri P, Burger R, Savino R, Shammas M, Catley L, Podar K, Chauhan D, Masciari S, Gozzini A, Tagliaferri P, Venuta S, Munshi NC, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005 Jun 01; 11(11):4251-8.
journal title abbreviation: Clin Cancer Res
publication date: 2005-06-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
PubMed Identifier: 16166312
author list: Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC
published in: Cancer research
information resource reference: A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Cancer Res. 2005 Sep 15; 65(18):8350-8.
journal title abbreviation: Cancer Res
publication date: 2005-09-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Current therapeutic uses of lenalidomide in multiple myeloma.
PubMed Identifier: 16433596
author list: Hideshima T, Richardson PG, Anderson KC
published in: Expert opinion on investigational drugs
information resource reference: Current therapeutic uses of lenalidomide in multiple myeloma. Expert Opin Investig Drugs. 2006 Feb; 15(2):171-9.
journal title abbreviation: Expert Opin Investig Drugs
publication date: 2006-02-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma.
PubMed Identifier: 12036895
author list: Bellucci R, Alyea EP, Weller E, Chillemi A, Hochberg E, Wu CJ, Canning C, Schlossman R, Soiffer RJ, Anderson KC, Ritz J
published in: Blood
information resource reference: Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7.
journal title abbreviation: Blood
publication date: 2002-06-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel biologically based therapies for multiple myeloma.
PubMed Identifier: 12430878
author list: Munshi NC, Hideshima T, Chauhan D, Richardson P, Anderson KC
published in: International journal of hematology
information resource reference: Novel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1.
journal title abbreviation: Int J Hematol
publication date: 2002-08-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein.
PubMed Identifier: 12517770
author list: Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.
journal title abbreviation: Cancer Res
publication date: 2003-01-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review.
PubMed Identifier: 12533739
author list: Hahn T, Wingard JR, Anderson KC, Bensinger WI, Berenson JR, Brozeit G, Carver JR, Kyle RA, McCarthy PL
published in: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
information resource reference: The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review. Biol Blood Marrow Transplant. 2003 Jan; 9(1):4-37.
journal title abbreviation: Biol Blood Marrow Transplant
publication date: 2003-01-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells.
PubMed Identifier: 12902539
author list: Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A. 2003 Aug 19; 100(17):9946-51.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2003-08-05T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis.
PubMed Identifier: 12947006
author list: Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JA, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC
published in: Blood
information resource reference: Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11.
journal title abbreviation: Blood
publication date: 2003-08-28T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
PubMed Identifier: 15319277
author list: Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, Stirling DI, Antin JH, Anderson KC
published in: Blood
information resource reference: Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
journal title abbreviation: Blood
publication date: 2004-08-19T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel immunomodulatory therapies in the treatment of multiple myeloma.
PubMed Identifier: 15328893
author list: Anderson KC
published in: Oncology (Williston Park, N.Y.)
information resource reference: Novel immunomodulatory therapies in the treatment of multiple myeloma. Oncology (Williston Park). 2004 Jul; 18(8):988-90.
journal title abbreviation: Oncology (Williston Park)
publication date: 2004-07-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
PubMed Identifier: 16796779
author list: Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP
published in: Clinical lymphoma & myeloma
information resource reference: CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma. 2006 May; 6(6):478-83.
journal title abbreviation: Clin Lymphoma Myeloma
publication date: 2006-05-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.
PubMed Identifier: 16818641
author list: Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82.
journal title abbreviation: Cancer Res
publication date: 2006-07-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide in multiple myeloma.
PubMed Identifier: 16925483
author list: Richardson PG, Mitsiades C, Hideshima T, Anderson KC
published in: Expert review of anticancer therapy
information resource reference: Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther. 2006 Aug; 6(8):1165-73.
journal title abbreviation: Expert Rev Anticancer Ther
publication date: 2006-08-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibition as a new therapeutic principle in hematological malignancies.
PubMed Identifier: 17073596
author list: Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC
published in: Current drug targets
information resource reference: Proteasome inhibition as a new therapeutic principle in hematological malignancies. Curr Drug Targets. 2006 Oct; 7(10):1341-7.
journal title abbreviation: Curr Drug Targets
publication date: 2006-10-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

New drugs for multiple myeloma.
PubMed Identifier: 17099617
author list: Anderson KC
published in: Clinical advances in hematology & oncology : H&O
information resource reference: New drugs for multiple myeloma. Clin Adv Hematol Oncol. 2006 Aug; 4(8):592-4.
journal title abbreviation: Clin Adv Hematol Oncol
publication date: 2006-08-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Body mass index, physical activity, and risk of multiple myeloma.
PubMed Identifier: 17627013
author list: Birmann BM, Giovannucci E, Rosner B, Anderson KC, Colditz GA
published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
information resource reference: Body mass index, physical activity, and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2007 Jul; 16(7):1474-8.
journal title abbreviation: Cancer Epidemiol Biomarkers Prev
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1012776
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: https://connects.catalyst.harvard.edu/Profiles/profile/88896453

https://connects.catalyst.harvard.edu/Profiles/profile/88896453
PubMed Identifier: 28466536
author list: Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orlowski RZ, Moreau P, Rosiñol L, Faber EA, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG
published in: British journal of haematology
information resource reference: A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma. Br J Haematol. 2017 08; 178(4):547-560.
journal title abbreviation: Br J Haematol
publication date: 2017-05-03T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource
label: A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma.

Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma.
PubMed Identifier: 19124510
author list: Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA
published in: Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
information resource reference: Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev. 2009 Jan; 18(1):282-8.
journal title abbreviation: Cancer Epidemiol Biomarkers Prev
publication date: 2009-01-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.
PubMed Identifier: 19737962
author list: Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Bouxsein ML, Munshi NC, Anderson KC, Raje N
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39.
journal title abbreviation: Clin Cancer Res
publication date: 2009-09-08T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.
PubMed Identifier: 19800576
author list: Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC
published in: Cancer cell
information resource reference: Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
journal title abbreviation: Cancer Cell
publication date: 2009-10-06T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
PubMed Identifier: 19965674
author list: Chauhan D, Singh AV, Ciccarelli B, Richardson PG, Palladino MA, Anderson KC
published in: Blood
information resource reference: Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2010 Jan 28; 115(4):834-45.
journal title abbreviation: Blood
publication date: 2009-11-13T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Pathogenesis of myeloma.
PubMed Identifier: 21261519
author list: Anderson KC, Carrasco RD
published in: Annual review of pathology
information resource reference: Pathogenesis of myeloma. Annu Rev Pathol. 2011; 6:249-74.
journal title abbreviation: Annu Rev Pathol
publication date: 2011-01-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma.
PubMed Identifier: 21975914
author list: Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Huff CA, Kassim A, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F
published in: Journal of the National Comprehensive Cancer Network : JNCCN
information resource reference: Multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1146-83.
journal title abbreviation: J Natl Compr Canc Netw
publication date: 2011-10-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide for the treatment of relapsed and refractory multiple myeloma.
PubMed Identifier: 22956884
author list: van de Donk NW, Görgün G, Groen RW, Jakubikova J, Mitsiades CS, Hideshima T, Laubach J, Nijhof IS, Raymakers RA, Lokhorst HM, Richardson PG, Anderson KC
published in: Cancer management and research
information resource reference: Lenalidomide for the treatment of relapsed and refractory multiple myeloma. Cancer Manag Res. 2012; 4:253-68.
journal title abbreviation: Cancer Manag Res
publication date: 2012-08-14T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1015619
type: Authorship
author rank in publication: 22
linked author: Anderson, Kenneth
linked information resource: Inhibition of USP10 induces degradation of oncogenic FLT3.

Authorship 1015535
type: Authorship
author rank in publication: 9
linked author: Anderson, Kenneth
linked information resource: Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.

Inhibition of USP10 induces degradation of oncogenic FLT3.
PubMed Identifier: 28967922
author list: Weisberg EL, Schauer NJ, Yang J, Lamberto I, Doherty L, Bhatt S, Nonami A, Meng C, Letai A, Wright R, Tiv H, Gokhale PC, Ritorto MS, De Cesare V, Trost M, Christodoulou A, Christie A, Weinstock DM, Adamia S, Stone R, Chauhan D, Anderson KC, Seo HS, Dhe-Paganon S, Sattler M, Gray NS, Griffin JD, Buhrlage SJ
published in: Nature chemical biology
information resource reference: Inhibition of USP10 induces degradation of oncogenic FLT3. Nat Chem Biol. 2017 Dec; 13(12):1207-1215.
journal title abbreviation: Nat Chem Biol
publication date: 2017-10-02T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
PubMed Identifier: 28742454
author list: McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, Bringhen S, Musto P, Anderson KC, Caillot D, Gay F, Moreau P, Marit G, Jung SH, Yu Z, Winograd B, Knight RD, Palumbo A, Attal M
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3279-3289.
journal title abbreviation: J Clin Oncol
publication date: 2017-07-25T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma.
PubMed Identifier: 14555701
author list: Shammas MA, Shmookler Reis RJ, Akiyama M, Koley H, Chauhan D, Hideshima T, Goyal RK, Hurley LH, Anderson KC, Munshi NC
published in: Molecular cancer therapeutics
information resource reference: Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. Mol Cancer Ther. 2003 Sep; 2(9):825-33.
journal title abbreviation: Mol Cancer Ther
publication date: 2003-09-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications.
PubMed Identifier: 14695887
author list: Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, Akiyama M, Chauhan D, Munshi N, Gu X, Bailey C, Joseph M, Libermann TA, Richon VM, Marks PA, Anderson KC
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2003-12-26T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibitors as therapeutics.
PubMed Identifier: 16250907
author list: Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC
published in: Essays in biochemistry
information resource reference: Proteasome inhibitors as therapeutics. Essays Biochem. 2005; 41:205-18.
journal title abbreviation: Essays Biochem
publication date: 2005-01-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Intracellular protein degradation and its therapeutic implications.
PubMed Identifier: 16361533
author list: Hideshima T, Bradner JE, Chauhan D, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Intracellular protein degradation and its therapeutic implications. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8530-3.
journal title abbreviation: Clin Cancer Res
publication date: 2005-12-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Time-domain frequency-selective processing in nuclear magnetic resonance: a spatial-spectral holographic perspective.
PubMed Identifier: 16715158
author list: Kiruluta AJ, Anderson K, Barbastathis G
published in: Journal of the Optical Society of America. A, Optics, image science, and vision
information resource reference: Time-domain frequency-selective processing in nuclear magnetic resonance: a spatial-spectral holographic perspective. J Opt Soc Am A Opt Image Sci Vis. 2006 Jun; 23(6):1391-9.
journal title abbreviation: J Opt Soc Am A Opt Image Sci Vis
publication date: 2006-06-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia.
PubMed Identifier: 17169789
author list: Yasui H, Hideshima T, Anderson KC
published in: Leukemia & lymphoma
information resource reference: Non-steroidal anti-inflammatory drug therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2006 Dec; 47(12):2445-6.
journal title abbreviation: Leuk Lymphoma
publication date: 2006-12-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell.
PubMed Identifier: 17548610
author list: Bae J, Mitsiades C, Tai YT, Bertheau R, Shammas M, Batchu RB, Li C, Catley L, Prabhala R, Anderson KC, Munshi NC
published in: Journal of immunology (Baltimore, Md. : 1950)
information resource reference: Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15; 178(12):7730-7.
journal title abbreviation: J Immunol
publication date: 2007-06-15T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

A strategic framework for novel drug development in multiple myeloma.
PubMed Identifier: 17593022
author list: Anderson KC, Hannah AL, Pazdur R, Farrell AT
published in: British journal of haematology
information resource reference: A strategic framework for novel drug development in multiple myeloma. Br J Haematol. 2007 Jul; 138(2):153-9.
journal title abbreviation: Br J Haematol
publication date: 2007-07-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.
PubMed Identifier: 17690257
author list: Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Miguel JS, Bladé J, Boccadoro M, Cavenagh J, Alsina M, Rajkumar SV, Lacy M, Jakubowiak A, Dalton W, Boral A, Esseltine DL, Schenkein D, Anderson KC
published in: Blood
information resource reference: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood. 2007 Nov 15; 110(10):3557-60.
journal title abbreviation: Blood
publication date: 2007-08-09T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Thalidomide and immunomodulatory drugs as cancer therapy.
PubMed Identifier: 12409654
author list: Raje N, Anderson KC
published in: Current opinion in oncology
information resource reference: Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol. 2002 Nov; 14(6):635-40.
journal title abbreviation: Curr Opin Oncol
publication date: 2002-11-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors.
PubMed Identifier: 12423511
author list: Ballen KK, Hicks J, Dharan B, Ambruso D, Anderson K, Bianco C, Bemiller L, Dickey W, Lottenberg R, O'Neill M, Popovsky M, Skerrett D, Sniecinski I, Wingard JR
published in: Transfusion
information resource reference: Racial and ethnic composition of volunteer cord blood donors: comparison with volunteer unrelated marrow donors. Transfusion. 2002 Oct; 42(10):1279-84.
journal title abbreviation: Transfusion
publication date: 2002-10-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Moving disease biology from the laboratory to the clinic.
PubMed Identifier: 12520480
author list: Anderson KC
published in: Seminars in oncology
information resource reference: Moving disease biology from the laboratory to the clinic. Semin Oncol. 2002 Dec; 29(6 Suppl 17):17-20.
journal title abbreviation: Semin Oncol
publication date: 2002-12-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.
PubMed Identifier: 12691914
author list: Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST
published in: Experimental hematology
information resource reference: Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells. Exp Hematol. 2003 Apr; 31(4):271-82.
journal title abbreviation: Exp Hematol
publication date: 2003-04-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion.
PubMed Identifier: 12750280
author list: Orsini E, Bellucci R, Alyea EP, Schlossman R, Canning C, McLaughlin S, Ghia P, Anderson KC, Ritz J
published in: Cancer research
information resource reference: Expansion of tumor-specific CD8+ T cell clones in patients with relapsed myeloma after donor lymphocyte infusion. Cancer Res. 2003 May 15; 63(10):2561-8.
journal title abbreviation: Cancer Res
publication date: 2003-05-15T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications.
PubMed Identifier: 15087402
author list: Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, Hideshima T, Chauhan D, Hamasaki M, Ishitsuka K, Richardson P, Treon SP, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
journal title abbreviation: Cancer Res
publication date: 2004-04-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1017889
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Authorship 1019510
type: Authorship
author rank in publication: 10
linked author: Anderson, Kenneth
linked information resource: Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.

Authorship 1019930
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma.

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.
PubMed Identifier: 29029544
author list: Wickström M, Nygren P, Larsson R, Harmenberg J, Lindberg J, Sjöberg P, Jerling M, Lehmann F, Richardson P, Anderson K, Chauhan D, Gullbo J
published in: Oncotarget
information resource reference: Melflufen - a peptidase-potentiated alkylating agent in clinical trials. Oncotarget. 2017 Sep 12; 8(39):66641-66655.
journal title abbreviation: Oncotarget
publication date: 2017-06-08T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma.
PubMed Identifier: 29050200
author list: Tagde A, Markert T, Rajabi H, Hiraki M, Alam M, Bouillez A, Avigan D, Anderson K, Kufe D
published in: Oncotarget
information resource reference: Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma. Oncotarget. 2017 Sep 19; 8(41):69237-69249.
journal title abbreviation: Oncotarget
publication date: 2017-08-10T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma.
PubMed Identifier: 29048129
author list: Cholujova D, Bujnakova Z, Dutkova E, Hideshima T, Groen RW, Mitsiades CS, Richardson PG, Dorfman DM, Balaz P, Anderson KC, Jakubikova J
published in: British journal of haematology
information resource reference: Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017 12; 179(5):756-771.
journal title abbreviation: Br J Haematol
publication date: 2017-10-19T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/910232
PubMed Identifier: 15574786
author list: Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, Tassone P, Chauhan D, Hideshima T, Denis L, Richardson P, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53.
journal title abbreviation: Cancer Res
publication date: 2004-12-01T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

A clinically relevant SCID-hu in vivo model of human multiple myeloma.
PubMed Identifier: 15817674
author list: Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC
published in: Blood
information resource reference: A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005 Jul 15; 106(2):713-6.
journal title abbreviation: Blood
publication date: 2005-04-07T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib.
PubMed Identifier: 16286248
author list: Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, Mitsiades C, Mitsiades N, Yasui H, Letai A, Ovaa H, Berkers C, Nicholson B, Chao TH, Neuteboom ST, Richardson P, Palladino MA, Anderson KC
published in: Cancer cell
information resource reference: A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell. 2005 Nov; 8(5):407-19.
journal title abbreviation: Cancer Cell
publication date: 2005-11-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
PubMed Identifier: 16418332
author list: Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC
published in: Blood
information resource reference: Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62.
journal title abbreviation: Blood
publication date: 2006-01-17T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
PubMed Identifier: 16840727
author list: Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, Schlossman RL, Rajkumar SV, Desikan KR, Hideshima T, Munshi NC, Kelly-Colson K, Doss D, McKenney ML, Gorelik S, Warren D, Freeman A, Rich R, Wu A, Olesnyckyj M, Wride K, Dalton WS, Zeldis J, Knight R, Weller E, Anderson KC
published in: Blood
information resource reference: A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64.
journal title abbreviation: Blood
publication date: 2006-07-13T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
PubMed Identifier: 16846475
author list: Shringarpure R, Catley L, Bhole D, Burger R, Podar K, Tai YT, Kessler B, Galardy P, Ploegh H, Tassone P, Hideshima T, Mitsiades C, Munshi NC, Chauhan D, Anderson KC
published in: British journal of haematology
information resource reference: Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56.
journal title abbreviation: Br J Haematol
publication date: 2006-07-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
PubMed Identifier: 17121904
author list: Francis LK, Alsayed Y, Leleu X, Jia X, Singha UK, Anderson J, Timm M, Ngo H, Lu G, Huston A, Ehrlich LA, Dimmock E, Lentzsch S, Hideshima T, Roodman GD, Anderson KC, Ghobrial IM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma. Clin Cancer Res. 2006 Nov 15; 12(22):6826-35.
journal title abbreviation: Clin Cancer Res
publication date: 2006-11-15T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Thalidomide and lenalidomide: Mechanism-based potential drug combinations.
PubMed Identifier: 18452080
author list: Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC
published in: Leukemia & lymphoma
information resource reference: Thalidomide and lenalidomide: Mechanism-based potential drug combinations. Leuk Lymphoma. 2008 Jul; 49(7):1238-45.
journal title abbreviation: Leuk Lymphoma
publication date: 2008-07-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/913533
PubMed Identifier: 18948577
author list: Okawa Y, Hideshima T, Steed P, Vallet S, Hall S, Huang K, Rice J, Barabasz A, Foley B, Ikeda H, Raje N, Kiziltepe T, Yasui H, Enatsu S, Anderson KC
published in: Blood
information resource reference: SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK. Blood. 2009 Jan 22; 113(4):846-55.
journal title abbreviation: Blood
publication date: 2008-10-23T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource
label: SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.
PubMed Identifier: 20228272
author list: Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC
published in: Blood
information resource reference: A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5.
journal title abbreviation: Blood
publication date: 2010-03-12T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1021080
type: Authorship
author rank in publication: 11
linked author: Anderson, Kenneth
linked information resource: Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.

Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7.
PubMed Identifier: 29056421
author list: Lamberto I, Liu X, Seo HS, Schauer NJ, Iacob RE, Hu W, Das D, Mikhailova T, Weisberg EL, Engen JR, Anderson KC, Chauhan D, Dhe-Paganon S, Buhrlage SJ
published in: Cell chemical biology
information resource reference: Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7. Cell Chem Biol. 2017 12 21; 24(12):1490-1500.e11.
journal title abbreviation: Cell Chem Biol
publication date: 2017-10-19T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Re: When you look matters: the effect of assessment schedule on progression-free survival.
PubMed Identifier: 18314478
author list: Richardson PG, Niesvizky R, Anderson KC, Bladé J
published in: Journal of the National Cancer Institute
information resource reference: Re: When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst. 2008 Mar 05; 100(5):373.
journal title abbreviation: J Natl Cancer Inst
publication date: 2008-02-26T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone.
PubMed Identifier: 23018640
author list: Lichter DI, Danaee H, Pickard MD, Tayber O, Sintchak M, Shi H, Richardson PG, Cavenagh J, Bladé J, Façon T, Niesvizky R, Alsina M, Dalton W, Sonneveld P, Lonial S, van de Velde H, Ricci D, Esseltine DL, Trepicchio WL, Mulligan G, Anderson KC
published in: Blood
information resource reference: Sequence analysis of ß-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone. Blood. 2012 Nov 29; 120(23):4513-6.
journal title abbreviation: Blood
publication date: 2012-09-27T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes.
PubMed Identifier: 15020249
author list: Akiyama M, Yamada O, Hideshima T, Yanagisawa T, Yokoi K, Fujisawa K, Eto Y, Yamada H, Anderson KC
published in: Biochemical and biophysical research communications
information resource reference: TNFalpha induces rapid activation and nuclear translocation of telomerase in human lymphocytes. Biochem Biophys Res Commun. 2004 Apr 02; 316(2):528-32.
journal title abbreviation: Biochem Biophys Res Commun
publication date: 2004-04-02T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1025359
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.

HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer.
PubMed Identifier: 29113288
author list: Hideshima T, Mazitschek R, Qi J, Mimura N, Tseng JC, Kung AL, Bradner JE, Anderson KC
published in: Oncotarget
information resource reference: HDAC6 inhibitor WT161 downregulates growth factor receptors in breast cancer. Oncotarget. 2017 Oct 06; 8(46):80109-80123.
journal title abbreviation: Oncotarget
publication date: 2017-07-05T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma.
PubMed Identifier: 15994968
author list: Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, Tournilhac O, Podar K, Hideshima T, Schlossman R, Richardson P, Munshi NC, Luqman M, Anderson KC
published in: Cancer research
information resource reference: Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906.
journal title abbreviation: Cancer Res
publication date: 2005-07-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
PubMed Identifier: 16344099
author list: Anderson KC
published in: Seminars in hematology
information resource reference: Lenalidomide and thalidomide: mechanisms of action--similarities and differences. Semin Hematol. 2005 Oct; 42(4 Suppl 4):S3-8.
journal title abbreviation: Semin Hematol
publication date: 2005-10-01T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapeutic avenues in myeloma: changing the treatment paradigm.
PubMed Identifier: 17722741
author list: Ghobrial J, Ghobrial IM, Mitsiades C, Leleu X, Hatjiharissi E, Moreau AS, Roccaro A, Schlossman R, Hideshima T, Anderson KC, Richardson P
published in: Oncology (Williston Park, N.Y.)
information resource reference: Novel therapeutic avenues in myeloma: changing the treatment paradigm. Oncology (Williston Park). 2007 Jun; 21(7):785-92; discussion 798-800.
journal title abbreviation: Oncology (Williston Park)
publication date: 2007-06-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Mouse models of human myeloma.
PubMed Identifier: 17996588
author list: Mitsiades CS, Anderson KC, Carrasco DR
published in: Hematology/oncology clinics of North America
information resource reference: Mouse models of human myeloma. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1051-69, viii.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1027283
type: Authorship
author rank in publication: 23
linked author: Anderson, Kenneth
linked information resource: Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.

Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
PubMed Identifier: 29150421
author list: Facon T, Dimopoulos MA, Dispenzieri A, Catalano JV, Belch A, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis NJ, Banos A, Tiab M, Delforge M, Cavenagh JD, Geraldes C, Lee JJ, Chen C, Oriol A, De La Rubia J, White D, Binder D, Lu J, Anderson KC, Moreau P, Attal M, Perrot A, Arnulf B, Qiu L, Roussel M, Boyle E, Manier S, Mohty M, Avet-Loiseau H, Leleu X, Ervin-Haynes A, Chen G, Houck V, Benboubker L, Hulin C
published in: Blood
information resource reference: Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018 01 18; 131(3):301-310.
journal title abbreviation: Blood
publication date: 2017-11-17T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.
PubMed Identifier: 18413829
author list: Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
journal title abbreviation: Clin Cancer Res
publication date: 2008-04-15T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells.
PubMed Identifier: 11830495
author list: Tai YT, Podar K, Gupta D, Lin B, Young G, Akiyama M, Anderson KC
published in: Blood
information resource reference: CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood. 2002 Feb 15; 99(4):1419-27.
journal title abbreviation: Blood
publication date: 2002-02-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
PubMed Identifier: 12036884
author list: Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC
published in: Blood
information resource reference: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
journal title abbreviation: Blood
publication date: 2002-06-15T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
PubMed Identifier: 12208752
author list: LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC
published in: Cancer research
information resource reference: Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000.
journal title abbreviation: Cancer Res
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapies for multiple myeloma.
PubMed Identifier: 12492571
author list: Hayashi T, Hideshima T, Anderson KC
published in: British journal of haematology
information resource reference: Novel therapies for multiple myeloma. Br J Haematol. 2003 Jan; 120(1):10-7.
journal title abbreviation: Br J Haematol
publication date: 2003-01-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Telomerase inhibitors as anticancer therapy.
PubMed Identifier: 12678724
author list: Akiyama M, Hideshima T, Munshi NC, Anderson KC
published in: Current medicinal chemistry. Anti-cancer agents
information resource reference: Telomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents. 2002 Sep; 2(5):567-75.
journal title abbreviation: Curr Med Chem Anticancer Agents
publication date: 2002-09-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma.
PubMed Identifier: 12786794
author list: Maecker B, Anderson KS, von Bergwelt-Baildon MS, Weller E, Vonderheide RH, Richardson PG, Schlossman RL, Menezes IA, Xia Z, Munshi NC, Anderson KC, Nadler LM, Schultze JL
published in: British journal of haematology
information resource reference: Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8.
journal title abbreviation: Br J Haematol
publication date: 2003-06-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells.
PubMed Identifier: 13679868
author list: Chauhan D, Li G, Sattler M, Podar K, Mitsiades C, Mitsiades N, Munshi N, Hideshima T, Anderson KC
published in: Oncogene
information resource reference: Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300.
journal title abbreviation: Oncogene
publication date: 2003-09-18T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma.
PubMed Identifier: 14760100
author list: Shammas MA, Shmookler Reis RJ, Li C, Koley H, Hurley LH, Anderson KC, Munshi NC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004 Jan 15; 10(2):770-6.
journal title abbreviation: Clin Cancer Res
publication date: 2004-01-15T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications.
PubMed Identifier: 21321360
author list: Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, Cholujova D, Kong SY, Leiba M, Blotta S, Ooi M, Delmore J, Laubach J, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS
published in: Blood
information resource reference: Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011 Apr 28; 117(17):4409-19.
journal title abbreviation: Blood
publication date: 2011-02-14T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Initial genome sequencing and analysis of multiple myeloma.
PubMed Identifier: 21430775
author list: Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR
published in: Nature
information resource reference: Initial genome sequencing and analysis of multiple myeloma. Nature. 2011 Mar 24; 471(7339):467-72.
journal title abbreviation: Nature
publication date: 2011-03-24T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.
PubMed Identifier: 21454451
author list: Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC
published in: Blood
information resource reference: A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells. Blood. 2011 May 26; 117(21):5692-700.
journal title abbreviation: Blood
publication date: 2011-03-31T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

CCR1 as a target for multiple myeloma.
PubMed Identifier: 21609295
author list: Vallet S, Anderson KC
published in: Expert opinion on therapeutic targets
information resource reference: CCR1 as a target for multiple myeloma. Expert Opin Ther Targets. 2011 Sep; 15(9):1037-47.
journal title abbreviation: Expert Opin Ther Targets
publication date: 2011-05-24T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
PubMed Identifier: 15690325
author list: Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC
published in: Cancer
information resource reference: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer. 2005 Mar 15; 103(6):1195-200.
journal title abbreviation: Cancer
publication date: 2005-03-15T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Management of myeloma-associated renal dysfunction in the era of novel therapies.
PubMed Identifier: 22272706
author list: Gaballa MR, Laubach JP, Schlossman RL, Redman K, Noonan K, Mitsiades CS, Ghobrial IM, Munshi N, Anderson KC, Richardson PG
published in: Expert review of hematology
information resource reference: Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
journal title abbreviation: Expert Rev Hematol
publication date: 2012-02-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1029907
type: Authorship
author rank in publication: 12
linked author: Anderson, Kenneth
linked information resource: Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Authorship 1029996
type: Authorship
author rank in publication: 4
linked author: Anderson, Kenneth
linked information resource: Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.

Authorship 1029525
type: Authorship
author rank in publication: 5
linked author: Anderson, Kenneth
linked information resource: The proteasome and proteasome inhibitors in multiple myeloma.

Authorship 1029250
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against.
PubMed Identifier: 29172855
author list: Richardson PG, Holstein SA, Schlossman RL, Anderson KC, Attal M, McCarthy PL
published in: Expert opinion on pharmacotherapy
information resource reference: Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against. Expert Opin Pharmacother. 2017 Dec; 18(18):1975-1985.
journal title abbreviation: Expert Opin Pharmacother
publication date: 2017-12-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

The proteasome and proteasome inhibitors in multiple myeloma.
PubMed Identifier: 29196868
author list: Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG
published in: Cancer metastasis reviews
information resource reference: The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017 12; 36(4):561-584.
journal title abbreviation: Cancer Metastasis Rev
publication date: 2017-12-01T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
PubMed Identifier: 29182495
author list: Schiffer CA, Bohlke K, Delaney M, Hume H, Magdalinski AJ, McCullough JJ, Omel JL, Rainey JM, Rebulla P, Rowley SD, Troner MB, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 01 20; 36(3):283-299.
journal title abbreviation: J Clin Oncol
publication date: 2017-11-28T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary.
PubMed Identifier: 29182492
author list: Schiffer CA, Bohlke K, Anderson KC
published in: Journal of oncology practice
information resource reference: Platelet Transfusion for Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. J Oncol Pract. 2018 02; 14(2):129-133.
journal title abbreviation: J Oncol Pract
publication date: 2017-11-28T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
PubMed Identifier: 17510321
author list: Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC
published in: Blood
information resource reference: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 09 01; 110(5):1656-63.
journal title abbreviation: Blood
publication date: 2007-05-17T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.
PubMed Identifier: 17908986
author list: Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9.
journal title abbreviation: Clin Cancer Res
publication date: 2007-10-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma. Preface.
PubMed Identifier: 17996584
author list: Anderson KC
published in: Hematology/oncology clinics of North America
information resource reference: Multiple myeloma. Preface. Hematol Oncol Clin North Am. 2007 Dec; 21(6):xiii-xiv.
journal title abbreviation: Hematol Oncol Clin North Am
publication date: 2007-12-01T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1031292
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.

Future cancer research priorities in the USA: a Lancet Oncology Commission.
PubMed Identifier: 29208398
author list: Jaffee EM, Dang CV, Agus DB, Alexander BM, Anderson KC, Ashworth A, Barker AD, Bastani R, Bhatia S, Bluestone JA, Brawley O, Butte AJ, Coit DG, Davidson NE, Davis M, DePinho RA, Diasio RB, Draetta G, Frazier AL, Futreal A, Gambhir SS, Ganz PA, Garraway L, Gerson S, Gupta S, Heath J, Hoffman RI, Hudis C, Hughes-Halbert C, Ibrahim R, Jadvar H, Kavanagh B, Kittles R, Le QT, Lippman SM, Mankoff D, Mardis ER, Mayer DK, McMasters K, Meropol NJ, Mitchell B, Naredi P, Ornish D, Pawlik TM, Peppercorn J, Pomper MG, Raghavan D, Ritchie C, Schwarz SW, Sullivan R, Wahl R, Wolchok JD, Wong SL, Yung A
published in: The Lancet. Oncology
information resource reference: Future cancer research priorities in the USA: a Lancet Oncology Commission. Lancet Oncol. 2017 11; 18(11):e653-e706.
journal title abbreviation: Lancet Oncol
publication date: 2017-10-31T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design.
PubMed Identifier: 29268619
author list: Richardson PG, Attal M, Campana F, Le-Guennec S, Hui AM, Risse ML, Corzo K, Anderson KC
published in: Future oncology (London, England)
information resource reference: Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2018 May; 14(11):1035-1047.
journal title abbreviation: Future Oncol
publication date: 2017-12-22T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
PubMed Identifier: 19561323
author list: Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV
published in: Blood
information resource reference: Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35.
journal title abbreviation: Blood
publication date: 2009-06-26T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias.
PubMed Identifier: 19707373
author list: Roccaro AM, Ghobrial IM, Blotta S, Treon SP, Malagola M, Anderson KC, Richardson PG, Russo D
published in: Biologics : targets & therapy
information resource reference: Advances in the treatment of monoclonal gammopaties: The emerging role of targeted therapy in plasma cell dyscrasias. Biologics. 2008 Sep; 2(3):419-31.
journal title abbreviation: Biologics
publication date: 2008-09-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia.
PubMed Identifier: 19755386
author list: Ngo HT, Azab AK, Farag M, Jia X, Melhem MM, Runnels J, Roccaro AM, Azab F, Sacco A, Leleu X, Anderson KC, Ghobrial IM
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Src tyrosine kinase regulates adhesion and chemotaxis in Waldenstrom macroglobulinemia. Clin Cancer Res. 2009 Oct 01; 15(19):6035-41.
journal title abbreviation: Clin Cancer Res
publication date: 2009-09-15T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
PubMed Identifier: 20395418
author list: Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC
published in: Blood
information resource reference: Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
journal title abbreviation: Blood
publication date: 2010-04-15T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients.
PubMed Identifier: 20795787
author list: Rourke M, Anderson KC, Ghobrial IM
published in: Leukemia & lymphoma
information resource reference: Review of clinical trials conducted in Waldenstrom macroglobulinemia and recommendations for reporting clinical trial responses in these patients. Leuk Lymphoma. 2010 Oct; 51(10):1779-92.
journal title abbreviation: Leuk Lymphoma
publication date: 2010-10-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.
PubMed Identifier: 21144845
author list: Uljon SN, Richardson PG, Schur PH, Anderson KC, Tanasijevic MJ, Lindeman NI
published in: Clinica chimica acta; international journal of clinical chemistry
information resource reference: Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma. Clin Chim Acta. 2011 Mar 18; 412(7-8):562-8.
journal title abbreviation: Clin Chim Acta
publication date: 2010-12-07T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study.
PubMed Identifier: 21534941
author list: Richardson PG, Chanan-Khan AA, Lonial S, Krishnan AY, Carroll MP, Alsina M, Albitar M, Berman D, Messina M, Anderson KC
published in: British journal of haematology
information resource reference: Tanespimycin and bortezomib combination treatment in patients with relapsed or relapsed and refractory multiple myeloma: results of a phase 1/2 study. Br J Haematol. 2011 Jun; 153(6):729-40.
journal title abbreviation: Br J Haematol
publication date: 2011-04-28T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Significant biological role of sp1 transactivation in multiple myeloma.
PubMed Identifier: 21856768
author list: Fulciniti M, Amin S, Nanjappa P, Rodig S, Prabhala R, Li C, Minvielle S, Tai YT, Tassone P, Avet-Loiseau H, Hideshima T, Anderson KC, Munshi NC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011 Oct 15; 17(20):6500-9.
journal title abbreviation: Clin Cancer Res
publication date: 2011-08-19T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells.
PubMed Identifier: 21950728
author list: Chauhan D, Bandi M, Singh AV, Ray A, Raje N, Richardson P, Anderson KC
published in: British journal of haematology
information resource reference: Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol. 2011 Dec; 155(5):588-98.
journal title abbreviation: Br J Haematol
publication date: 2011-09-26T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia.
PubMed Identifier: 18316628
author list: Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, Ngo HT, Runnels J, Azab A, Azab F, Burwick N, Farag M, Treon SP, Palladino MA, Hideshima T, Chauhan D, Anderson KC, Ghobrial IM
published in: Blood
information resource reference: Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood. 2008 May 01; 111(9):4752-63.
journal title abbreviation: Blood
publication date: 2008-03-03T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting NF-kappaB in Waldenstrom macroglobulinemia.
PubMed Identifier: 18334673
author list: Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT, Runnels J, Melhem MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM
published in: Blood
information resource reference: Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood. 2008 May 15; 111(10):5068-77.
journal title abbreviation: Blood
publication date: 2008-03-11T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo.
PubMed Identifier: 18676772
author list: Shammas MA, Qazi A, Batchu RB, Bertheau RC, Wong JY, Rao MY, Prasad M, Chanda D, Ponnazhagan S, Anderson KC, Steffes CP, Munshi NC, De Vivo I, Beer DG, Gryaznov S, Weaver DW, Goyal RK
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008 Aug 01; 14(15):4971-80.
journal title abbreviation: Clin Cancer Res
publication date: 2008-08-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
PubMed Identifier: 19389500
author list: Mitsiades CS, Hideshima T, Chauhan D, McMillin DW, Klippel S, Laubach JP, Munshi NC, Anderson KC, Richardson PG
published in: Seminars in hematology
information resource reference: Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
journal title abbreviation: Semin Hematol
publication date: 2009-04-01T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma.
PubMed Identifier: 19443661
author list: Azab AK, Azab F, Blotta S, Pitsillides CM, Thompson B, Runnels JM, Roccaro AM, Ngo HT, Melhem MR, Sacco A, Jia X, Anderson KC, Lin CP, Rollins BJ, Ghobrial IM
published in: Blood
information resource reference: RhoA and Rac1 GTPases play major and differential roles in stromal cell-derived factor-1-induced cell adhesion and chemotaxis in multiple myeloma. Blood. 2009 Jul 16; 114(3):619-29.
journal title abbreviation: Blood
publication date: 2009-05-14T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma.
PubMed Identifier: 19509231
author list: Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A, Raab MS, Vallet S, Zhou Y, Cartron MA, Hideshima T, Tai YT, Chauhan D, Anderson KC, Podar K
published in: Cancer research
information resource reference: Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res. 2009 Jun 15; 69(12):5082-90.
journal title abbreviation: Cancer Res
publication date: 2009-06-09T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma.
PubMed Identifier: 19786667
author list: Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, Mazumder A, Munshi NC, Ghobrial IM, Doss D, Warren DL, Lunde LE, McKenney M, Delaney C, Mitsiades CS, Hideshima T, Dalton W, Knight R, Esseltine DL, Anderson KC
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
journal title abbreviation: J Clin Oncol
publication date: 2009-09-28T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia.
PubMed Identifier: 20103671
author list: Ghobrial IM, Roccaro A, Hong F, Weller E, Rubin N, Leduc R, Rourke M, Chuma S, Sacco A, Jia X, Azab F, Azab AK, Rodig S, Warren D, Harris B, Varticovski L, Sportelli P, Leleu X, Anderson KC, Richardson PG
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenstrom's macroglobulinemia. Clin Cancer Res. 2010 Feb 01; 16(3):1033-41.
journal title abbreviation: Clin Cancer Res
publication date: 2010-01-26T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.
PubMed Identifier: 20530693
author list: Mateos MV, Cibeira MT, Richardson PG, Prosper F, Oriol A, de la Rubia J, Lahuerta JJ, García-Sanz R, Extremera S, Szyldergemajn S, Corrado C, Singer H, Mitsiades CS, Anderson KC, Bladé J, San Miguel J
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma. Clin Cancer Res. 2010 Jun 15; 16(12):3260-9.
journal title abbreviation: Clin Cancer Res
publication date: 2010-06-08T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma.
PubMed Identifier: 21090965
author list: Laubach J, Richardson P, Anderson K
published in: Annual review of medicine
information resource reference: Multiple myeloma. Annu Rev Med. 2011; 62:249-64.
journal title abbreviation: Annu Rev Med
publication date: 2011-01-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.
PubMed Identifier: 21114484
author list: Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, Anderson KC
published in: British journal of haematology
information resource reference: PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo. Br J Haematol. 2011 Jan; 152(2):155-63.
journal title abbreviation: Br J Haematol
publication date: 2010-11-29T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1.
PubMed Identifier: 21292775
author list: Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J
published in: Blood
information resource reference: Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5.
journal title abbreviation: Blood
publication date: 2011-02-03T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial.
PubMed Identifier: 21596852
author list: Jakubowiak AJ, Griffith KA, Reece DE, Hofmeister CC, Lonial S, Zimmerman TM, Campagnaro EL, Schlossman RL, Laubach JP, Raje NS, Anderson T, Mietzel MA, Harvey CK, Wear SM, Barrickman JC, Tendler CL, Esseltine DL, Kelley SL, Kaminski MS, Anderson KC, Richardson PG
published in: Blood
information resource reference: Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood. 2011 Jul 21; 118(3):535-43.
journal title abbreviation: Blood
publication date: 2011-05-19T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma.
PubMed Identifier: 21712538
author list: Jakubikova J, Cervi D, Ooi M, Kim K, Nahar S, Klippel S, Cholujova D, Leiba M, Daley JF, Delmore J, Negri J, Blotta S, McMillin DW, Hideshima T, Richardson PG, Sedlak J, Anderson KC, Mitsiades CS
published in: Haematologica
information resource reference: Anti-tumor activity and signaling events triggered by the isothiocyanates, sulforaphane and phenethyl isothiocyanate, in multiple myeloma. Haematologica. 2011 Aug; 96(8):1170-9.
journal title abbreviation: Haematologica
publication date: 2011-06-28T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.
PubMed Identifier: 22033517
author list: Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, Deng J, Anderson KC, Richardson P, Tai YT, Mitsiades CS, Matulonis UA, Drapkin R, Stone R, Deangelo DJ, McConkey DJ, Sallan SE, Silverman L, Hirsch MS, Carrasco DR, Letai A
published in: Science (New York, N.Y.)
information resource reference: Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
journal title abbreviation: Science
publication date: 2011-10-27T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma.
PubMed Identifier: 22246439
author list: McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, Yu J, Smith PG, Richardson PG, Anderson KC, Treon SP, Kung AL, Mitsiades CS
published in: Molecular cancer therapeutics
information resource reference: Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther. 2012 Apr; 11(4):942-51.
journal title abbreviation: Mol Cancer Ther
publication date: 2012-01-12T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function.
PubMed Identifier: 22289890
author list: McMillin DW, Delmore J, Negri JM, Vanneman M, Koyama S, Schlossman RL, Munshi NC, Laubach J, Richardson PG, Dranoff G, Anderson KC, Mitsiades CS
published in: Blood
information resource reference: Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
journal title abbreviation: Blood
publication date: 2012-01-30T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents.
PubMed Identifier: 22533681
author list: Leiba M, Jakubikova J, Klippel S, Mitsiades CS, Hideshima T, Tai YT, Leiba A, Pines M, Richardson PG, Nagler A, Anderson KC
published in: British journal of haematology
information resource reference: Halofuginone inhibits multiple myeloma growth in vitro and in vivo and enhances cytotoxicity of conventional and novel agents. Br J Haematol. 2012 Jun; 157(6):718-31.
journal title abbreviation: Br J Haematol
publication date: 2012-04-26T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
PubMed Identifier: 22955917
author list: Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, Jakubikova J, Kong SY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC
published in: Blood
information resource reference: Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
journal title abbreviation: Blood
publication date: 2012-09-05T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.
PubMed Identifier: 23333523
author list: Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N
published in: Bone
information resource reference: In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013 Apr; 53(2):487-96.
journal title abbreviation: Bone
publication date: 2013-01-17T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1036379
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Should minimal residual disease negativity be the end point of myeloma therapy?

Should minimal residual disease negativity be the end point of myeloma therapy?
PubMed Identifier: 29296970
author list: Anderson KC
published in: Blood advances
information resource reference: Should minimal residual disease negativity be the end point of myeloma therapy? Blood Adv. 2017 Mar 14; 1(8):517-521.
journal title abbreviation: Blood Adv
publication date: 2017-03-14T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias.
PubMed Identifier: 19228727
author list: Mitsiades CS, Rouleau C, Echart C, Menon K, Teicher B, Distaso M, Palumbo A, Boccadoro M, Anderson KC, Iacobelli M, Richardson PG
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Preclinical studies in support of defibrotide for the treatment of multiple myeloma and other neoplasias. Clin Cancer Res. 2009 Feb 15; 15(4):1210-21.
journal title abbreviation: Clin Cancer Res
publication date: 2009-02-15T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1037610
type: Authorship
author rank in publication: 3
linked author: Anderson, Kenneth
linked information resource: The bone-marrow niche in MDS and MGUS: implications for AML and MM.

The bone-marrow niche in MDS and MGUS: implications for AML and MM.
PubMed Identifier: 29311715
author list: Ghobrial IM, Detappe A, Anderson KC, Steensma DP
published in: Nature reviews. Clinical oncology
information resource reference: The bone-marrow niche in MDS and MGUS: implications for AML and MM. Nat Rev Clin Oncol. 2018 04; 15(4):219-233.
journal title abbreviation: Nat Rev Clin Oncol
publication date: 2018-01-09T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
PubMed Identifier: 20382844
author list: Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC
published in: Blood
information resource reference: A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
journal title abbreviation: Blood
publication date: 2010-04-09T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy.
PubMed Identifier: 21280893
author list: Runnels JM, Carlson AL, Pitsillides C, Thompson B, Wu J, Spencer JA, Kohler JM, Azab A, Moreau AS, Rodig SJ, Kung AL, Anderson KC, Ghobrial IM, Lin CP
published in: Journal of biomedical optics
information resource reference: Optical techniques for tracking multiple myeloma engraftment, growth, and response to therapy. J Biomed Opt. 2011 Jan-Feb; 16(1):011006.
journal title abbreviation: J Biomed Opt
publication date: 2011-01-01T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2.
PubMed Identifier: 21292777
author list: Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, Fonseca R, Stewart AK, Harousseau JL, Dimopoulos M, Jagannath S, Hajek R, Sezer O, Kyle R, Sonneveld P, Cavo M, Rajkumar SV, San Miguel J, Crowley J, Avet-Loiseau H
published in: Blood
information resource reference: Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 05; 117(18):4696-700.
journal title abbreviation: Blood
publication date: 2011-02-03T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3.
PubMed Identifier: 21292778
author list: Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S
published in: Blood
information resource reference: Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 05; 117(18):4701-5.
journal title abbreviation: Blood
publication date: 2011-02-03T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study.
PubMed Identifier: 21345726
author list: Ghobrial IM, Weller E, Vij R, Munshi NC, Banwait R, Bagshaw M, Schlossman R, Leduc R, Chuma S, Kunsman J, Laubach J, Jakubowiak AJ, Maiso P, Roccaro A, Armand P, Dollard A, Warren D, Harris B, Poon T, Sam A, Rodig S, Anderson KC, Richardson PG
published in: The Lancet. Oncology
information resource reference: Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
journal title abbreviation: Lancet Oncol
publication date: 2011-02-21T00:00:00
year: 2011
type: Academic Article
type: Article
type: Document
type: Information Resource

The treatment of multiple myeloma patients not eligible for asct.
PubMed Identifier: 21415962
author list: Richardson P, Laubach J, Mahindra A, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Raje N, Munshi N, Anderson K
published in: Mediterranean journal of hematology and infectious diseases
information resource reference: The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
journal title abbreviation: Mediterr J Hematol Infect Dis
publication date: 2010-05-03T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1038591
type: Authorship
author rank in publication: 2
linked author: Anderson, Kenneth
linked information resource: Targeting CD38 alleviates tumor-induced immunosuppression.

Authorship 1038906
type: Authorship
author rank in publication: 1
linked author: Anderson, Kenneth
linked information resource: Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update.
PubMed Identifier: 29341831
author list: Anderson K, Ismaila N, Flynn PJ, Halabi S, Jagannath S, Ogaily MS, Omel J, Raje N, Roodman GD, Yee GC, Kyle RA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 03 10; 36(8):812-818.
journal title abbreviation: J Clin Oncol
publication date: 2018-01-17T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting CD38 alleviates tumor-induced immunosuppression.
PubMed Identifier: 29348814
author list: Tai YT, Anderson KC
published in: Oncotarget
information resource reference: Targeting CD38 alleviates tumor-induced immunosuppression. Oncotarget. 2017 Dec 22; 8(68):112166-112167.
journal title abbreviation: Oncotarget
publication date: 2017-12-22T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma.
PubMed Identifier: 17452641
author list: Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Targeting the beta-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci U S A. 2007 May 01; 104(18):7516-21.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2007-04-23T00:00:00
year: 2007
type: Academic Article
type: Article
type: Document
type: Information Resource

Authorship 1040766
type: Authorship
author rank in publication: 6
linked author: Anderson, Kenneth
linked information resource: The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.

The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma.
PubMed Identifier: 29359239
author list: Breitkreutz I, Podar K, Figueroa-Vazquez V, Wilhelm S, Hayden PJ, Anderson KC, Raab MS
published in: Annals of hematology
information resource reference: The orally available multikinase inhibitor regorafenib (BAY 73-4506) in multiple myeloma. Ann Hematol. 2018 May; 97(5):839-849.
journal title abbreviation: Ann Hematol
publication date: 2018-01-23T00:00:00
year: 2018
type: Academic Article
type: Article
type: Document
type: Information Resource

Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy.
PubMed Identifier: 18980990
author list: Song W, van der Vliet HJ, Tai YT, Prabhala R, Wang R, Podar K, Catley L, Shammas MA, Anderson KC, Balk SP, Exley MA, Munshi NC
published in: Clinical cancer research : an official journal of the American Association for Cancer Research
information resource reference: Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62.
journal title abbreviation: Clin Cancer Res
publication date: 2008-11-01T00:00:00
year: 2008
type: Academic Article
type: Article
type: Document
type: Information Resource

Maximizing the clinical benefit of novel therapies in multiple myeloma.
PubMed Identifier: 19476274
author list: Laubach J, Mitsiades C, Anderson K, Richardson P
published in: Oncology (Williston Park, N.Y.)
information resource reference: Maximizing the clinical benefit of novel therapies in multiple myeloma. Oncology (Williston Park). 2009 Apr 30; 23(5):415-6, 419.
journal title abbreviation: Oncology (Williston Park)
publication date: 2009-04-30T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Multiple myeloma.
PubMed Identifier: 19541364
author list: Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC
published in: Lancet (London, England)
information resource reference: Multiple myeloma. Lancet. 2009 Jul 25; 374(9686):324-39.
journal title abbreviation: Lancet
publication date: 2009-06-21T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
PubMed Identifier: 19584292
author list: McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, Jakubikova J, Maira SM, Garcia-Echeverria C, Schlossman R, Munshi NC, Richardson PG, Anderson KC, Mitsiades CS
published in: Cancer research
information resource reference: Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
journal title abbreviation: Cancer Res
publication date: 2009-07-07T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
PubMed Identifier: 19587378
author list: Blotta S, Tassone P, Prabhala RH, Tagliaferri P, Cervi D, Amin S, Jakubikova J, Tai YT, Podar K, Mitsiades CS, Zullo A, Franco B, Anderson KC, Munshi NC
published in: Blood
information resource reference: Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84.
journal title abbreviation: Blood
publication date: 2009-07-08T00:00:00
year: 2009
type: Academic Article
type: Article
type: Document
type: Information Resource

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.
PubMed Identifier: 20194748
author list: Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2010-03-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
PubMed Identifier: 20618337
author list: Richardson PG, Chanan-Khan AA, Alsina M, Albitar M, Berman D, Messina M, Mitsiades CS, Anderson KC
published in: British journal of haematology
information resource reference: Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. Br J Haematol. 2010 Aug; 150(4):438-45.
journal title abbreviation: Br J Haematol
publication date: 2010-07-07T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.
PubMed Identifier: 20723011
author list: Kiziltepe T, Anderson KC, Kutok JL, Jia L, Boucher KM, Saavedra JE, Keefer LK, Shami PJ
published in: The Journal of pharmacy and pharmacology
information resource reference: JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo. J Pharm Pharmacol. 2010 Jan; 62(1):145-51.
journal title abbreviation: J Pharm Pharmacol
publication date: 2010-01-01T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
PubMed Identifier: 21030562
author list: Rosenblatt J, Vasir B, Uhl L, Blotta S, Macnamara C, Somaiya P, Wu Z, Joyce R, Levine JD, Dombagoda D, Yuan YE, Francoeur K, Fitzgerald D, Richardson P, Weller E, Anderson K, Kufe D, Munshi N, Avigan D
published in: Blood
information resource reference: Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
journal title abbreviation: Blood
publication date: 2010-10-28T00:00:00
year: 2010
type: Academic Article
type: Article
type: Document
type: Information Resource

Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies.
PubMed Identifier: 22726545
author list: Hideshima T, Anderson KC
published in: Seminars in hematology
information resource reference: Biologic impact of proteasome inhibition in multiple myeloma cells--from the aspects of preclinical studies. Semin Hematol. 2012 Jul; 49(3):223-7.
journal title abbreviation: Semin Hematol
publication date: 2012-07-01T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells.
PubMed Identifier: 22970818
author list: Klippel S, Jakubikova J, Delmore J, Ooi M, McMillin D, Kastritis E, Laubach J, Richardson PG, Anderson KC, Mitsiades CS
published in: British journal of haematology
information resource reference: Methyljasmonate displays in vitro and in vivo activity against multiple myeloma cells. Br J Haematol. 2012 Nov; 159(3):340-51.
journal title abbreviation: Br J Haematol
publication date: 2012-09-13T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

https://connects.catalyst.harvard.edu/Profiles/profile/978739
PubMed Identifier: 23233713
author list: San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Delforge M, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Deraedt W, Cakana A, van de Velde H, Richardson PG
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol. 2013 Feb 01; 31(4):448-55.
journal title abbreviation: J Clin Oncol
publication date: 2012-12-10T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource
label: Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma.

Authorship 1043766
type: Authorship
author rank in publication: 8
linked author: Anderson, Kenneth
linked information resource: Multiple myeloma.

Multiple myeloma.
PubMed Identifier: 28726797
author list: Kumar SK, Rajkumar V, Kyle RA, van Duin M, Sonneveld P, Mateos MV, Gay F, Anderson KC
published in: Nature reviews. Disease primers
information resource reference: Multiple myeloma. Nat Rev Dis Primers. 2017 Jul 20; 3:17046.
journal title abbreviation: Nat Rev Dis Primers
publication date: 2017-07-20T00:00:00
year: 2017
type: Academic Article
type: Article
type: Document
type: Information Resource

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.
PubMed Identifier: 12173037
author list: Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC
published in: Oncogene
information resource reference: Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
journal title abbreviation: Oncogene
publication date: 2002-08-22T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource

Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma.
PubMed Identifier: 14679006
author list: Hideshima T, Chauhan D, Hayashi T, Podar K, Akiyama M, Mitsiades C, MItsiades N, Gong B, Bonham L, de Vries P, Munshi N, Richardson PG, Singer JW, Anderson KC
published in: Cancer research
information resource reference: Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36.
journal title abbreviation: Cancer Res
publication date: 2003-12-01T00:00:00
year: 2003
type: Academic Article
type: Article
type: Document
type: Information Resource

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function.
PubMed Identifier: 15292069
author list: Craiu A, Saito Y, Limon A, Eppich HM, Olson DP, Rodrigues N, Adams GB, Dombkowski D, Richardson P, Schlossman R, Choi PS, Grogins J, O'Connor PG, Cohen K, Attar EC, Freshman J, Rich R, Mangano JA, Gribben JG, Anderson KC, Scadden DT
published in: Blood
information resource reference: Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function. Blood. 2005 Mar 01; 105(5):2235-8.
journal title abbreviation: Blood
publication date: 2004-08-03T00:00:00
year: 2004
type: Academic Article
type: Article
type: Document
type: Information Resource

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.
PubMed Identifier: 15659493
author list: Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, Frankel SR, Touroutoglou N, Turnbull B, Anderson KC, Maloney DG, Fox EA
published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
information resource reference: Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol. 2005 Jan 20; 23(3):474-81.
journal title abbreviation: J Clin Oncol
publication date: 2005-01-20T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.
PubMed Identifier: 15937109
author list: Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC
published in: Proceedings of the National Academy of Sciences of the United States of America
information resource reference: Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A. 2005 Jun 14; 102(24):8567-72.
journal title abbreviation: Proc Natl Acad Sci U S A
publication date: 2005-06-03T00:00:00
year: 2005
type: Academic Article
type: Article
type: Document
type: Information Resource

Bortezomib: proteasome inhibition as an effective anticancer therapy.
PubMed Identifier: 16409135
author list: Richardson PG, Mitsiades C, Hideshima T, Anderson KC
published in: Annual review of medicine
information resource reference: Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med. 2006; 57:33-47.
journal title abbreviation: Annu Rev Med
publication date: 2006-01-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma.
PubMed Identifier: 16412014
author list: Yasui H, Hideshima T, Richardson PG, Anderson KC
published in: British journal of haematology
information resource reference: Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma. Br J Haematol. 2006 Feb; 132(4):385-97.
journal title abbreviation: Br J Haematol
publication date: 2006-02-01T00:00:00
year: 2006
type: Academic Article
type: Article
type: Document
type: Information Resource

Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma.
PubMed Identifier: 22538852
author list: Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, Hu Y, Fabre C, Minami J, Ohguchi H, Kiziltepe T, Ikeda H, Kawano Y, French M, Blumenthal M, Tam V, Kertesz NL, Malyankar UM, Hokenson M, Pham T, Zeng Q, Patterson JB, Richardson PG, Munshi NC, Anderson KC
published in: Blood
information resource reference: Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81.
journal title abbreviation: Blood
publication date: 2012-04-26T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study.
PubMed Identifier: 23240658
author list: Rosovsky R, Hong F, Tocco D, Connell B, Mitsiades C, Schlossman R, Ghobrial I, Lockridge L, Warren D, Bradwin G, Doyle M, Munshi N, Soiffer RJ, Anderson KC, Weller E, Richardson P
published in: British journal of haematology
information resource reference: Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
journal title abbreviation: Br J Haematol
publication date: 2012-12-13T00:00:00
year: 2012
type: Academic Article
type: Article
type: Document
type: Information Resource

Histone deacetylase inhibitors in the treatment for multiple myeloma.
PubMed Identifier: 23475757
author list: Hideshima T, Anderson KC
published in: International journal of hematology
information resource reference: Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol. 2013 Mar; 97(3):324-32.
journal title abbreviation: Int J Hematol
publication date: 2013-03-10T00:00:00
year: 2013
type: Academic Article
type: Article
type: Document
type: Information Resource

Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment.
PubMed Identifier: 12492118
author list: Hayashi T, Hideshima T, Akiyama M, Richardson P, Schlossman RL, Chauhan D, Munshi NC, Waxman S, Anderson KC
published in: Molecular cancer therapeutics
information resource reference: Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. Mol Cancer Ther. 2002 Aug; 1(10):851-60.
journal title abbreviation: Mol Cancer Ther
publication date: 2002-08-01T00:00:00
year: 2002
type: Academic Article
type: Article
type: Document
type: Information Resource